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Thesis Abstract 
Chronic kidney disease (CKD) is increasing globally and is estimated to affect between 10 
and 16% of the world’s population. In the western world, type 2 diabetes mellitus (T2DM) is 
the largest contributor to this burden. Given that many of the risk factors for CKD (diabetes, 
obesity, metabolic syndrome, hypertension, hyperlipidaemia) are modifiable by diet, it is not 
surprising that dietary advice forms an important part of kidney disease management. While 
much is understood about the role that dietary modulation can play in patients with 
established CKD, little is known about whether specific dietary factors consumed over a 
lifetime influence kidney disease risk. What is understood is that the modern western diet, 
high in processed and packaged foods and energy dense, is implicated as a major driver of 
increases in global CKD burden. This is thought to be via effects on modifiable risk factors 
for kidney disease, including glucose tolerance and adiposity. However, macronutrients 
such as protein and fat have also been independently implicated. Despite this, no study has 
examined the synergistic effects of the three major macronutrients on kidney health. 
Additionally, there are other factors that are modified in the modern western diet as 
compared with more traditional diets. These include chemical modifications to proteins and 
fats, as the result of increasing sugar and fat content, manufacturing processes and altered 
cooking methods. One family of modifications dramatically increased both in content and 
diversity in the western diet are Advanced Glycation End products (AGEs). Consumption of 
diets high in AGE content have not only been linked to CKD risk factors such as metabolic 
syndrome and type 2 diabetes, but are also shown to exacerbate CKD per se. Therefore, to 
better understand these relationships, AGEs and dietary macronutrients are studied in this 
thesis, which includes four independent projects collectively focussed on further elucidating 
the role of dietary AGEs and macronutrients in diabetic and non-diabetic and kidney disease.  
Chapter 2 of this thesis examines the acute temporal trafficking of orally ingested AGEs 
across the gut and within the body of healthy mice. Here, I report that AGE modified proteins 
are indeed rapidly absorbed across the gastro-intestinal tract into the circulation, peaking 15 
minutes after intragastric delivery. However, intact AGE-modified protein uptake varied 
significantly among mice and uptake was consistent to that seen with intact control protein.  
Chapter 3 examines whether AGE modified proteins alter postprandial glucose or insulin 
responses in healthy C57Bl/6 mice, using an acute oral AGE challenge equivalent to that 
eaten in a meal. No effects of acute delivery of AGE modified protein on insulin responses 
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over 2 hours post intragastric delivery were observed. There was however, a trend towards 
increasing circulating blood glucose concentrations with increasing AGE-modified dosages 
as compared to unmodified control protein. We further examined the chronic effects of high 
AGE dietary consumption on feeding behaviour (food consumption, water consumption) and 
energy profile (body temperature and RER) using state of the art indirect calorimetry. A high 
AGE diet was found to increase water intake but not food consumption, RER or body 
temperature. 
Chapter 4 examines the role of glucose excursions, diabetes and gastrointestinal handling 
of dietary glucose on endogenous AGE production and circulating levels of their receptor 
sRAGE. These are measured in serum collected from a cohort of diabetic patients and 
matched healthy controls who each underwent OGTT at 3 glucose loads (25g; 75g; 125g) 
followed by three isoglycaemic intravenous glucose infusions. Only minimal effects of the 
glucose excursions on circulating levels of CML, were found, suggesting, acutely CML, a 
marker of circulating AGEs, is not produced proportionately to glucose regardless of 
gastrointestinal handling. However, the effects of glucose infusion vs ingestion on circulating 
levels of sRAGE were significant, with sRAGE suppression occurring during intravenous 
infusion, compared to glucose ingestion in patients with T2DM and healthy individuals at 
some dosages.  
In chapter 5 of this thesis I use a nutritional geometry in a murine platform, designed 
specifically to explore the contribution of dietary macronutrient ratios and caloric intake over 
a lifetime to cardio-metabolic disease. Here, I extrapolated this platform to explore 
macronutrient effects both individually and interactively on structural (glomerulosclerosis, 
tubulointerstitial fibrosis), functional (eGFR, urea, electrolyte balance) and molecular 
markers (fibrotic mediators, inflammatory cytokines, KIM-1 and Klotho expression) of kidney 
disease. Here I report that indeed macronutrients in isolation, but also in specific 
combinations, over a lifespan do affect markers of renal pathology and function. In particular, 
lower consumption of calories from protein in conjunction with higher consumption of fat or 
carbohydrate resulted in a phenotype with the lowest GFR and the most kidney structural 
damage as assessed by tubulointerstitial fibrosis, as well as reduced renal klotho expression 
and cortical increases in the inflammatory cytokines IL-23 and IL-1β.  
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Chapter 1: Literature review and research aims 
The kidney  
The kidneys present not only a highly complex and sophisticated system for clearing the 
body of waste, but are also complex regulators of metabolic homeostasis. Every day the 
kidneys filter around 200 litres of blood, producing about 2 litres of waste urine [1]. As such, 
the kidneys are responsible for maintaining the body’s water/electrolyte balance, pH and 
blood pressure. They also prevent calorie loss by actively reabsorbing nutrients from the 
urinary filtrate and excrete larger waste products that cannot be freely filtered into the urine. 
Beyond their role in waste clearance, they regulate a number of hormones and enzymes 
that control blood pressure, fluid balance, erythropoiesis and bone health. Additionally, the 
kidneys are highly synthetic producing metabolic substrates such as glucose through 
gluconeogenesis, post-prandially, when blood glucose is low and in response to “fight or 
flight” hormones, rapidly releasing glucose into the blood [2, 3].  
The structural and functional unit of the kidney is the nephron. Each kidney is composed of 
around 1 million nephrons at birth, but this number steadily declines with age [4]. The 
glomerulus sits at the beginning of each nephron and is a globular mass of intertwined 
capillaries, neurons and fibres, known as a capillary tuft encapsulated by a basement 
membrane. Blood flows into this capillary tuft whereby endothelial cells, extracellular 
proteins and contractile cells such as the podocyte sit at the basement membrane forming 
a molecular size and charge exclusion barrier that in a healthy kidney prevents larger 
proteins and cells from passing into the urinary filtrate [5]. The resulting filtrate then passes 
into the renal tubular lumen, which is a continuous tube divided into segments based on 
structural and functional differences. Here, urinary filtrate passes from the proximal tubule, 
to the loop of Henle, the distal tubule and collecting duct, before draining into the renal 
calyces, into the renal pelvis and then exiting the kidney via a single ureter.   
The kidney is a very high throughput system with 20% of resting cardiac output entering the 
kidneys every minute, although not all of this volume enters the glomerulus [6]. A complex 
communication feedback loop exists between glomeruli and the distal convoluted tubule of 
the kidney mediated by the juxta-glomerular apparatus. This feedback loop orchestrates the 
dilation and constriction of the afferent and efferent arterioles, regulating the blood volume 
entering and exiting the glomeruli. This regulates the internal glomerular pressure, which in 
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turn regulates the glomerular filtration rate (GFR). The average human adult GFR is around 
125mL/min [7]. Due to the role of the kidneys in the handling and excretion of toxins and 
their carefully balanced metabolic demands, the kidneys are particularly vulnerable to 
metabolic, inflammatory and systemic vascular disorders [8].  
Chronic kidney disease 
Chronic kidney disease (CKD) defines a spectrum of kidney disorders characterised by 
reduced kidney function and pathological structural changes (summarised in Figure 1-1) [9]. 
Clinically, CKD is defined as a decline in kidney function or renal damage, diagnosed by a 
decrease in GFR over 3 months or more. CKD may be the result of morbid obesity, diabetes, 
hypertension, cardiovascular or autoimmune disease, but may also occur in the absence of 
such drivers due to aging, inherited genetic mutations, exposure to toxins or infections [9].   
Pathophysiology of CKD 
CKD is stratified into 5 stages based on GFR and presence of albumin in the urine 
(albuminuria). Further to this, proteinuria is a hallmark of chronic kidney disease, thought to 
be indicative of the breakdown of the glomerular filtration barrier. Additionally, a number of 
other proteins are used as biomarkers of renal function and CKD including, but not limited 
to estimated GFR (calculated using either serum creatinine or serum cystatin C [10]), urinary 
type IV collagen [11] and markers of damage to the proximal tubule including urinary kidney 
injury molecule (Kim-1) [12]. The pathogenesis of kidney disease centres around the 
balance of ongoing injury and subsequent wound healing responses that ultimately lead to 
scarring and fibrosis of the kidney. Much of our understanding of the factors driving this 
pathology have been well characterised in vitro and in animal models but remain 
incompletely understood in human disease. 
Renal injury can be broken down into the various structural compartments of the kidney, 
glomerular changes, tubulointerstitial changes, and changes to the vasculature of the kidney 
(Figure 1-1). The order at which these changes occur is often debated, and varies depending 
on the underlying aetiology of disease. Regardless of the aetiology, the damage seen in the 
kidney parenchyma in CKD is commonly characterised by glomerulosclerosis, infiltration of 
leukocytes into the tubulointerstitium, tubular atrophy and tubulointerstitial fibrosis [13].
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Figure 1-1. Mechanisms and outcomes of the pathophysiology of kidney disease. 
Abbreviations; APCs, Antigen Presenting Cells; BM, Basement Membrane; ECM, Extra Cellular 
Matrix; ER, Endoplasmic Reticulum; ROS, Reactive Oxygen Species; TIF, Tubulointerstitial Fibrosis.  
 
Glomerular changes 
Progressive glomerulosclerosis is characterised by endothelial cell damage, subsequent 
localised inflammation and the activation and proliferation of mesangial cells. This leads to 
the expansion of the mesangial matrix of the glomerular basement membrane and 
deposition of collagens within the glomerular tuft (Figure 1-1) [14, 15]. Increased expression 
of angiotensin II (Ang II) and growth factors including transforming growth factor β1 (TGF-
β1), platelet derived growth factor (PDGF) and fibroblast growth factor (FGF) increase the 
production and deposition of matrix proteins and collagens by mesangial cells, eventually 
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damaging the filtration barrier and contributing to a reduced GFR [15-19]. As disease 
progresses, other molecules can also accumulate in the glomerulus, such as advanced 
glycation end products (AGEs) and fibronectin [20, 21].  
In addition to expansion of the mesangial matrix, podocyte loss is another glomerular 
change seen with progressive kidney disease. Podocytes are terminally differentiated and 
specialised cells, with unique structure and function (Figure 1-1). As they do not undergo 
mitosis, podocyte injury and loss forces the remaining cells to hypertrophy and stretch in an 
attempt to make up for lost cells and maintain the filtration barrier. As such, podocyte number 
can be an indicator of kidney disease progression [22, 23]. The loss of podocytes and 
subsequent stretching leaves areas of the capillary tuft exposed to the Bowman’s capsule 
which can form adhesions further exacerbating glomerulosclerosis [24]. 
Tubulointerstitial changes 
Tubulointerstitial fibrosis on biopsy is the most accurate predictor of progression to end 
stage renal disease [25]. This is characterised by infiltration of inflammatory cells, 
inflammatory cytokine production and subsequent fibrosis within the tubulointerstitium. This 
contributes to tubular atrophy or loss [14, 15]. In progressive kidney diseases, the degree of 
proteinuria appears to be strongly linked with proximal tubule cell death [26] and the degree 
of tubular atrophy [27]. Glomerular changes and the resulting loss or reduction in the size 
and charge exclusion barrier which contribute to proteinuria, means that tubular cells are 
exposed to, and reabsorb significant quantities of proteins and other substances they are 
not normally in contact with. These include pro-fibrotic and pro-inflammatory cytokines, 
components of complement, albumin bound lipids, immunoglobulins and immune 
complexes, and ferritin [13]. All of these substances are potent mediators of tubular epithelial 
cell injury, and apoptosis in vitro [28-30]. The increased protein reabsorption load 
experienced by the tubular epithelial cells also puts increased pressure on the endoplasmic 
reticulum (ER), increasing ER stress [31] (Figure 1-1). Moreover, glomerular injury can 
jeopardise post glomerular blood supply. This results in hypoxia, and ischaemic injury to the 
tubules and peritubular interstitium [25] (Figure 1-1). In response to stress, tubular cells as 
well as interstitial fibroblasts increase expression of chemokines, increasing vascular 
permeability, activation of peritubular vascular endothelial cells, and infiltration of leukocytes 
(Figure 1-1). Pro-fibrotic factors such as Ang II, TGF-β, PDGF, FGF, CTGF are also 
upregulated, recruiting macrophages, which further contributes to collagen and ECM 
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deposition and scarring [13]. Furthermore, the increased inflammatory milieu promotes the 
formation and accumulation of AGEs around the site of inflammation and fibrosis [32]. 
Ultimately these processes result in the loss of whole tubules, as well as the rarefaction and 
loss of peritubular capillaries and their replacement with fibrotic scar tissue. 
The epidemiology of CKD: the western diet and risk factors/accelerators 
for CKD 
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Figure 1-2. Main drivers of the burden of renal failure in Australia, the United States of America 
and India 
Sources [33-35] 
ANZDATA Registry. 41st Report, Chapter 1: Incidence of End Stage Kidney Disease. Australia and New 
Zealand Dialysis and Transplant Registry, Adelaide, Australia. 2018. Available at: 
http://www.anzdata.org.au 
United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease 
in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and 
Kidney Diseases, Bethesda, MD, 2018. 
In the 20 years from 1990 to 2010, CKD rose on the list of causes of global deaths from 27th 
to 18th, rising at a rate only surpassed by HIV [36]. Epidemiological evidence suggests that 
this is because the prevalence and underlying causes of kidney disease have shifted in the 
last 50-100 years from causes such as glomerulonephritis, hereditary or congenital disease 
and unknown causes, towards diabetes and hypertension (Figure 1-2) [35]. With this shift, 
the prevalence of mortality from CKD globally has also increased from 8 per 100000 in 1990 
to 13 per 100000 in 2013 [37]. These figures are conservative given that they do not account 
for deaths in patients with CKD from cardiovascular disease, who do not reach end stage 
kidney disease.  
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The modern western diet, specifically a diet high in animal protein, animal and trans fats, 
sugar and salt and low in fruits, vegetables and fibre has been implicated in the rising global 
incidence of CKD [38-40]. In addition to the changes in macro and micro nutrient intake, 
there has also been a significant increase in portion sizes and total calories consumed [40]. 
This has led to rising incidence of many key risk factors for CKD, all of which are modifiable 
by diet (Figure 1-3), in particular, obesity, diabetes and hypertension. 
 
Figure 1-3. Risk factors and comorbidities for CKD  
There are numerous factors that increase the risk of kidney disease. Many of these are lifestyle driven 
and modifiable by diet (Adapted from the content by Kazancioglu [41]). 
 
Diabetes 
As Figure 1-2 highlights, diabetes is the largest primary cause of kidney failure in many 
countries. Today there are estimated to be 382 million people living with diabetes globally. 
With current trends persisting, this will increase to 592 million people by 2035, equating to 
an increase of 55% [42]. In Australia, the incidence of diabetes has more than doubled in 
the past 10 years [43]. Economically, the total spend for our nation is estimated at $14.6 bn 
in direct health costs [44]. Furthermore, the persisting notion that diabetes is a disease of 
affluence, affecting countries with high gross domestic product is no longer true, with 
countries such as those within Africa having some of the greatest increases in diabetes per 
capita [45].  
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There are three well described types of diabetes, all of which are characterised by excessive 
blood glucose concentration (hyperglycaemia). Type 1 diabetes (T1DM) is considered an 
autoimmune disease that culminates in the destruction of the insulin producing β-cells within 
the Islets of Langerhans, which reside in the pancreata [46]. It commonly occurs early in life 
(before the age of 30) [47], although recent research suggests it may now equally affect 
those over 30 [48]. Although it only constitutes between 5-10% of diabetes cases, the 
incidence of T1DM is rapidly increasing. This increase contributes significantly to the general 
cost burden of diabetes complications, due to its complex management and the young age 
of onset [47, 49].  
Type 2 diabetes (T2DM) constitutes around 85% of all diabetes cases across the globe [47]. 
In 2014, the World Health Organisation (WHO) reported that 9% of adults over the age of 
18 have diabetes globally [50]. Furthermore, 80% of diabetes related deaths are reported to 
occur in low to middle income countries [51]. T2DM is characterised by progressive insulin 
secretory defects, changes in insulin action in peripheral tissues (insulin resistance) and 
excessive glucose output from both hepatic and renal sources. This disease was previously 
observed only in adults. However, incidence in children, adolescents and young adults has 
been rising rapidly, most likely due to shifts in dietary patterns, obesity and reduced levels 
of physical activity [52]. T2DM and diabetic nephropathy is also over-represented in 
indigenous populations including in Australia [33]. 
Gestational diabetes is a condition where women without previously diagnosed diabetes 
present with elevated blood glucose concentrations during pregnancy. Gestational diabetes 
increases the risk of developing T2DM in the future for both the mother and child. 
Diabetic kidney disease (DKD) affects approximately 30% of patients with T1DM and 
approximately 40% of patients with T2DM [53], with strong genetic and racial susceptibility 
[54]. The early stages of DKD are characterised by hypertrophy and hyperplasia of the 
kidney and glomeruli as well as hyperfiltration and proteinuria [47]. As disease progresses, 
other changes occur in line with progressive CKD as described above. Beyond, kidney 
disease, there are a number of acute and long-term complications associated with diabetes 
and its management. Acute complications include diabetic ketoacidosis and hypoglycaemia 
which can be life-threatening if not immediately treated. However, the majority of mortality 
associated with diabetes is from the long-term micro and macrovascular complications 
including kidney disease [47]. Indeed, kidney disease is the major risk factor for mortality in 
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individuals with diabetes [55, 56]. Microvascular complications include diseases of the 
nervous system (neuropathy), eye (retinopathy), and as discussed above, the kidney (DKD), 
whilst macrovascular complications include diseases of the large vessels such as coronary 
heart, cerebrovascular, and peripheral vascular diseases. Certainly, these vascular 
complications of diabetes increase the risk of an adverse cardiovascular event and mortality. 
Multiple studies of CKD indicate similar increase in risk of macrovascular complications in 
patients with CKD [47]. These complications of diabetes manifest from a number of 
processes which are incompletely understood but include haemodynamic changes 
(hypertension and hyperfiltration), metabolic changes (glucose toxicity, mitochondrial 
dysfunction, lipotoxicity, oxidative stress and carbonyl stress) and formation of AGEs [47].  
Hypertension and Hyperlipidaemia 
Hypertension is estimated to effect 20-40% of adults in developed countries and is projected 
to affect more than 1.5 billion people by 2025 [57]. Systemic hypertension accounts for 
approximately 28% of renal impairment in the US and 13 % in Australia (Figure 1-2). The 
MRFIT study, examined incidence of end stage renal disease (ESRD) in a cohort of more 
than 300 000 men, finding the adjusted relative risk of reaching ESRD was 1.9 for high-
normal blood pressure, 3.1 for stage I, 6.0 for stage II, 11.2 for stage III, and 22.1 for stage 
IV hypertension [58]. Similar findings have been reported elsewhere [59, 60].  
Generally hypertensive nephrosclerosis, the damage to the blood vessels and capillaries of 
the kidney, and especially the glomerulus, is thought to be the predominant underlying 
explanation for hypertensive related kidney disease [61]. Increased pressure in the 
glomerulus, ischemia, loss of autoregulation by the glomeruli and collapse and loss of 
capillaries, arterioles and vessels and the resulting hypoxia are all important drivers of this 
pathology [62].  
Increasing lipid and cholesterol levels and lipid abnormalities are another manifestation of 
the modern human diet [63]. Lipid abnormalities have been demonstrated to accelerate the 
progression of kidney disease in both animal models [64] and in cohort studies of patients 
with diabetes and established renal impairment [65]. Despite these insights, convincing 
evidence that lipid lowering therapies prevent or attenuate kidney disease or disease 
progression in humans remains to seen. Two studies have found heterogeneity in the risk 
contribution of hyperlipidaemia, finding the contribution to risk of CKD is higher in individuals 
without hypertension than in individuals with hypertension [66, 67], suggesting some 
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overlapping aetiology. Whether hypertension or hyperlipidaemia alone can cause chronic 
kidney disease has long been debated as genetic susceptibility and presence of co-
morbidities appear important.   
Dietary modulators of kidney disease  
 As highlighted above, diet has been suggested as an important mediator and accelerator 
of age related kidney disease risk. Indeed, nutritional imbalances precipitate many of the 
risk factors for CKD including obesity, diabetes, hypertension and dyslipidaemia discussed 
above. Research has attempted to examine the effects of “over-nutrition” as well as the 
individual effects of macronutrients on renal function and renal injury, and the associated 
structural and functional changes. Diet related risk factors for kidney disease are discussed 
at length below.  
Overconsumption of calories, obesity and weight gain. 
Over-nutrition and obesity are proposed as major contributors to the dramatic increases in 
CKD prevalence [68]. Many large population based studies show that body mass index 
(BMI) above a normal range associates with renal dysfunction as determined by proteinuria/ 
progression to proteinuria [69-72], low and declining estimated GFR (eGFR) over time [69, 
70, 72-74], rapid decline in eGFR over time [75] and incidence of ESRD [76-79]. 
Furthermore, these relationships hold when other measures of obesity such as weight and 
waist circumference are examined [80]. Emerging data suggests that obesity contributes to 
CKD even in the absence of diabetes [72, 81]. Animal models largely support the human 
observations. In rats, the development of more severe kidney functional impairment and 
renal pathology with aging is evident in strains where body size continues to increase 
beyond adolescence, such as Sprague Dawley and Fisher 344 rats [82-86]. By contrast, 
strains of rat that remain small despite ad libitum feeding such as the Wistar, Brown 
Norwegian and Long Evans strains, appear more resistant to age related declines in kidney 
function [87-89] and kidney damage as the result of obesity [90-92].  
The mechanisms by which obesity impairs renal function remain to be fully elucidated.  
Obesity induced hypertension is thought to be a major contributor to CKD [93]. Furthermore, 
excess adipose tissue is a major site of inflammation and pro-inflammatory cytokine 
synthesis, facilitating the chronic low grade inflammation observed in obesity and metabolic 
syndrome [94]. Given the blood volume filtered by the kidneys every day, there is significant 
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exposure to circulating pro-inflammatory factors. This makes the kidneys susceptible to 
states of chronic systemic low grade inflammation and increases local inflammation in the 
kidney. Certainly increased inflammatory cytokine production and increased infiltration of 
macrophages have previously reported in the context of obesity augmented kidney injury in 
rodent models [95]. Lipotoxicity, including the ectopic fat deposition in non-adipose tissue is 
another proposed mechanism of obesity induced renal damage. Broadly speaking, 
hyperlipidaemia, which is a common co-morbidity of obesity and diabetes is known to 
directly damage podocytes [96], inducing mitochondrial defects, oxidative stress [93], and 
altering lipid rafts in the podocyte affecting GFR [97]. 
Finally, at the physiological level obese individuals often have increased intra-abdominal 
pressure [98], whilst high fat fed obese animal models have shown an increase in renal 
sinus fat encapsulating the kidney and associated increases in renal interstitial pressure 
[99]. This increased physical pressure from peri-renal and intra-abdominal fat would likely 
elevate hydrostatic pressure, leading to changes in sodium reabsorption and ultimately 
alterations in blood pressure [93] and other conditions that increase the risk for CKD [93]. 
Influence of caloric restriction on kidney structure and function in ageing and 
disease.  
Calorie restriction of between 25% to 45% has been demonstrated to increase longevity in 
simple organisms such as C. elegans, D. melanogaster and a number of animal models, 
provided adequate nutrition is maintained [100]. In multiple rat models, caloric restriction to 
60-70% of ad libitum consumption limit obesity and significantly extends lifespan preventing 
and/or delaying chronic disease, including CKD [86]. Caloric restriction, even later in life has 
profound effects in retarding the onset of kidney disease in rats, and surprisingly, to prevent 
renal failure even in extremely old rats and mice [101] (reviewed here [102]). Indeed, total 
calories consumed throughout life is postulated to be a potent determinant of renal damage 
with aging [102]. Interestingly, at least one study found that simply restricting protein intake 
in rats was sufficient to delay renal decline with age and promote longevity [103], although 
other studies contradict this finding [104]. Taken together, these studies suggest that caloric 
restriction is a potent dietary manipulation that preserves renal structure and function into 
old age, potentially due to restriction of dietary protein intake.  
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Protein intake and kidney function/disease risk  
Dietary protein is considered a potential mediator of kidney disease. The central hypothesis 
is that habitual consumption of high dietary protein promotes CKD by increasing glomerular 
pressure and hyperfiltration [105, 106]. Whilst basic physiological studies suggest that high 
protein intake can impact renal function, population based studies and clinical trials suggest 
that a degree of renal insufficiency at baseline is required to observe this effect.  
Certainly, acute meal challenges containing a high proportion of animal protein (90g of meat 
or milk protein) increase GFR in healthy individuals [107] . Earlier studies also show 
elevations in renal blood flow and GFR in response to animal protein loads [108-110]. There 
are however, several studies where acute meal challenges comprised of protein from dairy, 
egg or plant sources did not influence GFR [111, 112]. Suggesting that the specific protein 
source, particularly protein sourced from meat, may be responsible. Mechanisms 
responsible for these animal protein specific changes in renal function might include 
changes in circulating post-prandial hormones and metabolism and differences in dietary 
micronutrients consumed during the meal tests [113].  
In the Nurses’ Health Study (NHS), a prospective cohort analysis was performed to assess 
if high dietary protein consumption was associated with a decline in kidney function over 
time (by GFR). The association was clearly shown in participants with mild renal 
insufficiency at baseline, suggesting that it may be an important driver in individuals pre-
disposed to kidney disease [114]. In other populations, greater dietary protein intake only 
associated with microalbuminuria in individuals with both diabetes and hypertension [115], 
but not in individuals with only diabetes or hypertension. There have been a number of 
clinical trials restricting dietary protein, in patients at risk of kidney disease such as diabetics. 
The results are conflicting however, most of studies have failed to show any benefit in 
slowing the decline in renal function [116, 117] as highlighted by systematic review of the 
literature [118-120].  
One limitation of these population based studies is that the source of protein was not 
considered. This may be important for renal function, as suggested by previous acute dosing 
studies [108]. Studies in vegan subjects who consume no animal sourced protein show that 
these individuals have lower GFR and urinary albumin excretion than omnivores [121]. 
However, these results could be confounded by other factors that influence renal function 
such as lower bodyweight and lower systolic and diastolic blood pressure which are 
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generally observed in vegan individuals [122]. Rodent studies of reduced kidney mass 
support that consumption of protein which is vegetal in origin, attenuates proteinuria and 
renal histological damage as compared with calorically matched protein from animal origin 
(casein) [123].  
Carbohydrate intake and kidney function/disease risk 
A complementary argument, to the assumption that protein restriction is protective of kidney 
function and increases longevity, is the hypothesis that a high carbohydrate to protein ratio 
in the diet is renoprotective. The vast majority of studies performed to date have focused on 
dietary protein and fat restriction or excess in order to alter kidney function and structure. By 
contrast, dietary carbohydrate intake has received relatively little attention except for the 
study of simple sugar intake, particularly fructose consumption. Typically, a high 
carbohydrate diet has a high glycaemic index (GI). Cross sectional data in humans suggests 
consumption of a high GI diet is associated with increased likelihood of a GFR <60ml/min-
1/1.73m-2 [124]. More recently, a randomised crossover trial in healthy adults confirmed this 
finding, showing that that a high GI diet impacts renal function, increasing GFR [125].  
In addition to the contribution of dietary carbohydrates to the glycaemic index of the diet, the 
sugar source appears to affect renal function. In animal models, consumption of a diet high 
in fructose can induce metabolic syndrome (obesity, hyperglycaemia, hypertension or 
dyslipidaemia) [126] and diabetes, as well as proteinuria, renal inflammation and cast 
formation in the kidney [127]. High fructose diets also exacerbate renal injury in animal 
models of CKD such as partially nephrectomised mice or rats [128]. In humans, the findings 
largely support those from animal models. As seen in in rats, high fructose consumption in 
an adolescent population increased circulating uric acid levels and hypertension [129], both 
of which are associated with incident CKD [130, 131]. Similar results were seen in healthy 
adult women, where higher consumption of fructose sweetened beverages (>2 per day) was 
associated with a more rapid decline in GFR per year over the 9 year study period [132].  
Fat consumption and kidney function/disease risk 
High dietary fat consumption induces renal injury, specifically fibrosis, inflammation, 
glomerular hypertrophy, mesangial matrix expansion, proximal tubule damage, vacuolation 
of tubular cells and dysfunction in lysosomal pathways, metabolic dysfunction by cells of the 
kidney and lipid accumulation [90, 133]. It is impossible to determine however, if this is a 
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direct effect or is being driven by increases in CKD risk factors such as obesity, 
hyperglycaemia and insulin resistance. Furthermore, high fat diets and their control diets 
generally have different caloric densities making it difficult to tell whether the calories 
themselves or the fat content were driving the renal changes. Unless studies include pair 
feeding, this can confound the literature regarding the origins of disease. AMP kinase, an 
enzyme responsible for energy and redox sensing, is an important mediator of fat induced 
renal damage in animal and human models [133]. Even in rodent models less susceptible 
to renal pathology, a high fat diet increases oxidative stress and changes mitochondrial 
function. Mitochondrial defects persisted even after the diet was reverted to standard chow 
and mice lost weight, suggesting a legacy effect [134]. In a rodent model susceptible to renal 
disease, the same high fat diet protocol induced albuminuria, fibrosis and podocyte loss 
[134].  
Of note, a ketogenic diet which is high in fat (87% fat) and extremely low in carbohydrate, 
can reverse DKD in preclinical models of both T1DM and T2DM [135]. This suggests that 
fat alone might not directly induce kidney disease, but may do so in the context of obesity 
induced hyperglycaemia and insulin resistance. Furthermore, in mice, restricted access to 
a high fat diet, where consumption is controlled to iso-calorically match low fat fed 
counterparts, ameliorates the renal pathology seen in ad libitum high fat fed mice [90]. 
Additionally, it has been noted that fatty acid oxidation (FAO) is a preferred fuel source for 
proximal tubule cells, but is defective in the tubules of patients or rodent models with CKD, 
promoting a cellular switch to a pro-fibrotic state [136]. Taken together, the evidence 
discussed above suggests that the source of fat and its composition are important factors 
determining the pathogenicity of high fat diets, in addition to the excess calories consumed. 
In humans, there is evidence that dietary fat consumption is both detrimental and beneficial 
to renal function depending on the fat source [137, 138]. Consumption of long chain n-3 fatty 
acids and n-6 fatty acids are associated with a decreased risk of CKD [139, 140]. By 
contrast, excess trans-fat consumption is positively associated with eGFR decline in 
individuals with T2DM, with this relationship being stronger in women [141].  
Food processing and CKD risk 
The western diet and AGEs as a risk factor for kidney disease 
Beyond changes in the quantity and macronutrient composition of the diet in the last 70 
years, the industrialisation of food processing has dramatically changed the chemical 
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components and structure of foods we eat. Rapid food production including the use of high 
temperature and preservatives to extend shelf life and other physical processes such as 
dehydration, decompression and irradiation of food, have significantly increased modified 
and extruded proteins and lipids, including Advanced glycation end products (AGEs) [142]. 
AGEs are present in most commonly consumed foods and are implicated in many acute and 
chronic diseases, but particularly in diabetes and kidney disease. Additionally, many of the 
factors associated with diet discussed above can increase AGE production within the body. 
The remainder of this introduction will focus on the biochemistry of AGEs, their potential role 
in chronic kidney disease pathogenesis and in general health and disease.  
Basic chemistry of AGEs 
The Maillard reaction, sometimes called the browning reaction, is named after the French 
physician and chemist responsible for its discovery in 1912, after watching apples 
spontaneously “brown” following peeling [143]. The reaction is comprised of the covalent 
non-enzymatic attachment of a sugar to an amino acid (AA) and can proceed via a number 
of chemical pathways (Figure 1-4). Advanced glycation is facilitated by heat, the presence 
of oxidants, increases in pH, atmospheric pressure and the concentrations of reducing 
sugars and AAs. Reducing sugars such as glucose, fructose, ribose, mannose and others 
are, by nature, reactive towards AAs and this non-enzymatic attraction underpins the 
Maillard reaction [144]. Initially, Maillard reaction intermediates, termed Schiff bases are 
formed and subsequently rearrange into ketoamines known as Amadori products or early 
glycation products. These are more stable products than Schiff bases, but at this point in 
the reaction, the chemistry is still reversible [145]. Other important intermediates of this 
chemistry are the reactive carbonyls, 3 deoxyglucose (3-DG) and methylglyoxal (MGO) 
[146-148]. The accumulation of such molecules is known as carbonyl stress. After further 
chemistry, the reaction becomes irreversible and forms AGEs. The term AGE refers to a 
heterogeneous population including high molecular weight (HMW) AGE modified proteins 
and low molecular weight (LMW) AGEs, such as single modified amines and small peptides. 
The Maillard reaction occurs not only in fruits and vegetables but in any system where there 
are reducing sugars and amino groups present, including within the cells and tissues of 
organisms. This is conserved all the way back to single cell organisms [149]. In humans 
where proteins, fatty acids and even DNA can be glycated.  
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Figure 1-4. Basic pathways of AGE chemistry and associated pathology 
Abbreviations ROS, Reactive Oxygen Species;  
 
AGEs in the clinical setting 
AGEs are often used as clinical markers of disease. Amongst the AGEs most widely 
recognised are the clinical markers of long term blood glucose control such as glycated 
haemoglobin A1C (HbA1C; a marker of glucose exposure over the preceding 3 months) and 
fructosamine modified albumin (an indicator of glucose exposure over the preceding 2 
weeks) [142]. The relationship between AGEs and glucose control is discussed in detail 
below. Other well studied AGEs in biological systems, are carboxymethyl-lysine (CML) and 
carboxyethyl-lysine (CEL) and crosslinking dimers such as pentosidine, glyoxal-lysine dimer 
(GOLD) and methylglyoxal-lysine dimer (MOLD) [150]. AGEs in the skin, particularly CML 
are predictors of future risk for complications in both Type 1 and Type 2 diabetes [151-155]. 
This has been most elegantly demonstrated in the Type 1 Diabetes Control and 
Complications Trial (DCCT) and the follow up study, The Epidemiology of Diabetes 
Interventions and Complications (EDIC), where AGE burden predicted cardiovascular and 
renal outcomes independently to glycaemic control [156]. Further to this, AGE burden, 
measured by skin auto-fluorescence was associated with a reduction in eGFR and 
increased mortality. In the bloodstream, the predictive potential of AGEs for disease is more 
complex. Several studies in patients with T1DM have shown that increases in circulating 
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CML predict adverse cardiovascular outcomes [157, 158]. Similar predictive potential was 
found for cardiovascular mortality in haemodialysis patients [159]. However, other studies 
have failed to show these relationships in patients with T2DM [160]. AGEs in the urine also 
offer some predictive potential in diabetes, with at least one study of individuals with T1DM 
demonstrating that increased clearance of CML into the urine predicts progression to 
functional renal impairment [161]. Specifically, the relationship between AGEs and CKD is 
discussed in greater detail below. 
AGE Receptors  
There are a number of receptors that have been characterised as binding AGEs, including 
the Receptor for Advanced Glycation End Products (RAGE), AGE Receptor 1 (AGER1; 
OST-48), AGE Receptor 2  (AGER2; 80K-H ), AGE Receptor 3 (AGER3; Galectin 3) and 
the class A macrophage scavenger receptors types 1 and 2 [162]. Most studies focus on 
RAGE since AGE binding induces cellular signal transduction, while the other AGE 
receptors may play a role in AGE clearance and detoxification [163]. As this thesis only deals 
with RAGE, only RAGE will be discussed here.  
RAGE   
RAGE is the most widely studied of the AGE receptors. It has a diverse pattern of 
expression, is highly expressed on mucous membranes such as the lung and is present on 
cells throughout the GI tract and within the immune system [164].  Early experiments 
demonstrated that in vitro prepared AGE modified albumin bound to RAGE with a high 
affinity [165]. Further studies demonstrated that AGEs isolated from the serum of diabetic 
patients could induce up-regulation of endothelial cells in a RAGE-dependent manner [166]. 
These findings have since been replicated in a number of experimental settings, although 
with a particular focus on cultured endothelial cell models [167-169]. Further to this, several 
studies were able to show that CML modified BSA binds RAGE both in cell culture and in 
animal models [170-172].  
RAGE is a member of the immunoglobulin superfamily of receptors [165, 173]. The RAGE 
gene, AGER, consists of 11 introns and exons that can be differentially spliced to form 
multiple variants [174]. Sequencing of mRNA encoded for by AGER, has identified twenty 
isoforms based on differential splicing in numerous different tissue types [175]. The full 
length form of RAGE, flRAGE, consists of three immunoglobulin like domains known as the 
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V1(variable), C1 and C2 domains; a transmembrane helix and a short highly charged 
cytoplasmic domain that is essential for signal transduction (Figure 1-5) [176]. As well as the 
full length isoform there is an N terminal truncated form of the receptor that lacks the AGE 
binding capacity (Figure 1-5) [177]. Further to this, there are two secreted forms of RAGE 
which make up the circulating pool; endogenous secretory RAGE (esRAGE), which is a 
product of the AGER transcription and soluble RAGE (sRAGE), which is cleaved from cell 
membranes by the protease (a disintegrin and metalloproteinase domain-containing protein 
10) ADAM-10 (Figure 1-5) [178, 179].  
As a multi-ligand receptor, RAGE also binds to s100 calgranulins [180], amphoterin/HMGB1 
[181], lipopolysaccharide (LPS) [182], β amyloid [183], transthyretin [184], Mac-1 [185], 
complement 1q [186] and potentially DNA [182] and new ligands are regularly discovered. 
For many years, it was not understood how a single receptor was able to have such a vast 
array of seemingly unrelated ligands. However, this has partly been explained by numerous 
structural studies of RAGE, including more recent crystallography based studies that 
suggest that RAGE-ligand interactions are based on common structural features, rather than 
specific AA patterns. For example, Park et al. demonstrated that whilst s100B binds to RAGE 
via hydrophobic interaction occurring at very particular residues, AGE binding was likely due 
to the negative charge of AGE modified proteins which bind to large positive domains on the 
V domain of RAGE [182]. Further to this, glycation is known to disrupt the secondary 
structure of proteins making the structure around the site of glycation flexible, allowing them 
to bind to RAGE even where initial structural geometry may have prevented binding [187]. 
Whilst protein bound CML and CEL are known to bind RAGE, free AGE adducts such as 
CML and CEL do not [188]. Furthermore, it has been suggested that constitutive 
oligomerisation of the receptor at the cell membrane increases the binding affinity, ligand 
size and diversity of molecules it can bind (Figure 1-5) [189-191]. In line with this theory, it 
has been noted that many of the known ligands of RAGE, including AGEs, are also pre-
disposed to oligomerisation [192]. Further to this, Penfold et al. demonstrated that the 
majority of circulating RAGE ligands were HMW ligands (>50kDa). These ligands had the 
greatest RAGE binding and RAGE mediated signal transduction capacity compared to 
medium molecular weight (<30kDa) and low molecular weight (LMW) ligands [193].  
RAGE is considered a signal transduction receptor as AGE-RAGE binding has been found 
to initiate a number of signalling cascades in a process that requires the cytoplasmic domain 
of RAGE. RAGE-ligand binding induces signalling cascades (Figure 1-5) including mitogen-
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activated protein kinase (MAPK) [194-196], janus kinase/signal transducer and activator of 
transcription (JAK/STAT) [197, 198] and rho GTPases [199-201]. Further to this, RAGE 
ligand binding also elicits a response from transcriptional factors such as nuclear factor 
kappa B (NF-κB) [184, 202] and early growth response protein 1 (Egr-1) [203]. These 
pathways, activate a number of pro-inflammatory genes as well as chemotactic cellular 
migration, proliferation and apoptosis (Figure 1-5) [204]. These are in line with the known 
physiological role for RAGE in host-pathogen defence. 
Largely because of its pro-inflammatory signalling, RAGE has been implicated in a number 
of diseases including Alzheimer’s disease [205, 206], arthritis [207], and particularly diabetes 
and its associated complications. RAGE knock-out and over expression mouse models have 
extensively demonstrated the importance of this receptor in mediating diabetic 
complications and other diseases (summarised by Xie et al.) [204]. RAGE knock-out diabetic 
mice have improved renal injury compared to wild type (WT) diabetic mice [208-210].  
RAGE expression is likely modulated by environmental factors including AGEs [211, 212] 
and disease states such as diabetes [213, 214]. Interestingly, whilst increased levels of full 
length RAGE are associated with disease progression and poor outcomes [176, 213, 215], 
increases in the soluble forms correlate with improved outcomes. Increases in sRAGE were 
found in healthy elderly populations as compared with elderly patients [216]. Similarly, 
circulating esRAGE levels are strongly and inversely correlated with metabolic parameters 
such as BMI, triglycerides, HbA1c and insulin resistance index, as well as risk factors for 
cardiovascular disease [217]. Declining levels of sRAGE have been identified at the point of 
seroconversion in T1DM [218]. This evidence has led to the hypothesis that sRAGE may 
act as a competitive antagonist for AGEs, modulating their ability to interact with other 
receptors. Alternatively, sRAGE may provide a feedback mechanism to prevent AGEs 
binding to membrane bound RAGE and activating downstream signalling [219, 220]. This 
has been supported by animal studies that have conclusively shown that administration of 
sRAGE or esRAGE is protective or has positive outcomes in a number of disease states 
[213, 221-223].  
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As well as acting as a signal transduction receptor and potential decoy receptor for AGEs, 
RAGE has also been demonstrated to be involved in transportation of molecules. As an 
example, RAGE is implicated as one of the key mediators of αβ amyloid transport across 
the blood-brain barrier [224]. RAGE has also been localised to caveolae in a number of cell 
lines where it may play a role in intracellular uptake of AGEs [225, 226]. 
Figure 1-5. Isoforms of the receptor for AGEs (RAGE) and their interactions with AGEs and 
downstream pathways activated. 
RAGE is a multi-ligand member of the immunoglobulin superfamily of receptors. It can exist as many 
different isoforms including membranous isoforms (full length RAGE, dominant negative RAGE, N 
truncated RAGE) as well as soluble secreted and cleaved isoforms. These secreted isoforms are 
thought to act as decoys, binding to RAGE ligands and preventing them from binding to membranous 
forms of RAGE activating downs stream signalling. In a low AGE environment, circulating sRAGE is 
believed to act as a decoy receptor, binding circulating RAGE ligand such as AGEs and preventing 
binding to membranous isoforms of RAGE. In a high AGE environment circulating sRAGE levels are 
commonly decreased or sRAGE capacity is saturated and is no longer sufficient to prevent RAGE 
downstream signalling.  
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Factors regulating AGE accumulation and turnover in the body 
There are numerous factors thought to influence circulating and tissue AGE concentrations. 
The two main sources of AGEs in the body are: 1) endogenous production of AGEs, in which 
oxidative stress, reactive sugar/carbonyl availability (hyperglycaemia), metabolism and 
dietary factors play an important role; 2) uptake of exogenous AGEs, which can be taken up 
from the environment from sources such as food, beverages and smoking; with these two 
sources of AGEs being counterbalanced by AGE clearance mechanisms. Additionally, a 
classical twin study found that circulating AGE concentrations demonstrate heritability [227], 
suggesting genetics may influence circulating levels of AGEs. Taken together, these findings 
suggest that AGE concentrations in the circulation are regulated via specific mechanisms, 
which affect their uptake, and clearance.  
Endogenous production of AGEs 
Aside from the Maillard reaction, there are other well-characterised pathways that lead to 
endogenous AGE production. The auto oxidation of glucose and the peroxidation of lipids 
generate -oxoaldehydes which can subsequently react with monoacids to generate AGEs 
[228, 229] (Figure 1-4). The highly reactive dicarbonyls, MGO and 3-DG, are produced from 
fatty acid catabolism and anaerobic glycolysis [230], as well as catabolism of ketone bodies 
[231]. These act as potent glycating agents and contribute to excess production of AGEs 
endogenously (also shown in Figure 1-4). Hence, in states of metabolic stress, such as 
diabetes, there is excessive generation of endogenous AGEs.  
Under physiological conditions, AGE formation was traditionally thought to be most common 
on long lived proteins in the circulation and connective tissues [47]. As a result, many of the 
best studied targets of endogenous glycation are structural components of the basement 
membrane and long lived circulating proteins (globulin, immunoglobulins and albumin) [147, 
232]. However, conditions such as chronic inflammation, hyperlipidaemia and oxidative 
stress further accelerate the process of glycation, increasing the likelihood of short-lived 
proteins becoming AGE modified [233]. AGEs are also believed to interfere in protein 
turnover by impairing cellular proteolysis pathways and by rendering proteins more resistant 
to degradation [234]. This leads to the accumulation of AGE modified proteins in tissues and 
organs [235]. While certain conditions such as renal or hepatic impairment are associated 
with increased accumulation of AGEs [236-238], little is understood about the regulation of 
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AGEs during homeostasis in healthy metabolically normal individuals and how this is 
perturbed to contribute to risk for diseases such as diabetes and kidney disease. 
Exogenous AGE production –the diet and AGE homeostasis 
AGEs and their highly reactive precursors are also produced exogenously during food 
manufacturing. In particular, cooking and processing conditions favour AGE production, as 
well as being widely used in the food industry to improve flavour, shelf life, colour, aroma 
and texture [239]. High temperature, dry cooking methods (frying, baking and broiling) 
produce much higher concentrations than low temperature aqueous cooking methods such 
as steaming and boiling [240, 241].  
Quantifying AGEs in commonly consumed foods 
Several studies have aimed to estimate the amount of AGEs found in commonly consumed 
foods. Frequently food based AGE measurements are represented by concentrations of 
CML in biological studies, since it is considered a good marker of overall glycation and is 
known to interact with AGE receptors when protein bound. Hart et al. estimated daily dietary 
CML intake in low and high AGE iso-caloric diets to be approximately 10.6 mg and 24.6 mg, 
respectively [242]. Uribarri et al. measured the AGE content of 549 different foods where 
they showed that whilst products high in saturated fat contain the highest relative proportion 
of AGEs, cooked meat products probably contribute the most AGEs in the western diet due 
to portion size and relative AGE content [241]. More recently, researchers have questioned 
this data, due to the use of immunological methods for determining AGE content of foods, 
leading them to establish a database of CML, CEL and MG-H1 contents of commonly 
consumed European foods measured by UPLC MSMS, a more robust quantitative 
technique [243]. Based on their findings foods such as peanut butter, manufactured biscuits, 
canned and processed meats had the highest quantities of these AGEs ranging from ∼2 to 
∼5 mg CML, from ∼2 to ∼7 mg CEL and from ∼15 to ∼60 mg MG-H1 per 100mg of each 
product [243]. 
The effects of AGE modification on digestibility of food 
Several studies have also examined the effect of AGE modifications on the digestibility of 
food derived proteins. Finot et al. demonstrated that AGE modified peptides are digested 
less easily than their native counterparts [244]. Further to this, in a small study of 
adolescents, AGE modification to diet has been shown to negatively alter digestibility and 
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bioavailability of proteins [245]. In another study, the availability of AGEs after “simulated” 
digestion of either CML modified, fructolysine modified or lysinoalanine modified casein 
protein was examined [246]. Here, casein became less digestible as the number of AGE 
modifications increased. In contrast to these findings, however, a nitrogen balance study in 
rats found that the digestibility of a diet high in AGEs appeared to be the same as the low 
AGE control diet [247]. Despite the quantity of AGEs consumed from foodstuffs being far 
greater than the quantities of AGEs endogenously produced [248], there is conflicting 
evidence regarding their bioavailability and contribution to disease development and 
progression.  
Absorption of dietary AGEs 
While excess consumption of dietary AGEs may be pathological, it has been difficult to 
ascertain the mechanisms by which exogenous AGEs contribute to these disease states. 
There is much controversy regarding AGE trafficking across the gastrointestinal (GI) tract. 
Specifically, it is unknown whether the AGEs contribute to disease via direct entry into the 
circulation resulting in (i) tissue deposition and increased burden on clearance mechanisms; 
(ii) via changes in intestinal health, intestinal permeability and entero-endocrine signaling; 
(iii) through modulation of the microbiome, or (iv) through the promotion of inflammation in 
the GI tract. It is possible that all of these factors are acting in concert to promote the 
pathophysiology seen in the context of increased dietary AGE consumption. This is 
discussed further below. 
Generally, it is approximated that 10% of dietary AGEs are absorbed from the GI tract. These 
estimates are based on early studies using radioactively labelled AGEs [249] and urinary 
excretion of AGEs as measured by ELISA [250]. However, extensive analysis of the 
literature shows little consensus regarding the uptake of AGEs from the diet, with some 
studies suggesting greater uptake in humans [251], particularly in infants [252]. There have 
been many studies examining the uptake, kinetics, and bio-distribution of orally and 
intravenously administered AGEs and AGE precursors (summarised in Table 1). Yet despite 
this, there have been no approaches that can conclusively follow the passage of dietary or 
orally derived AGEs into the circulation and into organs and tissues in real time either in 
rodents or humans. Better techniques are required for real time and live imaging of AGE 
uptake, trafficking and kinetics to strengthen understanding of the link between dietary AGE 
and their associated pathology.  
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Table 1-1. Uptake, elimination and biodistribution studies of AGEs and their precursor Amadori products. 
Author Amadori 
Product 
Study 
Population  
Methodology  Key Findings  Measurement 
Technique 
[253] 
Erbesdobler and 
Faist, 2001 
Fructoselysine, 
Fructoseglycine  
Rats and 
Humans 
In vitro, everted gut sack, in vivo 
ligated jejunal segments 
1-3% of ingested Amadori products ended up in the 
urine; faecal output persisted for several days. 
14C Radioactivity 
[254] Forster et 
al.2005 
Pyrralline, 
fructoselysine, 
pentosidine 
Humans   Exclusion diet, followed by a test meal Low MRP diet, lowered urinary pyrralline and 
fructoselysine by 90%, and pentosidine by 40%. After 
the high AGE test meals, 50% of the ingested pyralline 
and 60% of pentosidine were recovered in the urine. 
Only 2% of peptide bound pentosidine was recovered. 
Reversed Phase 
HPLC with UV 
detection 
[255] Hultsch et 
al. 2006 
Fructoselysine Rats Injected and gavaged 18F 
flourobenzoylated fructoselysine- 
biodistribution and catabolism study 
performed using PET scanning 
Orally administered fructoselysine did not appear in the 
circulation or tissues. Injected fructoselysine rapidly 
appeared in the circulation and was cleared into the urine 
over the 60min time frame. 
PET scanning / 
Radioactivity 
counting 
[256] 
Schwenger et 
al. 2006 
Lactuloselysine Humans Diet administered to healthy, diabetic 
and renal failure patients. Plasma 
concentrations and cumulative urinary 
excretion was examined   
Lactuloselysine does not accumulate in the circulation. 
Only a minor acute increase (2% of the administered 
dose) appeared in the urine, plasma concentrations didn't 
change. 
Reverse Phase 
HPLC 
Author AGEs Study 
Population  
Methodology  Key Findings  Measurement 
Technique 
[257] Liardon 
et al. 1987 
CML Rats Rats fed diets varying in quantity of 
protein treated with alkali or heated 
with reducing sugars- timed urine 
collection and analysis for CML 
Found that urinary CML varied according to diet 
suggesting it came from exogenous sources. 
Mass Spec 
[250] 
Koschinsky et 
al. 1997 
Protein bound 
AGEs 
Humans 
(including 
diabetics w/wo 
diabetic kidney 
disease)  
Single meal challenge, AGE egg white 
or fructose +egg white 
Absorption estimated to be around 10% of total AGEs 
ingested. Renal excretion was around 30% of the total 
absorbed. Excretion was inversely correlated with 
albuminuria in DM patients and was found to be slower 
in DM patients.   
ELISA 
[258] Miyata et 
al.1998 
Pentosidine Rats Rats underwent intravenous injection 
with radiolabelled pentosidine, housed 
in metabolic cages and urine collected 
over 72 hours 
Radioactivity peaked 1hr after administration, 80% of 
radioactivity was recovered after 72hrs, however only 
20% was intact pentosidine. Reabsorption of pentosidine 
by proximal tubule after glomerular filtration. 
Radioactivity/ 
ELISA 
[249] He et al. 
1999 
AGE-
Ovalbumin (+/-) 
free glucose 
Rats Rats fed a single dose of 14C or 125I 
labelled AGE-Ovalbumin. Collected 
tissues, plasma and 72hr urine 
collection 
~10% of radiolabelled AGEs were absorbed. Many of the 
AGEs were still bound to peptides 
Radioactivity/ 
ELISA 
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[259] Bergman 
et al. 2001 
CML and CEL  
(free) 
Rats Biodistribution study of intravenously 
administered 18F labelled AGEs using 
PET scanning and radioactive counting 
CML and CEL accumulated in the liver & kidney at 
20min, were rapidly excreted into the urine and were 
undetectable by 2hrs. Small amounts of both 
accumulated in the spleen, pancreas, heart, lungs stomach 
and intestine. Estimated renal clearance of CML and 
CEL was 1.73ml/min and 3.09 ml/min respectively 
PET scanning 
[260] Somoza 
et al. 2006 
CML, LAL, 
FAL (Casein 
linked) 
Rats Casein linked AGE feeding (2 different 
dosages used) to metabolic caged 
rodents 
AGE-modified casein was absorbed less than the 
unmodified control.  CML modified casein demonstrated 
the highest recovery in the urine and faeces. Only CML 
impacted kidney and liver weight and urinary excretion 
of AGEs compared to the controls. Dietary CML had a 
large impact on circulating levels of CML with the high 
CML diet increasing plasma CML 5 fold. 
HP-LC-UV 
fluorescence  
[252] Sebekova 
et al. 2008 
CML Human infants Comparison of circulating AGEs 
between breast and formula fed infants 
Plasma CML was found to be 60% higher in formula fed 
infants than breast milk fed infants. 
LC-MS/MS 
[261] Roncero-
Ramos et al. 
2013 
CML Rats 88 days on a high AGE diet - Bread 
crust or it's insoluble (HMW) or 
soluble fractions (LMW)- faeces and 
urine collected during the final week. 
At cull serum and tissues collected 
Circulating CML didn't change between groups, urinary 
CML did not correlate strongly with diet. faecal 
excretion influenced by the diet. Examined CML in 
cardiac tissue, bone, and tail tendon. Increased CML in 
cardiac tissue and tail tendon but not in bone.    
HPLC-MS/MS 
[247] Alamir et 
al. 2013 
Extruded or non-
extruded protein 
diet CML 
Rats 6week feeding on extruded or non-
extruded protein diet or single oral free 
CML challenge 
Protein bound serum CML levels increased 4 fold after a 
single oral dose and remained high for the 4 hours 
monitored, Unbound CML remained unchanged. 
LC-ESI-MS/MS 
[262] Xu et al. 
2013 
CML (free) Mice Biodistribution and elimination study 
18F labelled CML in mice. Tracer 
labelled CML was administered either 
intravenously or intra-gastrically. 
Intravenously administered CML was quickly distributed 
in the bloodstream and cleared via the kidneys within 20 
min. CML was detected in a number of other organs.  
Intragastric administered CML showed minimal 
absorption. 
PET scanning 
[263] Tessier et 
al. 2016 
CML (protein 
bound) 
Mice 30 days feeding with a diet enriched 
with 13C-CML that could be 
differentiated from native CML in 
C57BL/6J and RAGE-/- mice. 
Mice showed accumulation of the dietary derived CML 
in all tissues analysed, but this was highest in the kidney, 
intestine and lungs and this appeared to be independent 
of RAGE 
Stable isotope 
dilution analysis 
LC-MS/MS 
[264] Tsutsui et 
al. 2016 
AGE-Albumin Mice Single intravenous injection of Cy 7.5 
labelled AGE-BSA. Fluorescence 
kinetics assay was performed.  
Injected AGE-BSA showed strong localisation to the 
liver and impaired clearance compared to BSA. AGE-
BSA co-localised with scavenger cells of the liver. 
IVIS whole animal 
in vivo imaging 
system 
Abbreviations: BSA, Bovine Serum Albumin; ELISA, Enzyme Linked Immunosorbent Assay; HPLC, High Performance Liquid Chromatography;  IVIS,  In 
Vivo Imaging System; LC- MS/MS, Liquid  Chromatography Mass Spectrometry; LC-ESI-MS, Liquid Chromatography-Electrospray Ionization Mass 
Spectrometry;  PET, Positron Emission Tomography 
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AGE clearance 
Another major factor regulating the homeostasis of AGEs is their clearance from the body. 
At the tissue level this occurs through cellular proteolytic systems, which endocytose the 
AGEs and break them down via receptor mediated and non-receptor mediated pathways 
into AGE peptides, which are then released back into the circulation [265]. At the systemic 
level, clearance of AGEs is thought to occur via the liver and the kidney, where clearance of 
not only AGEs but AGE precursors, reactive carbonyl precursors such as MG-H1, 3-DG and 
glyoxal is important to maintain homeostasis of circulating AGE levels. This is suggested by 
several different studies. The first evidence comes from studies in humans that show AGE 
levels inversely correlate with renal function and creatinine clearance [233, 237, 266, 267].  
An early study in rats suggested that AGEs are filtered by the glomeruli, reabsorbed by 
proximal tubule cells and further processed and cleared into the urine [258]. However, as 
only one AGE (pentosidine) was used, and it does not bind to RAGE, this study is limited in 
scope. Nagai et al. showed that whilst highly modified AGE-BSA administered intravenously 
was largely cleared through the liver (60%), minimally modified AGE-BSA remained in the 
circulation for a significant duration, similar to that of unmodified BSA [268]. As discussed 
above, several of the AGE receptors appear to be involved in this clearance and 
homeostasis mechanism, however the mechanism and network of AGE handling is yet to 
be fully elucidated. Given their roles in AGE clearance, the liver and kidney have been 
highlighted as important sites of AGE mediated pathology [89, 269-276].  
AGE mediated pathology 
AGE mediated pathology appears to occur in two ways. Firstly, deposition of AGEs in tissues 
and the crosslinking of structural proteins can impair both tissue and cellular function. For 
example, collagen deposition and crosslinking of extracellular matrix proteins leads to 
structural alterations including changes in packing density [277] and surface charges [278]. 
This results in stiffening of the vasculature and expansion of the basement membrane in 
diabetes and CKD. Secondly, interactions of AGEs with receptors such as RAGE activates 
signal transduction cascades and the activation of pro-inflammatory pathways, cytokine 
expression and inappropriate growth factor expression [47, 279, 280], as described above. 
As well as the micro- and macrovascular complications of diabetes, AGE pathology is 
associated with many other chronic diseases including Alzheimer’s disease, 
atherosclerosis, ESRD, cataracts, Parkinson’s disease, sarcopenia, vascular dementia and 
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aging [145, 281]. Hence, understanding what regulates these molecules in the body is also 
important for a number of pathologies beyond kidney disease. 
AGEs in glucose control and insulin resistance 
Beyond these clearly established pathways of AGE mediated pathology AGEs appear to 
effect glucose homeostasis and insulin resistance, both of which are potent risk factors for 
progression to CKD. In animal models, increasing circulating AGEs [282, 283] and diets high 
in AGEs [284-287] irrefutably result in decreases in insulin sensitivity independent of 
macronutrient uptake and other dietary factors [211, 287]. While in humans several studies 
have demonstrated a relationship between high AGE diets and insulin signalling defects 
[242]. Vaaler et al. and Rizkalla et al. have both demonstrated acute changes in insulin 
secretion following high AGE meal challenges [288, 289].  
Although the role of AGEs in insulin resistance and glucose homeostasis is well 
documented, the mechanism is not fully understood. In vitro, AGE exposure induces insulin 
resistance in adipocytes and skeletal muscle cells [290, 291]. Cassese et al. also 
demonstrated RAGE may be involved, showing that glycated human albumin increased co-
precipitation of RAGE, Src tyrosine kinase and (protein kinase Cα) PKCα, demonstrating a 
direct interaction between RAGE, PKC and subsequently insulin receptor 1 (IRS1) [292]. 
This interaction was increased in a time dependent manner in response to AGE modified 
albumin. Our group have also demonstrated that AGE exposure applied to pancreatic islets 
and beta cells induces mitochondrial dysfunction associated with impaired insulin release 
[286]. These results potentially highlight a physiological role for AGEs in regulating glucose 
homeostasis and insulin resistance, that likely represents another pathway by which AGEs 
mediate pathology in chronic disease, although the full mechanism remains to be elucidated.  
Dietary AGEs and AGE pathology 
The contribution of dietary AGEs to AGE related pathologies remains to be fully elucidated. 
The best evidence that dietary AGE content contributes to the pathophysiology of AGE 
related conditions is observed in animal studies. Here, chronic feeding or administration of 
AGEs induces disease or exacerbates existing disease pathology. In preclinical studies in 
rodents, chronic dietary exposure to excess CML results in renal disease [293], insulin 
resistance [287, 294], and insulin secretory defects [286, 295]. This includes insulin 
resistance in wild type and Type 2 diabetic mouse models, where excess AGE dietary 
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consumption elevates fasting plasma glucose levels, and worsens proteinuria and kidney 
pathology [272, 296, 297] and liver injury [269]. Conversely, low AGE diets can prevent 
T1DM when administered to pregnant and weaning mothers in the NOD mouse model of 
T1DM [298] and attenuate insulin resistance; improve vascular and renal outcomes [274, 
284] and wound healing [299] in diabetic models.  
In humans, there is a paucity of data directly implicating dietary AGEs in disease, however 
many benefits have been shown with AGE restriction in the diet. In individuals with T2DM 
and renal failure, excessive AGE intake positively correlated with serum biomarkers of 
oxidative stress, inflammation, endothelial dysfunction, hyperglycaemia and hyperlipidaemia 
[300, 301]. Conversely, dietary AGE restriction studies in healthy individuals and those with 
T2DM have demonstrated favourable outcomes regarding circulating 8-isoprostanes and 
TNFα [302, 303] along with improvements in insulin sensitivity [302, 304]. Additionally, our 
group, in two independent randomised crossover studies, following a two week high and low 
AGE dietary protocol in overweight but otherwise healthy individuals has found that low AGE 
diets improve insulin sensitivity [305], and renal function [272]. 
AGEs and kidney disease 
The link between AGEs and CKD 
As the kidney is a major site of AGE clearance from the body, the relationship between 
kidney function, AGEs and AGE mediated renal pathology is an important one. As 
highlighted above, several studies demonstrate an increase in circulating AGEs with 
progressive decline in renal function, in both the presence or absence of diabetes [266, 306, 
307]. Additionally, AGEs also show a positive association with markers of inflammation and 
oxidative stress in uremic patients [308]. Moreover, elevated circulating concentrations of 
sRAGE associates with incidence of DKD [309] and CKD [310, 311]. In the ADVANCE study, 
a cohort of 3763 patients with T2DM both circulating AGEs and sRAGE were both positively 
associated with incident CKD, progressive CKD and mortality, leading researchers to 
propose that the AGE:RAGE axis may represent an important target for the prevention and 
management of diabetic nephropathy [312]. However, a recent prospective analysis of 
samples collected over 22 years of follow up, from the Wisconsin Epidemiologic Study of 
Diabetic Retinopathy (WESDR) in patients with T1DM, failed to replicate this relationship 
[309], reporting that only circulating sRAGE was associated with incident DKD, not CML. 
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Where changes in skin collagen fluorescence have been used to examine the relationship 
between endogenous AGE production and renal function, the results also show clear 
associations. Skin collagen fluorescence is significantly increased in CKD patients without 
diabetes [313-315] and as a biomarker, predicts those individuals with progressive CKD 
[313, 316]. In individuals with diabetes and established CKD, increased skin auto 
fluorescence is also inversely associated with eGFR [151, 152] and positively associated 
with increased incidence of CKD [152] and mortality [317]. In the Diabetes Control and 
Complications Trial (DCCT), a longitudinal clinical follow up of patients with T1DM, and its 
continuation, Epidemiology of Diabetes Interventions and Complications (EDIC), skin 
collagen CML concentrations predicted individuals who developed nephropathy and 
cardiovascular disease, [156, 318] and this was reported to be independent of glycaemic 
control.  
It is difficult to determine whether this increase in the body’s AGE concentrations is merely 
due to reduced renal clearance capacity or an increase in factors that accelerate and 
promote the endogenous production of AGEs. In vitro, AGEs (CML and pentosidine) and 
reactive precursors form more rapidly and to significantly greater levels in serum from uremic 
patients compared to serum from normal healthy controls [319]. This suggests that 
circulating factors that promote or stimulate the rapid formation of AGEs are present in the 
bloodstream of individuals with reduced renal function. Furthermore, as alluded to above, 
dietary AGEs exacerbate defects in glucose homeostasis and insulin resistance, increase 
inflammation and risk of cardiovascular disease, all of which are major risk factors for CKD. 
In patients with ESRD receiving renal replacement therapy via either haemo- or peritoneal- 
dialysis circulating CML and methylglyoxal levels are well above those of healthy controls 
[320], since dialysis does not effectively remove AGEs. Furthermore, in early CKD, a 
decrease in circulating AGEs might actually be an indicator of hyperfiltration, particularly in 
early DKD. This was demonstrated in a prospective study of patients with T1DM, which 
showed increased urinary CML clearance and a concordant decrease in circulating AGE 
concentrations present during hyperfiltration in early DKD. This was associated with future 
rapid GFR decline [161]. In agreement, another cross-sectional study in individuals with 
diabetes found that elevated urinary protein-bound AGEs were associated with worsening 
CKD [321]. However, it remains unclear as to whether AGEs are symptomatic of impaired 
renal clearance in CKD, or whether the accumulation of total body AGEs and/or exogenous 
AGEs derived from the diet are driving CKD. Taken together, these data suggest that 
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increases in circulating, tissue and urinary AGEs, are potent independent risk factors for 
progressive CKD. Further, studies must be interpreted carefully as circulating AGE levels 
may decrease early in disease due to increased clearance into the urine during 
hyperfiltration, which is likely a homeostatic mechanism to combat increasing accumulation 
of AGEs in the organs and tissues [1].  
Mechanisms by which AGEs damage the kidney 
AGEs mediate kidney damage in much the same way as they mediate damage in other 
tissues, as discussed above. Cross linking of matrix proteins leads to stiffness and altered 
structural function at sights such as the glomerulus, the peritubular vasculature and 
arterioles of the kidney, promoting glomerulosclerosis, atherosclerosis and thickening of the 
basement membrane [144]. AGE interactions with the membrane forms of RAGE, abundant 
in the kidney, lead to activation of NF-B and JAK-STAT pathways, promoting inflammation 
via IL-1 and TNF pathways [166, 322]. AGE-RAGE binding also stimulates NADPH 
oxidase and production of mitochondrial derived ROS [208, 213], leading to the induction of 
cytokines including monocyte chemoattractant protein (MCP-1), transforming growth factor 
(TGF-1), connective tissue growth factor (CTGF), and vascular endothelial growth factor 
(VEGF) [323-328]. These aforementioned pathways have been well described in the 
development and progression of diabetic complications in both humans and pre-clinical 
models.  
Renal handling and clearance of AGEs  
Given DKD is characterised by podocyte damage and loss, significant focus has been paid 
to studying the effects of AGEs on podocytes. Protein-bound AGEs have been 
demonstrated to enter podocytes in vitro, where they induced hypertrophy and markers of 
necrosis [329] and apoptosis via an AGE-RAGE mediated, FOXO4 dependent pathway 
[330]. In vivo uptake and trafficking studies in healthy rats show intravenously injected low 
molecular weight AGE-peptides, but not AGE-BSA, are freely filtered at the glomerulus and 
detected in urine [331]. However, both in vivo and in vitro data suggests that once filtered, 
both free and protein bound AGEs bind to and/or enter proximal tubule cells [258, 331-334], 
where their removal is dependent on lysosomal degradation and autophagy [335]. In vitro, 
renal proximal tubule cells can degrade AGE-modified albumin. However, exocytosis of 
glycated albumin peptide fragments was slow compared to non-glycated fragments. This 
suggests that processing of AGE modified proteins by the renal tubule was impeded by 
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glycation [333]. Ultimately this led to increased accumulation of AGEs within proximal tubule 
cells, disrupting the autophagosome lysosomal pathways [336]. Supporting this, ingestion 
of radioactive-labelled AGEs for five days in healthy rats followed by a 3-day washout period 
increased the tissue burden of AGEs, including within the kidney [249]. Furthermore, Tessier 
et al., showed that the kidneys were amongst those organs with the highest levels of dietary 
AGE accumulation following 30 days on an 13C-CML-BSA enriched diet [263]. Overall, it 
appears that the transport of free- and/or protein-bound AGEs across the renal filtration 
barrier and tubular cells may depend on the protein size and degree and site of glycation. 
Exogenous AGEs and kidney function 
There is a paucity of studies examining the longitudinal effects of high AGE consumption on 
risk of kidney disease. However, one prospective study using dietary questionnaires has 
demonstrated a two-fold increase in risk of developing CKD with high AGE consumption 
[337]. Similarly, studies in humans examining the effects of dietary AGEs on direct measures 
of renal function are also lacking, particularly with kidney function as a primary end point 
[338]. In overweight individuals without diabetes, a randomised cross-over study showed 
that increased AGE consumption for two weeks increased systemic inflammation, 
albuminuria and decreased eGFR while increasing AGE clearance into the urine and 
paradoxically reducing circulating levels [272]. In agreement, several studies have 
demonstrated a significant effect of dietary AGEs on other determinants of kidney disease 
such as endothelial dysfunction and oxidative stress, both risk factors for CKD. Acutely, a 
single oral AGE challenge induced endothelial dysfunction, and oxidative stress, in healthy 
individuals and in those with diabetes [339]. Similarly, both a two- and six-week dietary 
intervention, in individuals with diabetes, resulted in higher detectable levels of inflammatory 
mediators within peripheral leukocytes, compared to a diet that was five-fold lower in AGE 
content [340]. However, another study in healthy adults fed either a low or high AGE diet, 
did not show any differences in endothelial function or markers of inflammation, although 
the low AGE diet did reduce serum and urinary CML [341]. Similarly, in overweight but 
otherwise healthy adults, a two week crossover designed study designed to determine the 
effect of high or low AGE diets on inflammation and cardiovascular risk factors, found no 
effect of their dietary interventions on numerous markers of inflammation, blood pressure, 
cholesterol or triglycerides [342]. One possible explanation for the lack of effect seen in 
these studies was that the AGE content of the high AGE diet was similar to that of a typical 
Western diet and may have been comparable to the patients’ diets at baseline. By contrast, 
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when young, healthy university students underwent four weeks of high AGE dietary 
consumption as part of a randomized cross-over study, this not only increased circulating 
and urinary CML levels but also elevated plasma cholesterol and triglycerides. Decreases 
in insulin sensitivity were also seen in the high AGE group as compared to the low AGE 
dietary intervention group in these healthy young adults [304].  
In animal models, significantly more work has been undertaken to measure the direct effects 
of AGEs on the kidney. In healthy rats, five months of chronic intravenous administration of 
AGE-RSA resulted in albuminuria and glomerular structural injury, that were ameliorated by 
co-treatment with the AGE cross-link breaker, aminoguanidine [293]. Also in healthy rats, 
subcutaneous administration of AGE-RSA for four weeks increased renal hypertrophy and 
decreased GFR as well as components of the renin angiotensin system. Although it did not 
alter albumin excretion [343]. Similarly, four months of daily intraperitoneal AGE-RSA 
administration to healthy rats resulted in impaired complex 1 function in the mitochondria of 
the renal cortex, however it did not affect GFR or UAE [208]. Given all these studies 
delivered exogenous AGEs into the body directly, by injection, it is difficult to determine 
whether the effects are comparable to the consumption of AGEs as part of the diet. In 
healthy or 5/6th nephrectomised rats, a diet high in AGE content for six weeks, increased 
proteinuria, although GFR remained unaffected [297, 344]. A more recent study following a 
four week high fat (390g/kg lard) baked high AGE diet in healthy rats however, did observe 
increases in serum creatinine suggestive of decreased GFR, which was also associated 
with enhanced kidney CML deposition, and increased markers of oxidative stress and 
inflammation [345].  
Although few studies have directly assessed the impact of AGEs on renal function, the 
majority show significant effects of dietary derived AGEs on risk factors for kidney disease. 
However, as highlighted above, there is still much to be untangled regarding whether these 
changes are actioned via uptake and trafficking of AGEs from the diet to the kidney, are 
driven by other risk factors and mediated through other organs exacerbated by dietary AGEs 
or whether they are driven indirectly by interactions with the GI tract, enteroendocrine 
systems and the microbiome.  
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Summary and rationale for this thesis  
Despite many years of research, we are yet to fully understand the contribution of dietary 
factors to our global CKD burden. In this thesis, I have examined two aspects of a modern 
diet which could influence risk for CKD. Firstly, I specifically examine dietary factors which 
influence Advanced Glycation End Product homeostasis within the body using various 
approaches. Secondly, I examine specific dietary macronutrient intake and how varying the 
proportions of these in the diet influences renal function and structure over the long term. 
Characterising the impact of these two easily manipulated dietary components to CKD risk 
will help to guide research in this field, inform policy and public and scientific discourse 
around diet and food regulation.  
Chapter Aims 
Chapter 2: Bio-distribution of ingested AGEs implications for kidney and 
metabolic health. 
Rationale: In pre-clinical models, excess consumption of dietary derived AGEs induces 
kidney disease including clinical markers such as proteinuria, albuminuria and renal 
oxidative stress. In humans dietary AGE consumption is also associated with increased risk 
of CKD. Despite this, studies assessing the gastrointestinal uptake and trafficking of AGEs 
are limited. Furthermore, studies to date do not allow assessment of the size and structure 
of absorbed AGE products making it difficult to assess the bioavailability and bioactivity of 
absorbed dietary AGEs. Therefore, a method for imaging the uptake and trafficking of AGEs, 
suitable for acute trafficking and compatible with multiple macroscopic and microscopic 
imaging platforms and compatible with SDS-PAGE is warranted. 
Primary Aim: To develop a protocol to better understand acute AGE uptake, trafficking and 
kinetics following and dietary AGE-bolus and evaluate direct renal handling of ingested 
AGEs.  
1. To use this protocol to determine if dietary AGEs are able to be absorbed across the 
gastrointestinal epithelium into the circulation following ingestion. 
2. To study the acute kinetics of dietary absorption and trafficking of AGEs into the 
circulation in the hours following ingestion. 
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3. To determine the organs and tissues that orally absorbed AGEs traffick to in the hours 
immediately following ingestion.  
Chapter 3: The effects of dietary AGEs on postprandial glucose homeostasis 
and eating behaviour. 
Rationale: Metabolic function, and glucose control are potent risk factors for CKD, 
independent of diabetes, particularly post-prandial glucose excursions. Consumption of a 
high AGE diet in pre-clinical models is associated with impaired insulin secretion and 
sensitivity and elevated fasting blood glucose levels. Despite this, little work has been done 
to characterise the effects of acute AGEs ingestion on postprandial glucose homeostasis 
and insulin secretion in vivo. Furthermore, little work has been done to examine if AGE 
content of the diet alters feeding behaviour and gross metabolism in pre-clinical models.  
Primary aim: To characterise the acute and long term effects of AGEs on gross metabolism 
and glucose homeostasis. 
1. To determine how AGE modification of dietary protein affects glucose homeostasis 
following an acute oral AGE modified or unmodified protein bolus.  
2. To examine whether the glucose and insulin responses to an acute AGE bolus are 
dose dependent. 
3. To delineate how consumption of a high AGE diet affects gross metabolism, and 
feeding behaviour using the Phenomaster system for indirect calorimetry.  
Chapter 4: Endogenous AGE and RAGE production in response to oral and 
intravenous glucose loads in individuals with recently diagnosed Type 2 
diabetes. 
Rationale: Endogenously synthesized AGEs are significant contributors to the body’s AGE 
burden and impact risk for CKD, particularly in patients with diabetes. Both diabetes and 
impaired blood glucose control directly impact upon endogenous AGEs such as HbA1c and 
circulating CML-albumin. Despite this, how post prandial glucose excursions acutely affect 
circulating concentrations of AGEs and their receptor sRAGE following ingestion is poorly 
understood. Furthermore, the role of the gastro-intestinal system and handling of glucose 
within the gut has not been explored in this context.  
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Primary Aim: To characterise serum CML and sRAGE levels in response to escalating blood 
glucose excursions in patients with Type 2 diabetes mellitus (T2DM) and matched controls. 
To determine whether removing the influence of the GI tract by infusing glucose impacts 
circulating AGEs and sRAGE.  
1. To determine circulating CML and sRAGE levels over 4 hours during a standard 25g, 
a 75g and a 125g oral glucose tolerance test or matched intravenous glucose infusion 
in healthy participants and patients with T2DM.  
2. To study the influence of the gastrointestinal versus intravenous administration of 
glucose on AGE homeostasis in healthy individuals and patients with T2DM.  
Chapter 5: Using nutritional geometry and a geometric framework to explore 
the contribution of macronutrient consumption to kidney structure and 
function. 
Rationale: Although the role of macronutrients and caloric intake in driving kidney disease 
has been explored previously, researchers have focused on a single macronutrient in 
isolation. No research has been conducted to ascertain the combined and/or synergistic 
effects of fat carbohydrate and protein as well as energy density on risk factors for CKD. 
The emerging field of nutritional geometry has been recently applied to the study of cardio-
metabolic diseases of ageing using a murine geometric platform directly examining the 
effects of macronutrients and caloric intake [346]. This offers a new platform in which to 
explore the role of diet in driving kidney disease. 
Primary Aim: To determine the impact of different fat, carbohydrate and protein ratios 
consumed over a lifetime up to middle age on structural and functional markers of kidney 
disease in C57BL/6J mice.  
1. To determine whether macronutrient composition alone or in concert with net caloric 
consumption is sufficient to induce renal pathology and dysfunction in C57BL/6J mice 
at middle age.  
2. To examine whether sex differences occur in the kidney in response to the 
macronutrient composition of the diet, consumed over a lifetime to middle age. 
3. To determine if changes in kidney function with specific macronutrient combinations 
aligns with the development of known risk factors for CKD. 
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Chapter 2: Bio-distribution of ingested AGEs and the 
implications for kidney and metabolic health. 
Abstract 
Background & Objective:  
Advanced Glycation End Products (AGEs) are post translational modifications to proteins 
commonly seen in western diets. AGEs are known to affect glycaemic control and to be pro-
inflammatory. Despite this, little is known about gastrointestinal absorption of AGE modified 
proteins from the diet and their subsequent trafficking. We therefore aimed to determine this 
using a near infrared (IR) labelled AGE-modified model protein.  
Research Design and Methods:  
A pilot study examining the uptake and trafficking of near infrared tagged AGE modified 
proteins was conducted. AGE-modified bovine serum albumin (AGE-BSA) and unmodified 
BSA (66kDa protein) were labelled with a near infrared (IR) tag. Adult C57BL/6J mice were 
orally gavaged with near IR AGE-BSA (IR-AGE) or near IR tagged BSA control (IR-BSA), 
both delivered at 5 mg/kg bolus, (n= 8 mice/group). Control mice received IR-dye only or 
water (n= 2 mice/group). Plasma was collected from each mouse over 8 hours following 
gavage and uptake into the circulation was imaged on the LI-COR Odyssey. A second pilot 
was undertaken to determine tissue uptake. Adult C57BL/6J mice were orally gavaged with 
IR-AGE or IR-BSA control (5 mg/kg bolus, n= 3 mice/group). Plasma urine and tissues were 
collected at 15 minutes, 1, 4 and 8 hours post-gavage and imaged on the LI-COR Odyssey 
after SDS-PAGE.  
Results:  
Fifteen minutes post-bolus, 60% of mice in both BSA and AGE-BSA groups presented with 
a 66kDa band in plasma (6.00, IQR: 6.3 RFU vs 2.34, IQR 5.4 RFU; respectively (as 
determined by densitometry)). This is equivalent to the molecular weight of intact BSA. No 
intact IR proteins were observed in plasma at 1 and 4 hours, with the exception of a single 
mouse. However, by 8 hours post-gavage, a 66kDa band had reappeared in the circulation 
in 30% of mice from both the AGE-BSA and the BSA groups. We also found intact AGE-
BSA (66kD) and the control BSA (66kD) in the liver and duodenal tissues at 15 min after 
36 
 
gavage in 30-60% of mice receiving these. Small bands equivalent to proteins, cleavage 
products or IR dye complex <15kDa were also present in these tissues. Both the urine and 
kidney tissue contained cleavage products, ~30kDa and <15kDa at all time-points when 
compared with water only controls. 
Conclusions:  
These data suggest that intact AGE-modified BSA may enter the circulation within 15 
minutes of ingestion, traffic to tissues and later reappear in the circulation at 8 hours. The 
presence of intact AGE-modified BSA in the circulation and some tissues is important as 
large AGE modified proteins are believed to be more potent inflammatory agents.  
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Introduction  
Advanced Glycation End Products (AGEs) are a group of compounds formed by the non-
enzymatic combination and rearrangement of reducing sugars or aldehydes with the free 
amino groups of proteins, lipoproteins and DNA [347]. The term AGEs represent a whole 
spectrum and ever growing list of heterogeneous chemical outcomes of glycation chemistry 
including glucose derived AGEs such as CML, CEL, pyralline, pentosidine, more complex 
crosslinking AGEs such as MOLD, GOLD and DOLD and the lesser studied fructose derived 
AGEs such as fructoselysine. Additionally, AGEs can exist both as modifications on large 
complex proteins such as glycated albumin or casein, on smaller peptides or as free AGEs 
with a single glycated amino group.  
AGEs can form under physiological conditions in the body and have significant capacity to 
promote oxidation and inflammation in the body [348, 349]. As such, AGEs have been 
implicated in the pathogenesis of a number of diseases, including but not limited to renal 
and cardiovascular complications of diabetes [47], kidney disease [275], metabolic 
syndrome [47], liver diseases [350, 351], Alzheimer’s disease [352], amyotrophic lateral 
sclerosis [353, 354] and Parkinson’s disease [355]. In patient cohorts, increasing AGEs in 
the circulation predicts renal functional decline, even in the absence of diabetes [266, 306, 
307], and skin auto-fluorescence, a marker of AGE accumulation in tissues, accumulates in 
chronic kidney disease [313-315] and also predicts a reduction in eGFR and progression to 
CKD [313, 316, 356]. Furthermore, in preclinical models, AGE lowering therapies appear to 
alleviate markers of renal dysfunction and disease [357, 358].  
AGEs are not only produced physiologically through pathways in the body, but are also 
produced in food, during cooking and food processing [142]. In particular, they are formed 
by sterilisation and other processes which prolong shelf-life or impart other functional 
properties to manufactured foods, such as emulsification or flavour enhancement. Cooking 
methods such as toasting, frying, baking or broiling also increase the AGE content of food 
[359]. Due to the increasing reliance on food processing and increasing consumption of pre-
packaged and fast foods, dietary consumption of AGEs has risen dramatically in the last 
100 years [360]. However, the question has remained, do dietary AGEs contribute to the 
circulating pool of AGEs and to the AGE-related pathologies discussed above?  
In animal models, prolonged consumption of high AGE diets decreases fasting plasma 
insulin concentrations [286], increases inflammation [211], induces or exacerbates renal 
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dysfunction [274, 297, 344] and can be an environmental trigger of non-alcoholic fatty liver 
disease [269]. By contrast, dietary restriction of AGEs in models of diabetes reduces 
adiposity, attenuates hyperinsulinemia and increases in plasma HDL [284] in association 
with amelioration of complications, such as atherosclerosis [361], nephropathy [274] and 
impaired wound healing [299]. In humans, there have been limited studies. However, 
reduction of dietary AGEs has been reported to suppress inflammation [340, 362], improve 
lipid peroxidation [362, 363] and decrease glycation of low density lipoproteins [340, 363] in 
individuals with diabetes. In non-diabetic cohorts, two randomised controlled crossover 
studies both showed reduced insulin sensitivity on high AGE diets, with improved insulin 
sensitivity shown while on a low AGE diet [304, 342]. Importantly, even a single acute oral 
AGE challenge can rapidly induce rapid changes in clinical markers of endothelial 
dysfunction, an early precursor of vascular complications in diabetes [339].  
While previous data suggests that high dietary AGE consumption is pathological, it has been 
challenging to determine whether AGEs from the diet are directly passing into the circulation 
to elicit effects rather than having localised effects in the gut. Studies simulating digestion, 
suggest that some AGEs such as CML are available for absorption after digestion [246] and 
studies in humans and animals clearly show a positive relationship between urinary 
excretion of CML and dietary intake [257, 364]. Additionally, several animal studies have 
demonstrated increases in CML in organs and tissues following high dietary AGE 
consumption [261, 364-367]. In humans, associations have also been documented between 
dietary AGE intake and circulating AGE concentrations [300, 302, 340, 368]. Acute 
administration and short term studies demonstrate post-prandial increases in circulating and 
urinary excretion of AGEs following ingestion of a high AGE meals as compared to a meal 
with lower AGE content [250, 254]. While in the longer term, well controlled randomised 
crossover studies of high and low AGE diets (2-4 weeks) in non-diabetic individuals, using 
gold standard methodologies also show increased circulating or urinary AGEs following at 
least two weeks on a high AGE diet [304, 305]. Although the results of these studies are 
compelling, none of these studies conclusively show that these circulating or urinary AGEs 
originate from the diet. Indeed, it may be that the changes in glucose homeostasis shown 
with excess dietary AGEs consumption are responsible for the endogenous synthesis of 
AGEs, modifying circulating and urinary concentrations without absorption of ingested 
dietary AGEs. 
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All studies to date examining the uptake and elimination of dietary AGEs show incomplete 
elimination of these products into the urine and faeces. This suggests possible retention of 
dietary AGEs in organs and tissues within the body. To address this, a small number of 
studies have tracked specifically “labelled” AGEs in animal models. Pioneering work in this 
field, He et al. fed radioisotope (14C, 125I) containing AGE modified ovalbumin as a single 
meal challenge to rats, showing uptake into liver, kidney, spleen and lung [249]. However, 
as these were the only tissues examined, these studies do not rule out the uptake of AGEs 
at other sites. In more acute trafficking studies, a LMW CML derivative was synthesised 
using fluorine-18 (18F) and bio-distribution was studied by PET/CT [262, 369]. However, in 
both studies, very little of the 18F-CML product was absorbed from the GI tract, less than 
previous studies, suggesting that the 18F-CML was not absorbed in proportion to dietary 
CML. More recently, Tessier et al. used a 13C containing CML-BSA added to the diet of wild 
type and receptor for AGEs knock out (RAGE KO) mice [263]. Following 30 days on this 
diet, using a technique that could discriminate between CML of dietary origin and 
endogenously produced CML, they identified dietary CML in all major organs except within 
the adipose tissue. Interestingly CML accumulation was independent of the receptor of 
AGEs, RAGE.  
Although these studies have answered many important questions about the uptake and bio-
distribution of AGE modified proteins from the diet, none to date offer a technique to study 
the macroscopic and microscopic distribution of orally ingested AGEs. Furthermore, the 
majority of studies do not comprehensively explore the size of the resulting absorbed AGE-
protein products after digestion by the GI tract. Therefore, a selective and sensitive labelling 
technique to enable tracking of trafficking of AGE-modified proteins following ingestion is 
required. Here, I describe a series of pilot experiments assessing the functionality of using 
a near infrared tag to label AGE modified BSA (AGE-BSA) and control unmodified BSA and 
follow the uptake and bio-distribution of these labelled proteins into organs and tissues 
following intra-gastric delivery. 
Challenges associated with this chapter 
This chapter was initially intended to include the real-time trafficking of radiolabelled 64Cu- 
orally ingested AGEs in live mice, using PET/MRI scanning at the Centre of Advanced 
Imaging (CAI) at the University of Queensland and which globally would have been the first 
study of this kind. It also included radiolabels 18F and 64Cu that could be readily translated 
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to human studies. Ethics for this study was approved and a detailed research proposal 
worked up with the CAI. However, we encountered significant hurdles in obtaining the 
isotope labelled AGEs where the biggest issue pertained to the limited time of the 
radiochemist to prepare these for the project. Despite significant time investment from our 
side, this meant that progress was very slow and it became evident by the mid candidature 
milestone that progressing this further was not feasible during the candidature of this PhD. 
We therefore changed our research focus to use the near infrared label discussed further in 
this chapter. Although a useful strategy, the sensitivity of this label for real life imaging to the 
detail we required was limited which is further discussed in the chapter below. 
 
Aims and Hypothesis 
Aim 1: To develop a protocol to label AGEs, such that they that can be both detected in vitro 
and in vivo at the macroscopic and microscopic level. 
Aim 2: To determine the acute kinetics of dietary absorption and trafficking of AGEs into the 
circulation in the hours following ingestion. 
Aim 3: To determine the organs and tissues that orally absorbed AGEs traffick to in the 
hours immediately following ingestion.  
Aim 4: To determine whether dietary derived AGEs disproportionately accumulate in the 
kidney post ingestion.  
Hypotheses: 
1. AGE modified proteins will be trafficked less efficiently across the GI tract than unmodified 
proteins. 
2: AGE modified proteins will traffick to the liver and kidney where they will accumulate, 
demonstrating impaired clearance from these sites. 
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Methods 
Preparation of the AGE-BSA and control BSA 
Albumin is the most common circulating protein in the body and is commonly consumed in 
any diet that contains animal products such as meat and eggs. Hence, AGE modified 
albumin (AGE-BSA) and control albumin (BSA) were prepared as described previously 
[286]. Briefly, essentially fatty acid free BSA (50 mg/ml; Sigma Chemical, St. Louis, MO, 
USA) was incubated for 30 days at 37ᵒC in the presence and absence of 0.5 mol/L D-
glucose (Life Technologies, Waltham Massachusetts, USA). The resulting product was 
dialysed with sterile PBS and tested for the presence of endotoxin using the LAL method. 
The relative quantities of the AGEs carboxymethyllysine (CML) carboxyethyllysine (CEL) 
and methylglyoxal derived hydroimidazolone (MG-H1) were quantified using UPLC-MSMS 
by collaborators at Maastricht University, Netherlands using the method described 
previously [370].   
Near infrared (IR) labelling of AGE modified and control protein 
 
Figure 2-1. Schematic of the near IR labelling protocol. 
AGE modified BSA and control BSA stocks (50mg/ml) were labelled with 800CW NHS ester 
near infrared (IR) dye (LI-COR Biosciences, Lincoln, Nebraska, USA), according to the 
manufacturer’s instructions. Figure 2-1 illustrates the labelling process, however, in brief, 
AGE-BSA stock was diluted to a final concentration of 1mg/ml in sterile PBS. Where 
required, 1 M potassium phosphate buffer (K2HPO4) up to one tenth of the final volume was 
added to ensure a final pH of 8.5. Near IR dye (lyophilised) was dissolved in ultrapure water 
to a concentration of 4mg/ml. 17.9 μl of this stock was added for every mg of BSA or AGE-
BSA to a ratio of 1:1 near IR dye:BSA or AGE-BSA. This was incubated for 2 hours at room 
temperature on a rotor mixer, protected from light. Free unbound dye was removed using 
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Pierce Zeba Spin Desalting Columns, 7K MWCO for 5 ml and 10 ml volumes (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). In brief, columns were prepared by washing with 
ultrapure water, following the manufacturer’s instructions. Near IR dye protein mix was then 
added to the column and spun at 1000 x g for 2 minutes. This process was repeated using 
a new column so that each dye sample was purified twice to ensure minimal carryover of 
the free dye to the near IR labelled protein preparations. Additionally, equivalent molarities 
IR dye solutions were prepared without the protein, as an IR-Dye only control (IR-Dye). The 
resulting 1mg/ml near IR AGE-BSA (IR-AGE) and 1mg/ml near IR BSA (IR-BSA) and IR-
Dye control were checked prior to use by gel electrophoresis. Labelled protein preparations 
(500-1500 ng per well) or an equivalent volume of free dye were loaded onto 15 well, Bio-
Rad, TGX gels, run at 150-200V for 30-45 minutes. Gels were imaged on the Odyssey 
Classic, Infrared Scanner (LI-COR Biosciences, Lincoln, Nebraska). The relative quantities 
of AGEs were also measured using UPLC-MSMS by collaborators at Maastricht University 
as previously described. Near IR labelled protein stocks were prepared in bulk for each 
experiment and stored in the dark at 4ᵒC for a maximum of 14 days.  
Cell culture experiments 
Time-course of uptake of AGE modified albumin by the gut epithelial cell line, Caco-2 
Human colorectal cancer epithelial cells (Caco-2 cells, ATCC HTB-37) (passage 8-20) were 
grown in Minimum Essential Media (MEM) (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA), containing 5mM D-glucose, 2mM L-Glutamine, 100 U/ml 
Penicillin/Streptomycin cocktail (Thermo Fisher Scientific, Waltham, Massachusetts, USA), 
and 10% foetal calf serum (FCS) (Invitrogen, Waltham, Massachusetts, USA), until 70-80% 
confluent. Cells were plated onto coverslips in 6 well culture flasks at 2x105 cells per well 
and grown for 48 hours. Cells were then incubated in low FCS (1-2%) MEM (5mM D-
glucose, 2mM L-Glutamine, 100U/ml Penicillin/Streptomycin) overnight before being 
exposed to low FCS MEM containing either (i) IR-AGE (100μg/ml), (ii) IR-BSA (100μg/ml) 
or (iii) PBS for 5min, 10 min or 30 minutes and rapidly fixed in 4% paraformaldehyde (PFA). 
Cells were counterstained with DAPI, mounted with Fluoroshield (Sigma-Aldrich, St. Louis, 
Missouri, USA) and imaged on a FV1200 laser scanning confocal microscope (Olympus, 
Tokyo, Japan) fitted with a 780nm laser and dichroic mirror.  
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Cell uptake and interaction with AGEs – In vitro competition and binding assays 
Cell plating and washout 
Caco-2 cells passage (8-20) were seeded onto 96 well cell culture plates (Greiner Bio-One, 
Kremsmünster, Austria) at a density of 1.4 x 104 cells per well and grown in MEM growth 
media until confluent (~24-48 hrs). Cell were incubated overnight in minimal washout media 
MEM only. Competition and binding assays were then performed as per LI-COR bioscience 
protocols: In cell western assay competition and binding assay 800CW Doc # 988-16066 
(link below). Both protocols are also briefly described below. 
https://www.licor.com/documents/fkenxm083e54z4vq97bxfjlnhu9yj508 
In-plate binding curve 
Ten point IR-AGE or IR-BSA dilution curves from 200 μg/ml to 0.39 μg/ml were prepared in 
pre-warmed MEM (serum and antibiotics free) in triplicate to be added to Caco-2 cells grown 
in 96 well plates. MEM only wells were prepared as controls. Caco-2 cells were rinsed twice 
in PBS then IR-AGE or IR-BSA dilution curves were added to the cells (50μl per well, one 
dilution per well) and incubated at 37ᵒC for 5 minutes. IR-AGE and IR-BSA containing media 
was then removed, the cells washed in PBS and fixed using 4% PFA for 20 minutes. Cells 
were then permeabilised with 0.1% Triton X in PBS and blocked for 2 hours (Odyssey block 
(LI-COR Biosciences, Lincoln Nebraska, USA) 1:1 in PBS-T (0.05% Tween)). TO-PRO-3 
nuclear stain (1:5000 dilution; Molecular Probes, Thermo Fisher Scientific) was then applied, 
followed by washing 6 times in PBS-T (0.05% Tween 20) before finally being imaged on the 
Odyssey Classic, Infrared Scanner (LI-COR Biosciences, Lincoln, Nebraska). The binding 
and uptake of IR-AGE or IR-BSA was quantified using the 800CW channel while the total 
cell quantity was obtained based on TO-PRO-3 staining in the 700CW channel. Total 
fluorescent intensity (relative fluorescent units) in the 800 channel was normalised to TO-
PRO-3 staining. Quantification was performed using LI-COR Biosciences, Odyssey 
software V3.0.30 and analysed in Graph Pad Prism 7. Differences between IR-AGE and IR-
BSA binding and uptake curves were analysed by 2-way ANOVA with post hoc multiple 
comparisons testing (Sidak’s multiple comparisons) in GraphPad Prism 7. 
In-plate competition assay 
The competition assay was used to ensure that the labelling of AGE-BSA and BSA was not 
interfering with cellular binding using competition with un-tagged proteins. Ten point, two 
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fold, serial dilutions of un-tagged AGE-BSA or BSA from 10 000 μg/ml down to 19.5 μg/ml 
were prepared in triplicate across three rows of a sterile 96 well plate in pre-warmed MEM 
(serum and antibiotic free). To the AGE-BSA dilution series IR-AGE was then added to a 
final concentration of 50 μg/ml per well to prepare a competition dilution series; uniform in 
the concentration of the IR-AGE but ranging from 0-100 μg/ml for the untagged protein. An 
equivalent competition series was prepared using IR-BSA and untagged BSA. Once the 
dilution series were prepared Caco-2 cells, grown as described above in 96 well plates, were 
washed three times in PBS then 100μl of the prepared competition dilution series was rapidly 
added to the plate containing cells in triplicate. Cells were incubated with the competition 
dilution series for 5 minutes at 37°C. Cells then underwent the same washing, fixation, 
permeabilisation, blocking and nuclear staining as described above and the plate was 
scanned using the LI-COR Odyssey as described above. Normalisation to TO-PRO-3 
staining was performed as described above. Fluorescence across the competition curve 
was analysed by 2-way ANOVA with post hoc multiple comparisons testing (Sidak’s multiple 
comparisons) in Graph Pad Prism 7. 
IR-AGE-BSA trafficking across ex vivo intestinal sections  
To determine the rate of IR-AGE and IR-BSA trafficking across the gut, small intestines were 
obtained from male C57BL/6J, immediately after euthanasia by CO2 and 3 cm segments 
measured and excised from the duodenum, jejunum and ileum. One end of each segment 
was sealed with double loops of surgical sutures to form a pouch which was then filled with 
300μl of IR-AGE, IR-BSA or IR-Dye control at a concentration of 1mg/ml. The pouches were 
then completely sealed with double loops of surgical suture thread forming an intestinal sac. 
The intestinal sacs were then rinsed in warm PBS, added to 30 ml of pre-warmed and 
oxygenated DMEM and incubated in a water bath at 37ᵒC. One millilitre of the media was 
collected every 10 minutes for 2 hours and the extracted volume immediately replaced with 
fresh oxygenated media. The collected aliquots were plated into 96 well plates and near IR 
fluorescence determined on the 800nm channel of the Odyssey Classic, Infrared Scanner 
(LI-COR Biosciences, Lincoln, Nebraska) and quantified using the, Odyssey software 
V3.0.30. AUC was calculated in Graph Pad prism 7 and mean AUC were compared by Mann 
Whitney U Test.  
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In vivo AGE-BSA AND BSA Trafficking in mice 
Pilot Experiment 1: 8-hour time course to detect the appearance of ingested IR-AGEs or 
control protein in the circulation.  
Eighteen C57BL/6J mice were obtained from the Animal Resource Centre, Western 
Australia, at 10 weeks of age. Mice were given a baked AIN93G diet from 12 weeks of age 
which is considered a high AGE diet equivalent to standard mouse chow [371]. Mice 
remained on this diet until the time of the experiment at 20 weeks of age, and were weighed 
weekly to ensure growth was maintained. In the week prior to the experiment, animals were 
acclimatised to metabolic cages and handling. On the day of trafficking experiments (Figure 
2-2) (week 20), fasted mice were weighed and transferred to the metabolic cages with ad 
libitum access to water. Following collection of baseline blood (collected for plasma, tail 
bleed), urine and faeces samples, mice were intra-gastrically gavaged with either: (i) IR-
AGE (5 mg/kg), (ii) IR-BSA (5 mg/kg), (iii) IR-Dye or (iv) H2O and returned to their metabolic 
cage. Food was returned to the cage following gavage. Blood for plasma, urine and faeces 
were collected at 15 and 30minutes, 1 hr, 2 hr, 4 hr, 6 hr and 8 hrs post-gavage (Figure 2-2). 
At 8 hours, mice were euthanased by CO2 and immediately exsanguinated via cardiac 
puncture to collect ~1 ml of blood. All work was performed during the mouse active cycle 
(from 7pm to 7am) (Figure 2-2). Bloods samples (maximum 35l) for the 0-6hr time points 
were collected by tail bleed into 1.5 ml heparinised capillary tubes and transferred to tubes 
containing 10l of sodium citrate (100mM). The final cardiac puncture was performed using 
a 26 gauge needle containing 50l of sodium citrate. All collected blood samples were flick 
mixed and stored on ice for a maximum of two hours before being spun at 6000 x g for 6 
minutes at 4°C. Plasma was removed from the whole blood and stored at -80°C. 
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Figure 2-2. Schematic of animal experiment 1: Pilot experiment to examine the gastrointestinal 
transport of near IR labelled AGE modified bovine serum albumin (IR-AGE) into the circulation.  
 
Experiment 2: 8-hour time-course of tissue uptake and trafficking of ingested IR-AGEs 
Fifty-two male C57BL/6J mice were obtained from the Animal Resource Centre, Western 
Australia. Mice were given baked AIN93G diet from 12 weeks of age which is considered as 
a high AGE diet equivalent to standard mouse chow [371]. Mice remained on this diet until 
up to the time of the experiment at 20-22 weeks of age, and were weighed weekly to ensure 
growth was maintained. In the 2-4 weeks prior to the experiment, animals were acclimatised 
to a 13-hour reversed light cycle and handling. This was to facilitate studying of mice during 
their active (dark) cycle. On the day of the experiment, mice were fasted for 4 hours with ad 
libitum access to water. Mice were randomised to receive an intra-gastric bolus of either IR-
AGE or IR-BSA control at (5 mg/kg), IR-Dye or H2O vehicle. After gavage, mice were 
returned to the fasting cage with ad libitum food and euthanased by CO2 and then 
exsanguinated via cardiac puncture at 15 min, 1, 4 or 8 hours post-gavage (n=3 per 
treatment group per time-point; n=1 per treatment group per time-point for IR-Dye and H2O 
controls, Figure 2-3). Blood was processed as described above and organs were excised 
and half snap frozen for protein extraction, the other half was placed into Periodate-Lysine-
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Paraformaldehyde buffer (PLP) (0.075 M lysine, 0.37 M sodium phosphate (pH 7.2), 2% 
formaldehyde, and 0.01 M NaIO4) for 2-6 hours, rinsed in sucrose buffer and PBS before 
being transferred to OCT mounting media and frozen at -80ᵒC for immunofluorescence. All 
work was performed during the animal’s active cycle.  
Figure 2-3. Schematic of mouse experiment 2: Pilot experiment to examine the time-course of 
tissue uptake and trafficking of ingested IR-AGEs.  
 
Protein Extraction 
Ten to 30mg of tissue was homogenised in 200μl of RIPA buffer containing protease 
inhibitors (Complete EDTA free, Roche, Basel, Switzerland) for 5 minutes at 4°C using 
zirconium oxide or steel beads in a bullet blender (Next Advance, Troy, New York, USA). 
The resulting homogenate was centrifuged at 12000 x g for 5 minutes to remove any 
particulate matter and protein quantitated (Pierce BCA Protein Assay Kit, Life Technologies, 
Waltham, Massachusetts, USA).  
SDS PAGE 
Two microliters of plasma or urine or 50μg of protein were boiled for 10 minutes at 65°C in 
the presence of Laemmlli buffer containing β-mercaptoethanol and loaded onto, TGX Stain-
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free gels (Bio-Rad, Hercules, California, USA). Samples were electrophoresed for 45-55 
minutes at 150V, rinsed and near IR signal imaged using the LI-COR Odyssey (resolution 
169 μm; quality medium; intensity; (700 channel) 0.5, (800 channel) 0.5). After imaging on 
the Odyssey, the stain-free tri-halide compound contained in the gels was activated by 
exposure to UV light for 1 minute and imaged on the Gel Doc for determination of total 
protein content. The relative fluorescent intensity of the near infrared signal was analysed 
semi-quantitatively using the LI-COR gel software. A sample of the near IR tagged AGE-
BSA and BSA was loaded onto all gels as a control and to allow for normalisation across 
gels.  
Quantification methods/Data analysis 
Quantification of near IR signal from plate based assays and SDS-PAGE gels was 
performed using LI-COR Odyssey Infrared Imaging System Application Software version 
3.0.30. In vitro and ex vivo studies were analysed by 2way ANOVA followed by Sidak’s 
multiple comparisons testing in Graph Pad Prism 7. AUC were compared Mann Whitney U 
in Graph Pad Prism 7. Animal experiment 2 was performed as a pilot with n=3 per group 
and therefore no statistical analyses were performed.  
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Microscopy 
Imaging of frozen sections 
PLP fixed, OCT mounted, frozen sections were cut to 7μm thickness and mounted on 
superfrost plus slides. Tissue sections were allowed to reach room temperature, were 
washed in PBS and fixed in ice cold methanol for 10 minutes. Sections were rinsed again in 
PBS and mounted in fluoroshield containing DAPI nuclear counterstain (Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). Images were captured with an Olympus FV1200 
laser scanning confocal microscope fitted with a 780nm laser and dichroic mirror (Olympus, 
Tokyo, Japan). For the mice that received water, no manipulation was required. However, 
for the IR-Dye and IR-BSA groups, brightness was adjusted from 0 to 52 and contrast was 
adjusted from 0 to 61. For the IR-AGE, the top images were not adjusted, the lower images, 
brightness was adjusted from 0 to 52 and contrast from 0 to 34. 
Imaging of formalin fixed paraffin embedded sections 
Tissues were fixed overnight in 10% neutral buffered formalin and embedded.  Four m 
sections were cut and mounted on superfrost plus slides. Sections were dewaxed in xylene 
(2x 10 minutes), before being re-hydrated through immersion in graded ethanol solutions 
(100% 2 x 5 min, 90% 1x 5 min, 75% 1 x 5 min) and then rinsed in H2O. Sections were then 
counterstained with DAPI nuclear stain (Thermo Fisher Scientific, Waltham, Massachusetts, 
USA), dehydrated (75% EtOH, 1 x 5 min, 95% EtOH, 1 x 5min, 100% EtOH, 2 x 5 min, 
xylene, 2 x 5 min), before being mounted in DePEX mountant (Sigma-Aldrich, St Louis, 
Missouri, USA). Images were taken with an Olympus FV1200 Laser scanning confocal 
microscope fitted with a 780nm laser and dichroic mirror (Olympus, Tokyo, Japan). Image 
levels, brightness and contrast were manipulated to enhance visibility of positive signal for 
print. Brightness was adjusted from 0 to 20 and contrast was adjusted from 0 to 22. Levels 
in the blue channel and RGB channels were also adjusted. Blue channel adjusted to 0, 0.60, 
207. RGB was adjusted to 0, 1.14, 255.  
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Results  
Near IR conjugation 
The CML, CEL and MG-H1 content of AGE-BSA and control BSA master stocks (50mg/ml) 
and the near IR conjugated IR-AGE and IR-BSA stocks (1mg/ml) were measured by mass 
spectrometry and are reported both as total AGEs (nmol) and adjusted values, normalised 
for the total quantity of lysine residues available for modification (nmol/mmol of lysine) (Table 
2-1).  
Table 2-1. CML, CEL and MG-H1 content of AGE-BSA and BSA stock solutions pre and post near IR 
labelling. 
 AGE content (nmol) 
ID CML CEL MG-H1 
AGE-BSA (50 mg/ml) 222903 52334 163842 
BSA (50 mg/ml) 5956 1373 7273 
IR-AGE (1 mg/ml) 6173 484 28 
IR-BSA (1 mg/ml) 155 19 106 
 AGE content (nmol/mmol LYS) 
ID CML CEL MG-H1 
AGE-BSA 29149 6844 21426 
BSA 222 51 271 
IR-AGE 55548 4360 256 
IR-BSA 336 41 229 
AGEs Carboxymethyllysine (CML), carboxyethyllysine (CEL) and Methylglyoxal derived 
hydroimidazolone (MG-H1) levels in stock solutions and near IR labelled solutions administered to 
mice. AGE contents are represented as total AGEs (nmoles) and adjusted AGEs (nmol per mmol of 
lysine) in AGE- BSA stock, control BSA stock, the near IR labelled AGE-BSA stock (IR-AGE) and IR 
labelled BSA stock (IR-BSA).  
The labelling efficiency of the AGE-BSA (IR-AGE) and BSA (IR-BSA) was assessed. When 
equivalent amounts of IR-AGE and IR-BSA stocks were analysed by plate based, total 
fluorescence and SDS PAGE, the IR-BSA consistently showed higher relative fluorescent 
intensity as compared to IR-AGE using both quantification methods. A representative image 
of SDS-PAGE gel is shown (Figure 2-4 A). Total near IR fluorescence, assessed by plate 
based assays was 2.13 fold higher for IR-BSA than IR-AGE with a standard deviation of 
0.57, across four independent replicates (data not shown). As SDS-PAGE separated any 
unbound IR dye into the dye front, inter-gel variability of the 66 kDa band between the IR-
AGE and IR-BSA preparations was quantified across 22 different SDS-PAGE gels (200ng 
of IR-AGE or IR-BSA loaded). This represented three different batches of IR-AGE and IR-
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BSA (Figure 2-4 B). IR-BSA had a median of 2.9 (IQR 2.2) fold higher fluorescent intensity 
at the 66kDa band than IR-AGE for equivalent amounts of protein loaded. In vitro results, 
where reported, were normalised for this labelling efficiency bias. However, in vivo, we were 
not able to predict the effect of the gavage and digestion on the label and fluorescent 
intensity, and hence results reported from in vivo studies were not normalised for labelling 
efficiency.   
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Figure 2-4. Representative image of SDS-PAGE of IR-AGE and IR-BSA stock solutions used for 
trafficking experiments.  
A) Representative image of near IR-AGE (5g), IR-BSA (5g) and IR-Dye (2l) following separation by 
SDS-PAGE using a 10% stain free TGX gel. B) Inter-gel variability of IR-AGE and IR-BSA stocks, 
quantified as relative fluorescent units over 22 different SDS-PAGE gel replicates. Dots indicate the 
individual mean fluorescent units for a single gel and lines connect IR-AGE and IR-BSA preparations 
run simultaneously on the same gel. rfu (relative fluorescent units). 
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Part 1: Validation of near IR labelling for studying the uptake and trafficking of AGEs 
The uptake of IR-AGE and IR-BSA by the gut epithelial cell line Caco-2 (Figure 2-5, A-C) 
was first visualised by confocal microscopy. Both IR-BSA (Figure 2-5 B) and IR-AGE (Figure 
2-5 C) were visible as clear punctate staining at both the cell membrane and within the 
cytoplasm 5 minutes after their addition.  
Figure 2-5. In vitro uptake of IR-AGE and IR-BSA by Caco-2 gut epithelial cells 
Representative confocal images (40x magnification) of the gut epithelial cell line Caco-2 after 5 
minutes exposure to either A) PBS control; B) IR-AGEs (Purple, 100μg/ml) or C) IR-BSA (Yellow, 
100μg/ml). Nuclear staining with DAPI is shown in blue.  
Assays to determine the binding kinetics of near IR labelled AGEs were also performed 
using the Caco-2 cell line (Figure 2-6, below). At lower concentrations (<12.5 μg/ml), the 
uptake of the near IR tagged products was indistinguishable from background (Figure 2-6 A 
and B). Binding and uptake into Caco-2 cells was detected at all concentrations >12.5 μg/ml 
but did not differ between IR-AGE and IR-BSA up to 50 μg/ml. However, >100 μg/ml IR-BSA 
had greater binding to Caco-2 cells than near IR-AGE when data were not corrected for 
labelling efficiency (Figure 2-6 A). However, following correction for labelling efficiency, IR-
AGE binding to Caco-2 cells was significantly greater than near IR-BSA at both 100 and 
200μg/ml (Figure 2-6 B). Competitive binding assays using unlabelled AGE-BSA and BSA 
demonstrated that near IR labelled AGE-BSA and BSA binding was specific and was 
competed out by unlabelled AGE-BSA or BSA up to concentrations of 10mg/ml (Figure 2-6 
C-D). 
  
53 
 
Figure 2-6. The binding kinetics of near IR tagged AGE-BSA and BSA to Caco-2 gut epithelial cells.  
A-B Caco-2 polarised cell monolayers were exposed to varying concentrations (0.391 to 200 μg/ml) 
of IR-AGE (red) or IR-BSA (blue) for 5 minutes. A) Binding curves for IR-AGE and IR-BSA, without 
correction for labelling efficiency. B) Binding curves for IR-AGE and IR-BSA, adjusted for differences 
in near IR labelling efficiency. C-D Competitive binding assay of IR-AGE (50 μg/ml; red) and BSA (50 
μg/ml; blue) to Caco-2 cells in the presence of increasing concentrations of their unlabelled 
equivalents at (19.53 μg/ml-10000 μg/ml) without adjustment for labelling efficiency C), and after 
correction for labelling efficiency D). Data is expressed as relative fluorescent units and represent the 
mean and standard deviation at each concentration. *P<0.03, ***P<0.0002 and ****P<0.0001 
between AGE-BSA and BSA at that time point. n=6 technical replicates performed as two 
experimental replicates.  
 
Part 2: Ex Vivo gastrointestinal transport of AGEs across the gut epithelium 
The transport of near IR tagged AGE-BSA (IR-AGE) and BSA (IR-BSA) across different 
segments of the small intestine was assessed using the everted gut sac model. Both near 
IR labelled AGE-BSA (IR-AGE) and BSA (IR-BSA) were transported across the small 
intestinal segments but to varying degrees (Figure 2-7 A and B). There was significant 
transport of IR-BSA in the duodenum (Figure 2-7 B left), which was decreased with AGE 
modification (IR-AGE; Figure 2-7 A left). However, this only trended towards significance 
when AUC was compared (P = 0.1, Mann Whitney U, Figure 2-7 C). In other segments, the 
rate of transport across the segments did not differ between near IR labelled AGE-BSA and 
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BSA (Figure 2-7 A-C). Based on the cells in Caco-2 monolayers as well as ex vivo small 
intestine segments, we determined that near IR labelling would be an appropriate strategy, 
to study the trafficking of the AGE modified proteins in vivo.  
Figure 2-7. Modelling near IR-AGE trafficking in murine gut segments.  
Transport of IR-AGE A (red) and near IR-BSA B) (blue) over 2 hours across various segments of small 
intestine taken from healthy mice (n=3 per group). Transport across the duodenum A & B left), 
jejunum A & B middle), or ileum A & B right). C) Area under the curve for AGE-BSA and BSA uptake 
in various gut segments (median and IQR).  
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Part 3: In vivo trafficking and biodistribution of ingested AGE-BSA in healthy 
C57BL/6J mice 
 
  
Figure 2-8. Intact near IR labelled AGE-BSA can traffic across the GI tract into the bloodstream of 
healthy mice.  
Healthy male C57BL6/J mice (20 weeks of age) received either IR-AGE (5 mg/kg, red circles), IR-BSA 
(5 mg/kg, blue circles), IR-Dye (black circles) or H2O vehicle (clear circles) intra-gastrically (n=7/group 
for IR-AGE & IR-BSA; n=2/group for H2O & IR-Dye). Plasma was collected at time points over 8 hours 
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20 
25
IR-BSA IR-Dye IR-AGE
ouse56 (IR-
H2O 
0 15 30 2 4 6 8 1 0 30 2 4 6 8 1 15 
250 
100 
75 
50 
37 
15 
10 
150 
0 30 2 4 6 8 1 15 0 30 2 4 6 8 1 15 
C 
56 
 
IR fluorescent products in plasma separated by SDS-PAGE; intact AGE-BSA or BSA (66kD; left) and 
cleaved (<15kD; right) (mean ± SD shown, expressed in relative fluorescent units (rfu) for all graphs); 
C) Representative SDS-PAGE images showing near infrared signal (green) in plasma collected up to 
8-hour post intra-gastric gavage. Each gel represents samples collected across time from a single 
mouse. Yellow numbers indicate the time points 0-30 min, then 1 to 8 hours.  
We next undertook a small pilot study to examine if near IR tagged AGE-BSA could be 
detected in the bloodstream following intra-gastric gavage. Using plate based assessment 
of plasma taken from gavaged mice, total near infrared signal was detected in mice that 
received IR-BSA, IR-AGE or the IR-Dye from 15 minutes post-gavage (Figure 2-8 A). The 
near IR signal in plasma remained for 4 hours before declining to baseline levels by 8 hours 
post-gavage (Figure 2-8 A). The near IR signal however, varied significantly among mice, in 
particular in those administered IR-AGE (Figure 2-8 A). Significant total fluorescence was 
detected in mice that received near IR-Dye and some background signal was detected in 
mice that received only water (Figure 2-8 A). This is discussed below in the limitations 
component of the chapter discussion.  
We next examined if IR-AGE and IR-BSA present in the circulation following intra-gastric 
gavage had been cleaved during transport across the GI tract by examining molecular 
weight on SDS-PAGE. Some background signal was detected in plasma from mice that 
received either H2O or IR-Dye at 66kDa, the molecular weight of intact BSA and AGE-BSA 
(Figure 2-8, B left and C i and ii). In at least 3 out of 7 mice, there were clear bands observed 
at 66kDa in mice administered IR-AGE, that were significantly brighter than those detected 
in H2O or IR-Dye gavaged mice, indicating that intact un-cleaved AGE-BSA had been 
transported across the gut into the circulation of these mice (Figure 2-8 B left and 8 C iv). 
There was also a smaller <15kD fluorescent band detected in mice that received IR-BSA, 
IR-AGE and IR-Dye only. This was also analysed semi-quantitatively (Figure 2-8 B right). 
This was equally high in mice that received IR-AGE or IR-BSA and was present in at least 
one of the control mice administered IR-Dye (Figure 2-8 B, right). Since group numbers were 
small in this pilot study, no statistical analyses were performed.  
AGE-BSA appears in organs and tissues within 15 minutes of intra-gastric gavage 
Based on the promising results of the pilot time-course, we chose 4 key time points to 
examine organs and tissues from mice given either IR-AGE, IR-BSA, IR-Dye or H2O vehicle. 
Plasma and urine were also collected. Examination of the plasma collected at 15 minutes, 
1, 4 and 8 hours after intra-gastric gavage confirmed that intact IR-AGE (66kDa) could be 
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detected in plasma at both 15 minutes and 8 hours post gavage (Figure 2-9 A and B). No 
IR-BSA or IR-AGE was detected at 1 hour or 4 hours post gavage, except in a single mouse 
(Figure 2-9 A and B middle, Supplementary Figure 2-1). Smaller molecular weight near IR 
bands were also detected at ~15kDa in mice that received near IR-Dye but not in those mice 
which received H2O vehicle only. Given that this was a qualitative pilot study, with n=3 mice 
per group, no statistical analyses were performed. 
  
Figure 2-9. Trafficking of intact and cleaved near IR labelled AGE-BSA and BSA into the plasma 
of healthy mice. 
Male 20 week old C57Bl/6J mice were administered IR-AGE or IR-BSA (5 mg/kg) via intra-gastric 
gavage and followed for 15 minutes, 1, 4 or 8 hours. A) Quantification of intact (~66 kD; left panel) 
or cleaved (<15 kD; right panel) IR-AGE (red circles), IR-BSA (blue circles), IR-Dye (black circles) and 
H2O vehicle (clear circles) within the plasma at each time point (n=3; (n=1 H2O group only)). Each 
dot represents the value obtained from the plasma of a single mouse. B) Representative SDS PAGE 
showing near infrared signal (shown in green) in plasma 15 minutes, 1, 4 or 8 hours following intra-
gastric gavage of H2O vehicle, IR-Dye only, Near IR-BSA, IR-AGE. Each lane represents plasma from 
a single mouse.  
B 
15 minutes 1 hour 4 hours 8 hours 
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Urine is postulated to be a major site for the removal of AGE modified peptides and proteins 
from the body. In this study, there was no intact (66 kD) IR-AGE or IR-BSA detected in urine 
at any time point, except in a single mouse that showed extremely high levels at 1 hour post-
gavage (Figure 2-10 A top, Supplementary Figure 2-1). Since the near IR signal from this 
mouse was so high that it prevented detection of any other bands, SDS-PAGE was repeated 
excluding this mouse to ensure that products would be visible in the urine of other mice if 
present (Figure 2-10 B, 1 hour representative gel). Urine showed faint bands of IR-AGE 
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Figure 2-10. Excretion of primarily lower molecular weight products of IR-AGEs occurs via the 
urine.  
Healthy, adult, male C57Bl6/J mice were administered IR-AGE (5 mg/kg, red circles, n=3), IR-BSA (5 
mg/kg, blue circles, n=3), IR-Dye (black circles, n=3) or H2O (clear circles, n=1) via intra-gastric gavage 
and urine collected at 15 minutes, 1, 4 and 8 hours. A) Quantification of intact (~66 kD), cleaved (~30 
kD) and LMW fragments (<10 kD) of IR-AGEs or IR-BSA in the urine, separated and visualised by SDS-
PAGE. Each dot represents the value obtained from the urine of a single mouse. B) Representative 
images of SDS-PAGE showing urine from n=2-3 mice/group, collected at various time points post 
gavage. Lane markers indicate urine was obtained from mice that received H2O (white), IR-Dye 
(yellow), IR-BSA (blue), near IR-AGE (red). 
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around 30 kD in particular at 15 minutes post-gavage (Figure 2-10 B). Urine from mice which 
were administered IR-Dye, IR-AGE or IR-BSA also showed smaller products of <15 kD 
(Figure 2-10 A right).  
Intact AGE-BSA and BSA were detected in the proximal small intestine, but had mostly 
disappeared in the distal small intestine.  
Dietary AGEs are postulated to be absorbed largely through the small intestine, which is a 
major site of dietary protein, peptide and amino acid absorption. Therefore, we examined 
the levels of near IR tagged protein and peptide present in the segments of the small 
intestine (duodenum, jejunum and ileum), after removal of the gastric contents and mucosa. 
Semi-quantitative analysis following SDS-PAGE, identified intact near IR products (~66 kD) 
present in both the duodenum and jejunum of mice that received IR-AGE and IR-BSA. This 
was highest at 15 minutes and 1 hour, and largely absent by 4 hours (Figure 2-11 A and B). 
However, these results were not consistent across all mice, with some mice from each time 
point, including mice from both the AGE and the BSA groups showing no duodenal or jejunal 
uptake (Figure 2-11 A, B, and D). In the ileum, low levels of intact ~66 kD IR-AGE and IR- 
BSA were detected 1 hour post-gavage but again this was inconsistent and only seen in a 
single mouse from each group (Figure 2-11 C). Near IR products <15 kD were present in 
high amounts in all small intestine segments being greatest in the duodenum and jejunum 
at 15 minutes and then appearing in the ileum by 1-hour post gavage. There was no near 
IR signal seen in vehicle controls. We also examined a faecal homogenate, for the presence 
of intact IR-AGE, IR-BSA and the smaller cleavage products. Very small amounts of near-
IR fluorescence in 66 kD range were detected in faeces collected from within the colon of 
two different mice that received IR-AGE at 1 hour (Figure 2-11, D and E (bottom panel)). A 
single mouse that received IR-BSA also showed a faint band at the 66 kD at 1 hour post-
gavage (Figure 2-11 D and E (bottom panel)).  
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Figure 2-11. Trafficking of intact and cleaved IR-AGEs and IR-BSA through the small intestine of 
healthy mice. 
A-C; Quantitative analysis of the near IR fluorescent intensity in segments of the small intestine (A-
C) and faeces (D) taken from healthy adult C57BL/6J male mice at 15 minutes, 1, 4 and 8 hours post 
intra-gastric gavage with either control H20 (open circles, n=1), IR-Dye (black circles, n=3), IR-BSA (5 
mg/kg, blue circles, n=3) and IR-AGE, (5 mg/kg, red circles, n=3). Levels of near IR fluorescence 
detected in 66kD range and <15 kD band range following SDS-PAGE of homogenate from A) the 
duodenum, B) the jejunum, C) the ileum, D) and faeces. Dots represent the value obtained from a 
single animal. E); Representative images of SDS-PAGE of small intestine and faecal homogenates.  
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Figure 2-12. Uptake and trafficking of IR-AGEs through clearance tissues in healthy male mice. 
A-B) Quantitative analysis of the fluorescent intensity of intact (~66 kD, left panel) and cleaved (<15 
kD, right panel) fluorescent protein present following SDS PAGE of protein extracts from liver A), and 
kidney B), of healthy C57BL/6J male mice at 15 minutes, 1 hour, 4 hours and 8 hours following intra-
gastric gavage with either H20 (open circles, n=1), IR-Dye (black circles, n=3), IR-BSA (blue circles, 
n=3), IR-AGE (red circles, n=3). Dots represent the integrated intensity obtained from protein 
extracted from a single animal and separated by SDS-PAGE. C) Representative images of SDS PAGE 
of liver or kidney homogenates. 
C 
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Both the liver and kidney are postulated as major sites of AGE clearance from the body, 
although the mechanisms involved remain to be fully elucidated. The liver showed rapid 
trafficking of both cleaved and un-cleaved IR-AGE and IR-BSA, by 15 minutes post gavage 
(Figure 2-12 A and Figure 2-12 C top left). Liver positivity was gone by 1 hour post gavage 
except for a single mouse where strong positivity for IR-BSA was still evident (Figure 2-12 
A, and C top panel, middle left). By contrast, the kidney had no detectable intact IR-AGE at 
any time point, although intact IR-BSA was detectable at both 15 minutes and 1 hour in 
some mice (Figure 2-12 B, C lower panel left). There was also rapid trafficking of cleaved 
(<15 kD) IR-AGE to the kidney by 15 minutes and to a lesser extent 1 hour post-oral gavage 
(Figure 2-12 B). Very small amounts were also present in some mice at 4 hours and 8 hours 
post gavage in the kidneys of some mice (Figure 2-12 B and C).  
Pancreas did not appear to take up AGE modified protein.  
 
Figure 2-13. AGEs did not traffic to the pancreata in healthy male mice.  
A) Quantitative analysis of the fluorescent intensity of intact (~66 kD, left panel) and cleaved (<15 
kD, right panel) fluorescent protein present following SDS PAGE of protein extract from pancreas of 
healthy C57BL/6J male mice at 15 minutes, 1, 4 and 8 hours following intra-gastric gavage with 
either H20 (open circles, n=1), IR-Dye (black circles, n=3), IR-BSA (blue circles, n=3), IR-AGE (red circles, 
n=3). Dots represent the integrated intensity obtained from protein extracted from a single animal 
and separated by SDS-PAGE. B) Representative images of the SDS-PAGE gels of pancreas 
homogenate. 
B 
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The trafficking of AGE-BSA to other tissues relevant to glycaemic control was also 
examined. Following intra-gastric delivery there was no near IR-AGE signal detected in the 
pancreata. However, cleaved and un-cleaved IR-BSA was detected at both 15 minute and 
1 hour post gavage (Figure 2-13 A and B), although only a single mouse also showed un-
cleaved BSA at 1 hour post-gavage (Figure 2-13 A, B middle left).  
Microscopy of tissues showing positivity for near IR signal 
To assess the potential of the near IR tag to localise AGEs and control BSA at the 
microscopic level, we used confocal microscopy of tissues collected from mice that showed 
positivity for near IR signal in the duodenum (n=2 per group). The duodenum was chosen 
as it had consistently high signal in multiple animals compared to other tissues (Figure 2-14). 
The kidney was also chosen as bright, <15 kD bands were detected. Although previous in 
vitro work suggested the near IR tag was easily visualised with confocal microscopy, it was 
found that on a default pinhole setting, no signal was detected in the 780 nm channel (data 
not shown). However, when the pinhole was opened to greater than 380 μm, a signal was 
detected. Preliminary confocal scans of duodenal tissue found bright punctate staining in 
the crypts of mice that received IR-AGE and to a lesser degree mice that received IR-BSA 
(Figure 2-14, D and C). Initially no staining was observed in H2O controls, during set up an 
optimisation of the pinhole and laser settings. However, upon repeat, similar bright punctate 
staining was also found in the crypts and the smooth muscle of the duodenum from one 
mouse that received H2O only (Figure 2-14 A) and in the crypts of mice that received the IR-
Dye only (Figure 2-14 B). When the kidney was examined, some signal was detected when 
the pinhole was opened to 388 μm (Figure 2-15 A and B). There was also signal detected 
in a small number of sections from mice that received IR-BSA (n=2) (Figure 2-15 C), and 
IR-AGE (n=2) (Figure 2-15 D). This signal was localised to the brush border of tubules, 
however without co-localising markers, this cannot be accurately determined. We also 
examined the liver and pancreas, however no near IR signal was detected (data not shown).  
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Figure 2-14. Representative images of duodenal sections (frozen) from mice that received IR-AGEs 
or IR-BSA. 
Representative images of duodenal sections (frozen) from mice treated with either water A), IR-Dye 
B), IR-BSA C), or IR-AGE D) using near IR microscopy (40x; 780nm). Near infrared channel is shown 
in white, while nuclear staining (DAPI) is shown in blue. Two different images, sectioned in different 
planes are shown per treatment, white boxes indicate the region where some positive signal was 
detected. The zoomed in photomicrographs of this are shown below.  
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Figure 2-15. Representative images of kidney sections (paraffin embedded) from mice that 
received IR-AGEs or IR- BSA. 
Representative images of confocal microscopy (40x) of near IR signal in kidney sections (paraffin 
embedded) from mice treated with either water A), IR-Dye B), IR-BSA C), or IR-AGE D). Near infrared 
channel is shown in white, nuclear staining (DAPI) is shown in blue. Two images, sectioned in 
different planes are shown. White boxes indicate the region where some positive signal was 
detected, a photomicrograph of this is shown below. 
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Discussion 
Much controversy still exists about the extent to which dietary AGEs contribute to the pool 
of circulating AGEs in the body. Several studies to date have endeavoured to elucidate the 
metabolic fate of dietary AGEs, often quantifying circulating levels, or urinary excretion of 
CML or other AGEs following days or weeks on high or low AGE containing diets [247, 372]. 
While these studies concordantly demonstrate an increase in circulating and tissue AGEs 
with high AGE consumption, it is not possible to determine whether the AGEs detected are 
dietary in origin or the result of changes to glycaemic control and therefore endogenous 
AGE production. AGE-BSA is routinely used as a model AGE modified protein and is 
commonly ingested as the result of consumption of meat, eggs and dairy products within 
the diet [373]. However, few studies have directly examined the uptake and trafficking of 
AGE modified albumin through the GI tract in the hours immediately after consumption. Here 
we describe a pilot study where a near infrared labelling strategy allowed for real-time 
assessment of AGE trafficking after intra-gastric delivery of AGE modified albumin. We 
performed direct assessment of AGE modified protein uptake and cleavage within tissues 
and biological fluids. We also used confocal microscopy to localise near IR labelled AGE 
modified proteins within tissues, but this had significant methodological limitations. As this 
whole animal trafficking was a pilot study, to pre-empt nuclear medicine studies using metal 
labelled AGEs, statistical tests were not applied due to the small group numbers used. 
Firstly, in vitro studies in the gastrointestinal epithelial cell line Caco-2 and ex vivo gut sack 
models evaluated whether near IR labelling impacted cellular uptake of AGE modified 
proteins. Additionally, we confirmed, that we could detect the uptake of the near IR labelled 
AGEs by cells at a microscopic level. This study represents the first attempt to use an ex 
vivo intestinal pouch to evaluate uptake of AGEs in different segments of the intestinal tract. 
Overall, the data suggested that, ex vivo, both BSA and AGE-BSA pass across the epithelial 
barrier, in the jejunum and ileum. In the duodenal gut segment, AGE-BSA uptake appeared 
to be less than unmodified albumin (BSA) although this did not reach statistical significance. 
This was likely confounded by the technically challenging nature of this technique which 
contributed to variability. Ideally this technique requires considerably greater group numbers 
to overcome the large coefficient of variation observed. At the microscopic level, clear 
punctate staining was demonstrated in Caco-2 cells exposed to both AGE-BSA and BSA. 
Following correction for labelling efficiency, IR-AGE binding to Caco-2 cells was significantly 
greater at both 100 and 200μg/ml than IR-BSA using kinetic assays. 
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Having demonstrated the effectiveness of the IR-Dye labelling approach in vitro and ex vivo 
in gut segments, we trialled this near infrared labelling approach to study AGE modified 
albumin uptake and bio-distribution patterns in vivo, in healthy male mice. Overall, the 
uptake and bio-distribution patterns for AGE modified and unmodified BSA did not differ 
significantly in these in vivo studies, with the exception of the pancreas, however this may 
have been due to the limited sensitivity of the near IR labelling. There were also unknown 
factors that caused significant variation where some mice showed extremely high AGE 
and/or BSA uptake while other mice showed none. One factor which was not tested in the 
present study was the oral absorption of AGE modified and unmodified albumin. This is 
discussed further below. 
It was surprising to identify intact AGE-BSA and BSA (66 kD) rapidly in the circulation, the 
GI tract, the liver and to a lesser extent the kidney as early as 15 minutes after intra-gastric 
gavage in some mice. IR-AGE and IR-BSA had disappeared from these sites by 1-hour 
post-gavage, suggesting rapid passage and clearance of near IR tagged proteins through 
the GI tract, then liver and kidneys. Despite their absence at 1 and 4 hours, small amounts 
of intact product were again detected in the circulation at 8 hours in a small proportion of 
mice that receive AGE-BSA or BSA. This could indicate that either a second wave of 
absorption occurred further down in the GI tract or some temporal sequestration of these 
proteins and peptides in tissues or organs occurred. Although of interest for future studies, 
this fell beyond the scope of the present study. Lower molecular weight bands (<15 kD), 
potentially representing the cleavage products of IR-AGE and IR-BSA were seen in urine as 
early as 15 minutes and persisting for at least 4-hours post-intra-gastric gavage. However, 
uptake was not ubiquitous to all mice in each group, as alluded to above. As each mouse 
represents a single snapshot in time, it was difficult to determine if for these mice no uptake 
occurred, or whether the temporal distribution of uptake was highly variable and we missed 
the window at which these products were detectable in these mice.  
How do these findings compare to previous studies examining the uptake and 
trafficking of free AGEs in rodents? 
The rapid appearance of AGEs in the plasma following intra-gastric delivery is in agreement 
with more recent work by Alamir et al., who also demonstrated rapid increases in circulating 
CML levels using gold standard LC-ESI MS/MS following an oral free CML dose [247]. 
However, the very quick time frame of uptake into organs and tissues within 15 minutes and 
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rapid clearance reported here, is more concordant with previous studies using 18F labelled 
free AGEs which were i.v. injected and their metabolic fate studied by PET/MRI or PET/CT 
[255, 262, 369]. Concordant with our findings, the earliest of these studies, by Bergmann et 
al. saw no differences in the temporal distribution to organs and tissues between injected 
CML and lysine control [369]. However, in studies where 18F -AGEs (Fructoselysine and 
CML respectively) were intra-gastrically delivered, only a very small degree of uptake was 
observed [255, 262]. It has been suggested that the fluorobenzylation of these 18F –labelled 
molecules for detection by PET may have interfered with the absorption of free AGEs 
through the GI tract [263].  
How do these findings compare to previous studies examining the uptake and 
trafficking of AGE modified protein in rodents? 
There are only a few studies where glycated proteins rather than free AGEs have been used 
for acute bio-distribution. Here, the data from intact AGE modified protein, suggests that 
organ distribution is comparable between the AGE modified BSA and control BSA and that 
AGE modification did not significantly reduce the bioavailability of this protein. This is in 
contrast to a long term feeding study which found that glycation of ovalbumin significantly 
reduced the bioavailability of lysine following 3 weeks feeding of 14C labelled AGE ovalbumin 
to rats [374]. However, in agreement with our findings, He et al. also reported a rapid peak 
of AGEs in the circulation and additional accumulation in the liver, and kidney after they 
delivered a single meal containing 14C labelled AGE-ovalbumin to rodents [249]. 
Additionally, they also demonstrated 14C labelled product in the lungs and spleen which were 
not examined in the present study. Very recently, an in vivo study using a similar near 
infrared label for whole murine trafficking by IVIS following intravenous injection in BALB/c 
nu-nu mice was published [264]. Similar to our findings they saw significant accumulation in 
the liver of AGE modified Human Serum Albumin (AGE-HSA) compared to unmodified HSA 
[264], persisting in the liver for 24 hours after injection. They further localised the AGE-HSA 
to the Kupffer and endothelial cells of the liver. They concluded that the hepatic 
accumulation was non-specific due to impaired clearance of AGE-HSA compared to HSA. 
Only very small quantities of the near IR-AGE-HSA were detected in the kidneys, pancreas 
and brain, that were negligible compared to the quantities detected in the liver [264]. By 
contrast, IR-AGE-BSA was not detected in the liver beyond the 15 minutes in the present 
study. Given the administration route between these studies differed (injected vs intragastric 
gavage) these contrasting findings may be due to the significantly different quantities of AGE 
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modified albumin entering the circulation. Taken together this data suggests that dietary 
AGEs are indeed absorbed across the gastrointestinal tract, intact and in smaller peptide 
fragments where they predominantly traffick to the liver but also the kidney and other tissues.  
How does this compare to human studies of the metabolic fate of AGEs? And what 
does it mean for human disease?  
In the human diet, levels of CML consumed in a single meal can be as high as 85 mg in 
some averagely sized meat dishes [375]. Therefore, considerable efforts progressing 
understanding the metabolic fate and effects of AGEs on humans are warranted. Indeed, 
the purpose of my initial unsuccessful efforts to obtain metal labelled AGE-HSA, was to 
perform a mouse pilot with the aim of translating this into a human imaging study. In healthy 
humans, the majority of research has examined urinary and faecal output of AGEs following 
ingestion of a meal of known AGE content, following a low AGE washout period [254, 376, 
377]. Since larger protein bound AGEs, in theory should not pass the glomerular filtration 
barrier of the kidney into the urine, these studies generally focus on free AGEs. As such, 
these studies of free AGEs have demonstrated that dietary AGEs are absorbed through the 
GI tract, leading to a rapid increase in urinary free AGE excretion. However, this varies 
significantly according to the free AGE studied, with studies of pyralline for example, 
showing almost complete dietary release and resorption during digestion and rapid excretion 
into the urine [376]. Conversely, studies of the AGE intermediate MGO, suggest that almost 
all MGO is broken down by digestion and has little influence on urinary excretion of MGO 
[377]. Although dietary studies in humans have linked increased AGE consumption with 
increased circulating levels of AGEs, the link between dietary AGEs and pathology is less 
clear than in rodents. Furthermore, there is little to no data on the uptake and trafficking of 
dietary AGEs to organs or tissues in humans, aside from the skin, where auto-fluorescence 
can be used to estimate the total AGE load present in the body [378]. Interestingly, two 
studies examining dietary habits and skin auto-fluorescence in the general population and 
haemodialysis patients, have identified a positive association between habitual consumption 
of meat and animal products and skin auto-fluorescence [379, 380]. However, whether 
dietary AGEs traffic intact into the circulation in humans, remains to be substantiated. 
Indeed, these studies are confounded by recent findings which show that dietary AGEs 
modify insulin sensitivity and insulin secretion in humans, and hence, are likely to impact 
endogenous AGE production [305, 381]. The near infrared tag used in the present study 
was chosen as it has passed FDA safety toxicity testing in animals [382] and is progressing 
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towards approval for clinical and surgical use in humans and may offer a solution for in vivo 
human trafficking experiments. However, the heterogeneity of uptake observed in this study 
suggests that this dye is unsuitable for the study of gastrointestinal uptake and trafficking in 
humans. Hopefully as further methodology for safe, in vivo imaging in humans are 
developed more rigorous metabolic fate studies will be possible. Our data highlights the 
need to consider not only free AGEs but also AGE modified proteins and fatty acids as 
models AGEs for these studies.  
Evidence for the kidney as a major site of AGE-BSA and BSA accumulation. What 
does this mean for human disease? 
Consistently, long term studies, highlight the kidneys as a major site of AGE accumulation 
with aging and diabetes in both humans and rodents [383, 384]. Further, acute bio-
distribution and trafficking studies have also consistently identified the kidneys as important 
sites of AGE clearance in rodents [372]. Additionally, the accumulation of and interaction of 
AGEs with the kidney has been implicated in renal pathology and disease in rodents [250, 
274] and both dietary AGE restriction or blockade of intestinal AGE absorption have been 
demonstrated as effective therapeutic strategies in patients with kidney disease [303, 385, 
386]. Although we saw significant amounts of AGE modified BSA and BSA in the liver, it 
was predominantly the smaller products <15 kD present in the kidney parenchyma in the 
present study. Similarly, almost exclusively lower molecular weight products were excreted 
into the urine, consistent with previous data from rats [331] and humans [251, 376]. 
However, whether this is due to filtration or active secretion at the tubular level remains to 
be confirmed. The microscopy, although problematic, indicates that the kidney tubules may 
be a site of AGE-BSA accumulation but this needs to be substantiated by co-staining with 
renal tubular markers. We were not however, confident enough with the performance of the 
near infrared dye for microscopy to pursue this further within the scope of this PhD. Previous 
studies suggest that AGEs, both free and protein-bound, bind to and/or enter proximal tubule 
cells in vivo and in vitro [258, 331-334]. Additionally, many of the pathways activated by 
AGEs and AGE-RAGE signalling are known to drive renal pathology in CKD [1] and are 
upregulated in response to CML-BSA exposure in proximal tubule cells in vitro [387]. 
Interestingly, these lower molecular weight products are thought to be less potent activators 
of RAGE downstream signalling, so their effects on the kidney may not be via RAGE pro-
inflammatory pathways [187]. A high AGE diet has also been associated with reduced 
estimated glomerular filtration rate, albuminuria and increased inflammatory markers [272] 
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suggesting dietary AGEs may directly impact upon renal function, interacting with any 
underlying genetic or environmental risk.  
Comments on other tissues. 
Dietary AGEs can modulate insulin sensitivity, secretion and adiposity, which may also 
contribute to risk for chronic kidney disease. Hence, we also evaluated trafficking after acute 
intra-gastric delivery of AGE-BSA to the pancreas and liver. Although the pancreas showed 
no detectable AGEs after this single delivery, significant accumulation of IR-AGE and IR-
BSA was detected in the liver by 15 minutes. Both acute trafficking studies [249, 264] and 
long term feeding studies [263] suggest the liver is an important site of AGE sequestration 
and clearance in rodents. This is not surprising, given the liver receives greater than 70% of 
its blood supply from the GI tract [388]. Accumulation and interaction of AGEs with the liver 
has been identified as important, with dietary AGEs implicated as environmental co-factors 
exacerbating hepatic steatosis in rodent models of NASH and NAFLD [269, 270]. In vitro 
studies suggest that impaired scavenger function of hepatic cells may contribute to the 
observed AGE accumulation [389]. Somewhat in concordance with these previous findings, 
we did detect IR-AGE and IR-BSA in the liver at both 15 minutes and 8 hours post gavage, 
although not in all mice. Dietary AGE accumulation in the liver has yet to be substantiated 
in humans. However, our data and that of others [249, 263, 264, 269, 270] supports the liver 
as a major target of dietary AGE modified proteins. Further work is required to determine 
whether this is an important contributor to the metabolic phenotype observed with high AGE 
dietary consumption.  
The GI tract as a major sight of AGE interaction, implications for metabolism and the 
gut-renal axis. 
Unsurprisingly, we demonstrated an interaction between near IR labelled AGE albumin with 
all three small intestinal segments examined, that persisted in some mice until the 8-hour 
time limit of this study. Specifically, there was significant accumulation of the <15 kD 
products in the small intestinal segments. Despite this being a major site for interaction with 
ingested AGEs, very little is known about deposition and accumulation of AGEs with the 
intestinal wall. Bergmann et al., using PET scanning observed an accumulation of their 18F 
fluorobenzylated CML in the intestinal region after intra-gastric delivery for the length of the 
study (120 minutes) [369]. Tessier et al. also reported significant accumulation of 13C 
containing CML following 30 days feeding with 13C enriched rodent chow [263]. Very little 
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research to date has examined the impact of high or low AGE diets in inflammatory diseases 
of the GI tract, despite the receptor for AGEs, RAGE, being implicated in the 
immunopathology of these diseases [390]. AGE accumulation in the gastrointestinal wall of 
diabetic mice has been implicated in the loss of gastric motility seen with diabetes [391]. 
Furthermore, AGE interactions with the microbiome are as yet largely unexplored. Studies 
suggest that AGEs can be metabolised by bacterial species found in the GI tract and colon 
[392] and may contribute to a more immune-pathological microbiome [393]. Although 
outside of the scope of this PhD, going forward this would be an interesting research 
question to pursue.  
In the present study, mice were fasted and near IR-AGE and BSA were delivered as a liquid, 
enabling rapid passage through the stomach and small intestine. Hence, this may not be 
representative of how AGEs would be trafficked and absorbed by the gastrointestinal system 
if delivered in solid food and represents one limitation of this study. Previous research in 
humans has demonstrated different rates of urinary elimination of AGEs when healthy 
individuals were given different solid and liquid foods containing high levels of AGEs [254].  
The rapid time frame of trafficking in our study are consistent with at least one other study 
using intra-gastric delivery, where 18F labelled fructoselysine was detected in the small 
intestine within 2 minutes post-delivery to the stomach [255]. Furthermore, there are other 
examples where intact dietary proteins have shown absorption into the circulation in small 
amounts [394]. In the present study, we show that this occurs regardless of glycation. This 
is important, as larger protein bound AGEs are known to be more potent activators of RAGE 
[187]. As RAGE activation is proposed as the major pathway associated with AGE pathology 
[166, 180] understanding the contribution of dietary AGEs to RAGE activation is an important 
research area.  
Comments on the mechanism of uptake. 
There are many hypotheses as to how dietary AGEs are transported across the 
gastrointestinal tract, but the exact mechanism remains unknown. In vitro studies of trans-
epithelial flux using gastrointestinal epithelial cells have concluded that no active transport 
exists for free AGE modified peptides and amino acids, concluding that they likely enter the 
body through passive diffusion [395]. However, more recent findings suggest AGE-modified 
peptides and proteins are, in fact, actively transported [396]. The data obtained from the gut 
sack experiments does not suggest site specific uptake and trafficking by any particular 
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segment of the small intestine with no statistical difference between the three segments 
tested, or between AGE-BSA and BSA. However, in our Caco-2 polarised monolayer and, 
AGE-BSA flux, did appear different to unmodified BSA and a similar trend was seen within 
the duodenum. When plasma levels of detected intact protein were adjusted for labelling 
efficiency, however, it did appear that in vivo uptake was equivalent between the two 
proteins, suggesting intestinal uptake maybe specific to the protein used, not the AGE 
modifications. However, this study was not powered for rigorous quantitative analysis, 
therefor these findings must be interpreted carefully.  
Technical comments and limitations. 
While this study represents a quick, easy and sensitive workflow to study the uptake and 
trafficking of AGE modified proteins, there are several important limitations to this study. 
Given this was a pilot and technically laborious, only three mice per group, per time-point 
were used in experiment 2 and all mice were male. Therefore, it was not statistically powered 
to make rigorous quantitative comparisons or to assess sex differences in uptake and 
trafficking. Due to the number of time points examined and the controls required, this study 
still equated to 18 mice in experiment 1 examining the uptake into plasma and excretion into 
the urine over an 8-hour time course and 40 mice in experiment 2 which addressed the 
tissue distribution over an 8-hour time course. Given the variability seen within groups and 
between mice it was concluded that repeating this study with greater numbers would be 
unfeasible. Furthermore, several other published studies were similarly powered. For 
example, in their acute AGE trafficking studies Xu et al. and Tsutsui et al. used only an n of 
4 and n of 3 animals respectively [262, 264]. Therefore, small sample sizes have been 
typically used for trafficking and uptake studies. Another major limitation of this study, is that 
the mice were not perfused with saline or PBS prior to removing the organs. Therefore, it is 
also possible that some near IR signal detected in the organs and tissues analysed was due 
to residual blood in the organ and representative of the IR-AGE or IR-BSA present in the 
circulation. However, nearly 50% of the total blood volume was collected during the cardiac 
bleed and our findings are in accordance with a previous study where perfusion was 
performed [263]. Another important caveat, is that while the dosing strategy used in this 
model was based on estimated average consumption of CML in human high AGE diets from 
previous studies, the model albumin protein is not representative of the whole spectrum of 
AGEs observed in the diet, both free and protein bound [397-399]. It needs to be established 
whether the uptake and bio-distribution of AGE modified albumin is consistent with other 
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commonly consumed AGE modified proteins. This would resolve whether the uptake and 
trafficking observed in this study was an albumin mediated response. Given the increasing 
prevalence of other reducing sugars in the western diet, particularly fructose, [400], it would 
be worth exploring the uptake and bio-distribution of fructose-derived glycated proteins in 
future studies. 
Significant variability between AGE-BSA and BSA uptake was observed in experiment 1 
and 2, and also between individual mice randomised to the same treatment and time points 
in this study. This variation may be explained by differences between peripheral and central 
blood collection points used between experiment 1 and 2. This would also explain why more 
native endogenous albumin was observed in gels from mouse experiment 1 contributing to 
background auto-fluorescence. It is possible that some of the variation may have arisen due 
to accidental delivery into the oral cavity, during withdrawal of the gavage needle. Absorption 
of albumin across the oral buccal mucosa has been demonstrated ex vivo and in vivo in 
rodent models [401, 402]. These studies also found a high degree of heterogeneity in oral 
absorption. It is unlikely that absorption through the oral cavity would be greater than the 
gastrointestinal absorption, but this may explain why intact albumin was observed in some 
mice and not others, in particular at 15 minutes. A small comparative study, examining direct 
and deliberate delivery to the oral cavity would resolve this. However, this was outside of 
the scope of the present study.  
As well as the intact ~66 kD band, a smaller band of ~15 kD was also present following 
SDS-PAGE of plasma, urine and tissue homogenates. These products were found to be 
present in the unbound dye prep and the IR-AGE and IR-BSA, and were not able to be 
removed by the desalting purification protocol used to remove unbound dye, nor by an 
additional size exclusion spin column step (data not shown). The presence of these products 
in the plasma, urine and organs of mice that received only the IR-Dye also suggests that 
there may be some aggregate or complex of the dye forming or some small peptides and 
protein fragments present in the preparations. These products were highest in the small 
intestine and the urine suggesting a large proportion were absorbed and cleared through 
the urine. It would appear, based on the very large aggregation of these smaller <15 kD 
band, that a significant proportion of the near IR dye becomes detached in the stomach and 
GI tract. In the future it would be worth using higher percentage gels and lower voltage SDS 
PAGE to improve the separation and resolution of the lower molecular weight products in 
these samples. However, it was largely for this reason and the limited utility for ex-vivo 
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microscopy, that I did not pursue this study beyond the pilot described here. It is also 
possible that these small products are due to dye separation during the preparation of the 
protein extracts, plasma, urine and dye prep for SDS PAGE. The reducing conditions of the 
dye prep likely resulted in some of the amide bonds binding the unbound dye being broken. 
As the unbound dye has a molecular weight of only 1.1 kDa, this might have aggregated 
into larger complexes explaining why a band was detectable in the 15kDa range. In the 
future, a native PAGE approach may yield better results. 
Conclusions 
Here we demonstrate a near infrared labelling strategy that allowed us to semi-quantitatively 
determine the fate of AGE modified and non-modified protein following acute intra-gastric 
delivery. AGE modified protein was absorbed within the same timeframe as the unmodified 
control protein appearing in the circulation rapidly, within 15 minutes. Both proteins show 
the same anatomical distribution, appearing predominantly in the circulation, the liver and 
small intestine. Further work is required to elucidate the mechanism behind this uptake. 
Although this labelling strategy has many strengths, it would appear that a significant 
proportion of the near infrared label is separated from the target protein following delivery 
into the stomach, representing the major limitation of this labelling approach.  
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Supplementary data 2 
Supplementary figures for chapter 2 
 
Supplementary Figure 2-1. Representative gels showing a single mouse outlier from animal 
experiment 2. 
Representative gels showing plasma (2 μl loaded), urine (2μl loaded) and liver (50 μg of protein 
loaded) from the mice randomised to the 1-hour time point in animal experiment two. A single 
mouse, that receiver IR-BSA showed extremely high uptake into the circulation, this mouse also 
showed high levels of excretion of this product into the urine and high levels in all tissues examined, 
but particularly the liver. The signal from this single mouse, was so bright that it caused significant 
difficulty imaging and quantifying.  
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Chapter 3: The effects of dietary AGEs on postprandial glucose 
homeostasis and eating behaviour. 
Abstract 
Background 
In rodent models time spent on a high AGE diet results in reduced insulin sensitivity and 
secretion, and elevates fasting blood glucose levels, independent of macronutrient intake. 
In humans, low AGE dietary interventions appear to improve insulin sensitivity and reduce 
fasting insulin concentrations. Despite this, little is understood about the postprandial effects 
of a high AGE intake on glucose homeostasis.  
Methods 
A pilot study using an oral AGE tolerance test (OATT) was conducted. Fasted healthy male 
C57Bl6/J mice (15 weeks of age, habituated to low (LAD) or high AGE (HAD) diets for 3 
weeks) received one of three dosages of AGE modified BSA (AGE-BSA) or unmodified BSA 
control (1 mg/kg, 5 mg/kg or 20 mg/kg, n=8-9/group for HAD, n=3 for LAD) by oral gavage. 
Blood was collected by tail bleed before gavage and then at 5, 15,30, 60 and 120 minutes 
post gavage for determination of blood glucose and plasma insulin concentrations. A subset 
(n=5) of these mice remained on their allocated high or low AGE diet for a further 5 weeks 
before undergoing indirect calorimetry using the Phenomaster system.  
Results 
Short (3 weeks) habituation to high or low AGE diets led to equivalent weight gain and fasting 
plasma insulin but tended to increase fasting plasma glucose concentrations (P=0.058). No 
effects of an acute AGE modified protein bolus (OATT) on insulin responses over 2 hours 
were observed at any dose, and habituation to a low AGE diet for 3 weeks prior to 
undergoing OATT did not change this. There was however, a statistically significant linear 
trend in HAD mice towards a dose dependent effect on net blood glucose concentrations 
(glucose AUC0-120) with increasing AGE-modified dosages (P=0.01). This wasn’t seen with 
unmodified control protein. Longer habituation (8 weeks) to a high AGE diet did not change 
food consumption, RER, physical activity or body temperature but did increase water intake 
compared to a low AGE diet in the small subset of these mice analysed. 
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Conclusions 
AGE modifications do not appear to acutely influence insulin response to protein in rodents. 
However, there was a dosage trend in post prandial glucose concentrations following 
intragastric AGE delivery. Further to this the AGE content of the diet does not appear to 
impact upon satiety sensing measures, eating behaviour nor metabolic rate in rodents.  
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Introduction 
Consumption of highly processed and heat treated foods has more than doubled, both in 
developed and developing nations over the past 60 years [403-405]. Concomitantly rising 
has been the incidence of chronic diseases such as diabetes mellitus and associated 
complications, CKD, Alzheimer’s disease and cancer [404]. Increased consumption of heat 
treated and highly processed foods also contributes to obesity, insulin resistance and other 
aspects of the metabolic syndrome which are risk factors for many chronic diseases [406]. 
One important factor increased by food processing are the quantities of AGEs present in 
foods [407] and it is widely accepted that the most highly processed food and beverages 
contain the highest quantities of AGEs [142, 243]. Although there are limited observational 
studies quantifying the change in dietary intake of AGEs over the past 50-100 years, it has 
been estimated that for a modernised country that AGE consumption has almost tripled in 
the past 60 years [360].  
This increased prevalence and consumption of dietary AGEs is a likely contributor to the 
adverse pathology associated with excessive intake of processed foods [241]. In vitro, high 
AGE treatment has been found to impair insulin signalling in skeletal muscle cells and 
adipocytes [290-292, 408]. In animal models, increased consumption of AGEs, via the diet 
or by daily injections of AGE modified proteins such as bovine serum albumin (BSA), 
reduces insulin sensitivity, and elevates fasting blood glucose levels [285, 287, 294]. This 
appears independent of macronutrient and caloric intake, and adiposity [287]. Similarly, in 
animal models which include obesity and hyperphagia such as the db/db mouse model of 
T2DM and high fat fed C57BL/6J, decreasing dietary AGE intake results in weight loss, and 
improves glucose tolerance and islet morphology [284, 285]. More recently, studies have 
shown that maternal restriction of dietary AGEs can impact glucose control in the offspring 
of mice susceptible to T1DM development [298, 409]. Similarly, chronic exposure to high 
dietary AGE consumption over 4 generations, in otherwise healthy mice leads to cumulative 
increases in adiposity and insulin resistance in each subsequent generation [294].  
In human studies, there is also mounting evidence that dietary AGEs influence metabolic 
health. In young healthy university students, consumption of a high AGE diet, as compared 
to a low AGE diet matched for macronutrient intake, decreased insulin sensitivity and 
increased plasma cholesterol and triglycerides [304]. Similarly, in overweight but otherwise 
healthy individuals, a randomised cross-over study showed that as little as two weeks of 
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consumption of a low AGE diet can improve insulin sensitivity, while two weeks of a high 
AGE diet tended to decrease insulin sensitivity [305]. These findings were supported by a 
recent meta-analysis which concluded that reducing AGE consumption improves insulin 
sensitivity and reduces fasting insulin, HDL and LDL cholesterol and fasting leptin 
concentrations [410]. Increasing the AGE content of a single meal can also acutely increase 
post prandial glycaemia and increase ghrelin in overweight individuals [411] as well as 
significantly reduce post-prandial leptin concentrations in individuals with T2DM [412]. 
Despite mounting evidence that high AGE intake alters risk for metabolic disease, only two 
studies to date have used indirect calorimetry to study the effects of high and low AGE diets 
on metabolism [270, 413]. The first of these studies examined the effects of 12 weeks of 
CML supplementation by gavage in conjunction with a high fat diet, reporting increases in 
RER and thermogenesis. However, in that study, no group received CML without the 
modified fat content, making it difficult to differentiate the effects of AGEs from those of the 
high fat diet. The second study, which only reported activity counts, food intake, RER and 
heat production, found no changes in any parameters between C57BL6/J male mice fed on 
a normal chow diet or a high AGE baked diet for 24 weeks, but only included a 12-hour 
acclimatisation period prior to data collection. Both studies used the Comprehensive Lab 
Animals Monitoring System (CLAMS). 
Taken together, the research to date suggests that prolonged consumption of a diet high in 
AGE content can influence glucose homeostasis in rodent models and humans. However, 
little is understood about whether acute intake of a high AGE meal has immediate effects 
on post prandial insulin secretion and sensitivity and plasma glucose levels. Furthermore, 
few studies have used indirect calorimetry to explore the systemic effects of dietary AGEs 
on feeding behaviour, the utilisation of specific fuels for energy generation and 
thermogenesis. Given, that our preliminary study in chapter 2 suggests that ingested AGE-
BSA is able to enter the circulation rapidly after intragastric delivery, we aimed to determine 
whether ingestion of a high AGE load could immediately influence glucose or insulin 
responses in the body. To examine this, we performed a pilot experiment in healthy mice 
using an orally delivered AGE bolus followed by timed collection of blood samples for 2 
hours post-delivery. Additionally, we examined the effect of chronic feeding of high and low 
AGE diets to healthy mice on food consumption, fluid intake, activity, body temperature and 
respiratory exchange ratio, using the Phenomaster indirect calorimetry system.  
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Aims and Hypotheses  
Aim 1: To develop a protocol to test the effects of AGEs on the post-prandial glucose and 
insulin response to an oral protein bolus. 
Aim 2: To determine whether a high AGE diet compared to a low AGE diet, alters feeding 
behaviour, respiratory exchange rate and thermogenesis.  
Hypotheses: 
1. Highly AGE modified proteins acutely modify post-prandial plasma glucose and insulin 
responses in a dose dependent manner. 
2: Chronic AGE feeding does not affect food and water consumption, activity, but decreases 
metabolic rate.  
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Methods 
Animal work 
Animal Husbandry 
Healthy male C57BL/6J mice (10-11 weeks of age) were purchased from the Animal 
Resource Centre (Perth, Australia) and acclimatised for at least one week after transport. 
Groups of mice were randomised to consume isocaloric diets from 12 to 15 weeks of age 
which were either low in AGEs (AIN93G, Specialty Feeds, Perth, Australia, LAD; n=6/group) 
or high in AGE content (AIN93G, Specialty Feeds, Perth, Australia, baked 1hr, 160°C; HAD; 
n= 52). At week 15, all mice were given an oral AGE-protein bolus (oral AGE tolerance test; 
OATT) as described below. Mice were acclimatised to handling over a 2-week period prior 
to the AGE tolerance test. A subset of 12 mice, remained on the high and low AGE diets for 
an additional 5 weeks after which indirect calorimetry was performed at 20 weeks of age. All 
animal work was approved by the Animal Ethics Committee, University of Queensland, 
Australia and adhered to the NHMRC guidelines for animal handling (Appendices 2). 
AGE tolerance test (OATT) 
All AGE tolerance tests were performed during the active phase for mice, after 8pm. On the 
day of the experiment, mice were weighed and then fasted with ad libitum access to water 
for 4 hours from 4 pm to 8 pm, after which point they underwent the OATT (Figure 2-1). 
Groups of mice (n=8) were randomised to intragastric gavage of either AGE-modified bovine 
serum albumin (AGE-BSA) delivered at 1 mg/kg, 5 mg/kg or 20 mg/kg, or unmodified BSA 
delivered at the same protein concentrations. An additional control group (n=8) received an 
equivalent volume of vehicle (drinking water). Table 1 shows the specific AGE dose 
delivered, expressed as the dose of AGE modifications of carboxymethyllysine (CML), 
carboxyethyllysine (CEL) and methylglyoxal derived hydroimidazolone (MG-H1). The CML, 
MG-H1 and CEL content was ~40 fold higher in the AGE-BSA bolus, when compared to the 
equivalent unmodified BSA bolus. Blood glucose was monitored (SensoCard Glucose 
Meter, 77 Elektronika, Budapest, Hungary) at baseline, 5, 15, 30 minutes, 1 hour and 2 
hours post AGE-BSA or BSA gavage by tail tipping. At each time point 30μl tail vein blood 
samples were collected into tubes containing 5 μl of sodium citrate, flick mixed and placed 
on ice until centrifugation. Samples were centrifuged at 6000 x g for 6 minutes at 4ᵒC and 
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the plasma transferred to a clean 0.6 ml Eppendorf tube and stored at -80ᵒC for assessment 
of plasma insulin concentrations. 
Rationale behind the dosing used.  
AGE-BSA and BSA were prepared as previously described in chapter 2 of this thesis 
according to Coughlan et al., [286]. The AGE content of the stock solutions is shown below 
(Table 3-1). As lysine is the primary site of AGE modification, the AGE content is also shown 
relative to total lysine available for modification. 
Table 3-1. AGE content of the AGE-BSA and BSA stock solutions used. 
  AGE (nmol) 
ID CML CEL MG-H1 
AGE-BSA 222903 52334 163842 
BSA 5956 1373 7273 
  AGE (nmol/mmol LYS) 
AGE-BSA 29149 6844 21426 
BSA 222 51 271 
Concentrations of the AGEs, CML, CEL and MG-H1 are shown in units of nanomoles and nanomoles 
per millimole of lysine available for modification (nmol/mmol LYS).  
The dosing strategy chosen in this study was based on previous studies by our group which 
demonstrated that rodent chow high in AGE content contains approximately 101.9 nmol of 
the AGE, CML per 100 g (Forbes, unpublished data). The average C57BL/6J mouse 
consumes approximately 3.5-4.5 g of chow per day [414] which equates to between 3 and 
5 nmol of CML. Therefore, the 5 mg/kg AGE-BSA bolus was chosen to reflect this given that 
a 26 g mouse would receive 3.4 nmol of CML as a single oral challenge. As this was a pilot 
study, we also used doses five-fold lower and four-fold higher for comparison. Table 3-2 
outlines each dose and the relative quantities of protein, lysine and the commonly studied 
AGE, CML delivered per gram of mouse.  
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Table 3-2. Dosing strategy for Oral AGE Tolerance Tests (OATT). 
Dose 
Protein              
μg / g bw 
lysine (pmol 
/g bw) 
CML (pmol / g 
bw) 
AGE-BSA 1 mg/kg 2.00 894 26 
AGE-BSA 5 mg/kg  10.00 4470 130.2 
AGE-BSA 20 mg/kg  40.00 17879 520.9 
BSA 1 mg/kg 2.00 894 0.2 
BSA 5 mg/kg 10.00 4470 1.0 
BSA 20 mg/kg 40.00 17879 4.0 
Relative dose of total protein, lysine and the AGE, CML per gram (g) of body weight (bw) are shown 
for AGE modified BSA (AGE-BSA) and BSA control protein.  
 
Indirect Calorimetry 
At 18 weeks of age, 12 mice (6 maintained on a low AGE diet and 6 maintained on a high 
AGE diet, HAD were anaesthetised using isoflurane (Oxygen 1 L/min, isoflurane 2.5%) and 
had a G2 E-mitter (Starr Life Sciences Corp, Oakmont, USA) implanted into their peritoneal 
cavity to collect body temperature and physical activity. The E-mitters were passed through 
a small abdominal incision (7 to 12 mm) and fastened to the abdominal wall. The internal 
wall was sutured and the external abdominal wall secured with surgical staples. The 
analgesic Carprofen (5 mg/kg body weight) was immediately delivered subcutaneously and 
topical lignocaine cream applied which continued post-surgery as required. Two mice were 
removed from the study one with poor recovery from surgery and one with a faulty E-mitter 
leaving 5 mice per group in the study. Immediately following surgery, mice had their light 
and dark cycle shifted by 13 hours to facilitate testing during their active (dark) phase. After 
two-weeks, mice were housed individually and acclimatised to the Phenomaster home-cage 
system (TSE Systems, Bad Homburg, Germany), with ad-libitum access to food and water, 
a 12-hour light/dark cycle and at an ambient temperature of 23°C. During all of these 
procedures, mice were maintained on the same high or low AGE diet assigned at the start 
of the study. Following acclimatisation for one week, mice underwent 2-3 days of baseline 
recording of activity, body temperature, gas exchange as well as food and water intake. 
Biochemical Assays 
Plasma insulin was measured by ELISA (Ultrasensitive insulin ELISA, Crystal Chem Inc., 
Illinois, USA). The assay performed as per the manufacturer’s instructions for small sample 
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volumes, using the wide range standard curve. For insulin there were 3 mice where insulin 
concentrations at one or more time points was below the detectable limit of the ELISA; 
usually this was due to the amount of plasma collected being of insufficient volume, these 
mice were excluded from the insulin analysis such that there were N=7 rather than N=8 in 
the following groups; BSA (5mg/kg), AGE-BSA (1mg/kg) and AGE-BSA (5mg/kg).  
Glucose to insulin ratio 
Blood glucose values were expressed as ng/ml. The ratio of glucose in ng/ml to insulin in 
ng/ml was then calculated at each time point where both values were present.  
Statistical Analysis 
Statistical analysis was performed using GraphPad, Prism 7. Difference in glucose and 
insulin responses over time were plotted and analysed by 2 way repeated measures ANOVA 
(2 way rmANOVA) followed by post hoc testing using Dunnett’s test. AUC was calculated 
using the trapezoidal rule, where all time points were available. Four mice were excluded 
for AUC insulin0-120 as data for at least one time point was below the detectable limit. Data 
were tested for normality using the Shapiro-Wilk test. Baseline characteristics and Area 
Under the Curve (AUC) were compared by student’s T test or one-way ANOVA with post 
hoc testing by Bonferroni’s multiple comparisons testing, where data were normally 
distributed, or the Kruskal-Wallis test, followed by Dunn’s multiple comparisons testing 
where data violated the assumption of normality. Post-test for linear trend was also 
undertaken, where appropriate. All data is presented as the mean and standard deviation 
unless otherwise stated.  
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Figure 3-1. Schematic of experimental design.  
Abbreviations: AGE-BSA, AGE modified bovine serum albumin; BSA, Bovine Serum Albumin; LAD, Low AGE diet; HAD, High AGE diet 
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Results 
Metabolic characteristics following three weeks on LAD or HAD 
Figure 3-2. A diet high in AGEs fed from week 12-15 of life alters glucose homeostasis without 
affecting body weight in healthy adult mice. 
A) Fasting blood glucose concentrations; B) Fasting plasma insulin concentrations and C) Body 
weight; at 15 weeks of age in healthy C57BL/6J mice that received a high AGE diet (HAD; red, n=54) 
or an isocaloric low AGE diet (LAD; green, n=6) for 3 weeks.  
At baseline, prior to OATTs, following three weeks of consumption of a high AGE diet, adult 
mice (15 weeks of age) had fasting blood glucose concentrations that tended to be elevated 
as compared to mice that consumed a low AGE diet (Figure 3-2 A). However, there was no 
difference in fasting plasma insulin concentrations or body weight between groups at this 
time (Figure 3-2 B and C).  
AGE modification appears to have a dose dependent effect on postprandial glucose 
homeostasis following a protein bolus in mice.  
Intragastric gavage of a protein bolus (BSA) induced no statistically significant changes in 
plasma glucose concentrations at any dose (Figure 3-3 A-C). This was further supported by 
comparison of AUC glucose0-120 which showed no statistically significant effect of BSA 
dosage (Figure 3-3 D). In contrast, intragastric delivery of either a 1 mg/kg or 20 mg/kg AGE 
modified protein bolus, significantly decreased plasma glucose at later time points, t=60 and 
t=120 minutes’ post bolus (Figure 3-3 A and C). A trend towards increasing AUC glucose0-
120 was observed with increasing AGE-BSA boluses (Figure 3-3 E) (P=0.012), which was 
not seen with unmodified BSA (Figure 3-3 D). However, when AUC glucose0-120 were 
compared between equivalent BSA and AGE-BSA dosages or to AUC glucose0-120 for 
vehicle (Supplementary Figure 3-1), no statistical differences were found (Supplementary 
Tables 3-1 and 3-2) making these results difficult to interpret. 
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Figure 3-3: Advanced glycation end products appear to have a dose dependent effect on the post-
prandial glucose response to a protein bolus in healthy mice. 
Healthy C57BL/6J mice (n= 8/group) were maintained on a HAD from 12-15 weeks of age at which 
point they underwent OATTs. A-C Peripheral blood glucose curves over time following an oral AGE 
modified protein or a matched control protein bolus, delivered at 1 mg/kg (A), 5 mg/kg (B), and 20 
mg/kg (C) (n=8-9 per group). D-E Glucose AUC0-120min, in mice that received BSA control (D) or the 
AGE-BSA bolus (E). Curves were analysed by 2 way rmANOVA with post hoc multiple comparisons 
testing by Dunnett’s test; † P<0.05 compared with time=0 in mice that received the AGE modified 
protein bolus. AUC were compared by one-way ANOVA with post hoc testing for trend.  
Short exposure (3 weeks) to a low AGE diet did not change the post-prandial glucose 
response to glycated protein in healthy mice. 
Mice fed a low AGE diet, experienced equivalent increases in circulating glucose 
concentrations in response to both AGE-BSA and BSA (Figure 3-4 A and B), with significant 
rises in glucose at 5 and 15 minutes post-bolus. However, there were no differences in the 
glucose AUC0-120 between diets (Figure 3-4 C and D, Supplementary Table 3-3). 
 
90 
 
Figure 3-4. Short term consumption of a low AGE diet did not change the physiological glucose 
homeostasis response to a protein or AGE-modified protein bolus. 
Male C57Bl6/J mice were fed diets with AGE contents that were either low (LAD) (n=3/group) or high 
(HAD) (n=8/group) from weeks 12-15 of life. At 15 weeks of age mice underwent OATTs. A-B, 
Peripheral blood glucose curves over 2 hours following a 5 mg/kg oral protein bolus (BSA; blue HAD, 
purple LAD) (A) or a matched AGE modified protein bolus (AGE-BSA; green HAD, orange LAD) (B). C-
D, glucose AUC0-120min, in mice that received the BSA control (C) and mice that received AGE-BSA (D). 
Curves were analysed by 2 way rmANOVA with post hoc multiple comparisons testing by Dunnett’s 
test; ‖ P<0.05 compared with time = 0 in LAD fed mice that received the control BSA protein bolus. § 
P<0.05 compared with time = 0 in LAD fed mice that received the AGE modified protein bolus. 
 
High AGE modification does not alter postprandial insulin response to protein in 
healthy mice.  
In all groups of mice maintained on the high AGE diet, oral gavage with BSA elicited a rapid 
decrease in plasma insulin concentrations within the first 5 minutes post gavage regardless 
of glycation. Except in the mice that received 20 mg/kg AGE-BSA, which did not show a 
decrease until 30 minutes post gavage (Figure 3-5 A-C). The decrease in insulin was 
consistently observed across a number of time points during the OATTs, at all three dosages 
and treatments, (Figure 3-5 A-C).Two way rmANOVA confirmed that both AGE-BSA and 
BSA influenced insulin secretion in a time dependent manner (P<0.05), but did not differ 
from each other. Analysis of insulin AUC0-120 showed no dose effect of AGE-BSA (Figure 
3-5 E) or BSA control (Figure 3-5 D) nor differences between BSA and AGE-BSA at 
equivalent dosages (Figure 3-5 D and E, Supplementary Table 3-5). Furthermore, when 
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insulin AUC0-120 for any dosages of BSA or AGE-BSA were compared to insulin AUC0-120 for 
vehicle (Supplementary Figure 3-1) no significant differences were found (Supplementary 
Table 3-6). 
 
Figure 3-5. Advanced glycation end products do not change the insulin response to a protein bolus 
in healthy mice. 
Healthy C57BL/6J mice (n= 8/group) were maintained on a HAD from 12-15 weeks of age at which 
point they underwent OATTs. A-C Peripheral plasma insulin curves over time following an OATT with 
AGE modified protein (AGE-BSA) or a matched control protein bolus (BSA), delivered at 1 mg/kg (A), 
5 mg/kg (B), and 20 mg/kg (C). D-E Insulin AUC0-120min, in mice that received the BSA control (D) or 
the AGE-BSA bolus (E). Curves were analysed by 2 way rmANOVA with post hoc multiple comparisons 
testing by Dunnett’s test; † P<0.05 compared with time=0 in mice that received the AGE modified 
protein bolus, ‡ P<0.05 compared with time=0 in mice that received the BSA control protein bolus. 
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Short term exposure to a low AGE diet did not change the post prandial insulin 
response to glycated protein in healthy mice. 
In mice fed a low AGE diet for 3 weeks prior to the OATT, those that received BSA 
experienced no change in plasma insulin concentrations from baseline (Figure 3-6 A). 
Furthermore, they did not differ in their insulin response from mice from the HAD group that 
received BSA (Figure 3-6 C, Supplementary Table 3-7). Mice from the LAD group that 
received AGE-BSA did demonstrate a decrease in plasma insulin at 30 minutes post bolus 
which was sustained until the test completion at 120 minutes (Figure 3-6 B). Regardless of 
this reduction in insulin, LAD fed mice that received AGE-BSA did not differ from the HAD 
group that received AGE-BSA when the curves or insulin AUC0-120 were compared (Figure 
3-6 D, Supplementary Table 3-7). Nor were there differences between LAD fed mice that 
received BSA and those that received AGE-BSA. 
Figure 3-6. Glycation does not alter the insulin secretion response to a protein bolus in low AGE 
habituated mice. 
Male C57BL/6J mice were fed diets either low (LAD)(n=3/group) or high in AGEs (HAD) (n=8/group) 
for 3 weeks from weeks 12-15 of life. At 15 weeks of age mice underwent OATTs A-B, plasma insulin 
curves over time following a 5 mg/kg oral protein bolus (BSA; blue HAD, purple LAD)) (A) or a 
matched AGE modified protein bolus (AGE-BSA; green HAD, orange LAD) (B). C-D, glucose AUC0-120min, 
in mice that received the BSA control (C) and mice that received AGE-BSA (D). Curves were analysed 
by 2 way rmANOVA with post hoc multiple comparisons testing by Dunnett’s test; † P<0.05 compared 
with time=0 in HAD mice that received the AGE modified protein bolus, ‡ P<0.05 compared with 
time=0 in HAD mice that received the BSA control protein bolus. § P<0.05 compared with time=0 in 
LAD mice that received the AGE modified protein bolus.  
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High AGE modification does not alter postprandial glucose disposal response to 
protein in healthy mice.  
 
Figure 3-7. Glucose to insulin ratio (glucose disposal) in response to a high or low AGE protein 
bolus was not altered by protein dose or AGEs.   
A-C Glucose to insulin ratio curves and the associated AUC plots following an oral AGE modified 
protein or a matched control protein bolus, delivered at 1 mg/kg (A), 5 mg/kg (B), and 20 mg/kg (C). 
D-E Glucose:Insulin AUC0-120min, in mice that received the BSA control (D) or the AGE-BSA bolus (E). ‡ 
denotes a difference from baseline in mice that received the BSA control protein bolus based on 2-
way ANOVA, post hoc multiple comparisons testing (Dunnett’s test) (P<0.05). No statistical 
differences were found between treatments. 
 
In mice receiving the high AGE diet, (Figure 3-7 A-C) the glucose to insulin ratio remained 
at levels equivalent to baseline throughout the OATT at all three dosages, except in the 20 
mg/kg BSA control group where a large peak 15 minutes post-bolus was observed (Figure 
3-7 C). Analysis of AGE-BSA and BSA curves by 2 way rmANOVA did not reveal a dose 
effect, an effect of time, or an interaction of dose and time in any groups except the 20 mg/kg 
BSA group. No difference was observed between any of the groups when glucose:insulin 
AUC0-120 were compared (Figure 3-7 D and E, Supplementary Table 3-9). 
  
94 
 
In the low AGE fed mice the glucose:insulin ratios throughout the OATTs remained similar 
between LAD and HAD mice given either a BSA (Figure 3-8A) or an AGE-BSA (Figure 3-8 
B) protein bolus (5 mg/kg) and did not differ from baseline levels in any group at any time 
point. Similarly, glucose:insulin AUC0-120 between groups given a BSA or AGE-BSA bolus 
were not different (Figure 3-8 C and D, Supplementary Table 3-11), and did not differ from 
the mice that received vehicle only (Supplementary Table 3-12). 
Figure 3-8. Glycation does not alter glucose:insulin ratios in response to a high or low AGE protein 
bolus in low AGE habituated mice. 
Male C57BL/6J mice were fed diets either low (LAD)(n=3/group) or high in AGEs (HAD) (n=8/group) 
from weeks 12-15 of life. At 15 weeks of age mice underwent OATTs A-B, Glucose to insulin ratio 
curves over time following a 5 mg/kg oral protein bolus (BSA 5 mg/kg; blue HAD, purple LAD)) (A) or 
a matched AGE modified protein bolus (AGE-BSA 5 mg/kg; green HAD, orange LAD) (B). C-D, 
Glucose:Insulin AUC0-120min, in mice that received the BSA control (5 mg/kg) (C) and mice that received 
AGE-BSA (5 mg/kg) (D). No statistical differences were observed. 
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Indirect calorimetry of mice following 8 weeks of high or low AGE diets 
 
Figure 3-9. In healthy adult male mice, body weight and food intake were not influenced by dietary 
AGE consumption. 
Healthy male C57Bl6/J mice consumed either a LAD (green) or HAD(red) diet for 8 weeks prior and 
during indirect calorimetry (n=5 per group). At 20 weeks of age indirect calorimetry was performed 
using the Phenomaster system. (A) weekly body weight prior to and during calorimetry, (B) 24-hour 
food intake curve, 24 hr mean and diurnal mean food intake; (C) 24-hour water intake curve, 24 hour 
and diurnal mean water intake. Statistical analysis on curves was performed by 2 way rmANOVA, P 
values for the independent effect of diet and interactive effect of time and diet are shown; 24-hour 
total intake was analysed by student’s T test, diurnal intake was analysed by one-way ANOVA with 
post hoc testing. Dark (active) phase is indicated by the shaded area * indicates statistical 
significance (P≤0.05).  
A subset of mice remained on their allocated high or low AGE diets for an additional 5 weeks, 
to a total of 8 weeks, before undergoing indirect calorimetry. Weight gain was equivalent 
between high and low AGE diet fed mice, including during acclimatisation to reverse light 
cycling and the phenomaster home cage (Figure 3-9 A). Consistent with this, indirect 
calorimetry did not show any influence of dietary AGE content on 24 hour food consumption 
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or eating patterns (Figure 3-9 B). Total water intake tended to be greater in mice consuming 
a high AGE diet (Figure 3-9 C), but this did not reach significance (P=0.06).  
 
Figure 3-10. Dietary AGE consumption did not influence respiratory exchange rate, physical 
activity or body temperature in healthy adult male mice. 
Indirect calorimetry using a Phenomaster system. Mice consumed either a low AGE (green) or high 
AGE (red) diet for 8 weeks prior and during indirect calorimetry (n = 5 per group). 24hour repeated 
collection and 24hr and diurnal means for respiratory exchange ratio (RER) (A), physical activity 
(counts) (B) and body temperature (C). Data are plotted as group means ± SD. (n = 5 per group). 
Curves show, repeated collection over 24 hours, with P values for the independent effect of diet and 
the interaction of diet and time reported; dot plots show the mean for 24 hours and separated for 
diurnal light and dark phase, (grey shading indicates dark phase, white background indicates light 
phase). Statistical analysis on curves was performed by 2 way rmANOVA in GraphPad Prism 7. P 
values for the independent effect of diet and interactive effect of time and diet are reported; 24-hour 
means were analysed by T test and light and dark phase means were analysed by one-way ANOVA 
with post hoc testing. * indicates statistical significance (P≤0.05). 
Mice on low and high AGE diets demonstrated normal diurnal rhythm in their respiratory 
exchange ratio (RER) (Figure 3-10 A) which approached 1 during the dark (active) phase 
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and was lower, approaching 0.8 during the light (inactive) phase (Figure 3-10 A). There were 
no differences, between mean RER over 24 hours, or during the active and inactive phase 
between diets (Figure 3-10 A). When activity over time curves were compared by 2 way 
rmANOVA, the interactive effect of diet and time was significant (P<0.006), and independent 
effect of time, was also observed (P<0.001;Figure 3-10 B). Mice on the low AGE diet had 
significantly greater intergroup variation and when mean activity counts were compared by 
T test, with Welch’s correction for unequal variance there was no significant difference 
between groups. Diurnal temperature pattern was normal between both groups and did not 
differ between the two diets over 24 hours or during the dark or light phases (Figure 3-10 
C).  
Discussion 
Main findings from the OATTs, comments on the experimental rationale and existing 
data. 
Long term studies show that chronic consumption of a diet high in AGE content alters 
metabolism and glucose handling in a manner that may be pathological to rodents and 
humans. However, little is understood about acute physiological responses to orally ingested 
AGEs. Here, we conducted a pilot study in mice to examine the acute glucose and insulin 
responses to a gastrically administered AGE bolus. For this study, we chose a glycated 
protein bolus as our test treatment, since typically glycated animal proteins are a major 
contributor to dietary AGE intake [241]. Furthermore, as protein elicits significantly lower 
gluconeogenic response compared to a mixed meal test or carbohydrate meal [415], we 
anticipated that any gluconeogenic effect from AGEs, were less likely to be masked by co-
administered dietary components. Previous research by our group demonstrated increases 
in fasting blood glucose after 24 weeks consuming a diet high in AGE content in rodents 
[286]. In the present study, despite only a short run in period, we found that consumption of 
a high AGE diet for 3 weeks tended to elevate blood glucose concentrations, consistent with 
previous studies [416]. However, this did not influence glucose responses after an acute 
oral AGE bolus, although some subtle variation in the effects over time were observed. 
There was a trend towards an increase in the glucose AUC0-120 with increasing AGEs. 
Despite this trend, and the temporal differences observed glucose AUC0-120 and insulin 
AUC0-120 showed no overall difference to control mice that received water. Furthermore, 
there was not significant difference between mice that received AGE-BSA and BSA at 
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equivalent dosages, calling into question this trend effect and suggesting that acutely, at the 
dosages tested, AGEs do not significantly raise glucose levels through impairing insulin 
secretion. The aforementioned trend however, does indicate that increasing the group 
numbers as well as the number of dosages tested could be warranted to determine if a AGE 
mediated dose effect real.  
AGEs and post prandial hormonal regulation in humans and animals. 
To my knowledge, a protocol equivalent to the OATT has not been tested in rodent models. 
However, the findings are somewhat consistent with mixed meal tests in humans, where 
meals were prepared either using high or low AGE generating cooking methods [411]. In 
these human studies, the AGE content of the food did not acutely influence plasma insulin 
or the concentrations of other hormones involved in glucose and appetite regulation [411]. 
Despite this, a high AGE meal did acutely increase blood glucose concentrations one hour 
post-prandially as compared with the low AGE meal [411]. Interestingly, in the rodent study 
described in this chapter, blood glucose actually decreased at both the lowest (1 mg/kg) and 
the highest dose AGE-BSA tested (20 mg/kg), with T60 and T120 blood glucose levels 
dropping below fasting levels. The reasons for this remain unclear as there was no specific 
elevation of insulin noted at these times and this effect warrants future investigation.  
We hypothesised that an AGE-BSA bolus would reduce insulin levels, compared to the BSA 
bolus. Previous studies that have artificially raised AGE levels in animal models through 
chronically administering AGE-BSA show significant insulin secretory defects [286, 295], in 
agreement with studies in  cells and isolated islets [286, 417]. In humans, there is also 
evidence that dietary AGEs influence insulin secretion and sensitivity [305, 418], but most 
commonly these are in chronic contexts. In the present study however, we did not observe 
an acute effect of a single AGE bolus on insulin secretion. However, given chronic exposure 
was used in the aforementioned animal models [286, 295] and high concentrations delivered 
to islets and cells in these previous studies [286, 417] this discordance is not surprising. 
Taken together, these data suggest that although a single acute oral bolus of AGEs may not 
immediately alter insulin secretion, repeated exposure to dietary AGEs does adversely 
impact insulin secretion and is likely the result of chronic systemic effects. 
The fact that we and others [411] acutely see a subtle trend in glucose response but not 
insulin signalling suggests that dietary AGEs may subtly modulate gluconeogenic pathways 
through mechanisms independent of insulin. The data presented in chapter 2 of this thesis, 
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in conjunction with previous studies, suggest that ingested AGEs largely interact with the 
gut, but those that are absorbed commonly traffick to the liver and are cleared, 
predominantly by the kidney [270]. Given the gut, the liver and the kidneys are major 
contributors to glucose homeostasis AGEs may impact upon any or all of these sites 
affecting glucose release and mobilisation from these organs. Further research is required 
to investigate this. Particular focus should be paid to the effect of ingested AGEs on the 
function of the entero-endocrine cells following a meal or protein bolus. In particular, to 
elucidate whether the AGE content of a meal or protein bolus impacts on post-prandial levels 
of incretin hormones, GIP and GLP-1 and glucagon secretion. We have previously identified 
that rats chronically fed a high AGE diet for 24 weeks have lower plasma GLP-1 
concentrations when compared to a low AGE diet [287]. However, contrary to this Mark et 
al. did not find any effects of dietary AGEs on GLP-1 in overweight women [242]. In that 
study, the high and low AGE diets were supplemented with high fructose or high glucose 
drinks which may have masked any acute AGE effects, which appear, at least from the data 
reported here, to be subtle. Interestingly there is also some evidence that AGE modification 
impacts upon satiety regulation at the biochemical level. At least one study to date has found 
increased postprandial ghrelin following a high AGE meal compared to an isocaloric low 
AGE meal in overweight individuals. Further research characterising the effect of AGEs in 
the diet on incretin hormones and gastrointestinal cells is required.  
Comments on high AGE diets, feeding behaviour and metabolism. 
There is a paucity of data examining if AGEs affect food preferences and intake in rodents. 
There have only been two studies to date that have used indirect calorimetry to assess the 
effect of AGEs on respiration, food and water consumption and animal behaviour, with both 
studies utilising the CLAMS system [270, 413] In the present study, there were no effects of 
dietary AGEs on food consumption, RER, body temperature. However, a trend towards 
increased water intake was observed. Consistent with our findings, neither previous studies 
utilising CLAMS reported differences in RER, food and water consumption or activity (where 
measured)  [270, 413]. Li et al. did report increased thermogenesis in Sprague Dawley rats, 
following 12 weeks on a high fat diet with additional daily gavage with free CML [413]. This 
could be due to the longer duration on a high AGE protocol in that study or an interaction of 
AGEs with high fat feeding. However, given their control group did not receive sham gavage, 
it is plausible that this increased thermogenesis was due to increased stress associated with 
daily gavage, as repetitive non-thermal stress is associated with increases in brown adipose 
100 
 
tissue and thermogenesis [419]. We did see an interaction of time and diet on activity levels, 
with LAD fed mice appearing to have higher activity levels. However, no mean differences 
were found for 24 hour, or light and dark phase comparisons. This suggests that mice on 
the high AGE diet were active at different times throughout the 24 hour data collection period 
compared to their low AGE counterparts. There was significantly greater intergroup variation 
in the LAD mice, as indicated by the large standard deviation and although body 
temperature, RER and feeding behaviour curves showed appropriate diurnal rhythm, this 
diurnal rhythm was less evident in the activity curves. It is not clear from the data why this 
was the case, as the E-mitters implantation was successful and the temperature data also 
collected by the E-Mitters appears robust. Taken together, we can conclude that in the 
timeframes studied to date, AGEs do not induce changes on overall metabolic rate and fuel 
utilisation or feeding behaviour.  
Limitations and challenges 
There were limitations to this study that warrant discussion. Given this study was designed 
as a pilot, the lack of statistically significant changes in response to AGEs may have simply 
been a statistical Type II error, the product of small n numbers, with only 8 mice per group 
and n=3 in the LAD groups. Based on the effect size observed in this pilot however, we 
calculated that we would need greater than 30 mice per group to reach significance, 
suggesting the effect size of AGE consumption on glucose and insulin at the dosages tested 
here is minimal and might not explain the chronic changes observed in longer AGE feeding 
studies. Based on this power calculation, we did not pursue this study further within the 
scope of this PhD.  
A further challenge of this study is that the specific AGE concentration which may have the 
greatest impact on insulin and glucose responses in vivo remains unknown. Therefore, this 
pilot was designed to investigate both whether this line of reasoning was worth pursuing and 
to determine the optimal physiologically relevant dosages. Indeed, the dosage strategy was 
an attempt to detect physiological responses to AGE modified protein, without these being 
masked by protein responses. Furthermore, we also wished to match the middle dose to 
that being given in the uptake and trafficking experiments (chapter 2), which were based on 
previous human dietary data. Additionally, no preliminary data were available for power 
calculations and hence it appears that this study was underpowered to observe the small 
effect sizes that may be present from acute dietary AGEs exposure on glucose and insulin 
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concentrations, if any. Although not statistically significant, a moderate stress response to 
vehicle only gavage was noted. Previous studies, have highlighted that oral gavage is a 
highly stressful technique for animals and they do not habituate well to the technique even 
with significant training [420]. Hence, any future experiments should be higher powered, 
should be performed by a single operator and should consider alternative delivery methods 
to reduce the stress response. Additional to this, reducing the number of time points for 
blood collection should be considered as this would facilitate the collection of plasma 
volumes sufficient for analysis of other circulating factors such as incretin hormones or 
glucagon; which we were unable analyse here, due to the limited plasma able to be 
collected. Finally, inclusion of a marker of gastric emptying would also be worthwhile.  
Conclusion  
These data taken together, suggest that the AGE content of a meal does not acutely impact 
upon satiety sensing measures, eating behaviour nor metabolic rate in rodents. 
Furthermore, AGE modifications do not appear to acutely influence insulin response to 
protein. However, there was a trend towards ab AGE dose dependent effect on post prandial 
glucose concentrations following acute intragastric AGE delivery, but further studies would 
be required to substantiate this.  
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Supplementary Data 3.  
 
Supplementary Figure 3-1. Circulating blood glucose, plasma insulin and glucose to insulin ratio in 
control mice that received water only. 
Healthy C57BL/6J mice (n= 8) were maintained on a HAD from 12-15 weeks of age at which point 
they underwent OATTs receiving only the vehicle (H2O) control. (A) Peripheral blood glucose curve 
over time; (B) Peripheral plasma insulin curves over time; (C) Glucose to Insulin ratio over time during 
an OATT in mice that received vehicle (H2O) only. 
 
Supplementary Table 3-1. Supplementary statistics table for figure 3-3 
Comparison of glucose AUC0-120 at equivalent BSA and AGE-BSA dosages 
Dunn's multiple comparisons test Significant 
BSA 1mg/kg vs. AGE-BSA 1mg/ml ns 
BSA 5mg/kg vs. AGE-BSA 5mg/kg ns 
BSA 20mg/kg vs. AGE-BSA 20mg/kg ns 
 
Supplementary Table 3-2. Supplementary Statistics table for figure 3-3 
Comparison of glucose AUC0-120 at all dosages to mice that received vehicle (drinking water) instead 
of the protein bolus during the OATT.  
Dunn's multiple comparisons test Significant 
Drinking water vs. BSA 1mg/kg ns 
Drinking water vs. BSA 5mg/kg ns 
Drinking water vs. BSA 20mg/kg ns 
Drinking water vs. AGE-BSA 1mg/ml ns 
Drinking water vs. AGE-BSA 5mg/kg ns 
Drinking water vs. AGE-BSA 20mg/kg ns 
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Supplementary Table 3-3. Supplementary Statistics table for figure 3-4 
Comparison of glucose AUC0-120 at equivalent BSA and AGE-BSA dosages Between mice that received 
the standard diet that was high in AGEs (unmarked) or those that received the LAD.   
Dunn's multiple comparisons test Significant 
BSA 5mg/kg vs.  LAD BSA 5mg/kg ns 
AGE-BSA 5mg/kg vs. LAD AGE-BSA 
5mg/kg ns 
BSA 5mg/kg vs. LAD AGE-BSA 5mg/kg ns 
AGE-BSA 5mg/kg vs. LAD BSA  5mg/kg ns 
 
Supplementary Table 3-4. Supplementary statistics table for figure 3-4 
Comparison of glucose AUC0-120 between the mice that received LAD for 3 weeks prior to undergoing 
the OATT at either 5mg/kg BSA or AGE-BSA, compared to control mice, maintained on the standard, 
HAD and given vehicle drinking water.  
Dunn's multiple comparisons test Significant 
Drinking water vs. LAD BSA 5mg/kg ns 
Drinking water vs. LAD AGE-BSA 
5mg/kg ns 
 
Supplementary Table 3-5. Supplementary statistics table for figure 3-5 
Comparison of insulin AUC0-120 at equivalent BSA and AGE-BSA dosages. 
Dunn's multiple comparisons test Significant 
BSA 1mg/kg vs. AGE-BSA 1mg/ml ns 
BSA 5mg/kg vs. AGE-BSA 5mg/kg ns 
BSA 20mg/kg vs. AGE-BSA 20mg/kg ns 
 
Supplementary Table 3-6. Supplementary Statistics table for figure 3-5 
Comparison of insulin AUC0-120 at all dosages to mice that received vehicle (drinking water) instead 
of the protein bolus during the OATT.  
Dunn's multiple comparisons test Significant 
Drinking water vs. BSA 1mg/kg ns 
Drinking water vs. BSA 5mg/kg ns 
Drinking water vs. BSA 20mg/kg ns 
Drinking water vs. AGE-BSA 1mg/ml ns 
Drinking water vs. AGE-BSA 5mg/kg ns 
Drinking water vs. AGE-BSA 20mg/kg ns 
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Supplementary Table 3-7. Supplementary Statistics table for figure 3-6 
Comparison of insulin AUC0-120 at equivalent BSA and AGE-BSA dosages Between mice that received 
the standard diet that was high in AGEs (unmarked) or those that received the LAD.   
Dunn's multiple comparisons test Significant 
BSA 5mg/kg vs.  LAD BSA 5mg/kg ns 
AGE-BSA 5mg/kg vs. LAD AGE-BSA 
5mg/kg ns 
BSA 5mg/kg vs. LAD AGE-BSA 5mg/kg ns 
AGE-BSA 5mg/kg vs. LAD BSA  5mg/kg ns 
 
 
Supplementary Table 3-8. Supplementary statistics table for figure 3-6 
Comparison of insulin AUC0-120 between the mice that received LAD for 3 weeks prior to undergoing 
the OATT at either 5mg/kg BSA or AGE-BSA, compared to control mice, maintained on the standard, 
HAD and given vehicle drinking water.  
Dunn's multiple comparisons test Significant 
Drinking water vs. LAD BSA 5mg/kg ns 
Drinking water vs. LAD AGE-BSA 
5mg/kg ns 
 
Supplementary Table 3-9. Supplementary statistics table for figure 3-7 
Comparison of glucose:insulin AUC0-120 at equivalent BSA and AGE-BSA dosages. 
Dunn's multiple comparisons test Significant 
BSA 1mg/kg vs. AGE-BSA 1mg/ml ns 
BSA 5mg/kg vs. AGE-BSA 5mg/kg ns 
BSA 20mg/kg vs. AGE-BSA 20mg/kg ns 
 
Supplementary Table 3-10. Supplementary Statistics table for figure 3-7 
Comparison of glucose:insulin AUC0-120 at all dosages to mice that received vehicle (drinking water) 
instead of the protein bolus during the OATT.  
Dunn's multiple comparisons test Significant 
Drinking water vs. BSA 1mg/kg ns 
Drinking water vs. BSA 5mg/kg ns 
Drinking water vs. BSA 20mg/kg ns 
Drinking water vs. AGE-BSA 1mg/ml ns 
Drinking water vs. AGE-BSA 5mg/kg ns 
Drinking water vs. AGE-BSA 20mg/kg ns 
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Supplementary Table 3-11. Supplementary Statistics table for figure 3-8 
Comparison of glucose: insulin AUC0-120 at equivalent BSA and AGE-BSA dosages Between mice that 
received the standard diet that was high in AGEs (unmarked) or those that received the LAD.   
Dunn's multiple comparisons test Significant 
BSA 5mg/kg vs.  LAD BSA 5mg/kg ns 
AGE-BSA 5mg/kg vs. LAD AGE-BSA 
5mg/kg ns 
BSA 5mg/kg vs. LAD AGE-BSA 5mg/kg ns 
AGE-BSA 5mg/kg vs. LAD BSA  5mg/kg ns 
 
Supplementary Table 3-12. Supplementary statistics table for figure 3-8 
Comparison of glucose:insulin AUC0-120 between the mice that received LAD for 3 weeks prior to 
undergoing the OATT at either 5mg/kg BSA or AGE-BSA, compared to control mice, maintained on 
the standard, HAD and given vehicle drinking water.  
Dunn's multiple comparisons test Significant 
Drinking water vs. LAD BSA 5mg/kg ns 
Drinking water vs. LAD AGE-BSA 
5mg/kg ns 
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Chapter 4: Endogenous AGE and RAGE production in response 
to oral and intravenous glucose loads in individuals with 
recently diagnosed Type 2 diabetes.  
Abstract 
Background and objectives 
Post-prandial glucose excursions in individuals with type 2 diabetes (T2DM) are postulated 
to increase risk for chronic complications of diabetes via the production of Advanced 
Glycation End-products (AGEs). Recent studies suggest that AGEs may be acutely formed 
in response to post-prandial glucose excursions. The objective of this study was to 
investigate the effects of increasing glucose loads during oral glucose tolerance tests 
(OGTT) and matched isoglycaemic intravenous glucose infusions (IIGI) on circulating AGEs 
and their receptor, sRAGE.  
Research Design and Methods 
Eight individuals with recently diagnosed T2DM and eight controls matched for age, gender 
and BMI were recruited. All participants underwent three OGTTs at three different D-glucose 
loads (25g, 75g and 125g) and three matched IIGIs in random order. Serum AGE CML and 
serum sRAGE were measured by ELISA over 240 minutes post administration of the D-
glucose loads.  
Results 
In individuals with T2DM or controls AGEs were not produced in proportion to glucose 
excursions. Furthermore, net CML (AUC0-240) did not differ between administration routes 
(oral vs intravenous) for controls or diabetics. However, in individuals with T2DM, 
concentrations of circulating AGEs and sRAGE significantly differed over time between 
OGTT and dose matched IIGIs at all three tiers of D-glucose dosage (temporal effect on 
CML concentrations during OGTT vs IIGI; at 25g, P=0.0024; 75g; P=0.0112, 125g; 
P=0.0023). 
In patients with T2DM lower levels of sRAGE were consistently seen with IIGI compared to 
OGTT at 25g and 125g (P=0.015 and P=0.007 respectively).  Furthermore, AUC0-240 sRAGE 
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across all three IIGI tested positive for linear trend by dosage (P=0.0002), decreasing with 
increasing glucose dosage. Control individuals also showed a decrease in AUC0-240 sRAGE 
during IIGI compared to OGTT at the 25g glucose dosage. However, no other dosage effects 
were observed in control patients. 
Conclusions 
These data suggest that a complex relationship exists between oral glucose ingestion and 
post-prandial sRAGE concentrations, that may be altered in diabetes. This requires further 
investigation in larger cohorts. 
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Introduction 
Variability in blood glucose concentrations termed “excursions” has gained increasing 
attention as a risk factor for diabetes complications including kidney disease [421-423]. 
Here, HbA1C variability and other markers of glucose variability such as “time in range”, show 
greater predictive capacity for progression to microalbuminuria in individuals with diabetes, 
than mean HbA1C [424-426]. Despite these associations, the mechanisms by which glucose 
excursions may mediate end-organ complications and particularly kidney disease are not 
fully understood.  
Advanced glycation end products (AGEs) are a heterogeneous group of post-translational 
modifications, produced by the binding and rearrangement of reducing sugars. AGEs are 
formed at accelerated rates in response to chronic hyperglycaemia, hyperlipidaemia and 
increased oxidative stress [427]. Increases in circulating concentrations of clinically relevant 
AGEs such as carboxymethyl-lysine (CML) [158, 428-430] and their precursors, such as 
HbA1C, [424-426] predict cardiovascular mortality in individuals with both T2DM [428, 429], 
and T1DM [431]. Furthermore, increases in circulating AGEs associate with progressive 
decline in renal function, in both the presence and absence of diabetes [266, 306, 307]. 
Where skin auto-fluorescence has been examined as a marker of endogenous production 
of AGEs, these have also been found to inversely associate with eGFR, a marker of renal 
function [151, 152], and positively associate with increased incidence of CKD [152]. 
Many AGEs, including CML, interact with the receptor for AGEs (RAGE) [173], a full length 
membrane bound isoform, to elicit signalling pathways facilitating inflammation, autophagy, 
proliferation and apoptosis [432]. A number of soluble isoforms of RAGE have been 
characterised and are thought to act as competitive decoys, diminishing the signalling 
capacity of membrane bound RAGE [432]. These include soluble RAGE (sRAGE), which 
occurs following cleavage of the membrane bound isoform by metalloproteinases or through 
alternative splicing as endogenous secretory RAGE (esRAGE), which is actively secreted 
[433-435]. Prospective cohort studies have found that elevations in circulating sRAGE are 
associated with reduced incidence of both cardiovascular disease and all-cause mortality in 
the context of both type 1 and type 2 diabetes [436-438]. Conversely elevations in circulating 
concentrations of sRAGE have also been found to associate with severity of renal functional 
decline [439], including in diabetic nephropathy [440], and development and incidence of 
CKD [310, 311]. In addition, the ratio of CML to sRAGE, as a reflection of AGE burden, is 
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also reported as a predictor of vascular function [441]. Furthermore, in the ADVANCE study, 
a cohort of >3000 patients with T2DM, both circulating levels of AGEs and sRAGE were 
predictive of CKD (incident and progressive), leading researchers to speculate that the 
AGE:RAGE axis represents an important target for the prevention and management of 
diabetic complications and particularly nephropathy [312]. 
Due to the complex chemistry involved in AGE formation, it was previously postulated that 
AGEs were produced in the body over long periods, such as days to months and persisted 
for the life of the protein they were formed on [442]. As such, fructosamine albumin and 
glycated haemoglobin (HbA1c), made via AGE pathways, are used clinically to assess 
glycaemic control over several months [443, 444]. However, recent studies suggest more 
rapid AGE formation in the circulation in response to an oral glucose load or following acute 
modulation of blood glucose concentrations [445, 446], which is exacerbated in individuals 
with T2DM [446]. Therefore, it is postulated that AGEs and their precursors formed rapidly 
during acute elevations in blood glucose concentrations may also contribute to risk for micro 
and macro-vascular disease in diabetes.  
Gastrointestinal factors meticulously control circulating glucose concentrations by 
stimulating appropriate insulin secretion via the actions of the incretin hormones GLP-1 and 
GIP [447, 448]. These two incretin hormones are responsible for up to 60% of the insulin 
secretion due to a carbohydrate rich meal, and this effect is termed the incretin effect [449]. 
In T2DM, the incretin effect is impaired thereby exacerbating hyperglycaemia [449, 450]. It 
is not clear from any study to date, whether glucose excursions, as would occur post-
prandially, contributes to acute AGE formation. The impact of gastrointestinal factors in the 
formation of AGEs is also unclear. Hence, the objective of the present study was to assess 
the production of AGEs and their receptor sRAGE in response to increasing glucose loads 
when administered either orally or intravenously during matched infusions of glucose.  
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Aims and Hypotheses 
Aim 1: To determine circulating CML and circulating sRAGE levels over 4 hours following a 
standard 25g, a 75g and a 125g oral glucose tolerance test or matched intravenous glucose 
infusion in healthy participants and patients with T2DM. 
Aim 2: To determine the influence of the gastrointestinal versus intravenous administration 
of glucose on post-glucose AGE homeostasis in healthy individuals and patients with T2DM. 
Hypotheses: 
1. Circulating CML and sRAGE levels will remain stable during OGTT and matched IIGI in 
healthy participants. 
2. Circulating CML levels will increase over the 4 hours post OGTT and IIGI in patients with 
T2DM, this increase will higher with increasing glucose dosages and the increasing glucose 
excursions experienced.  
3. CML production will be greater during IIGI compared to paired OGTT in patients with 
T2DM.  
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Methods 
Study Participants 
Retrospective analysis using an existing cohort of individuals with well controlled T2DM 
(n=8) and matched healthy controls (n=8) was performed [450]. The characteristics of 
recruited participants have been reported in detail elsewhere [450]. The participants with 
T2DM were diagnosed according to the criteria of the World Health Organization (8), with 
an average duration of diabetes of 8 (range: 6-36) months. These subjects were treated with 
diet and exercise only. Healthy control subjects were without family history of diabetes and 
had normal glucose tolerance ascertained by a 75-g oral glucose tolerance test (OGTT) 
performed immediately before inclusion in the study. None of the patients had impaired renal 
function, microalbuminuria, proliferative retinopathy or impaired liver function. All 
participants were negative for islet cell and glutamic acid decarboxylase-65 autoantibodies. 
No medications thought to influence glucose, insulin, C-peptide, or incretin hormone 
responses during oral and i.v. glucose administration were used by participants. This study 
was completed in accordance with the Declaration of Helsinki, following ethical approval 
from the Scientific-Ethics Committee of the Capital Region of Denmark (H-A-2007-0048) 
and registered at clicicaltrials.gov (NCT00529048).  
Experimental Protocol 
Each participant underwent three separate oral glucose tolerance tests (OGTT) using 
increasing D-glucose amounts 25g, 75g and 125g, in randomised order. The subjects were 
studied in the morning in a recumbent position after an overnight (10 h) fast. Blood samples 
were drawn from a catheter inserted into the cubital vein for the OGTT. Three paired 
isoglycaemic intravenous glucose infusions (IIGI) of the same duration were then performed, 
during which blood glucose concentrations were matched to each OGTT load. IIGI were 
performed in randomized order under the same conditions as the OGTTs. On IIGI days, 
cannulas were inserted into cubital veins in both arms for collection of arterialized blood 
samples (as per OGTT time-points) and glucose infusion. Glucose infusion rate was 
adjusted and reproduced plasma glucose concentrations obtained during the matched 
OGTT as previously described [450]. Serum prepared from blood collected at 0, 10, 30, 60, 
120, 240 minutes after ingestion or infusion of glucose was used for subsequent assays in 
this study. All tests were performed within a 4-week period.  
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Assessment of serum CML and RAGE concentrations  
Carboxymethyl-lysine (CML) was measured in serum samples collected during OGTT and 
IIGI. This was performed using a competitive ELISA according to the manufacturer’s 
instructions (Oxiselect Human CML ELISA; Cell Biolabs Inc., STA-888). Circulating soluble 
RAGE was assayed using a solid phase sandwich ELISA (Duo Set Human RAGE ELISA, 
R&D systems, product number DY1145) according to the manufacturer’s instructions.  
Statistical methods 
Statistical analysis was performed using GraphPad Prism 7. AUC were calculated using the 
trapezoidal rule. Comparison of the three dosages (dose effect) and comparison of AUC 
between OGTT and their matched IIGI, was performed using repeated measures ANOVA 
(parametric) or Friedman’s Test (non-parametric). Post hoc, multiple comparisons testing 
was performed using Paired T test or Wilcoxon matched-pairs sign rank (non-parametric) 
test. Comparison of curves (all time points) between OGTT and IIGI at each dosage was 
performed by two-way repeated measured ANOVA (2way rmANOVA) with Geisser- 
Greenhouse correction to correct for violations of sphericity. Post hoc testing by Dunnett’s 
multiple comparisons test was also used to determine any effect of time, as difference from 
baseline (time 0) at all subsequent time points. Spearman’s correlation was performed in R 
using the Rcmdr package. Students two tailed t test were also used, following normality 
testing, as indicated.   
Results 
At Baseline 
By design, participants with T2DM had higher fasting plasma glucose and HbA1c at baseline, 
but did not differ from the control group in bodyweight, BMI, waist: hip ratio or age. Baseline 
serum CML concentrations did not associate with other baseline participant characteristics 
(Table 4-1). However, there was a trend towards a positive relationship identified between 
circulating CML and sRAGE concentrations in individuals with T2DM (P=0.058, Table 4-1). 
This relationship became significant when controls and patients with T2DM were analysed 
as a single cohort (Table 4-1). Baseline fasting serum sRAGE was also negatively 
associated with adiposity as assessed by waist/hip ratio in the patients with T2DM but was 
not significant in the control cohort (Table 4-1). When all participants were analysed as a 
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combined group, the negative relationship between baseline serum sRAGE and adiposity 
as assessed by waist/hip ratio was strengthened (Table 4-1). Baseline fasting serum sRAGE 
was also positively related to the duration of diabetes in individuals with T2DM (Table 4-1). 
Table 4-1. Study participant anthropometric characteristics and their relationship with circulating 
CML and sRAGE at baseline. 
 
Control 
Group 
n=8 
Patients 
(T2DM) 
n=8 
P value 
Baseline associations, r, P 
 Serum CML Serum sRAGE 
 Control Patients 
(T2DM) 
All Control Patients 
(T2DM) 
All 
           
Sex (M : F) 3 : 5 3 : 5 NS - - - - - - 
Age (years) 56.5±11.4 57.0 ± 11.9 NS 
-0.24 
NS 
0.24 
NS 
-0.02 
NS 
0.12 
NS 
0.00 
NS 
0.04 
NS 
BMI (kg/m2) 28.9 ± 2.1 29.5 ± 3.2 NS 
-0.33 
NS 
-0.41 
NS 
-0.35 
NS 
-0.26 
NS 
-0.07 
NS 
-0.13 
NS 
Waist/Hip-ratio 0.9 ± 0.1 1.0 ± 0.1 NS 
-0.23 
NS 
-0.52 
NS 
-0.40 
NS 
-0.49 
NS 
-0.738  
0.046 
-0.643 
0.008 
HbA1C (%) 5.4 ± 0.3 7.0 ± 0.7 <0.001 
-0.60 
NS 
-0.07 
NS 
-0.19 
NS 
-0.45 
NS 
-0.024 
NS 
-0.25 
NS 
Duration of 
Diabetes (months) 
- 8.4 ± 11.8 - - 
0.43 
NS 
- - 
0.732        
0.049 
- 
Serum Glucose 
t=120mins 
(mmol/L) 
6.0 ± 0.6 16.0 ± 2.7 <0.001 
-0.18 
NS 
0.10 
NS 
-0.13 
NS 
0.55 
NS 
-0.52 
NS 
-0.13 
NS 
Fasting Serum 
sRAGE (pg/ml) 
877± 
378.5 
782.4 ± 
351.6 
NS 
0.59 
NS 
0.714 
0.058 
0.609 
0.014 
- - - 
Anthropometric data is shown as mean and standard deviation. Spearman’s coefficients of 
correlation and P values (italicised) are shown where significant for correlations between CML or 
sRAGE and anthropometric characteristics in controls, patients with type 2 diabetes (T2DM) and 
both controls and patients combined to a single cohort (All). CML – carboxymethyllysine, sRAGE – 
soluble Receptor of Advanced Glycation End Products. 
 
Glucose homeostasis during OGTT and IIGI 
Glucose, insulin, C-peptide, GLP-1, glucagon and gastric emptying in this cohort during 
OGTT and IIGI have been previously reported [450, 451]. In summary, increasing plasma 
glucose concentrations were observed with escalating oral glucose loads in individuals with 
T2DM. This was due to impaired insulin secretion and impaired incretin responses to oral 
glucose, when compared to matched control individuals, who did not experience significant 
increases in peak glucose levels. Suppression of glucagon secretion following a glucose 
bolus was also blunted in individuals with T2DM [451]. 
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 Circulating CML following glucose administration: 
At all three levels of glucose load (25g; 75g; 125g), circulating CML concentrations 
significantly differed over time between OGTT and matched IIGI in individuals with T2DM 
(Figure 4-1B, Table 4-2). These differences in circulating CML during OGTT and IIGI over 
time, were also seen to a lesser degree at the 25g and 75g loads in control participants, as 
an interactive effect of time and administration route (oral or intravenous) (Figure 4-1 A; 
Table 4-2). In control individuals, an oral 75g D-glucose bolus induced no change in CML 
concentrations, while matched intravenous glucose infusion decreased circulating CML over 
the first 60 minutes (Figure 4-1 A; Table 4-2). This pattern differed in individuals with T2DM 
(Figure 4-1 B, second panel), where 75g oral glucose decreased circulating CML 
concentrations by 60 and 120 minutes, showing a bimodal relationship between OGTT and 
IIGI. However, circulating CML concentrations during IIGI did not differ from baseline at this 
dose in any group (Figure 4-1 B). Following a 125g glucose bolus, circulating CML was 
elevated briefly in both individuals with T2DM and controls, while matched intravenous 
glucose appeared to decrease circulating CML, although this was only significant in controls 
(Figure 4-1 A-B, third panel). However, although there were different temporal patterns seen 
in the CML concentration curves between controls and participants with T2DM, AUC glucose 
comparisons did not reach significance for OGTT nor IIGI (Table 4-4). When AUC at all three 
dosages was compared, no dosage effect of glucose on circulating CML concentrations 
during IIGI or OGTT were seen in either group (Table 4-4), and post-test for linear trend by 
dose was not significant (data not shown). When all participants were analysed as a single 
group, circulating CML concentrations during OGTT and IIGI significantly differed across 
time at every glucose load tested (Figure 4-1 C, Table 4-2). However, net CML AUC did not 
differ between administration routes at any glucose dose (Table 4-4)   
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Figure 4-1. Circulating CML concentrations during paired OGTT and IIGI at different D-glucose dosages. 
Three oral D-glucose tolerance tests (OGTT) (25g, 75g or 125g; filled circles) and three paired D-glucose infusions (IIGI; open circles) were performed 
over 240 minutes in each individual and circulating CML plotted over 240minutes. Participants either had no diabetes (A) (Controls; n=8 participants, 
green) or were matched individuals with recently diagnosed Type 2 diabetes (T2DM) (B) (n=8 participants, blue) or both patients and controls were 
combined as a single cohort (C) (n=16, purple). The actual D-glucose load delivered during each test is shown in the key. Data are shown as MeanSEM 
and analysed by 2 way rmANOVA by time and administration with multiple comparison testing *P<0.05 between OGTT and IIGI at the indicated time 
point (Sidak’s multiple comparisons test); † P<0.05 vs baseline during OGTT and ‡ P<0.05 vs baseline during IIGI (Dunnett’s multiple comparison testing). 
Table 4-2. P values from 2way RM ANOVA 
for Figure 4-1. 
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Circulating sRAGE following glucose administration 
Figure 4-2. Circulating sRAGE concentrations during paired OGTT and IIGI at different D-glucose dosages. 
Table 4-3. P values from 2way RM ANOVA 
for Figure 4-2. 
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Three OGTT (25g, 75g or 125g; filled circles/bars) and three paired D-glucose infusions (IIGI; open circles/bars) were performed over 240 minutes in 
groups of controls (A) (n=8 participants, green) and matched individuals with recently diagnosed Type 2 diabetes (T2DM) (B) (n=8 participants, blue) 
and circulating sRAGE concentration measured. These were also plotted for patients and controls as a combined cohort (n=16, purple) (C). The actual 
D-glucose load delivered during each test is shown in the key. Data are shown as MeanSEM and analysed by 2 way rmANOVA with multiple comparison 
testing *P<0.05 between OGTT and IIGI at the indicated time point (Sidak’s multiple comparisons test); † P<0.05 vs baseline during OGTT and ‡ P<0.05 
vs baseline during IIGI (Dunnett’s multiple comparison testing). AUC 0-240 sRAGE were analysed by Wilcoxon matched-pairs sign ranks test; *P<0.05 
between OGTT and IIGI 
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Table 4-4. Statistical comparisons of AUC0-240 between OGTT and IIGI within groups and between patients with T2DM and controls. 
AUC from time 0 to 240 minutes for oral glucose tolerance test (OGTT) and intravenous glucose infusions (IIGI) at 25g, 75g and 125g, between patients 
with type 2 diabetes (T2DM) and age, BMI and gender matched controls and all participants were analysed as a combined cohort. AUC0-240 is shown as 
mean ± SEM and p values when compared by T test (p value Ɛ). Dose effect shows the p value for one-way ANOVA (p value Ƙ) when AUC0-240 was 
compared for the three dosages (α denotes a non-parametric equivalent test was used).  
 CML (ng/ml)   sRAGE (pg/ml)  CML:sRAGE  
 Control 
 
T2DM p  Combined  Control 
 
T2DM p Combined  Control 
 
T2DM p Combined 
  AUC 0-240min    AUC 0-240min   AUC 0-240min  
25g OGTT 3177.75 ± 
810.52 
3349.475 ± 
857.90 
ns 3264 ± 570.5  214687 ± 
29810 
196404 ± 
27091 
ns 205545 ± 
19600 
 3550 ± 
793.8 
4033 ± 
808.1 
ns 3791 ± 
550.7 
(Matched 
IIGI) 
3216.75 ± 
752.09 
3705.84 ± 
1048.34 
ns 3461 ± 626.4  183055 ± 
28221 
173273 ± 
24646 
ns 178164 ± 
18143 
 4389 ± 
970.4 
5069 ± 1270 ns 4729 ± 
777.1 
p value Ɛ 0.6863 0.1417  0.5954  * 0.0168 * 0.0156a  *0.0016  * 0.0082 0.0793  *0.0231 
75g OGTT 3352.50 ± 
946.29 
3054.4 ± 
843.15 
ns 3203 ± 613.4  188918 ± 
25976  
177221 ± 
32657 
ns 183070 ± 
20213 
 4254 ± 
1066 
4108 ± 
847.8 
ns 4181 ± 
658.3 
(Matched 
IIGI) 
3038.13 ± 
747.40 
3403.93 ± 
1037.89 
ns 3221 ± 619.6  196902 ± 
25566 
162134 ± 
25122 
ns 179518 ± 
17886 
 3665 ± 
781.4 
4981 ± 1409 ns 4323 ± 
796.5 
p value Ɛ 0.8298 0.7854  >0.9999  0.4802 0.3828  0.9994  0.1594 0.2761  0.8999 a 
125g OGTT 3315.63 ± 
884.10 
3215.19 ± 
859.15 
ns 3265 ± 595.6  195369 ± 
26642 
177627 ± 
24802 
ns 186498 ± 
17731 
 4201 ± 
1172 
4216 ± 
872.9 
ns 4208 ± 706 
(Matched 
IIGI) 
2957.36 ± 
725.78 
3047.53 ± 
774.67 
ns 3002 ± 512.9  184702 ± 
18642 
150453 ± 
23955 
ns 167578 ± 
15314 
 3878 ± 963 4700 ± 932 ns 4289 ± 656 
p value Ɛ 0.2107 0.1407  0.4166  0.3219 *0.0078α  *0.0486  0.3828α 0.0659  >0.9999 
OGTT Dose 
comparison  
              
p value  κ 0.4284 0.8251  0.1157  0.1304 0.1663  *0.0033  0.2359α 0.8251  0.1417 
IIGI Dose 
comparison  
              
p value κ 0.8486 0.0921  0.7532  0.5064 *0.0024α  *0.0119  0.2359α 0.7016  0.3679α 
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At all three glucose loads, sRAGE concentrations differed over time between oral and 
matched IIGI glucose loads in individuals with T2DM (Figure 4-2 B; Table 4-3). There was 
also a significant dose effect of glucose on circulating sRAGE seen during IIGI in these 
individuals (Table 4-4). This was supported by decreases in AUC0-240 sRAGE during IIGI at 
both 25g and 125g glucose loads in participants with T2DM (Figure 4-2 B, first and third 
panel). Furthermore, in patients with T2DM AUC0-240 sRAGE across all three IIGI tested 
positive for a linear trend by dosage (P=0.0002). 
In control participants, there were no significant differences between circulating sRAGE 
concentrations during OGTT and IIGI at the two higher glucose loads (Figure 4-2 A, second 
and third panel; Table 4-3). A modest statistically significant effect of time was observed at 
the 25g dose between the OGTT and IIGI (Figure 4-2 A, first panel; Table 4-3) and AUC for 
sRAGE was lower at this dose during IIGI as compared with OGTT (Figure 4-2 A). However, 
there were no glucose dosage effects on sRAGE seen in control participants (Table 4-4). 
When all participants were analysed as a single group, circulating sRAGE concentrations 
during OGTT and IIGI significantly differed at the 25g and 125g glucose loads (Figure 4-2 
C, Table 4-4). Additionally, AUC0-240 sRAGE during OGTTs differed for all three glucose 
dosages (Table 4-4), and post-test for linear dosage trend was significant (P=0.017). 
However, for AUC0-240 sRAGE during IIGIs no linear trend for dose effect was found.  
CML:sRAGE ratios following glucose administration 
Soluble RAGE alters the bioavailability of circulating CML to bind cellular receptors such as 
membrane bound isoforms of RAGE [452], therefore, the circulating CML:sRAGE ratio was 
calculated. In matched controls and individuals with T2DM, CML:sRAGE ratio differed 
across time between oral and matched IIGI at 25g, additionally these differences were also 
seen at the 75g glucose loads in individuals with T2DM (Table 4-5; Figure 4-3 A-B). At the 
lowest dosage of glucose (25g, Figure 4-3 A and B, first panel), CML:sRAGE ratios were 
elevated in all participants from 60-120 minutes during IIGI, with AUC CML:sRAGE 
significantly higher during IIGI in controls (Figure 4-3 A and C, Table 4-4). Following an oral 
75g glucose bolus, control individuals had rapid elevations in circulating CML:sRAGE ratio 
over the first 60 minutes, which were not seen in individuals with T2DM (Figure 4-3 A-B, 
second panel), however, there were no differences in AUC0-240 between OGTT and IIGI 
within the T2DM or the control group or between the two cohorts (Figure 4-3, Table 4-4). No 
differences in circulating CML:sRAGE ratios were seen at 125g D-glucose dose in either 
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group of participants (Figure 4-3 A and B, third panel). When all participants were analysed 
as a single group, circulating CML:sRAGE ratios during OGTT and IIGI significantly differed 
by an effect of time and interaction of administration route, at every glucose load tested 
(Figure 4-3 C, Table 4-5, interactive effect), However AUC0-240 was found to only differ at 
25g dose (Figure 4-3 C, Table 4-4)
121 
 
Figure 4-3. Circulating ratio of CML to sRAGE during paired OGTT and IIGI at different D-glucose dosages.  
Table 4-5. P values from 2way RM ANOVA 
for Figure 4-3. 
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Three oral glucose tolerance tests (OGTT) (25g, 75g or 125g; filled circles/bars) and three paired glucose infusions (IIGI; open circles/bars) were 
performed over 240 minutes in groups of controls (A) (n=8 participants, green) and matched individuals with Type 2 diabetes (T2DM), (B) (n=8 
participants, blue) and CML:sRAGE plotted. CML:sRAGE was also plotted for the combined cohort (C) (n=16, purple)Data are shown as MeanSEM and 
analysed by 2 way rmANOVA with multiple comparison testing *P<0.05 between OGTT and IIGI at the indicated time point (Sidak’s multiple comparisons 
test); † P<0.05 vs baseline during OGTT and ‡ P<0.05 vs baseline during IIGI ( Dunnett’s multiple comparison testing).AUC 0-240 sRAGE were analysed by 
Paired T test; *P<0.05 between OGTT and IIGI
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Discussion 
Summary of novelty and main findings 
In the present study, we used an existing novel clinical cohort to examine whether circulating 
levels of the commonly studied AGE, CML and its receptor sRAGE, changed in response to 
increasing glucose loads. We also examined whether gastro-intestinal factors such as the 
interaction with gut microbiome, enterocytes, and portal delivery of glucose were important 
by comparing plasma CML and sRAGE in response to orally delivered (OGTT) compared 
with matched intravenous infusion of glucose. Furthermore, these glucose challenges were 
performed in a unique clinical cohort of individuals with recently diagnosed T2DM mellitus, 
receiving only lifestyle modifications as treatment which were compared to control 
individuals without diabetes, matched for AGE, gender, and BMI.  
Here we report that increasing glucose loads did not result in a proportionate increase in the 
formation of CML, and although modest temporal differences were observed, no gross 
differences between oral and iv administration were seen. On the other-hand we show that 
sRAGE was significantly reduced in response to iv administration of glucose as compared 
to oral glucose in our patients with T2DM. This difference was not seen in healthy subjects.   
Baseline correlations 
In contrast to previous studies comparing individuals with T2DM to age matched controls, 
[453-455], no differences in baseline levels of CML or sRAGE were identified between the 
control participants and patients with T2DM mellitus. This may reflect the short duration 
since diagnosis of diabetes or small group numbers in this study, although, it should be 
noted that duration of diabetes cannot be fully ascertained in patients with T2DM, as disease 
may have been present for some time before diagnosis. Overall, many factors thought to 
influence circulating levels of AGEs [456-458] were stringently matched between groups 
including age and adiposity and gender in this study. However, concordant with previous 
studies in various populations [459-463], we do report a strong positive association between 
baseline sRAGE and CML concentrations. Baseline sRAGE plasma concentrations were 
also inversely related to waist to hip ratios. Lower circulating sRAGE [460, 463, 464] and 
AGE [458, 460, 463-466] concentrations have also been reported in obese or overweight 
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populations as compared to lean controls. These studies suggest a down regulation of 
sRAGE expression with obesity. There is also some evidence from animal models that 
increased sequestration of AGEs by sRAGE with increasing adipose mass may explain the 
reduction circulating AGEs in this population [467]. Here, we report no association between 
baseline CML and waist hip ratio, but this likely reflects the narrow BMI range represented 
by our participants. 
Temporal changes in CML 
Overall, the patients with diabetes showed greater effect of time in combination with 
administration route (oral vs intravenous glucose administration) on circulating CML 
concentrations as compared to controls. There were no rapid, significant increases in CML 
in response to the increasing glucose excursions either during OGTT or IIGI in this study. 
This suggests that, in this cohort, CML is not produced rapidly and proportionally in response 
to glucose excursions in either control nor in participants with T2DM. Further supporting this, 
there were no differences between AUC for plasma AGEs with escalating glucose dosages. 
In individuals recruited to the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) 
cohort study, significantly higher plasma concentrations of reactive dicarbonyls (precursors 
to AGEs), during a 75g OGTT have been reported in participants with T2DM or metabolic 
syndrome when compared to matched healthy controls [446]. Since reactive dicarbonyls 
can be rapidly produced in response to glycolysis and cleared via intracellular pathways 
such as the glyoxalase 1 and aldose reductase pathways, this may be why we did not see 
increases in CML in our study [468]. We also did not measure AGEs such as MG-H1 which 
are formed directly from reactive dicarbonyls such as methylglyoxal. Another study by 
Schiekofer et al., has observed a proportional rise in CML in response to sustained glucose 
elevations during a hyperglycaemic clamp [445]. However, in that study, CML was assessed 
in circulating lymphocytes but not within the plasma. Measurement of reactive dicarbonyls 
in the serum collected in this study remains an important research priority.  
Although no gross differences between AUC0-240 CML were observed we did observe a 
tendency towards a decrease in circulating CML concentrations following an oral glucose 
bolus in patients with T2DM mellitus, although this decrease was not ubiquitously statistically 
significant at all dosages and was preceded by a brief elevation in CML concentrations. This 
decrease however, was surprising, given that these patients with T2DM had impaired 
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capacity to deal with ingested glucose. Specifically, in these patients the insulinotropic 
capacity of the incretin hormones was blunted, insulin secretion was lower and suppression 
of glucagon production was delayed [450, 451] which conceptually should each facilitate 
AGE synthesis. However, the decline in circulating CML in response to oral glucose is 
consistent with a previous study in pregnant women, where a decline in circulating CML at 
120min after a 50g glucose bolus [469] was reported. Of note, this trend towards a decrease 
in CML in response to glucose was largely absent in age, gender and BMI matched control 
individuals where blood glucose concentrations remained lower and insulinotropic effects of 
the incretin hormones were sustained [450], only presenting at the 25g glucose bolus.  
Furthermore, this drop in circulating AGEs was effectively absent during the glucose 
matched isoglycaemic IIGI when the enteroendocrine signalling was bypassed, except in 
control patients at the 36g IIGI (matched to the 75g OGTT). Taken together, these data 
suggest that circulating AGE concentrations are dynamic and that perhaps, incretin 
hormones or other gastrointestinal factors influence circulating AGE concentrations post-
prandially. However, given the absence in differences seen between net CML (AUC0-240 
CML) for OGTT and IIGI at all dosages, further analysis of larger cohorts is required to 
confirm this.  
Circulating CML concentrations represent the balance between production, sequestration 
into organs and clearance, with the kidney representing a major site of AGE clearance [271]. 
As such, changes in glomerular filtration rate (GFR) may explain the differences observed 
between OGTT and IIGI in this cohort. Elevations in GFR also occur post-prandially [470], 
during persistent hyperglycaemia [471] and in response to an acute 75g glucose bolus 
during OGTT in individuals with diabetes [472]. GFR can be influenced by GLP-1 although 
the direction of such changes has varied amongst studies [473-475]. It is possible that the 
hormonal milieu present following an oral glucose challenge or post-prandially may increase 
clearance of CML from the circulation by elevating GFR or as a consequence of greater 
renal glucose excretion thereby limiting AGE precursor availability in the individuals with 
T2DM. Indeed, in our subjects with diabetes, renal glucose excretion was six to 10 fold 
higher [450]. Supporting this postulate are studies showing that circulating CML 
concentrations are decreased in healthy, obese individuals where eGFR is elevated [272, 
305]. Further analysis would be required to determine whether GFR was altered in response 
to the glucose challenges in the patient and control cohorts in this study. The interface 
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between gastrointestinal post-prandial hormone secretion of incretin hormones and AGEs, 
and how this influences AGE burden also remains an important research area with 
considerable scope for further study.  
Temporal changes in sRAGE 
The production of circulating sRAGE occurs through proteolytic cleavage of membrane 
bound RAGE and alternative splicing during gene expression [476]. sRAGE serves as a 
decoy receptor mediating the interaction of RAGE ligands such as CML with the membrane 
bound RAGE and is a central mechanism by which RAGE can orchestrate cellular signalling 
and function [476, 477]. sRAGE levels can be dynamically and rapidly upregulated in acute 
settings, such as following trauma [478] and myocardial infarction [479]. To our knowledge, 
this is the first time that circulating levels of sRAGE have been studied in the context of oral 
glucose tolerance tests. Changes in sRAGE did not appear proportional to glucose dose or 
CML concentrations during either the OGTT or the IIGI, with AUC sRAGE0-240 consistently 
lower during IIGI compared to OGTT.  
In a randomised cross-over study of dietary AGE intake in healthy overweight individuals, 
there were no changes in sRAGE observed with either low or high dietary AGE consumption 
suggesting that circulating sRAGE is not made in proportion to circulating AGEs [305]. In 
the present study, plasma sRAGE concentrations declined acutely following intravenous 
glucose infusion, but were less influenced by oral glucose dosage, even though circulating 
glucose levels were equivalent in patients with T2DM, whereas this was not seen in the 
healthy individuals who remained euglycaemic, unaffected by increasing glucose loads. This 
suggests that maintaining constant levels of sRAGE may be highly dependent on 
gastrointestinal factors during high fluctuations in circulating glucose and insulin.  However, 
this needs to be substantiated in a larger cohort. One in vitro study challenges this, where 
supra-physiological insulin administration did acutely increase cellular sRAGE expression, 
production and secretion by THP-1 macrophages [480]. Additionally, several in vitro studies 
have demonstrated a down regulation of RAGE in response to GLP-1 or GLP-1 receptor 
agonists in renal mesangial cells [481], and human umbilical vein endothelial cells [482], so 
although no changes were observed in circulating levels of sRAGE, this may not be the case 
for membrane bound isoforms of RAGE.  
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As a read out of AGE availability in the circulation, CML to sRAGE ratios were assessed. 
These differed between OGTT and IIGI in individuals with T2DM at all glucose loads again 
suggesting that they are influenced by gastrointestinal factors. In control individuals, CML to 
sRAGE ratios only differed between OGTT and IIGI at the 25g D-glucose load. Since 
circulating sRAGE appears to be lower when CML concentrations are stable and higher 
when CML concentrations were decreasing, sRAGE could be orchestrating the decreases 
seen in CML during OGTT.  
Limitations 
This study was statistically powered to detect differences in incretin hormones and glucagon 
[450]. As evidenced, considerably smaller effects sizes were seen in the present study in 
circulating sRAGE and CML in response to increasing glucose loads. Although the repeated 
measures design and pairing of oral and intravenous glucose loads for every participant 
increased the statistical power of this study, these findings need to be confirmed and 
strengthened in larger cohorts. Additionally there has been some criticism of the use of 
immunological methods for assessment of AGEs, and CML but most studies have shown 
these assays are reliable [294, 409, 483, 484] and concordant with more complex mass 
spectrometry based measurements [485]. 
Conclusion 
This study suggests that the AGE, CML and its soluble receptor sRAGE are not produced 
in a dose dependent manner in response to oral glucose challenges in control individuals or 
the significantly greater glucose elevations seen in patients with T2DM. Net sRAGE and 
CML as assessed by AUC did not differ between individuals with T2DM and age, gender 
and BMI matched controls at equivalent dosages and administration routes. However, 
comparison of OGTT and IIGI at each dose found an interaction of time and administration 
at all dosages for CML and sRAGE in patients with T2DM. Furthermore, sRAGE levels 
appeared to be significantly reduced with IIGI compared to OGTT in diabetes, and in the 
combined cohort. This suggests that gastrointestinal regulation and post prandial hormonal 
response, which are dysregulated in T2DM, may play a role in acute regulation of CML and 
sRAGE, however cause and effect remains to be ascertained. 
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Chapter 5: Using nutritional geometry and a geometric 
framework to explore the contribution of macronutrient 
consumption to kidney structure and function.  
Abstract 
Aims 
The influence of dietary macronutrients consumed over a lifetime on kidney health, has 
never been comprehensively examined. Here, we have used a novel geometric framework 
to assess kidney function and structure in mice following consumption of diets varied in 
macronutrient and caloric combinations over a lifetime into late middle age.   
Methods 
A mouse model based nutritional geometric framework (GF) was produced. In summary, 
wild type mice (C57BL/6J; male and female; N=187) were given ad-libitum access to 1 of 
26 diets from weaning, with each diet representing one combination of a spectrum of protein, 
(5-60%) carbohydrate (20-75%) and fat (20-75%) and one of three energetic tiers. At 15 
months of age (middle age), organs and blood were collected. Metabolic risk factors for 
kidney disease were assessed just prior to death using gold standard measures including 
adiposity (lean/fat mass), glucose tolerance, blood pressure (SBP and DBP) and circulating 
lipid profiles. Structural, functional and biochemical markers of kidney disease were 
assessed. Using the geometric framework (GF), 3-dimensional general additive modelling 
(GAMs) was performed in R to assess the impact of macronutrients as individual and 
interactive variables on renal structural, functional and biochemical outcomes.  
Results 
Serum cystatin C, assessed by ELISA, was used as a surrogate for kidney function (as an 
inverse marker of GFR) and ranged from 126 to 1006 ng/ml. GFR was positively associated 
with dietary protein intake (P=0.03) and negatively influenced by dietary consumption of 
carbohydrate (P=0.01). GFR was lowest in mice consuming a low protein but high 
carbohydrate diet. Renal expression of the longevity gene klotho was also lowest in mice 
consuming the least amount of protein showing an inverse relationship to protein intake 
(P=0.05). Renal cortical concentration of inflammatory cytokine IL-23 was also inversely 
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correlated with protein consumption (P=0.002) and therefore highest in mice consuming the 
least amount of protein, as was IL-1β in the context of high fat consumption (P=0.01 and 
P=0.05, respectively). Additionally, as an interactive variable in the context of higher 
carbohydrate intake, low protein was also seen to increase renal cytokines IFNγ (P=0.006), 
IL12p70 (P=0.05), and elevate renal cortical KIM-1 levels at a population level in the context 
of increased fat intake. 
A spectrum of renal tubulointerstitial fibrosis (TIF) was seen in GF mice (0.5 to 9%), however, 
no relationships were found to macronutrient consumption. Consistent with this finding, gene 
expression of renal markers of fibrosis (Ctgf, Tgf β1, Col4a1) were not affected by dietary 
intake. Glomerular fibrosis measured as GSI, trended (P=0.083) towards a positive 
relationship with fat intake in the GF mice and further sex differences were seen.  
Most surprisingly, macronutrient combinations which elevated BP, circulating lipids or 
induced glucose intolerance did not associate with adverse kidney outcomes.  
Conclusions 
Taken together, this study demonstrates that both individual macronutrients and their 
relative combinations over a lifespan, affect renal function and structure. Overall, lower 
protein intake resulted in a phenotype with the lowest GFR, lowest expression of klotho and 
highest levels of cytokines IL-23 and IL-1β.  
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Introduction 
Ageing, diet and kidney disease 
Aging and chronic kidney disease are inextricably linked. Ageing is associated with a decline 
in kidney function, characterised by a decrease in GFR and renal blood flow (RBF) in concert 
with other haemodynamic changes such as a reduction in glomerular capillary perfusion and 
primary afferent arteriolar resistance [486, 487]. Structural changes include a loss of renal 
mass [488, 489]; tubular atrophy; hardening of the walls of the small arteries and arterioles 
of the kidney and major arteries (nephrosclerosis) [490]; glomerulosclerosis [489, 491-493]; 
tubulointerstitial fibrosis [486], and arteriosclerosis and hyalinosis of major renal arteries, as 
reviewed here [20]. The rate of renal age related changes, can be accelerated by 
hypertension [494, 495], smoking [495, 496], dyslipidaemia [495], atherosclerosis [496], and 
excess caloric or fluid consumption [497, 498]. Nutritional imbalances are well-characterised 
drivers of many of these factors and have been proposed as one of the major contributors 
to the dramatic increase in the prevalence of CKD globally [68]. Large population based 
studies show that a body mass index (BMI) above a normal range associates with renal 
dysfunction [69-74] and end stage renal disease (ESRD) [76-79]. It is postulated that 
increased adiposity and the associated glucose intolerance, diabetes and metabolic 
dysfunction precipitates renal changes through hypertension [93], chronic low grade 
inflammation [94, 95] and dyslipidaemia [93, 96]. Further supporting this theory, caloric 
restriction to 60-70% of ad libitum consumption has shown profound effects in retarding the 
onset of kidney disease in rodent models [101, 102], however, the challenges inherent with 
caloric restriction means these findings have not been recapitulated in humans to date.  
Beyond excess caloric consumption however, it remains to be fully elucidated whether the 
quantity and relative ratios of protein, fat and carbohydrate consumed in everyday diets over 
a lifespan, directly impacts renal function. Research to date has almost exclusively focussed 
on dietary consumption of a single macronutrient in isolation and has primarily been 
undertaken in rodent models. In rodent studies, high fat feeding induces renal injury, 
characterised by inflammation, glomerular hypertrophy and mesangial matrix expansion and 
tubular lysosomal dysfunction [133]. Clinically, excess dietary fat consumption has been 
found to be both detrimental and beneficial to renal function in different studies [137, 138]. 
Dietary protein has also been considered as a potential mediator of kidney disease with the 
persisting hypothesis that habitual consumption of dietary protein promotes CKD [105, 106]. 
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Whilst basic physiological studies suggest that protein has a profound impact on GFR, when 
consumed both acutely and long-term [107-110], population based studies and clinical trials 
suggest that a degree of renal insufficiency at baseline is required to observe a detrimental 
effect from dietary protein [114]. These epidemiological studies also suggest that the protein 
source (animal or vegetable) might be important. Gross carbohydrate intake has garnered 
the least amount of attention with only a few studies to date examining the effects of 
carbohydrate consumption on the kidney. These suggest that the consumption of diets 
where carbohydrate levels exceed 50% of the total calories deteriorate renal function in 
healthy rodents [499] and exacerbate obesity/diabetes induced nephropathy [500], however, 
it should be noted that the source of carbohydrate in the majority of these studies comprised 
of simple sugars.  
The Geometric Framework and nutritional geometry 
As highlighted above, dietary macronutrients are postulated to affect renal function through 
modification of cardio-metabolic risk factors for chronic kidney disease. However, from the 
research conducted to date it is difficult to ascertain whether these macronutrients also exert 
direct effects on the kidney. Furthermore, recently it has become understood that the 
balance of macronutrients, and particularly dietary protein to non-protein energy sources in 
food is fundamental to growth, development and susceptibility to obesity and metabolic 
disease [346]. Many species, including humans, eat to fulfil a macronutrient “requirement” 
where dietary constituents regulate the actual dietary intake [501]. For example, mice fed a 
low protein diet will increase their dietary intake to obtain a pre-programmed protein 
requirement [346], a behaviour termed compensatory feeding. 
The geometric framework is a multidimensional murine platform designed specifically for 
quantifying and modelling the individual and interacting impacts of macronutrients and 
energy intake on longevity, reproductive capacity and metabolic health [346, 502]. It has 
proven to be a resource capable of modelling and understanding the impact of macronutrient 
and energy intake on immune status, mitochondrial function, microbiota and nutrient 
signalling, liver structural changes and dermal function [503-506]. In this chapter, we utilise 
the geometric framework to explore if specific dietary energy and macronutrient 
consumption into late middle age, impacts upon kidney function and structure. Importantly 
unlike previous studies, this geometric framework provides a platform to tease out the 
individual and combined effects of all three macronutrients and three tiers of caloric intake, 
in a genetically heterogeneous population without the confounding effects of lifestyle.  
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Aims and Hypotheses 
Overall Aim: To determine the influence of the dietary content of protein, carbohydrate and 
fat consumed over a lifetime on kidney health. 
Aim 1: To determine if dietary protein, carbohydrate and fat intake are independent and/or 
interacting variables which act to modify renal structure and function over a lifespan.  
Aim 2: To study dietary intake of protein, carbohydrate and fat as independent and 
interactive variables influencing markers of renal inflammation, haemodynamic changes and 
renal ageing.  
Aim 3: To determine if changes in kidney function with specific macronutrient combinations 
aligns with the development of known risk factors for CKD 
 
Hypotheses  
Hypothesis 1: Consuming a diet high in protein and high in fat will result in increased 
structural markers of renal pathology, resulting in the lowest GFR and highest levels of 
inflammation.  
Hypothesis 2: Low protein consumption will be associated with improved renal outcomes, 
lowest renal fibrosis, lowest glomerular sclerotic index, lowest inflammation. 
Hypothesis 3: Dietary macronutrient ratios previously found to worsen cardio-metabolic 
health, specifically serum cholesterol, blood pressure, and body weight, will also show 
strong associations with markers of renal pathology and poor renal outcomes.    
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Methods 
Animals- Geometric Framework (GF) study 
Three week old, male and female C57BL/6J mice (N=187; M:F=90:97), were obtained from 
the Animal Resource Centre, Perth, WA, Australia and housed in the ANZAC Research 
Institute, Sydney Australia in a pathogen free facility. Mice were randomised to consume 
one of twenty-six diets ad libitum, (Specialty Feeds, Perth, Australia) or a standard mouse 
chow (Specialty Feeds, Irradiated Rodent Chow). The manufactured diets were 
systematically varied in their composition of protein, carbohydrate and fat, and calories 
manipulated by the addition of indigestible cellulose yielding energy density regimens fixed 
at 8, 13, and 17 kJ/g (Table 5-1outlines the macronutrient and energy density of the diets 
used in this study). Mice remained on the diets from week 3 to 15 months of life and had 
their food consumption measured weekly for the first 6 months of the study and monthly for 
the remaining 9 months. Mice on diets that were found to be unsustainable were terminated 
early and removed from the study. Full dietary details can be found here [346] 
(https://www.ncbi.nlm.nih.gov/pubmed/24606899). 
Body weight, adiposity and lean mass were measured at 15 months of age by DEXA scan. 
Mean systolic and diastolic blood pressure was also assessed at 15 months of age by tail 
cuff plethysmography. At this time point, all mice underwent an intraperitoneal glucose 
tolerance test, using a D-glucose bolus of 1.5 g/kg, with the detailed methods of these 
techniques published elsewhere [346]. Mice were euthanized by cervical dislocation at 15 
months of age, blood collected and the kidneys snap frozen for protein and gene expression 
analysis. One pole of the kidney was removed and bisected, with half being embedded in 
OCT mountant and frozen and half fixed in 10% NBF and paraffin embedded.  
Note: The animal study was performed by our collaborators at the Charles Perkins Centre, 
The University of Sydney. Kidneys, and plasma were generously shared with us for this 
study. 
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Table 5-1. Diets used for the GF study organised by their macronutrient ratios and their respective 
caloric tiers 
%P/%C/%F Low 
(8 kJ/g)  
Medium 
(13 kJ/g) 
High 
(17 kJ/g)  
5:20:75 - -  
5:48:48 - -  
5:75:20    
14:29:57    
14:57:29    
23:38:38    
33:20:47    
33:47:20    
42:29:29    
60:20:20    
23:65:12 - -  
Ten dietary macronutrient ratios were chosen for the diets, this is shown in column one as 
the relative percentages of protein (%P), carbohydrate (%C) and fat (%F). These ratios were 
then used to generate diets at low (column 2), medium (column 3) and high (column 3) 
caloric densities resulting in 30 different diets. Six of the diets marked with a dash (-) were 
included in the original study design but were excluded from the study at an early time point 
as they were unsustainable. Standard mouse chow was also included and is shown in green 
at the bottom of this table, this was only represented at a single caloric tier. 
Histology 
Periodic Acid Schiff staining was performed on 2 μm kidney sections from N=167 mice. In 
brief, sections were deparaffinised (100% Xylene, 2x 5 min), and hydrated (100% EtOH, 2 
x 5 min; 95% EtOH, 1 x 3min; 75% EtOH, 1 x 3min; distilled water, 2 x 1 min). Sections were 
then placed for 5 minutes in 1% Periodic Acid solution (Amber scientific, Midvale, WA, 
Australia), immersed for 15 minutes in Schiff’s Reagent (Sigma-Aldrich, United States) and 
rinsed in warm tap water until sections were pink in colour. Nuclei were counter stained in 
Mayer’s Haematoxylin (Sigma-Aldrich, United States), before being dehydrated (70% EtOH 
1 x 3 min, 95% EtOH 2 x 3 min, 100% EtOH 2 x 3 min, xylene 2 x 5 min) and mounted for 
imaging. Masson’s trichrome staining was performed on 4 μm kidney sections from N=167 
mice at the Translational Research Institute Histology Core Facility, Woolloongabba, QLD 
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Australia. Stained slides were imaged using the slide scanner (Virtual Slide System VS120, 
Olympus, Tokyo, Japan) at a magnification of 400X. Glomerular sclerotic index (GSI) was 
scored as described previously by Gallo et al. [507]. In summary, 20-30 glomeruli per kidney 
section were scored, based on the percentage of the total glomerular area visible that 
contained thickening of the basement membrane and mesangial matrix expansion. In the 
rare instance where a section did not have 20 glomeruli, all viable glomeruli were scored. 
Images of glomeruli representative of the scoring system used are shown (Figure 5-1). The 
degree of interstitial fibrosis in the kidney cortical sections was quantified is tissue sections 
stained with Masson’s trichrome. Photomicrographs of eight to twenty fields of view 
encompassing the stained kidney cortex without overlap were taken and analysed in image 
J using colour thresholding as per Zhuang et al. [270].  
 
Figure 5-1. Photomicrographs of glomeruli representative of GSI scoring  
i. Representative images of a glomeruli typical of a score 0, based on the GSI scoring 
matrix 
ii. Representative images of a glomeruli typical of a score 1, based on the GSI scoring 
matrix 
iii. Representative images of a glomeruli typical of a score 2, based on the GSI scoring 
matrix 
iv. Representative images of a glomeruli typical of a score 3, based on the GSI scoring 
matrix  
v. Representative images of a glomeruli typical of a score 4, based on the GSI scoring 
matrix  
 
Protein extraction 
Protein was extracted from a cortex enriched piece of kidney tissue (20-40 mg) using lysis 
buffer (10 mM Tris–HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 10% Glycerol, 5 mM EDTA) 
including a protease inhibitor cocktail (Roche, Complete EDTA free, Sigma Aldrich, St Louis, 
Missouri, USA). Frozen kidney tissue, enriched for cortex, was cut on dry ice and rapidly 
homogenised using a Bullet Blender at 4ᵒC (Next Advance, Troy, NY, USA) for 5 minutes 
on setting 8, using 0.5 mm zirconium oxide beads (Next Advance, Troy, NY, USA). The 
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resulting homogenate was then spun at 12000 x g for 20 minutes to clear the lysate. Cleared 
lysate was aliquoted and stored at -80°C. The protein concentration of the cleared lysate was 
measured by BCA (Thermo Fischer Scientific, Waltham, Massachusetts, USA). 
Biochemical assays 
Cystatin C  
Glomerular filtration rate was estimated by measuring serum cystatin C concentrations by 
ELISA (Mouse Cystatin C ELISA, BioVendor Research and Diagnostic Products, Karasek, 
Czech Republic) according to the manufacturer’s instructions. Body weight adjusted serum 
cystatin C was calculated by dividing serum cystatin C by total body weight for each mouse. 
Lean mass adjusted serum cystatin C was calculated by dividing serum cystatin C by lean 
mass for each mouse. Lean mass and body weight data have been previously published for 
this cohort [346]. A cystatin C based assessment of GFR was used as dietary protein has 
been shown to interfere with assessment of GFR by creatinine based methods [508]. 
Kidney Injury Molecule 1 
Kidney Injury Molecule 1 (Kim 1) concentration was measured in protein extracted from 
kidney tissue (cortex enriched) by ELISA (Mouse ELISA for Kidney Injury Molecule 1, Cloud 
Clone Corp, Houston, Texas). 100 μg of protein was loaded per well. Curve fitting and 
analysis was performed in GraphPad Prism 7. 
Inflammatory Cytokines 
A LEGENDplex cytokine assay (Mouse Inflammatory cytokines panel 13-plex; Bio legend, 
San Diego, CA, USA) was performed as per the manufacturer’s instructions, in kidney 
cortex-enriched protein extract using 180 μg of protein per replicate and run on a CytoFLEX 
flow cytometer (Beckman and Coulter, Brea, CA, USA). Analysis was performed using 
LEGENDplex v.8.0. Cytokines measured by this kit include: interleukin 23 (IL-23), interleukin 
1 alpha (IL-1α), Interferon gamma (IFN-γ), Monocyte chemoattractant protein 1 (MCP-1), 
Interleukin 12 p70 (IL12p70), Interleukin 1 beta (IL-1β), Interleukin 10 (IL-10), Interleukin 6 
(IL-6), Interleukin 27 (IL-27), Interleukin 17A (IL-17A), Interferon-beta (IFNβ), and 
granulocyte-macrophage colony-stimulating factor (GM-CSF). 
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Gene Expression Analysis 
RNA extraction.  
RNA was extracted using an adapted Phenol/Chloroform extraction. In short, 20 mg of snap 
frozen kidney cortex tissue was added to snap lock tubes containing 200 μl of chilled 
QIAZOL (QIAGEN, Venlo, Netherlands), and 0.5 mm zirconium oxide beads (Next Advance, 
Troy, USA). Tissue was homogenised using the Bullet Blender (Next Advance, Troy, NY, 
USA) for 5 minutes on setting 8 at 4°C. The supernatant was transferred to a fresh tube and 
the residual beads were washed with an additional 300 μl of QIAZOL. The wash supernatant 
was then pooled with the first aliquot. Chloroform was added (100 μl) to the supernatant, the 
solution was vortexed for 15 seconds and then incubated at room temperature for 15 
minutes before being centrifuged at 12000 x g for 15minutes at 4°C to separate the RNA 
containing aqueous phase from the DNA containing interphase and the protein containing 
phenol phase. 200 μl of the aqueous phase was then added to a QIAGEN RNeasy column 
(RNeasy mini kit, QIAGEN, Venlo, Netherlands) the column was washed and the RNA 
eluted according to the manufacturer’s instructions. Total RNA was quantified using the 
NanoDrop1000 micro-volume spectrophotometer (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA).  
One microgram of RNA was DNase treated, (DNase 1, amplification grade, Invitrogen, 
California, USA) and then reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad, 
California, USA), as per the manufacturer’s instructions. Gene-expression analysis was 
performed using the TaqMan fast advance platform (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA), with gene expression probe and primer kits for murine collagen type 
IV alpha 1 chain (Col4a1) Mm01210125_m1; connective tissue growth factor (Ctgf) 
Mm01192933_g1; Tumour growth factor α (Tgfα) Mm00446232_m1 and klotho 
Mm00502002_m1. 
Urea 
Serum urea was measured at the Concord Hospital Pathology Department (this data was 
kindly provided by our collaborators). Urea levels were adjusted to body weight and lean 
mass as per cystatin C.  
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Statistics 
Generalised additive models (GAMs) with thin plate splines were used to model the 
response variables (structural and functional markers of kidney disease and associated 
cardio-metabolic risk factors) over mouse macronutrient intake spaces, as per Solon-Biet & 
McMahon et al., 2014 [346]. This was performed in R (version 3.4.0) using the mgcv 
package for the R language (R Core team, version 1.8-17), with an additional penalty 
included in the fit, to allow specific terms to have 0 estimated degrees of freedom and 
essentially be excluded from the model as per Solon-Biet & McMahon et al. [346]. For this 
modelling approach, each mouse is plotted in a three dimensional nutrient space (where the 
dimensions represent protein, carbohydrate and fat), based on each mouse’s actual median 
daily intake of each (Supplementary Figure 5-1). The relationship of the response variable 
is then plotted within this three dimensional nutrient space to determine the individual and 
combinatorial relationship between macronutrients and the variable of interest. The 
macronutrient effects were divided into main effects of individual macronutrients in isolation 
and into interacting effects of each combination of macronutrient. To support the GAMs 
analysis, three heat maps termed “response surfaces”, cut as slices through the median 
intake for each macronutrient (shown on the x axis in parentheses) were used to visualise 
the relationship between the response variable and each paired combination of the 
macronutrients. In all surfaces, red represents the highest values whilst dark blue represents 
the lowest. Colours are standardised across all slices. Comparison of the distributions of 
response variables between males and females was performed by Student’s T test or non-
parametric equivalent in GraphPad Prism 7. Correlations were performed using the Rcorr 
package (version 2.3-2) in R and a correlogram visualised using corrplot (version 0.84). 
Interpretation of the response surfaces. 
The surface plots are designed to give a snapshot of combinatorial effects of macronutrients 
on the renal outcomes “response variables”. All surface plots take the same format and 
supporting statistical tables are provided in the supplementary data. Supplementary Figure 
5-1 A-C show the relationship of these two dimensional surfaces fit as slices within the in 
the 3D nutrient space. Taking as an example Supplementary Figure 5-1 A, surface 1 (left) 
shows median daily protein intake on the X axis, while carbohydrate intake, is shown on the 
Y axis. The multi-coloured terrain plot within then indicates the relationship of a hypothetical 
response variable to median daily protein and carbohydrate intake. This plot represents a 
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single slice cut through the 3rd axis of the three dimensional model (Supplementary Figure 
5-1 B), at median intake for fat (10 kJ/mouse/day, shown in parentheses below the X axis). 
This surface can be interpreted to show that protein and carbohydrate intake both inversely 
effect the response variable, indicated by the transition from red (highest) to blue (lowest) 
on the surface as protein intake or carbohydrate increase, with actual values of the size 
changing from 3.6 to 2.2 as indicated by the contour lines. The slant and shape of the 
contour lines give some idea of how the interactive effect of protein and carbohydrate 
together influence the hypothetical response variable. The second surface (middle) shows 
protein intake (X axis), with median daily fat intake indicated along the Y axis, sliced through 
median carbohydrate intake (14 kJ/mouse/day, Supplementary Figure 5-1 B). The third 
panel (right) shows the relationship of the response variable to fat and carbohydrate intake 
with carbohydrate intake shown on the X axis and fat intake shown on the Y axis, cut through 
the 3D model at the median intake for protein (10 kJ/mouse/day). Here, carbohydrate intake 
has a strong inverse relationship to the hypothetical response variable compared to fat 
intake, indicated by the more dramatic colour change in the direction of the X axis as 
compared to the Y axis. This was more pronounced at the higher intakes for carbohydrate 
as indicated in the bulge in the contour lines.  
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Results 
Protein intake imparts the greatest influence on kidney weight.  
Kidney weight ranged from 170 mg to 538 mg (Figure 5-2 A), with males showing a larger 
total kidney weight overall, (Male, 0.391  0.083 vs Female, 0.318  0.062 g; P<0.0001). 
However, when adjusted relative to lean mass, kidney mass did not differ between sexes 
(Male, 0.018  0.0024 vs Female, 0.018  0.0026 g/lean muscle mass; P=0.5, Figure 5-2 
B). Total kidney weight, body weight and lean mass adjusted kidney weight were all mapped 
as response surfaces onto the intake based nutrient space; (Figure 5-2 C-E) and modelled 
using GAMs (Supplementary Table 5-1). Surfaces in (Figure 5-2 C) show that unadjusted 
kidney weight was driven by protein, carbohydrate and fat intake as independent variables 
(P<0.001 for all), with kidney size increasing as intake of any of these macronutrients 
increased. Additionally, total kidney mass increased as total energy intake (protein, 
carbohydrate and fat as interactive variables) increased (P <0.01). 
When kidney mass was adjusted for either body weight or lean mass (Figure 5-2 D and E, 
respectively) the relationship to carbohydrate and fat as independent variables was lost 
(Figure 5-2 D and E, Supplementary Table 5-1). Further, the relationship to total energy 
intake also disappeared (Figure 5-2 D and E, Supplementary Table 5-1). These relationships 
were, in general, also present when male and female mice were analysed separately (Figure 
5-3 A and D). In male mice, total kidney weight was not influenced by total energy intake or 
fat intake, but by protein or carbohydrate as independent variables, P<0.0001 and P<0.01 
respectively (Figure 5-3 A, Supplementary Table 5-2). Following correction for body weight 
or lean mass only protein intake remained significant in males (Figure 5-3 B and C, 
Supplementary Table 5-2). Conversely, in female mice, kidney weight was influenced by all 
three macronutrients as independent variables (Protein: P<0.00001; Carbohydrate, 
P<0.0001; Fat, P<0.01), (Figure 5-3 D, Supplementary Table 5-2). After correction for lean 
muscle mass or body weight, protein intake remained the most significant driver of kidney 
weight (P0.0001), (Figure 5-3 E) or lean mass adjusted kidney weight, (Figure 5-3 F; 
Supplementary Table 5-2). 
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Figure 5-2. The effect of dietary macronutrients on kidney weight.   
A and B Scatterplots showing the range of total kidney weight A), and lean mass adjusted kidney 
weight B), for all mice (N=171) at 15 months of age (blue circles, male, red circles, female). C-E 
Response surfaces showing the effect of macronutrient intake by 15 months of age on; C) total kidney 
weight (g), D) kidney weight adjusted for total body weight (g); E) kidney weight adjusted for lean 
muscle mass (g). Response surfaces are a 2D slice through the third macronutrient parameter at its 
median intake (shown on the x axis in parentheses in kJ/mouse/day). In all surfaces, red represents 
the highest value whilst dark blue represents the lowest. Colours are standardised across all slices. P 
values are presented in supplementary data, (Supplementary Table 5-1).  
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Figure 5-3. The influence of dietary macronutrient intake on kidney weight between the sexes.   
Response surfaces for male (n=82, A-C) and female (n=89, D-F) mice at 15 months of age showing 
the effect of macronutrient intake on total kidney weight (g) (A & D); kidney weight adjusted for 
total body weight (g) (B & E); kidney weight adjusted for lean muscle mass (g) (C & F). Full P values 
associated with these surfaces are presented in supplementary data, (Supplementary Table 5-2). 
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Protein intake has the greatest positive influence on glomerular filtration rate  
Kidney function was assessed by serum cystatin C concentration as a surrogate measure 
of GFR. Serum cystatin C has an inverse relationship to GFR and showed variation from 
126 to 1006 ng/ml (Figure 5-4 A). As with kidney weight, protein as an independent variable 
(P=0.031) and carbohydrate as an independent variable (P=0.013) had the greatest 
influence on serum cystatin C. Here, GFR(cystatin C) was the lowest in mice which consumed 
less protein and more carbohydrate each day (Figure 5-4 B).  
As GFR calculations in humans are generally adjusted for body weight or BMI, we also 
adjusted for lean mass or body weight. Here, the relationship between lower protein intake 
and low GFR was further strengthened (P<0.0001, body weight adjusted; P<0.0001, lean 
mass adjusted), (Figure 5-4 C & D). While the association between higher carbohydrate 
intake and lower GFR was lost following adjustment, the interactions between protein and 
carbohydrate became significant, (P<0.01 for body weight adjusted; P<0.029 for lean mass 
adjusted; Supplementary Table 5-3). These relationships did not differ between male and 
female mice. (Supplementary Figure 5-2). Serum urea concentrations varied from 2.1 
mmol/L to 20.7 mmol/L (Figure 5-5 A) with the lowest concentrations seen in mice with lower 
GFRs. As expected, circulating urea concentrations were elevated as protein consumption 
increased and decreased as fat and carbohydrate intake increased (Figure 5-5 B). Analysis 
by GAMs found that all three macronutrients influenced serum urea as independent 
variables (P<0.001, for all three macronutrients) (Supplementary Table 5-4).  
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Figure 5-4. Glomerular filtration rate is driven by dietary protein intake. 
A) Scatterplot showing the range of GFR as measured using serum cystatin C (ng/ml) across all mice 
(n=153) at 15 months of age. Blue circles represent males (n=74); red circles represent females 
(n=79). B-D Response surfaces showing the effect of macronutrient intake on B) serum cystatin C 
ng/ml, C) serum cystatin C adjusted for body weight (g), D) Serum cystatin C (ng/ml) adjusted for 
lean mass (g), at 15 months of age. In all surfaces red represents the highest value whilst dark blue 
represents the lowest. Colours are standardised across all slices. Full P values associated with these 
surfaces are presented in supplementary data, (Supplementary Table 5-3).  
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When circulating urea was adjusted relative to body weight or lean mass the relationship to 
macronutrients changed significantly compared to unadjusted urea, (Figure 5-5 C and D), 
where protein became less significant, changing from P<0.0001 to P=0.01 after body weight 
adjustment. After adjustment for lean mass the relationship to protein was lost completely, 
with mice consuming the least carbohydrate and at the lower half of protein intake showing 
the highest urea to body weight ratio (Figure 5-5 C). In both adjusted models the influence 
of carbohydrate and fat intake on circulating urea became more significant (P<0.0001 in 
both models for both macronutrients), with mice consuming the lowest fat and carbohydrate 
having the highest urea to body weight ratio (Supplementary Table 5-4). Carbohydrate and 
fat as interactive variables also contributed to body weight adjusted serum urea levels 
(P=0.0009).  
The effects of macronutrient intake on blood urea were influenced by gender 
(Supplementary Figure 5-3). Males did not differ significantly from the total cohort but for 
female mice unadjusted serum urea was only influenced by protein intake (P=0.0001) and 
total energy consumption, (P=0.005), but not carbohydrate and fat independently 
(Supplementary Figure 5-3). However, the body weight and lean mass adjusted values, 
when plotted by GAMs remained similar to the models for male and the entire cohort 
(Supplementary Figure 5-3 E and F). 
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Figure 5-5. Blood urea is influenced predominantly by protein intake, but this changes when body 
weight is accounted for. 
A) Scatter plot showing the distribution of serum urea across a subset of the GF mice at 15 months 
of age (males blue (n=60), females red (n=65)). Response surfaces showing the effect of 
macronutrient intake on; B) serum urea (mmol/L); C) serum urea (mmol/L) adjusted for body weight 
(g) (n=118), D serum urea (mmol/L) adjusted for lean mass (g) in GF mice at 15 months of age. Full 
P values associated with these surfaces are presented in supplementary figures, (Supplementary 
Table 5-4). 
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Kidney Injury Molecule is influenced by caloric intake and carbohydrate. 
KIM-1, a marker of tubular injury, was measured in cortex-enriched kidney tissue and ranged 
from 6.72 pg/μg of protein to 216.9 pg/μg of total protein (Figure 5-6A). Renal cortical KIM-
1 showed a strong association with carbohydrate and total energy consumption (protein 
carbohydrate and fat) (P=0.0003 and P=0.002 respectively, Figure 5-6 B, Supplementary 
Table 5-5).  
A) Scatter plot showing the distribution of values obtained for tissue Kidney Injury Molecule 1 (KIM-
1 pg/μg of total protein) in the kidney cortex-enriched protein fractions in a subset of the GF mice at 
15 months (N=154, males, blue; females, red). B) Response surfaces showing the effect of 
macronutrient intake on KIM-1 (pg/μg of total protein) in these mice. Full statistics can be found in 
Supplementary Table 5-5. 
 
When stratified for sex, male mice (n=72) had greater renal KIM-1 concentrations as 
compared to female mice (n=82) (Male, median, 108 (IQR 73.06) vs Female, 77.14 (IQR 
58) pg/μg of total protein; P<0.001). Despite this both genders showed that low carbohydrate 
intake was most strongly associated with elevated renal KIM-1 concentrations (P= 0.001, 
males and females) (Figure 5-7 and Supplementary Table 5-6). However, in male mice the 
highest renal KIM-1 concentrations were present at the extremes of protein intake and fat 
intake (P=0.003 for interactive effect of protein and fat), when carbohydrate intake was also 
Figure 5-6. KIM-1 is influenced by dietary carbohydrate and total calorie intake. 
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low (Figure 5-7A, Supplementary Table 5-6). In female mice the highest KIM-1 
concentrations were seen with greater protein intake in the context of low carbohydrate 
intake (Figure 5-7B, Supplementary Table 5-6, P=0.005 for interactive effect of protein and 
carbohydrate). Fat intake did not appear to influence KIM-1 levels in the renal cortex, in 
female mice  
Figure 5-7. KIM-1 retained a similar relationship to macronutrient intake regardless of sex. 
Response surfaces showing the effect of macronutrient intake on the concentration of Kidney Injury 
Molecule 1 (KIM-1) in the kidney cortex of male (n=72) (A) and female (n=82) (B) GF mice at 15 
months of age. Full statistics can be found in Supplementary Table 5-6. 
 
Glomerulosclerosis tended to increase with increased dietary fat consumption.  
Glomerulosclerosis, the expansion of the mesangial matrix of the glomeruli, is a histological 
hallmark of diabetic kidney disease and is seen in some glomeruli during aging. In the GF 
mice GSI varied from 0.75 to 4.0 (Figure 5-8 A) and median scores did not differ between 
sexes (females 1.425 (IQR 0.55) vs males 1.55 (IQR 0.40) P=0.21). Representative images 
of glomeruli according to median GSI scores by diet are shown in Supplementary Figure 
5-4. In the entire cohort, GSI modestly increased proportionally to fat intake (Figure 5-8 B) 
but this did not reach statistical significance (P=0.08 Supplementary Table 5-7). In female 
mice the effect of fat on GSI was more obvious, although this did not reach significance 
(P=0.082), (Figure 5-9 B, Supplementary Table 5-8). In male mice GSI was more strongly 
149 
 
influence by protein to carbohydrate ratio (P=0.015) with no relationship to fat intake evident 
(Figure 5-9 A, Supplementary Table 5-8).  
Figure 5-8. Glomerulosclerosis tended to increase as calories consumed from fat increased. 
A) Scatter plot showing the spread of individual scores for glomerulosclerosis across GF mice (N= 
168). B) Response surfaces showing the effect of macronutrient intake on glomerulosclerosis as 
scored by GSI (0-4), at 15 months of age. For full statistical analysis, see Supplementary Table 5-7. 
C) Representative images showing PAS stained glomeruli at different intake levels for fat and energy.  
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Figure 5-9. The effects of macronutrient intake on glomerulosclerosis differ between males and 
females. 
A) Response surfaces showing the effect of macronutrient intake on glomerulosclerosis as scored by 
GSI (0-4), in male mice only at 15 months of age, n=82. B) Response surfaces showing the effect of 
macronutrient intake on glomerulosclerosis as scored by GSI (0-4), female mice only at 15 months of 
age, n=86. Full P values associated with these surfaces can be found in Supplementary Table 5-8.  
 
Low protein intake was associated with tubulointerstitial fibrosis, a marker of 
progressive kidney disease.  
Tubulointerstitial fibrosis, the progressive deposition of connective tissue in the parenchyma 
of the kidney was assessed histologically by Masson’s Trichrome staining. Renal 
tubulointerstitial fibrosis ranged from 0.3% to 12.5% (Figure 5-10 A). No statistically 
significant association was found between macronutrients and fibrosis, as independent or 
interacting variables. However, protein tended toward significance (P=0.12, Supplementary 
Table 5-9) with the model suggesting that greatest fibrosis occurred at the lowest protein 
intake but increasing at the lowest and highest tiers of carbohydrate intake. Representative 
images of the stained kidney cortices from diets sorted on protein and carbohydrate intake 
are presented (Figure 5-10 C). When analysed for gender specific effects, there were no 
statistically significant differences seen (Figure 5-11 A and B; Supplementary Table 5-10). 
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Figure 5-10. Fibrosis did not show a statistically significant relationship to macronutrient intake.  
A) Scatter plot showing the spread of individual scores for fibrosis of the renal cortex across all mice. 
Individual scores are represented as the median score across 10+ photomicrographs of the renal 
cortex, N= 165. B) Response surfaces showing the effect of macronutrient intake on fibrosis of cortex 
at 15 months of age. See Supplementary Table 5-9 for full statistics. C) Representative images 
showing Masson’s Trichrome stained cortex at different intake levels for protein and carbohydrate.  
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Figure 5-11. The influence of macronutrients on fibrosis is not significant in males or females. 
Response surfaces showing the relationship between macronutrient intake and the percentage 
measurable fibrosis in the kidney cortex in male mice n=80 (A) and female mice, n=85 (B) at 15 
months of age. See Supplementary Table 5-10 for full statistical output. 
 To support the histological analysis of fibrosis, gene expression of the key fibrotic mediators 
connective tissue growth factor (Ctgf), transforming growth factor β1 (Tgf-β1) and pre-
procollagen type IV alpha 1 chain (Col4a1) was assessed in kidney cortices. Although both 
Ctgf and Tgf- β1 had similar response surface plots, there was no influence of macronutrient 
intake on their gene expression (Figure 5-12 A and B, Supplementary Table 5-11) seen in 
this study. Similarly, there was no relationship between Col4a1 expression and specific 
macronutrient intake (Figure 5-12 C, Supplementary Table 5-11)  
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Figure 5-12. There was no relationship between macronutrient consumption and expression of key 
fibrotic mediators at 15 months of age. 
A Response surface showing the effect of macronutrient intake on kidney expression of connective 
tissue growth factor (Ctgf), at 15 months of age (N=148). B Response surface showing the effect of 
macronutrient intake on kidney expression of tumour growth factor β (TGF-β1), at 15 months of age 
(N=149). C Response surface showing the effect of macronutrient intake on kidney expression of 
collagen 4 a1, (Col4a1), at 15 months of age (N=152). Results for all surfaces show fold expression, 
relative to expression of 18S housekeeping gene. For full P values associated with this figure, see 
Supplementary Table 5-11.  
 
The relationship between dietary macronutrients and inflammation within the kidney. 
Inflammation in the kidney was assessed using the LEGENDplex inflammation panel. Seven 
of the thirteen cytokines assessed showed a significant relationship to dietary 
macronutrients (Figure 5-13 A, Supplementary Table 5-12). Consistent with lower renal 
function and more fibrosis, renal pro-inflammatory cytokines IL-23 and IL-1  were both 
elevated as protein consumption decreased independent of fat and carbohydrate intake 
(Figure 5-13 A, B and D, Supplementary Table 5-12). IFNγ and IL-12p70 were also 
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increased with lower protein consumption within a specific dietary carbohydrate intake 
(Figure 5-13 C, Supplementary Table 5-12). Monocyte chemoattractant protein (MCP-1) 
tended to be most affected by of the ratio of carbohydrate and fat consumption but this did 
not quite reach significance (P=0.0523, Figure 5-13A, Supplementary Figure 5-5). Other 
cytokines did not show an association with macronutrient consumption in this study. 
Figure 5-13. Inflammatory cytokines in cortex enriched tissue and macronutrient intake. 
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A) Table showing statistically significant P values for the relationships between the 13 cytokines 
analysed in kidney cortex homogenate and macronutrient intake in GF mice (N=152) at 15 months 
of age using GAMs. P values are reported for all statistically significant relationships or those 
approaching significance. P values spanning two or more macronutrient cells in the table indicate 
interactive effects were significant in the model. B-D, Response surfaces for cytokines (pg/ml) with 
simple independent effects; IL-23 B), IFNγ C), and IL-1β D), reported in figure A. Full statistics for 
figure 12 are reported in Supplementary Table 5-12. 
 
Decreasing protein consumption is associated with reduced renal klotho expression. 
A decline in renal klotho has been associated with premature aging, CKD and diabetic 
kidney disease [509-512]. Renal klotho expression showed a linear positive relationship with 
protein consumption, where mice consuming more calories from protein had the highest 
renal klotho expression (Figure 5-14; P=0.05, Supplementary Table 5-13).  
 
Figure 5-14. The relationship between macronutrients and expression of klotho within the kidney 
cortex. 
Response surface showing the effect of macronutrient intake on gene expression of klotho by the 
kidney cortex at 15 months of age (N=151). Results show fold expression, relative to expression of 
18S housekeeping gene. Protein as an independent variable was a statistically significant 
explanatory variable (P=0.05). For full statistical analysis see Supplementary Table 5-13.  
 
Dietary macronutrients were not associated with changes in circulating electrolytes. 
The kidneys play an important role in fluid electrolyte balance and imbalances in circulating 
electrolyte concentrations are often indicative of a decline in renal function. Surfaces were 
plotted showing the relationship of macronutrient consumption with circulating chloride, 
sodium and potassium (Figure 5-15 A-C). There was little variation in electrolytes across 
mice with the spectrum of dietary macronutrient consumption used here and no statistical 
differences were found (Supplementary Table 5-14). 
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Figure 5-15. Response surfaces showing the effect of macronutrients on electrolyte balance. 
Response surfaces showing the relationship of macronutrient intake on circulating A) chloride ions 
(mmol/L; N= 175), B) sodium ions (mmol/L; N= 176) and C) potassium ions (mmol/L; N=116) in GF 
mice at 15 months of age. See Supplementary Table 5-14 for full statistics associated with these 
models. 
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Low protein intake over a lifetime results in poor kidney function and structural 
damage which is not attributable to traditional CKD risk factors.  
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Figure 5-16. Common risk factors for CKD do not explain the decline in renal function seen with 
low protein intake. 
Key metabolic risk factors for CKD were examined at 15 months of age. Response surfaces are shown 
for the relationship of macronutrients to key CKD risk factors specifically, (A) systolic blood pressure, 
(B) diastolic blood pressure, (C) percentage body fat, (D) glucose tolerance expressed as the 
AUCGLUCOSE following a 1g/kg bolus of intraperitoneal glucose, (E) HDLc, (F) LDLc, (G) total 
cholesterol, (H) triglycerides, in GF mice at 15 months of age. Figures reproduced from Solon-Biet et 
al., 2014 with permission of the journal (Appendices 1). 
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Figure 5-16 shows surfaces for key cardio-metabolic risk factors for chronic kidney disease, 
including markers of dyslipidaemia, hypertension, glucose intolerance and adiposity 
reproduced from Solon-Biet et al. [346]. These surfaces were compared to those produced 
for GFR (cystatin C), glomerulosclerosis, tubulointerstitial fibrosis and renal inflammation 
following low protein consumption. No clear associations were observed by examining the 
surfaces between the risk factors examined and the structural and functional markers of 
CKD. To support these observations, Spearman’s univariate correlations were performed 
for known risk factors for kidney disease and the major markers of renal structural and 
functional changes assessed in this study and a univariate correlation matrix produced 
(Figure 5-17, Supplementary Figure 5-6). Total kidney weight was positively correlated with 
increases in anthropometric measures (body weight, fat mass, lean mass, bone mineral 
density) and glucose intolerance (plasma glucose and insulin and HOMA-IR) (Figure 5-17 
and Supplementary Figure 5-6). Consistent with comparison of surfaces produced by GAMs, 
using Spearman’s univariate correlations and Bonferroni’s correction for multiple 
comparisons, cystatin C, fibrosis and glomerulosclerosis showed only limited associations 
with CKD risk factors (Figure 5-17, Supplementary Figure 5-6). Specifically, higher cystatin 
C (adjusted or unadjusted) indicative of a low GFR, was negatively related lean muscle mass 
and bone mineral density. Tubulointerstitial fibrosis, which was also evident in mice with 
lower GFR, showed a modest negative relationship to glucose (AUC) during an I.p GTT 
(Figure 5-17, Supplementary Figure 5-6). Kim-1 levels in the renal cortex shows strong 
inverse relationships to body weight, fat mass and bone mineral density. While renal klotho 
demonstrated a positive relationship to AUCglucose and negative association with insulin 
HOMA IR and blood sodium levels.   
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Figure 5-17. Correlations between kidney markers and cardio-metabolic risk factors for CKD. 
Correllogram showing positively and negatively correlated risk factors and renal parameters 
examined in this study. Colour intensity and the size of the circle are proportional to the correlation 
coefficients. Only correlations where P<0.05 (adjusted, Bonferroni’s correction for multiple 
comparisons) are shown by a circle. Supporting correlation matrices for R values and associated 
adjusted P values are shown in Supplementary Figure 5-6.  
  
161 
 
Discussion 
Summary of the major findings 
Here we have shown the outcomes of using a geometric framework study design to examine 
the influence of dietary macronutrient consumption and caloric intake on markers of renal 
structure and function in ageing mice. In our study, a lower protein intake was found to have 
a major influence on renal parameters. Surprisingly, the lowest GFRs, lowest kidney 
weight:body weight, highest serum urea, lowest klotho expression and highest levels of renal 
inflammatory cytokines, were seen in mice consuming less calories from protein. 
Additionally, mice consuming less calories from protein tended towards greater 
tubulointerstitial fibrosis, especially in association with high or low carbohydrate intake, 
although this did not reach statistical significance. Additionally, as an interactive variable in 
the context of higher carbohydrate intake, low protein was also seen to increase renal 
cytokines such as IFNγ and IL12p70, and elevate renal cortical KIM-1 levels at a population 
level in the context of increased fat intake. There were however, significantly different effects 
in these parameters noted between sexes.  
Beyond protein intake effects, a number of other important macronutrient associated effects 
were present. KIM-1 showed a significant relationship to total caloric intake (Protein: 
carbohydrate: fat, as synergistic effects). Other important markers of kidney ageing and 
disease, such as GSI and expression of pro-fibrotic genes did not associate with 
macronutrient consumption in the longer term although some interesting trends were 
present which are discussed further below.  
Finally, a major advantage of this study was that characterisation of important cardio-
metabolic risk factors for CKD in these mice had already been measured and published 
[346]. It is not statistically possible to undertake multivariate modelling using the GAMs 
approach to assess their influence on the relationships identified between dietary protein 
intake and the renal parameters. However, more simplified univariate analyses found no 
relationships between renal parameters measured and known risk factors for chronic kidney 
disease including serum lipids, adiposity and glycaemic control. This was also confirmed by 
visual comparison of the GAMs surfaces produced showing the relationships between 
protein intake and renal parameters as compared with protein consumption and these 
independent CKD risk factors. This uniquely suggests that many of the renal changes 
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captured in this study were occurring independent of the traditional risk factors, typically 
thought to drive disease in humans.  
The relationship between macronutrient consumption, kidney weight and GFR- a 
crucial role for protein intake.  
In the present study however, both unadjusted and adjusted cystatin C were significantly 
elevated by lower protein consumption indicative of a lower GFR; this relationship was 
consistent between sexes. However, one could argue that this might be explained by 
increased demand on the kidney to remove nitrogenous waste as protein consumption 
increased. Supporting this, when surfaces for the model are compared cystatin C and urea 
show an almost perfect inverse association in their relationship to macronutrients. Serum 
urea, a nitrogenous bi-product of protein metabolism can also influence glomerular filtration 
rate. Perturbation of circulating urea concentrations can be indicative of kidney dysfunction. 
Indeed, other studies have shown that blood urea nitrogen concentrations can influence 
glomerular filtration rate [513, 514].  However, in our study, when blood urea and cystatin C 
were adjusted for body weight the relationship between protein and cystatin C strengthens. 
Meanwhile, the relationship of blood urea to protein consumption is lost completely, with 
mice at the lower end of carbohydrate and fat consumption having the highest levels of urea 
relative to body weight. It should be noted however, that significant differences in urea 
kinetics have been observed between obese and lean individuals in human studies [515]. 
Regardless, these results were somewhat surprising given low protein diets, similar to those 
used in our study, have demonstrated protective effects in rodent models of CKD by 
preventing a progressive reduction in GFR [516]. However, previous meta-analysis of over 
20 studies examining the effects of dietary protein intake on renal function in healthy 
individuals, demonstrated a mean increase in GFR with increasing protein intake in both 
men and women [517]. By contrast however, the Modification of Diet in renal Disease Study 
(MDRD) showed a greater decline in GFR in the earlier stages of CKD with lower dietary 
protein intake [518], consistent with our findings. Hence, the reasons for this disparity remain 
unclear but could stem from the degree of underlying renal injury that is present when the 
low protein diet was undertaken. Here, in the present study where all genetic and 
environmental variables beyond diet are controlled, it is likely that protein is having a 
profound effect on GFR, with lower protein consumption associated with lower GFR, but 
with the vast majority of this occurring within a non-pathological range for GFR. Taken 
163 
 
together one might caution that a lower protein diet in healthy individuals and in those with 
early kidney disease may adversely impact kidney health in the longer term.  
It was clear from the model that mice consuming more protein had a greater kidney mass 
relative to body weight or lean mass, which may, in part, explain the relationship between 
protein consumption and GFR. Lower renal mass, associated with reduced nephron and 
glomerular number, is thought to be an important determinant of CKD risk [519], particularly 
in children [520] or populations where reduced renal mass is evident at birth such as 
Aboriginal and Torres Strait Islander peoples [521]. Furthermore, a decrease in protein 
consumption and subsequent increase in circulating urea and other nitrogenous waste 
products, due to cachexia and muscle wasting is commonly seen in chronic kidney disease 
[522]. In line with this, it has been shown that circulating ketones from dietary protein 
significantly reduce catabolism of lean muscle and promote the production of lean muscle 
mass [523]. Anorexia and over-exercising are both conditions that result in catabolism of 
muscle and are both associated with acute kidney injury [524], however, whether chronic 
low protein intake is associated with muscle catabolism and a mechanistic link to kidney 
injury or decline in GFR is yet to be established outside of these conditions. It is possible 
that the lower lean mass could be increasing rates of cachexia, in these mice, leading to 
mild renal insufficiency.  
Importantly in our experiments, mice were randomised to their respective diets from weaning 
at three weeks of age and consumed the same diets through adolescence and early growth 
and development periods into late adulthood. It is possible that mice consuming less protein 
during growth and development may be pre-disposed to a smaller kidney to body weight or 
lean mass ratio resulting in a lower GFR. Whether this is a pathologically low GFR or could 
become so with secondary challenges is not clear from the present study. Once could 
certainly speculate that mice with smaller renal mass would be more susceptible to renal 
insults. Taken together, these data suggest that while a low protein diet, if well managed, 
may be beneficial in reducing the burden of end stage kidney disease and slowing renal 
disease progression [525], lifetime consumption does not alleviate kidney ageing, where all 
non-dietary variables are controlled in mice.  
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Tubulointerstitial fibrosis and glomerulosclerosis were not associated with 
macronutrient intake. 
We found no relationship between macronutrient intake and tubulointerstitial fibrosis or 
glomerulosclerosis, despite a significant spread in pathology for both GSI and fibrosis being 
evident in the GF mice. This was highly surprising as previous data from the GF showed 
that cardio-metabolic risk factors for CKD, including increased adiposity, insulin resistance 
and glucose abnormalities were present by this age [346] and were facilitated by diets low 
in protein and high in fat, and diets high in protein and low in carbohydrate. Furthermore, 
that lifetime consumption of diets with the highest fat or protein intake did not induce a 
significant renal pathology was unexpected. The highest fat and highest protein containing 
diets used in the present study, had equivalent amounts of calories ingested from protein 
and fat sources as studied in previous models where significant renal pathology in shorter 
timeframes was observed. For example, Wakefield et al. found that consumption of a diet 
with 35% of energy from protein led to glomerular hypertrophy, glomerulosclerosis, and 
proteinuria in female Sprague Dawley rats [526]. Six of the 26 diets used in the geometric 
framework exceeded this percentage of protein, with two of these diets also being within the 
highest tier of caloric intake and a further six diets almost equivalent, with 33% of calories 
derived from protein. Similarly a recent study in C57BL/6 mice showed that compared to a 
low fat diet (10% lard), a high fat diet (45% lard) induced significant glomerulosclerosis and 
fibrosis after 52 weeks  [527]. In our study however, eight of the diets used exceeded 45% 
of calories from fat but we did not observe any relationship between renal effects including 
a lack of tubulointerstitial fibrosis or glomerulosclerosis and fat consumption.  
Renal tubulointerstitial fibrosis is one of the most accurate predictors of progressive renal 
disease [25]. Although not statistically significant, our data suggested that tubulointerstitial 
fibrosis was the greatest in mice consuming the least calories per day from protein, in 
combination with either the highest and lowest dietary intake of carbohydrate. This suggests 
that there may be two separate mechanisms contributing to fibrosis “hot spots” associated 
with low protein and either high or low carbohydrate intake. At the highest intakes of 
carbohydrate, it is possible that the driver of fibrosis is increased adiposity, as adiposity is 
above 30% in these mice. However, it should be noted that all mice consuming a low protein 
diet over the long term had among the lowest systolic and diastolic blood pressure, low 
cholesterol and triglycerides and normal glucose tolerance [346]. Therefore, adiposity may 
be acting independently of these mechanisms to moderately increase fibrosis in these mice. 
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However, univariate correlation actually found an inverse relationship between fat mass and 
tubulointerstitial fibrosis. A second hot spot is present at where mice had low carbohydrate 
and protein intake, which conceptually should align with highest fat intake, however, no trend 
or relationship to fat intake was evident in the model. This macronutrient ratio of low protein 
and low carbohydrate however, also aligns with small renal weight to body weight and higher 
urea to body weight and may indicate increased fibrosis due to increased strain on the 
kidney caused by their proportionally smaller kidneys.  
There was also a trend towards fat as an independent variable impacting 
glomerulosclerosis. Van der Heijden et al. showed a significant increase in 
glomerulosclerosis in 45% lard fed mice compared to those on a low fat regimen after 52 
weeks [527]. Similarly, Decleves et al. reported a marked increase in glomerular pathology 
after only 12 weeks on a high fat diet [528]. Hence, it is surprising that dietary macronutrient 
and particularly fat consumption did not show a significant relationship to GSI. Possible 
explanations for this could include the use of soy bean oil as the source of fat in these diets, 
and/or the inclusion of indigestible fibre in the diets: these possibilities are discussed in detail 
below.  Interestingly, in this study, the trend towards a relationship between fat intake and 
GSI appeared to be largely driven by female mice. In agreement with our findings, one 
human study has reported an effect of dietary fat consumption on renal function, which was 
only present in the female population [141], but did not include any histological assessment. 
However, unlike our study, the vast majority of animal studies of dietary macronutrients on 
renal function have included only male mice, making it difficult to extrapolate their findings 
to humans.  
Somewhat paradoxically, KIM-1, a marker of tubular injury upregulated by proximal tubule 
cells in CKD and ischaemic or nephrotoxic serum forms of kidney disease [12, 529, 530], 
was also highest in mice consuming more calories from fat. Although it only showed a 
significant relationship to carbohydrate, and to total caloric intake (all three macronutrients 
as interactive variables). Surprisingly the relationship of KIM-1 levels to macronutrient 
consumption did not align with tubulointerstitial fibrosis scoring, despite previous research 
indicating it may play a role in macrophage recruitment and fibrosis [531].  
Dietary macronutrient intake and renal inflammation- influences on IL-1 and IL-23 
Inflammation and the subsequent infiltration of immune cells are considered one of the major 
drivers of fibrosis in both diabetic and non-diabetic kidney disease. Cytokines IL-6, TNFα 
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have consistently been demonstrated to be key mediators of progressive kidney disease  in 
vitro and in animal models [91, 532-534] and particularly associated with metabolic 
dysfunction, diabetes and diabetic kidney disease, [535, 536]. Here however, they showed 
no associations with macronutrient intake in this cohort. Similarly other key cytokines which 
are postulated mediators of renal pathology in the presence and absence of metabolic 
dysfunction or diabetes, including TNFα and MCP1 [537-539], also showed no association 
with macronutrient consumption. We did however see a strong relationship of both renal IL-
1β and IL-1α and macronutrient intake in this study. Renal IL-1β associated with both protein 
and fat intake as independent variables showing highest levels with low protein and high fat 
intake. This is interesting as a number of studies have implicated IL-1β in the pathogenesis 
of interstitial fibrosis [540, 541] and in particular, as a metabolic switch that promotes the 
initiation of fibrosis [542].  
A strong association was also demonstrated between lower protein consumption and 
elevated renal quantities of another pro-inflammatory cytokine IL-23, consistent with the 
pattern of fibrosis, and decreased Klotho expression. IL-23 is a potent inducer of Th17 cells, 
a subset of CD4+ T cells implicated in inflammation and autoimmune diseases, including 
those of the kidney [543, 544]. Little is understood about the role of IL-23 and Th17 cells in 
chronic kidney disease. The IL-23/IL-17 pathway has been implicated in the pathogenesis 
of experimental glomerulonephritis [544] although this is a severe form of immune mediated 
glomerular disease. It should be noted however, that we saw no concomitant increase in 
renal IL-17, the cytokine required for Th17 activation. Interestingly, leptin deficiency has 
previously been reported to down regulate the Th17 response, and reduce MCP-1 
expression and macrophage infiltration in murine models of nephrotoxic serum nephritis and 
could represent one link between IL-23, the diet and CKD [545]. Given how little research 
has been undertaken of IL-23 in CKD this represents and interesting area warranting further 
research.  
Low protein consumption, renal klotho expression and its relationship to longevity 
and aging.   
The kidney is the predominant source of potent anti-ageing factor, klotho [512]. Klotho has 
received significant attention as the major link between kidney disease and ageing since the 
absence of klotho in mice results in a rapid and accelerated ageing. Reduced klotho has 
previously been linked to chronic kidney disease in patients with CKD [510]. Furthermore, 
upregulation or administration of klotho is reno-protective in multiple models of renal injury. 
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Klotho expression was assessed in the present study in the renal cortex and showed a 
strong linear decline with decreasing dietary protein consumption. Indeed, the lowest klotho 
expression was identified in groups with the lowest GFR and increased renal fibrosis. This 
is consistent with previous studies that show reduced klotho leads to declining GFR [546], 
increased fibrosis [509] and increased inflammation [547] in rodent models of progressive 
nephropathy.  
Beyond its potent anti –ageing properties, klotho has also been demonstrated to be 
important for phosphate regulation. Less demand for phosphate handling by the kidney with 
lower protein intake may explain why klotho expression is down regulated with lower 
consumption of calories from protein. In support of this, high protein diets are associated 
with increased phosphorus and upregulation of phosphorus regulating hormones such as 
the klotho ligand FGF-23 [548], which in a klotho dependent fashion suppresses tubular re-
absorption of phosphate [549]. Unfortunately, we were not able to examine phosphate levels 
in this study as we did not have sufficient serum available. Quantification of klotho protein 
levels is required in the future to support the klotho expression findings reported here before 
this hypothesis can be pursued further.  
Comments on study design and future directions 
As this study was not designed from its outset as a renal study, there are a number of 
methodological limitations. Firstly, although it would have been interesting to characterise 
the effect of macronutrients on circulating factors such as gut derived uraemic toxins, 
circulating klotho, klotho ligands, phosphate and circulating AGEs, there was a limited 
volume of plasma available. Secondly, due to the absence of a direct measure of GFR and 
the absence of a timed urine collection, serum cystatin C, a surrogate marker for GFR, was 
used. Serum cystatin C has been demonstrated in both human and animal studies to be an 
excellent surrogate for GFR and a predictor of eGFR [550]. However, timed urine and 
plasma collections at multiple time-points throughout the study from adolescence through to 
the study completion at 15 months would be highly desirable in future studies to determine 
changes in proteinuria and urinary albumin creatinine ratios across the study. This would 
allow for the tracking of changes in renal function over time. Changes in GFR over time, 
even within a normal range, has been shown to be a useful marker of CKD risk in humans 
[551, 552]. In the context of this study, where renal impact is quite mild compared to animal 
models of renal injury, measuring the change in GFR over time, may be more informative 
than the single time snapshot used. Thirdly, cross sectional study of living kidney donors 
168 
 
have demonstrated increased glomerular volume, tubular dilation and decreased tubular 
vacuolization in renal tissue collected from obese donors [553]. Going forward, assessment 
of parameters such as these may be a better indicator of dietary induced changes than 
markers of more advanced disease such as GSI and tubulointerstitial fibrosis. One possible 
explanation for why a stronger relationship between fat and renal pathology was not 
observed, was that the fat source used was soybean oil. Typically, fats sourced from animal 
products have been found to be more pathological to the kidney than vegetable derived fats, 
affecting both risk factors for CKD such as glucose tolerance [554], and renal pathology 
[527]. Conversely, soybean oil is comparatively high in poly-omega 6 fatty acids [555] and 
dietary studies show increased inflammation, lower GFR and greater risk of CKD in at least 
one human cohort [138]. Furthermore, the addition of indigestible fibre (cellulose) to the diets 
at the medium and low energy tiers may have mitigated the effects of protein and fat in the 
medium and low caloric tiered diets. Increased dietary fibre intake has consistently been 
shown to have protective effect on cardiovascular disease outcomes [556], with positive 
effects on kidney function thought to be an important mediator of these benefits [557]. Direct 
causation has yet to be established, but studies in humans have consistently found a 
positive association with high dietary fibre intake and better kidney function [557, 558]. 
However, it must be noted that higher fibre intake is generally associated with higher diet 
quality in participants, including increased consumption of fruit and vegetables.   
As discussed previously, many studies have found that the impact of diet and diet mediated 
risk factors on renal function is often evident in populations that already have at least mild 
established kidney dysfunction or in populations at higher risk for CKD. This study highlights 
the novelty and utility of nutritional geometry to further our understanding of diet and kidney 
function, but also highlights the need to use this approach in a dedicated renal study. This 
could be performed either in the context of an induced mild renal insufficiency model, 
surgical or pharmacological, or by using a model genetically predisposed to developing 
nephropathy such as the FVB mouse or the DBA/2 model of T2DM.  
Conclusions 
Ultimately this study has some important findings. Lifetime macronutrient intake can 
influence renal function with protein intake having the strongest influence on kidney size 
relative to body weight, GFR, blood urea nitrogen and renal klotho expression. Contrary to 
expectations, this study found that lowest protein intake was associated with the lowest GFR 
and highest degree of fibrosis, although for fibrosis, this did not reach significance. 
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Additionally, low protein consumption was associated with the lowest expression of klotho 
and increased levels of cytokines, IL1β and IL-23. Furthermore, observed renal changes to 
renal function and structure did not appear to be substantially mediated by the major known 
risk factors. Further investigations via a dedicated renal study using the geometric 
framework design is important to consolidate the observations of this study.  
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Supplementary data 5 
 
Supplementary Figure 5-1 Example surfaces and how they fit within the 3D nutrient space.  
A Figure showing hypothetical response surfaces showing the relationship between a hypothetical 
variable and median daily protein, carbohydrate and fat intake. B-C The three dimensional nutrient 
space A and how the three response surfaces sit as slices within this space.  
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Statistics tables  
Supplementary statistics tables show the coefficients of the GAMS for the various markers 
of renal structure and function investigated.  
Supplementary Table 5-1. Summary of statistics for figure 5-2 
 
 
 
 
 
edf Ref.df F p-value
s(eaten.P)                 2.98E+00 8 21.53  < 2e-16 ***
s(eaten.C)               9.84E-01 8 7.625  9.39e-14 ***
s(eaten.F) 1.44E+00 8 3.231 2.67e-08 ***
s(eaten.P,eaten.C)        2.52E-05 3 0 0.9285
s(eaten.P,eaten.F)         9.55E-05 3 0 0.4269
s(eaten.C,eaten.F)        5.18E-05 3 0 0.6407
s(eaten.P,eaten.C,eaten.F) 8.32E-01 7 0.705 0.0068 **
edf Ref.df F p-value
s(eaten.P) 1.43E+00 8 5.702 5.21e-11 ***
s(eaten.C)   5.26E-04 8 0 0.447
s(eaten.F)                 2.92E-04 8 0 0.944
s(eaten.P,eaten.C)        3.21E-03 3 0.001 0.34
s(eaten.P,eaten.F)      4.27E-05 3 0 0.707
s(eaten.C,eaten.F)        9.12E-05 3 0 0.683
s(eaten.P,eaten.C,eaten.F) 1.96E-04 7 0 0.635
edf Ref.df F p-value
s(eaten.P)                 1.959919 8 5.649 8.79e-12 ***
s(eaten.C)               0.522073 8 0.135 0.144
s(eaten.F)              0.000651 8 0 0.397
s(eaten.P,eaten.C)        0.000405 3 0 0.392
s(eaten.P,eaten.F)        0.000196 3 0 0.608
s(eaten.C,eaten.F)     0.000203 3 0 0.714
s(eaten.P,eaten.C,eaten.F) 0.000767 7 0 0.4
Figure 2. The effect of dietary macronutrients on kidney weight.  
Figure 2 C) Total kidney weight (g) 
Figure 2 D) Total kidney weight bodyweight adjusted 
Figure 2 E) Total kidney weight lean mass adjusted
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Supplementary Table 5-2. Supplementary statistics for figure 5-3 
 
 
 
edf Ref.df F p-value
s(eaten.P)              2.27E+00 8 4.868 4.95e-09 ***
s(eaten.C)                 1.71E+00 8 1.262  0.0017 ** 
s(eaten.F)                6.67E-01 8 0.25 0.0774
s(eaten.P,eaten.C)         6.10E-05 3 0 0.2965
s(eaten.P,eaten.F)        6.66E-06 3 0 0.3652
s(eaten.C,eaten.F)       8.04E-06 3 0 0.6253
s(eaten.P,eaten.C,eaten.F) 6.49E-05 7 0 0.4201
edf Ref.df F p-value
s(eaten.P)               8.21E-01 8 0.573 0.0157 *
s(eaten.C)                2.87E-05 8 0 0.9088
s(eaten.F)              6.06E-04 8 0 0.3404
s(eaten.P,eaten.C)        2.79E-05 3 0 0.7304
s(eaten.P,eaten.F)         1.08E+00 3 0.589 0.1818
s(eaten.C,eaten.F)        2.70E-05 3 0 0.9218
s(eaten.P,eaten.C,eaten.F) 2.54E-04 7 0 0.2869
Figure 3 C) Total kidney weight, lean mass adjusted (male mice)
edf Ref.df F p-value
s(eaten.P)               9.91E-01 8 0.986 0.00406 **
s(eaten.C)                 1.64E-04 8 0 0.3645
s(eaten.F)                8.19E-05 8 0 0.78382
s(eaten.P,eaten.C)        3.11E-05 3 0 0.59797
s(eaten.P,eaten.F)         4.31E-05 3 0 0.54457
s(eaten.C,eaten.F)        1.81E-05 3 0 0.82716
s(eaten.P,eaten.C,eaten.F) 4.22E-05 7 0 0.9171
edf Ref.df F p-value
s(eaten.P)                3.88E+00 8 17.837  < 2e-16 ***
s(eaten.C)               9.36E-01 8 1.784  1.83e-05 ***
s(eaten.F)               8.97E-01 8 1.09 0.001154 ** 
s(eaten.P,eaten.C)        1.99E+00 3 5.484  5.62e-05 ***
s(eaten.P,eaten.F)         1.72E+00 3 4.057 0.000738 ***
s(eaten.C,eaten.F)       4.49E-05 3 0 0.493327
s(eaten.P,eaten.C,eaten.F) 5.65E-05 7 0 0.952011
Figure 3. The influence of dietary macronutrient intake on kidney 
weight between the sexes
Figure 3 A) Total kidney weight( g)(male mice)
Figure 3 B) Total kidney weight  body weight adjusted (male mice)
Figure 3 D) Total kidney weight (g) female mice
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edf Ref.df F p-value
s(eaten.P)                 0.984762 8 7.996 4.08e-15 ***
s(eaten.C)                0.498765 8 0.124 0.1558
s(eaten.F)              0.000105 8 0 1
s(eaten.P,eaten.C)       0.000101 3 0 0.7979
s(eaten.P,eaten.F)       0.002595 3 0.001 0.3449
s(eaten.C,eaten.F)         0.00013 3 0 0.7778
s(eaten.P,eaten.C,eaten.F) 0.75897 7 0.449  0.0423 *  
edf Ref.df F p-value
s(eaten.P)                 1.31E+00 8 16.227 < 2e-16 ***
s(eaten.C)                9.33E-01 8 1.733  0.000157 ***
s(eaten.F)                1.34E+00 8 2.863 3.38e-06 ***
s(eaten.P,eaten.C)        8.79E-05 3 0 0.39882
s(eaten.P,eaten.F)      8.80E-05 3 0 0.486262
s(eaten.C,eaten.F)     1.11E-04 3 0 0.618179
s(eaten.P,eaten.C,eaten.F) 5.15E-05 7 0 0.861342
Figure 3 E) Total kidney weight, body weight adjusted (female mice)
Figure 3 F) Total kidney weight tolean mass adjusted (female mice)
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Supplementary Table 5-3. Supplementary statistics for figure 5-4 
 
 
 
 
 
 
 
 
 
edf Ref.df F p-value
s(eaten.P)              0.760536 8 0.396 0.0309 *
s(eaten.C)              0.819543 8 0.567 0.0130 *
s(eaten.F)            0.575366 8 0.166 0.0943
s(eaten.P,eaten.C)       0.00042 3 0 0.5231
s(eaten.P,eaten.F)     0.000472 3 0 0.3533
s(eaten.C,eaten.F)         0.744949 3 0.422 0.1569
s(eaten.P,eaten.C,eaten.F) 0.000479 7 0 0.7331
edf Ref.df F p-value
s(eaten.P)                 9.61E-01 8 3.056  4.43e-07 ***
s(eaten.C)              1.87E-04 8 0 0.5735
s(eaten.F)               1.42E-05 8 0 0.45634
s(eaten.P,eaten.C)         2.29E+00 3 3.468  0.00456 ** 
s(eaten.P,eaten.F)       2.12E-06 3 0 1
s(eaten.C,eaten.F)         3.58E-06 3 0 1
s(eaten.P,eaten.C,eaten.F) 6.15E-06 7 0 0.80703
edf Ref.df F p-value
s(eaten.P)                 9.65E-01 8 3.426 7.17e-08 ***
s(eaten.C)               1.68E-04 8 0 0.475
s(eaten.F)               4.21E-06 8 0 1
s(eaten.P,eaten.C)       1.99E+00 3 2.066  0.029 *  
s(eaten.P,eaten.F)     3.30E-06 3 0 0.944
s(eaten.C,eaten.F)        4.88E-06 3 0 0.934
s(eaten.P,eaten.C,eaten.F) 9.05E-06 7 0 0.998
Figure 4 B) Cystatin C (ng/ml)
Figure 4 C) Cystatin C (ng/ml) body weight adjusted
Figure 4 D) Cystatin C (ng/ml) lean mass adjusted
Figure 4. Glomerular filtration rate is driven by protein intake.
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Supplementary Table 5-4. Summary statistic to figure 5-5 
 
 
 
 
 
 
 
 
urea mmol/L/g edf Ref.df F p-value
s(eaten.P)                 2.56E+00 8 2.964 7.57e-06 ***
s(eaten.C)                9.24E-01 8 1.527  0.000329 ***
s(eaten.F)              9.32E-01 8 1.719 0.000170 ***
s(eaten.P,eaten.C)         4.26E-06 3 0 0.548239
s(eaten.P,eaten.F)       2.16E-06 3 0.000 0.620307    3 0. 00 0.620307
s(eaten.C,eaten.F)       4.55E-06 3 0 0.900961
s(eaten.P,eaten.C,eaten.F) 6.67E-06 7 0 0.685911
edf Ref.df F p-value
s(eaten.P)                8.40E-01 8 0.655 0.010024 *  
s(eaten.C)                 9.65E-01 8 3.417 1.14e-08 ***
s(eaten.F)               8.95E-01 8 1.066 2.53e-06 ***
s(eaten.P,eaten.C)         6.60E-06 3 0 0.816861
s(eaten.P,eaten.F)         1.02E-05 3 0 0.797879
s(eaten.C,eaten.F)         2.05E+00 3 2.446  0.000947 ***
s(eaten.P,eaten.C,eaten.F) 1.64E+00 7 0.396 0.067703
edf Ref.df F p-value
s(eaten.P)               2.26E-06 8 0 0.626
s(eaten.C)                9.76E-01 8 5.142 7.73e-11 ***
s(eaten.F)                9.28E-01 8 1.617 7.51e-07 ***
s(eaten.P,eaten.C)         1.51E-06 3 0 0.724
s(eaten.P,eaten.F)        1.63E-06 3 0 0.509
s(eaten.C,eaten.F)         6.34E-01 3 0.284 0.116
s(eaten.P,eaten.C,eaten.F) 1.84E+00 7 0.41 0.111
Figure 5. Blood urea is influenced predominantly by protein intake but 
this changes when body weight is accounted for.
Figure 5 B) Blood urea (mmol/L)
Figure 5 C) Urea : Bodyweight adjusted (mmol/L/g)
Figure 5 D) Urea lean mass  adjusted (mmol/L/g)
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Supplementary Table 5-5. Supplementary statistics for figure 5-6  
 
Supplementary Table 5-6. Supplementary statistics for figure 5-7 
 
 
 
 
 
 
edf Ref.df F p-value
s(eaten.P) 1.03E-04 8 0 0.433527
s(eaten.C)           1.79E+00 8 1.746 0.000298 ***
s(eaten.F)   1.65E-04 8 0 0.279682
s(eaten.P,eaten.C)       3.86E-04 3 0 0.251709
s(eaten.P,eaten.F)    3.77E-04 3 0 0.605714
s(eaten.C,eaten.F)       1.63E-05 3 0 0.864032
s(eaten.P,eaten.C,eaten.F) 8.99E-01 7 1.27 0.001889 ** 
Figure 6. KIM-1 is influenced by dietary carbohydrate and total 
caloric intake 
Figure 6. Kidney Injury Molecule (pg/ug of protein )
edf Ref.df F p-value
s(eaten.P) 5.03E-05 8 0 0.6727
s(eaten.C)           1.58E+00 8 1.087  0.00122 **
s(eaten.F)   5.43E-05 8 0 0.57273
s(eaten.P,eaten.C)       1.08E-05 3 0 0.61425
s(eaten.P,eaten.F)    2.17E+00 3 3.228 0.00332 **
s(eaten.C,eaten.F)       5.06E-01 3 0.234 0.16225
s(eaten.P,eaten.C,eaten.F) 2.38E-05 7 0 0.82687
edf Ref.df F p-value
s(eaten.P) 1.14E-03 8 0 0.30996
s(eaten.C)           8.82E-01 8 0.927 0.00108 **
s(eaten.F)   1.12E-04 8 0 0.8183
s(eaten.P,eaten.C)       1.93E+00 3 3.026 0.00452 **
s(eaten.P,eaten.F)    8.53E-05 3 0 0.50148
s(eaten.C,eaten.F)       9.13E-04 3 0 0.42563
s(eaten.P,eaten.C,eaten.F) 1.92E-04 7 0 0.50626
Figure 7. KIM-1 retained a similar relationship to macronutrient 
intake regardless of sex
Figure 7. A) Kidney Injury Molecule (pg/ug of protein ) (Male mice)
Figure 7. B) Kidney Injury Molecule (pg/ug of protein ) (Female mice)
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Supplementary Table 5-7. Supplementary statistics for figure 5-8 
 
Supplementary Table 5-8. Supplementary statistics for figure 5-9 
 
 
 
 
 
 
edf Ref.df F p-value
s(eaten.P) 1.90E-05 8 0 0.841
s(eaten.C)           4.26E-05 8 0 0.402
s(eaten.F)   6.31E-01 8 0.214 0.101
s(eaten.P,eaten.C)       1.85E-05 3 0 0.703
s(eaten.P,eaten.F)    1.59E-05 3 0 0.831
s(eaten.C,eaten.F)       1.13E-05 3 0 0.97
s(eaten.P,eaten.C,eaten.F) 8.78E-05 7 0 0.603
Figure 8. Glomerulosclerosis tended to increase as calories consumed 
from fat increased.
Figure 8. C) Glomerular sclerosis ( mean score 0-4)
edf Ref.df F p-value
s(eaten.P)                1.42E-05 8 0 0.623
s(eaten.C)                1.16E-05 8 0 0.429
s(eaten.F)                   5.88E-06 8 0 0.659
s(eaten.P,eaten.C)         1.84E+00 3 2.282  0.015 *
s(eaten.P,eaten.F)         6.813e-01      3 0.397   0.163  6.8 E-01 3 0.397 0.163
s(eaten.C,eaten.F)       3.88E-06 3 0 0.472
s(eaten.P,eaten.C,eaten.F) 4.42E-06 7 0 0.829
edf Ref.df F p-value
s(eaten.P)                5.44E-06 8 0 1
s(eaten.C)              2.51E-06 8 0 0.7903
s(eaten.F)                 6.26E-01 8 0.209 0.0819
s(eaten.P,eaten.C)        4.69E-06 3 0 0.584
s(eaten.P,eaten.F)         6.02E-06 3 0 0.8118
s(eaten.C,eaten.F)         3.00E-05 3 0 0.4699
s(eaten.P,eaten.C,eaten.F)  1.31E-01 7 0.021 0.2094
Figure 9. The effects of macronutrient intake on glomerular sclerosis 
differ between males and females
Figure 9. A) Glomerular sclerosis ( mean score 0-4) (male mice)
Figure 9. B) Glomerular sclerosis ( mean score 0-4) (female mice)
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Supplementary Table 5-9. Supplementary statistics for figure 5-10 
 
Supplementary Table 5-10. Supplementary statistics to figure 5-11 
 
 
 
 
 
 
edf Ref.df F p-value
s(eaten.P)                6.36E-01 8 0.134 0.126
s(eaten.C)                 2.21E-04 8 0 0.443
s(eaten.F)               5.95E-05 8 0 1
s(eaten.P,eaten.C)        9.32E-01 3 0.478 0.16
s(eaten.P,eaten.F)        1.28E-05 3 0 1
s(eaten.C,eaten.F)         5.60E-05 3 0 0.54
s(eaten.P,eaten.C,eaten.F) 1.43E-04 7 0 0.616
Figure 10. Fibrosis did not show a statistically significant relationship 
to macronutrient intake. 
Figure 10 B) % Fibrosis 
edf Ref.df F p-value
s(eaten.P)                7.59E-05 8 0 0.444
s(eaten.C)                1.45E-05 8 0 0.555
s(eaten.F)                1.64E-05 8 0 0.774
s(eaten.P,eaten.C)         4.41E-05 3 0 0.435
s(eaten.P,eaten.F)         1.14E-05 3 0 0.489
s(eaten.C,eaten.F)        1.27E+00 3 0.762 0.155
s(eaten.P,eaten.C,eaten.F) 9.53E-05 7 0 0.653
edf Ref.df F p-value
s(eaten.P)                 1.35E-05 8 0 0.637
s(eaten.C)                9.02E-05 8 0 0.532
s(eaten.F)                2.43E-05 8 0 0.62
s(eaten.P,eaten.C)         8.35E-06 3 0 0.746
s(eaten.P,eaten.F)         1.09E-05 3 0 0.609
s(eaten.C,eaten.F)         1.33E-05 3 0 0.577
s(eaten.P,eaten.C,eaten.F) 3.28E-05 7 0 0.988
Figure 11. The influence of macronutrients on fibrosis is not significant 
in males and females.
Figure 11 A) % Fibrosis (male mice)
Figure 11 B) % Fibrosis (female mice)
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Supplementary Table 5-11. Supplementary statistics for figure 5-12 
 
 
 
 
 
 
 
 
edf Ref.df F p-value
s(eaten.P)                0.00014 8 0 0.968
s(eaten.C)                 0.00031 8 0 0.502
s(eaten.F)                 0.110601 8 0.016 0.285
s(eaten.P,eaten.C)         0.702131 3 0.328 0.239
s(eaten.P,eaten.F)         0.000144 3 0 0.88
s(eaten.C,eaten.F)        0.000158 3 0 0.803
s(eaten.P,eaten.C,eaten.F) 0.000334 7 0 0.805
edf Ref.df F p-value
s(eaten.P)                 5.82E-05 8 0 1
s(eaten.C)                 1.19E-04 8 0 0.556
s(eaten.F)                 9.83E-05 8 0 0.623
s(eaten.P,eaten.C)         2.56E-03 3 0.001 0.376
s(eaten.P,eaten.F)         5.38E-05 3 0 0.89
s(eaten.C,eaten.F)         1.51E-04 3 0 0.543
s(eaten.P,eaten.C,eaten.F) 8.92E-05 7 0 0.859
edf Ref.df F p-value
s(eaten.P)                 0.000107 8 0 0.69
s(eaten.C)                0.000244 8 0 0.552
s(eaten.F)                0.000174 8 0 0.379
s(eaten.P,eaten.C)         0.00079 3 0 0.389
s(eaten.P,eaten.F)         0.000153 3 0 0.627
s(eaten.C,eaten.F)         1.114804 3 0.806 0.119
s(eaten.P,eaten.C,eaten.F) 0.000104 7 0 0.654
Figure 12. There was no relationship between macronutrient 
consumption and expression of key fibrotic mediators at 15 months of 
age.
Figure 12 A) CTGF (relative gene expression) 
Figure 12 B) TGFβ (relative gene expression) 
Figure 12 C) COLIV 1a (relative gene expression) 
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Supplementary Table 5-12. Supplementary statistics for figure 5-13 
 
edf Ref.df F p-value
s(eaten.P)                8.97E-01 8 1.078 0.00229 **
s(eaten.C)                 2.05E-05 8 0 0.72442
s(eaten.F)                 6.00E-05 8 0 0.46551
s(eaten.P,eaten.C)         1.45E-05 3 0 0.84803
s(eaten.P,eaten.F)         4.54E-05 3 0 0.472
s(eaten.C,eaten.F)        9.72E-06 3 0 0.72355
s(eaten.P,eaten.C,eaten.F) 2.97E-05 7 0 0.70588
edf Ref.df F p-value
s(eaten.P)                 2.92E-04 8 0 0.5257
s(eaten.C)                 1.23E-04 8 0 0.7929
s(eaten.F)                 6.30E-05 8 0 0.651
s(eaten.P,eaten.C)         5.50E-06 3 0 0.7428
s(eaten.P,eaten.F)         3.87E-06 3 0 0.7131
s(eaten.C,eaten.F)         1.39E+00 3 1.734 0.0269 *
s(eaten.P,eaten.C,eaten.F) 3.78E-05 7 0 0.9977
edf Ref.df F p-value
s(eaten.P)                 2.92E-04 8 0 0.5257
s(eaten.C)                1.23E-04 8 0 0.7929
s(eaten.F)                6.30E-05 8 0 0.651
s(eaten.P,eaten.C)         5.50E-06 3 0 0.7428
s(eaten.P,eaten.F)         3.87E-06 3 0 0.7131
s(eaten.C,eaten.F)         1.39E+00 3 1.734 0.0269 *
s(eaten.P,eaten.C,eaten.F) 3.78E-05 7 0 0.9977
edf Ref.df F p-value
s(eaten.P)                 1.89E-04 8 0 0.492
s(eaten.C)                1.04E-04 8 0 0.575
s(eaten.F)                1.28E-04 8 0 0.785
s(eaten.P,eaten.C)         7.59E-04 3 0 0.408
s(eaten.P,eaten.F)         1.18E-05 3 0 0.936
s(eaten.C,eaten.F)         8.40E-01 3 0.521 0.159
s(eaten.P,eaten.C,eaten.F) 4.86E-05 7 0 1
Figure 13 Inflammatory cytokines in cortex enriched tissue and 
macronutrient intake.
Figure 13 IL-23 
Figure 13 IL-1α
Figure 13 IFNγ
Figure 13 TNFα
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edf Ref.df F p-value
s(eaten.P)                1.11E-04 8 0 0.8222
s(eaten.C)                 5.39E-05 8 0 0.8921
s(eaten.F)                 1.82E-04 8 0 0.8249
s(eaten.P,eaten.C)         2.07E-04 3 0 0.5914
s(eaten.P,eaten.F)         6.32E-06 3 0 1
s(eaten.C,eaten.F)        1.31E+00 3 1.318 0.0523
s(eaten.P,eaten.C,eaten.F) 1.83E-05 7 0 0.9699
edf Ref.df F p-value
s(eaten.P)                 2.87E-04 8 0 0.6369
s(eaten.C)                 3.78E-05 8 0 0.9997
s(eaten.F)                 1.85E-04 8 0 0.8065
s(eaten.P,eaten.C)         1.28E+00 3 1.333 0.0481 *
s(eaten.P,eaten.F)         5.07E-05 3 0 0.624
s(eaten.C,eaten.F)         4.98E-05 3 0 0.7747
s(eaten.P,eaten.C,eaten.F) 8.46E-05 7 0 0.9197
edf Ref.df F p-value
s(eaten.P)                 1.45E+00 8 0.79 0.0114 *
s(eaten.C)                6.43E-04 8 0 0.7874
s(eaten.F)                1.17E+00 8 0.439 0.0492 *
s(eaten.P,eaten.C)         1.30E-05 3 0 0.9385
s(eaten.P,eaten.F)         3.37E-05 3 0 0.3869
s(eaten.C,eaten.F)         4.92E-05 3 0 0.7424
s(eaten.P,eaten.C,eaten.F) 3.07E-04 7 0 0.7439
edf Ref.df F p-value
s(eaten.P)                 2.28E-03 8 0 0.34
s(eaten.C)                1.83E-04 8 0 1
s(eaten.F)                1.16E-04 8 0 0.667
s(eaten.P,eaten.C)         2.77E-04 3 0 0.88
s(eaten.P,eaten.F)         6.87E-05 3 0 0.772
s(eaten.C,eaten.F)         7.27E-05 3 0 0.543
s(eaten.P,eaten.C,eaten.F) 6.15E-01 7 0.228 0.109
Figure 13 IL-10
Figure 13 IL-1β
Figure 13  MCP1
Figure 13 IL-12p70
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edf Ref.df F p-value
s(eaten.P)                4.45E-04 8 0 0.495
s(eaten.C)                 7.26E-05 8 0 1
s(eaten.F)                 5.11E-04 8 0 0.362
s(eaten.P,eaten.C)         7.85E-05 3 0 0.727
s(eaten.P,eaten.F)         4.96E-05 3 0 0.812
s(eaten.C,eaten.F)        2.96E-05 3 0 1
s(eaten.P,eaten.C,eaten.F) 1.63E-03 7 0 0.42
edf Ref.df F p-value
s(eaten.P)                 1.24E-04 8 0 0.65
s(eaten.C)                 4.88E-05 8 0 0.502
s(eaten.F)                 6.28E-04 8 0 0.474
s(eaten.P,eaten.C)         2.01E-04 3 0 0.828
s(eaten.P,eaten.F)         4.57E-05 3 0 0.736
s(eaten.C,eaten.F)         1.30E-05 3 0 0.611
s(eaten.P,eaten.C,eaten.F) 3.81E-01 7 0.088 0.205
edf Ref.df F p-value
s(eaten.P)                 1.65E-01 8 0.025 0.2716
s(eaten.C)                8.55E-05 8 0 1
s(eaten.F)                1.50E-04 8 0 0.5488
s(eaten.P,eaten.C)         5.42E-05 3 0 0.8743
s(eaten.P,eaten.F)         5.23E-04 3 0 0.3767
s(eaten.C,eaten.F)         5.30E-05 3 0 0.8203
s(eaten.P,eaten.C,eaten.F) 7.12E-01 7 0.352 0.0629 .
edf Ref.df F p-value
s(eaten.P)                 4.09E-04 8 0 1
s(eaten.C)                1.61E-04 8 0 1
s(eaten.F)                9.83E-01 8 0.339 0.0681 .
s(eaten.P,eaten.C)         2.80E-04 3 0 0.9895
s(eaten.P,eaten.F)         8.51E-05 3 0 0.5852
s(eaten.C,eaten.F)         5.40E-05 3 0 0.967
s(eaten.P,eaten.C,eaten.F) 1.88E-04 7 0 0.9451
edf Ref.df F p-value
s(eaten.P)                 1.84E-04 8 0 0.706
s(eaten.C)                1.08E-04 8 0 0.406
s(eaten.F)                1.54E-04 8 0 0.551
s(eaten.P,eaten.C)         1.91E-04 3 0 0.789
s(eaten.P,eaten.F)         1.46E-01 3 0.052 0.332
s(eaten.C,eaten.F)         2.12E-05 3 0 0.956
s(eaten.P,eaten.C,eaten.F) 7.90E-05 7 0 0.783
Figure 13 IFNβ
Figure 13  IL-6
Figure 13 IL-27
Figure 13 IL-17A
Figure 13  GM-CSF
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Supplementary Table 5-13. Supplementary statistics for figure 5-14 
 
Supplementary Table 5-14. Supplementary statistics for figure 5-15 
 
edf Ref.df F p-value
s(eaten.P)               1.33E+00 8 0.493 0.0508
s(eaten.C)                8.40E-05 8 0 0.9961
s(eaten.F)                1.10E-04 8 0 0.7275
s(eaten.P,eaten.C)        1.23E-04 3 0 0.6647
s(eaten.P,eaten.F)      1.23E-04 3 0 0.7835
s(eaten.C,eaten.F)         1.11E-04 3 0 0.9289
s(eaten.P,eaten.C,eaten.F) 3.04E-04 7 0 1
Figure 14. The relationship between macronutrients and expression of 
marker of renal aging, Klotho.
Figure 14 A) KLOTHO (relative gene expression)
edf Ref.df F p-value
s(eaten.P)                1.86E-04 8 0 0.712
s(eaten.C)                6.62E-01 8 0.244 0.08
s(eaten.F)                 1.17E-04 8 0 0.719
s(eaten.P,eaten.C)        3.54E-05 3 0 0.768
s(eaten.P,eaten.F)         1.16E-04 3 0 0.4
s(eaten.C,eaten.F)        7.94E-01 3 0.413 0.193
s(eaten.P,eaten.C,eaten.F) 7.67E-05 7 0 1
edf Ref.df F p-value
s(eaten.P)                1.41E-04 8 0 0.68
s(eaten.C)                 3.65E-05 8 0 0.739
s(eaten.F)                5.84E-05 8 0 0.859
s(eaten.P,eaten.C)        3.08E-05 3 0 0.898
s(eaten.P,eaten.F)         2.02E-05 3 0 0.718
s(eaten.C,eaten.F)       7.96E-01 3 0.519 0.145
s(eaten.P,eaten.C,eaten.F) 7.35E-05 7 0 1
edf Ref.df F p-value
s(eaten.P)                 4.21E-01 8 0.068 0.172
s(eaten.C)                8.90E-05 8 0 0.415
s(eaten.F)                 4.44E-05 8 0 0.759
s(eaten.P,eaten.C)         1.18E+00 3 0.725 0.108
s(eaten.P,eaten.F)         8.78E-06 3 0 0.592
s(eaten.C,eaten.F)         3.92E-05 3 0 0.473
s(eaten.P,eaten.C,eaten.F) 2.64E-01 7 0.051 0.218
Figure 15 A) Chloride ions Cl-
Figure 15 B) Sodium ions Na+
Figure 15 C) Potassium ions K+
Figure 15. Response surfaces showing the effect of macronutrients on 
electrolyte balance.
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Supplementary Figure 5-2. Serum cystatin C, gender differences. 
A-C Response surfaces showing the effect of macronutrient intake on (A) serum cystatin C (ng/ml; 
n=74), (B) serum cystatin C adjusted for body weight (ng/ml/g; n=74), (C) cystatin C adjusted for lean 
mass (ng/ml/g; n=70) male mice only, at 15 months of age. D-F Response surfaces showing the effect 
of macronutrient intake on (D) serum cystatin C (ng/ml; n=79), (E) serum cystatin C adjusted for body 
mass (ng/ml/g; n=79), (F) serum cystatin C adjusted for lean mass (ng/ml/g; n=75) in female GF mice 
only, at 15 months of age. Associated statistics for GAMS models are shown in tables below. 
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edf Ref.df F p-value
s(eaten.P)              8.03E-01 8 0.509 0.0221 *
s(eaten.C)              8.12E-01 8 0.54 0.0107 *
s(eaten.F)            3.51E-05 8 0 0.5897
s(eaten.P,eaten.C)       1.06E+00 3 0.75 0.1078
s(eaten.P,eaten.F)     4.84E-05 3 0 0.5159
s(eaten.C,eaten.F)         2.54E-05 3 0 0.6807
s(eaten.P,eaten.C,eaten.F) 1.39E-05 7 0 0.6423
edf Ref.df F p-value
s(eaten.P)                 9.57E-01 8 2.759 2.34e-06 ***
s(eaten.C)              2.76E-06 8 0 0.7305
s(eaten.F)               4.86E-01 8 0.118 0.1555
s(eaten.P,eaten.C)         2.03E+00 3 1.677  0.0654 . 
s(eaten.P,eaten.F)       1.44E-06 3 0 0.7988
s(eaten.C,eaten.F)         1.40E-06 3 0 1
s(eaten.P,eaten.C,eaten.F) 8.03E-06 7 0 0.7049
edf Ref.df F p-value
s(eaten.P)                 2.10E+00 8 5.038  1.42e-08 ***
s(eaten.C)              1.84E-04 8 0 0.512
s(eaten.F)               2.28E-04 8 0 0.459
s(eaten.P,eaten.C)         7.22E-05 3 0 0.454
s(eaten.P,eaten.F)       7.36E-06 3 0 0.995
s(eaten.C,eaten.F)         3.75E-05 3 0 0.957
s(eaten.P,eaten.C,eaten.F) 4.05E-05 7 0 0.563
 Cystatin C (ng/ml) (Male mice)
Cystatin C (ng/ml/g) body weight adjusted (Male mice)
 Cystatin C (ng/ml/g) lean mass adjusted (Male mice)
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edf Ref.df F p-value
s(eaten.P)                 5.82E-01 8 0.173 0.1183
s(eaten.C)              1.75E-04 8 0 0.9593
s(eaten.F)               6.76E-01 8 0.26 0.0692 .
s(eaten.P,eaten.C)         4.33E-05 3 0 0.9727
s(eaten.P,eaten.F)       5.22E-04 3 0 0.3467
s(eaten.C,eaten.F)         9.41E-02 3 0.033 0.309
s(eaten.P,eaten.C,eaten.F) 2.57E-04 7 0 0.6193
edf Ref.df F p-value
s(eaten.P)                 1.41E+00 8 0.866 0.00549 **
s(eaten.C)              1.11E+00 8 0.35 0.07065 . 
s(eaten.F)               3.53E-05 8 0 0.96225
s(eaten.P,eaten.C)         3.22E-04 3 0 0.20509
s(eaten.P,eaten.F)       1.84E-05 3 0 0.84496
s(eaten.C,eaten.F)         2.28E-05 3 0 0.78062
s(eaten.P,eaten.C,eaten.F) 8.25E-05 7 0 0.90856
edf Ref.df F p-value
s(eaten.P)                 1.11E+00 8 0.596 0.0206 *
s(eaten.C)              8.66E-05 8 0 0.6391
s(eaten.F)               3.87E-05 8 0 0.6643
s(eaten.P,eaten.C)         3.35E-05 3 0 0.4727
s(eaten.P,eaten.F)       4.21E-05 3 0 0.629
s(eaten.C,eaten.F)         4.31E-01 3 0.194 0.2171
s(eaten.P,eaten.C,eaten.F) 3.09E-01 7 0.064 0.1708
 Cystatin C (ng/ml) (Female mice)
Cystatin C (ng/ml/g) body weight adjusted (Female mice)
 Cystatin C (ng/ml/g) lean mass adjusted (Female mice)
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 Supplementary Figure 5-3. Serum urea, gender differences.  
A-C, Response surfaces showing the effect of macronutrient intake on (A) serum urea (mmol/L, n=60) 
(B) serum urea adjusted for body mass (mmol/L/g, n=56) (C) serum urea adjusted for lean mass 
(mmol/L/g, n=56) in male GF mice only, at 15 months of age. D-F, Response surfaces showing the 
effect of macronutrient intake on (D) serum urea (mmol/L, n=65) (E) serum urea adjusted for body 
mass (mmol/L/g, n=62) (F) serum urea adjusted for lean mass (mmol/L/g, n=62) in female GF mice 
only, at 15 months of age. Associated statistics for GAMS models are shown in tables below 
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(Continued below) 
edf Ref.df F p-value
s(eaten.P)                 3.13E+00 8 3.506 9.31e-06 ***
s(eaten.C)                 9.33E-01 8 1.75 0.000181 ***
s(eaten.F)                 9.17E-01 8 1.388 0.000693 ***
s(eaten.P,eaten.C)        2.49E-05 3 0 0.327075
s(eaten.P,eaten.F)        2.83E-05 3 0 0.54394
s(eaten.C,eaten.F)        1.15E+00 3 0.971 0.082465
s(eaten.P,eaten.C,eaten.F) 8.38E-05 7 0 0.204583
edf Ref.df F p-value
s(eaten.P)                 1.32E+00 8 1.087 0.00223 ** 
s(eaten.C)                 5.47E+00 8 12.339 2.27e-15 ***
s(eaten.F)                 8.54E-01 8 0.729 0.00632 ** 
s(eaten.P,eaten.C)           3.95E-05 3 0 0.29027
s(eaten.P,eaten.F)         2.23E-05 3 0 0.53097
s(eaten.C,eaten.F)       9.43E-05 3 0 0.18206
s(eaten.P,eaten.C,eaten.F) 4.18E+00 7 2.45  0.00111 ** 
edf Ref.df F p-value
s(eaten.P)                 5.07E-06 8 0 0.75041
s(eaten.C)                9.81E-01 8 6.431 1.14e-10 ***
s(eaten.F)                 8.87E-01 8 0.982 0.00147 ** 
s(eaten.P,eaten.C)         1.05E-05 3 0 0.439
s(eaten.P,eaten.F)         2.30E-06 3 0 0.57955
s(eaten.C,eaten.F)        3.65E-05 3 0 0.61442
s(eaten.P,eaten.C,eaten.F) 2.53E+00 7 0.758 0.07799
Urea (mmol/L) (Male mice)
Urea : Bodyweight (mmol/L/g) (Male mice)
Urea : lean mass  (mmol/L/g) (Male mice)
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edf Ref.df F p-value
s(eaten.P)                 9.39E-01 8 1.909 0.000118 ***
s(eaten.C)                 1.96E-04 8 0 0.353929
s(eaten.F)                     5.50E-05 8 0 0.584815
s(eaten.P,eaten.C)         1.27E-05 3 0 0.636729
s(eaten.P,eaten.F)         9.77E-05 3 0 0.447628
s(eaten.C,eaten.F)         1.44E-04 3 0 0.378401
s(eaten.P,eaten.C,eaten.F) 8.81E-01 7 1.052 0.004873 ** 
edf Ref.df F p-value
s(eaten.P)                 9.02E-06 8 0 0.664973
s(eaten.C)                9.25E-01 8 1.534 0.000468 ***
s(eaten.F)                8.47E-01 8 0.694 0.007252 ** 
s(eaten.P,eaten.C)         5.71E-06 3 0 0.860945
s(eaten.P,eaten.F)         2.88E-06 3 0 0.616824
s(eaten.C,eaten.F)         1.89E+00 3 1.721 0.046021 *  
s(eaten.P,eaten.C,eaten.F) 8.64E-06 7 0 0.547922
edf Ref.df F p-value
s(eaten.P)                2.90E-06 8 0 0.66317
s(eaten.C)           9.48E-01 8 2.273 3.62e-05 ***
s(eaten.F)                8.88E-01 8 0.995 0.00151 ** 
s(eaten.P,eaten.C)         1.52E-06 3 0 0.71513
s(eaten.P,eaten.F)        9.99E-05 3 0 0.2703
s(eaten.C,eaten.F)         1.27E+00 3 0.775 0.14135
s(eaten.P,eaten.C,eaten.F) 3.20E-06 7 0 0.67803
Urea (mmol/L) (Female mice)
Urea : Bodyweight (mmol/L/g)(Female mice)
Urea : lean mass  (mmol/L/g)(Female mice)
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Supplementary Figure 5-4. Example PAS stained glomeruli by diet 
Representative images of PAS stained kidney sections at 400x magnification, showing a single 
glomeruli representative of the mean of the score achieved per diet. Diets are given by their specialty 
feeds product number. Glomeruli are ordered based on the protein and carbohydrate content of the 
diet. Images were taken at  
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C 
D 
E
Supplementary Figure 5-5. Response surfaces for inflammatory cytokines that demonstrated a 
statistically significant relationship to macronutrient consumption.  
Response surfaces showing the effect of macronutrient intake on renal cortex concentrations of 
inflammatory cytokines (pg/ml) (A) IL-1α, (B) MCP-1, (C) IL-12p70, (D) IL-17A, (E) IFNβ. Only 
cytokines that show a significant or close to significant relationship with macronutrient intake as 
individual or interactive variables are shown. See supplementary table 13 for full statistics. 
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A 
B 
Supplementary Figure 5-6. Correlations between cardio-metabolic risk factors for CKD and kidney outcomes in the GF mice.  
Spearman’s correlation matrix R values (A) and associated adjusted P values (B) for associations between major risk factors for CKD and kidney outcomes 
seen in the GF mice at 15 months of age. Colour tone in A indicates the directionality and size of the R value (blue for positive correlations, red for 
negative correlations). Red colour in B indicates statistical significance.  
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Chapter 6: General Discussion  
Dietary intake should be considered one of the most important modifiable pathways for 
intervention in the field of medicine, as unlike other behaviours that increase of risk of 
morbidity, we all have to eat. The kidney, as the primary waste clearance and filtration 
system for the body, is largely responsible for removing the metabolic bi-products of our 
food choices, making it particularly vulnerable to a poor diet. The global prevalence of CKD 
is rapidly increasing and while better diagnosis, screening and awareness may have 
temporarily inflated estimates of this increase, there is no doubt that the modern western 
lifestyle and particularly the diet, is contributing to increased risk for CKD. RAS blockade 
can slow disease [559-564], but there is a paucity of effective treatments once renal decline 
is underway. As one physiologist put it, “the current strategy of intervening after the onset of 
albuminuria (i.e., after the onset of sclerosis) may be akin to closing the barn door after the 
horses are out” [565]. Therefore, it is imperative that we look at the factors in the modern 
diet that may be driving CKD risk. Understanding not only how dietary macronutrient 
composition over a lifespan impacts our kidney function; but also how the chemical 
modifications resulting from modern cooking and processing techniques interact with 
underlying susceptibility to disease will create a platform on which to better inform dietary 
guidelines, not only for individuals with, or at risk of CKD, but also for the general population. 
Therefore, in this thesis I explored the role of two key aspects of the diet that have changed 
significantly with modernisation; 1. the chemical modifications AGEs; and 2. the interactive 
effects of protein, carbohydrate and fat, on kidney structure, function, pathology and risk 
factors for kidney disease.  
Understanding AGE uptake and trafficking from the diet  
Firstly, in chapter 2 of this thesis, I aimed to determine whether a commonly ingested AGE 
modified protein, AGE-BSA, is absorbed across the gastrointestinal tract. Ultimately, the 
goal was to use the imaging techniques I developed to answer the following key questions 
regarding dietary AGEs. 1. Do AGEs directly enter the circulation from the GI tract? 2. If they 
do indeed enter the circulation, what organs and tissues do they traffic to? 3. In what time 
frame does this occur? 4. Are the kidneys being disproportionately directly burdened with 
AGEs, or impacted indirectly, by modification for CKD risk factors via AGE interactions with 
other organs and tissues? 
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Answering these questions proved to be challenging. This may explain why they remain 
inadequately answered by previous studies. The initial vision was to use a metal based 
radioisotope labelling approach and PET/ MRI at the Centre for Advanced Imaging (CAI), at 
the University of Queensland. This would have facilitated real-time trafficking and live 
imaging. Furthermore, it is a highly sensitive technique that could ultimately be translated 
into humans. However, after significant work up, completion of animal ethics and labelling 
optimisation, we found the time frame and resources available at the CAI prevented the 
project progressing in the time frame suitable for completion of a PhD. Therefore, we 
decided to look at alternative approaches. Ultimately, a simpler labelling approach was 
developed using a near infrared NHS ester label, that avoided many of the challenges we 
had encountered using the isotope labelling. Furthermore, it could be used for in vivo, ex 
vivo and potentially for microscopic evaluation of trafficking and did not require specialised 
facilities or extensive safety training to use. 
Using this technique, we identified that intact AGE-modified albumin was indeed absorbed 
and within a similar timeframe to unmodified albumin in vivo. As discussed in chapter 2, this 
was contrary to the findings of other groups [255, 262, 369, 374]. However, our findings do 
align with those from other researchers using similar AGE modified proteins [249, 264] and 
to long term feeding studies with isotopically labelled AGEs [263]. Possible explanations for 
these discrepancies were discussed at length in chapter 2, but are likely the result of 
variation in the type of AGE modified protein used, the sensitivity of the detection system 
and differences between AGEs administered orally vs intravenously. Importantly we did 
show that AGE modified albumin can be variably absorbed and enter the circulation. The 
most interesting finding of this study however, was that intact AGE modified and un-modified 
albumin was rapidly detected in the circulation, liver and GI tract tissues within 15 minutes 
of oral ingestion in some mice. This was very surprising as we had hypothesised based on 
previous studies [247, 263] that only free AGEs or digested AGE peptides would be 
absorbed and appear in the circulation. Significant variation was seen between mice; 
therefore, it is important not to over interpret these results. These experiments need to be 
confirmed in other animal models and with alternative AGE modified proteins. However, 
these findings are important as they challenge the persisting dogma that only free AGEs 
from the diet contribute to the circulating AGE pool. Furthermore, AGE modified proteins, as 
more potent RAGE ligands [187] will have more capacity to induce the numerous pro-
apoptotic, pro-inflammatory pathways regulated by RAGE.  
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Although intact AGE modified albumin trafficked across the GI tract into the circulation, it did 
not show accumulation in the kidney that was significantly greater than other tissues. The 
greatest accumulation of AGEs was seen in the gastro-intestinal tract and the liver. This is 
consistent with previous studies  [263, 369]. One could hypothesise that many of the renal 
effects observed with high AGE diet therefore, could be mediated through direct AGE 
interactions with the GI tract, perhaps through perturbation to the enteroendocrine 
responses to food, gastrointestinal inflammation and the microbiome rather than direct 
effects on the kidney. We have certainly reported previously the effects of dietary AGEs on 
GI secreted incretin hormones [287]. Similarly, it has been known for some time that at least 
some AGEs can be metabolised by bacterial species found in the GI tract and colon [392]. 
However, the interaction between dietary AGEs and the microbiota is burgeoning area of 
investigation. There is some evidence that a high consumption of AGEs biases gut 
microbiota towards immuno-pathological species in patients with ulcerative colitis [393]. 
Similarly another a recent human study in patients with ESRD reported significant changes 
in relative abundance of key species, although no changes in alpha diversity following one 
month low AGE intervention [566]. As many nephrotoxins are produced by the microbiome 
of the GI tract [567], the gut-renal axis is an important research area. Recently, interesting 
work in rodents has demonstrated that supplementation of a high AGE diet with resistant 
starch ameliorates the renal damage induced by chronic consumption of the standard high 
AGE diet [568]. This supports the postulate that gastrointestinal handling of AGEs and AGE 
interactions with the microbiome are important in driving kidney damage. The findings 
described here add further validation to the argument that research into the impact of dietary 
derived AGEs on enteroendocrine signalling, gastrointestinal permeability, microbial 
diversity and host biome interactions is warranted.  
Despite the many advantages to the approach described in chapter 2 we encountered a 
number of technical limitations. Although microscopy worked well in cell lines, in-vivo uptake 
was impeded by low signal to noise ratio and tissue auto-fluorescence within the same 
spectrum, which was particularly high in the kidney and small intestine. Therefore, although 
this approach was also trialled in the liver, pancreas, duodenum, ileum, and on all 
compatible microscopes within the greater Brisbane area, I decided not to pursue the ex 
vivo microscopy outside of a few key organs. This was disappointing, as there are no 
published studies to date examining the uptake and distribution of AGEs using labelling 
strategies compatible with microscopy, with the exception of the recent publication by 
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Tsutsui et al. which was limited to study of the liver only [264]. Therefore, microscopy would 
have offered significant insight and differentiation beyond existing literature. The lack of 
specific, real-time in vivo to ex vivo imaging has hindered AGE biology. Within AGE biology 
a substantive part of understanding of AGE handling by organs and cellular AGE uptake is 
reliant on data from experiments performed in vitro and often using supra-physiological AGE 
concentrations. Meanwhile, the in vivo evidence supporting specific tissue and cellular 
uptake remains lacking.  
A further limitation of the labelling strategy is that it relies upon “indirect” chemistry, whereby 
the label is conjugated onto primary amines by hydrolysis, altering the native structure of 
the protein. This means that the near infrared label can be more readily cleaved from the 
protein than direct chemistry approaches such as incorporation of carbon isotopes. Going 
forward, greater efforts should focus on incorporation of traceable elements into the 
chemical structure of the AGE modified protein for imaging studies. It has been highlighted 
that the fluorobenzylation approaches used to produce traceable AGE modified proteins for 
PET/MRI and PET/CT result in significant chemical changes to the AGEs/AGE modified 
proteins and may prevent absorption [263]. It is paramount that any approach to label and 
track AGEs in vivo or in vitro should be mindful of the pitfalls and challenges presented by 
the preceding research. Technologies that would allow a direct chemistry approach, that 
would also be compatible with microscopy and in vivo imaging systems are in their infancy. 
However, every attempt should be made to develop technologies that incorporate 
fluorescent or isotope labels into the structure of the AGE modified protein, ideally by way 
of the AGE modification itself. Furthermore, strategies should minimise structural changes 
the protein or AGEs and delivery of these compounds to animals or humans should try to 
mimic the natural consumption of these products as closely as possible.  
Finally, despite the considerable efforts made in rodents, it remains unclear as to the 
proportion of dietary AGEs that really do get absorbed by humans and how they contribute 
to the circulating pool of AGEs. This was indeed, the rationale for our unfortunately 
incomplete attempts to generate radioisotope labelled AGEs suitable for studies in humans. 
Unfortunately, our study does not bring us closer to solving this problem. Going forward, it 
is important that AGE biologists work towards a platform for imaging the uptake and 
trafficking of these compounds that is translatable to humans.  
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AGEs and changes in glucose homeostasis 
Impaired glucose control, metabolic syndrome and diabetes are amongst the most potent 
risk factors for chronic kidney disease [35]. While diabetes, metabolic syndrome and 
impaired glucose tolerance each promote AGE production, so it seems that increased AGE 
consumption in the diet contributes to metabolic dysfunction and impaired glucose tolerance 
[211, 269, 283-287]. Therefore, both chapter 3 and 4 of this thesis aimed to explore the 
interactions between AGEs and glucose control. In chapter 3 I firstly examined the acute 
effects of orally ingested AGEs on glucose homeostasis in rodent models. Conversely, in 
Chapter 4 I examine the impact of acute oral glucose administration on endogenous AGE 
production and circulating concentrations of the AGE receptor sRAGE.  
As discussed at length in this thesis, high AGE diets appear to elevate blood glucose and 
lower fasting plasma insulin in pre-clinical models [285, 287, 294] and decrease insulin 
sensitivity in humans [304, 305, 410]. These metabolic defects have been attributed by some 
to the pro-oxidant and pro-inflammatory effects of AGEs [211, 285, 569, 570]. Despite this, 
there exists a paucity of data regarding post-prandial glucose homeostasis following 
isocaloric high AGE or low AGE meals. Furthermore, despite significant advances in the 
technology available for performing indirect calorimetry in pre-clinical models there have 
been only very limited studies assessing the effects of extended high or low AGE diets on 
feeding behaviour and gross metabolism. Therefore, to address this I used a simple orally 
administered AGE tolerance test, to assess the effects of increasing protein and AGE 
dosages on circulating insulin and glucose concentrations in mice. Additionally, I also tested 
the effect of 8 weeks of high AGE or low AGE, isocaloric diets on measures of energy 
consumption and expenditure, feeding behaviour and activity using indirect calorimetry in 
healthy mice.   
The major findings from these OATTs was that the AGE content of a protein bolus does not 
appear to effect post prandial circulating insulin levels. However, increasing AGE loads did 
appear to elicit a dose effect on circulating blood glucose levels, that wasn’t seen with the 
equivalent delivery of matched control protein. Taken together this suggests that AGE 
content of a meal potentially does effect post prandial glucose levels, although the direction 
of these effects appeared to depend on dose and does not appear to occur via direct effects 
on insulin secretion. Although somewhat consistent with data from humans [411], there was  
a large degree of variation between mice in the same group and a larger cohort and a larger 
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range of tested dosages is required to confirm this. Furthermore, as discussed in chapter 3, 
the stress response of the animals may have masked or blunted any effects, due to the 
gluconeogenic effects of stress.  
There are a number of ways that one could speculate that this acute effect of oral AGEs to 
modulate circulating glucose may occur. Given the bolus these animals were given did not 
contain any glucose, this post prandial changes in blood glucose may come from regulation 
of the enteroendocrine response and subsequent regulation of the glucagon. When a protein 
bolus, such as this is ingested this should signal though the production of gastrointestinal 
hormones from the enteroendocrine cells that a meal has been consumed, suppressing 
glucagon secretion and promoting insulin secretion by the pancreas [571]. One hypothesis 
is that AGEs either directly or indirectly alter enteroendocrine signalling leading to continued 
or increased glucagon signalling or a failure to suppress glucagon despite the ingestion of 
a meal. Our results partially support this. However, at the lowest AGE dosages, a decrease 
in glucose was observed. Further to this, when glucose AUC0-120 as a measure of net 
glucose, over the 120 minutes was compared to that of the equivalent unmodified protein 
does, no statistical differences were found. Making these results difficult to interpret. Going 
forward, some key experiments in pre-clinical models that would help to test these different 
pathways could include a comparison of intravenous vs oral administration of AGE-modified 
and unmodified protein, to untangle the contribution of the GI tract on the glucose response. 
However, exactly matching circulating AGE levels in real time would be difficult within the 
limitations of current technology. Alternatively, utilisation of larger model organism such as 
the rat would facilitate collection of larger blood volumes, allowing simultaneous assessment 
of glucagon and the incretin hormones GLP-1, and GIP in addition to glucose and insulin 
and would overcome a number of hurdles encountered in the present study. If confirmed, 
functional tests in isolated islets or small intestine derived, differentiated organoids could 
also prove valuable. Finally, it would be interesting to deliver the AGE-protein bolus in mice 
where the receptors of AGEs have been manipulated and examine post prandial responses. 
Although these mice do not appear to show differences in the uptake of AGEs across the 
GI tract [263], they do appear to have differences in their susceptibility to chronic pathology 
induced by chronic high AGE feeding [209, 210, 213, 467].   
When considering further experiments, one important factor to control for is the significant 
stress response that was observed in mice with oral gavage. As discussed in chapter 3, 
there is evidence that mice cannot be habituated to gavage or blood collection [420]. Given 
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AGEs are habitually eaten as part of a normal human diet, and pose no barriers as far as 
safety and ethical considerations. Conducting future experiments with human participants is 
a worthwhile consideration. AGEs could be delivered as a high AGE drink or AGE 
supplemented meal and would overcome the confounding effects of the stress response 
observed in animal models.  
Despite this trend towards elevations in blood glucose concentrations in response to 
increasing AGE loads, we saw no differences in gross metabolism as assessed by indirect 
calorimetry between mice fed on either a high or low AGE diet for 8 weeks. Gas exchange, 
body temperature, food and water consumption were not impacted by the AGE content of 
the diet. Although these findings were largely negative, they are informative, as no studies 
using the phenomaster indirect calorimetry system had been undertaken previously. 
Furthermore, these results are important as they indicate that the changes in blood glucose 
and insulin previously reported in high AGE diet fed rodents, are unlikely to be driven by 
differences in food consumption or gross metabolic changes, where comparable diets have 
been used.  
This study represents only a single snapshot at 8 weeks, which compared to many studies 
of chronic high AGE consumption in rodent models [211, 286, 287, 371, 572, 573] is 
relatively short. In the future it would be worthwhile to consider undertaking a longer feeding 
protocol with animals undergoing multiple periods calorimetry over time, to determine if shifts 
in RER, food consumption exist later in life with further chronic feeding, more akin to a 
lifetime spent consuming a western diet. Furthermore, a number studies utilise high AGE, 
high fat diets, as this is considered to more accurately represent the western eating habits 
than AGEs alone [285, 574]. Future experiments, may also benefit from additional groups 
that receive diets high in fat and AGEs.   
While chapter 3 of this thesis aimed to better understand how AGEs may regulate blood 
glucose, Chapter 4, aimed to examine acute production of AGEs following oral glucose 
ingestion. Here, the relationship between post prandial glucose excursions, gastrointestinal 
handling of glucose and circulating levels of the AGE CML and, sRAGE were studied in 
humans. This was performed using serum obtained from a unique cohort of patients with 
recently diagnosed T2DM and controls who were age, gender and BMI matched. All subjects 
underwent OGTTs at three different glucose dosages (25g, 75g, 125g) and three matched 
isoglycaemic glucose infusions (IIGI) during which glucose was infused intravenously to 
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precisely mirror circulating glucose concentrations during the dose-equivalent OGTT for 
each individual.  
In this cohort, CML, although dynamic over time, was not produced or released 
proportionately to the glucose excursions and acute regulation was not impacted by diabetes 
status. However, CML tended to decrease during OGTTs but not in matched IIGI in 
individuals with T2DM. This was surprising given that we anticipated that AGE formation 
would be augmented in people with T2DM after glucose ingestion, given the findings of a 
previous study [446] and given these patients experience significant hyperglycaemic events, 
particularly at the higher glucose dosages [450]. As n numbers are small in this study, our 
findings require confirmation in a larger cohort. It would be worthwhile to confirm this finding 
in a cohort of patients with longer duration of diabetes, to determine if these findings hold as 
diabetes progresses. Although finding additional cohorts of patients that have been studied 
as extensively as the cohort used here is challenging. It would also be worth considering 
using the gold standard LC-MS/MS to measure AGEs in future studies, although this would 
have proved prohibitively expensive for the present study and was therefore not considered.  
In individuals with recently diagnosed T2DM, net circulating concentrations of sRAGE were 
lower in response to intravenous but not oral glucose loads. This was also seen at the 25g 
dosage matched IIGI in control individuals and when both the controls and diabetics were 
combined into a single cohort. Although sRAGE levels have been demonstrated to be 
dynamic in acute settings such as ICU [478, 479]. To our knowledge this is the first time that 
circulating sRAGE concentrations have been shown to be modified by acute glucose 
challenges. It is also novel that circulating sRAGE concentrations remained stable following 
oral glucose delivery suggesting that sRAGE may be regulated by gut associated hormones. 
Indeed, gastrointestinally released signalling molecules such as GLP-1 and GIP may 
maintain or prevent suppression of sRAGE following a meal, as this is the major difference 
between the OGTT and IIGI [450]. Currently there is a clinical trial registered which is 
examining sRAGE pre- and post-glucose loads in pregnant women undergoing 50g OGTT 
as part of the standard maternal screening practices (NCT03029546) which should shed 
further light on this phenomenon. Studies in humans have frequently shown that circulating 
sRAGE correlates with a number of chronic diseases (diabetes, CKD, COPD) [439, 440, 
459, 461, 575-578] and predicts disease and mortality risk in diabetes and CKD [310, 311, 
436-440, 579, 580]. Certainly, disease states where glucose is perturbed such as obesity 
and metabolic syndrome are associated with lower circulating sRAGE [580, 581] while the 
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opposite is true for diseases such as T2DM and ESRD, where it appears that circulating 
sRAGE concentrations are heightened [439, 459, 461, 575, 576]. Furthermore, temporal 
changes in sRAGE appear to be important, where in T1DM, sRAGE levels appear to be 
higher in high risk patients prior to seroconversion, declining during seroconversion in those 
individuals that do progress to T1DM [582]. However, it is difficult to discern from what are 
largely associative studies whether changes in sRAGE are driving disease or merely 
symptomatic of other underlying issues. More broadly, understanding the seemingly 
complex relationship between glucose control and the function of circulating sRAGE is 
important and warrants further investigation in future studies.  
Macronutrients, the western diet and kidney function   
Beyond AGEs, perhaps the most prominent shift that has occurred with the westernisation 
of the diet, is the increase in calories consumed and the changes in the macronutrient 
content of the diet [38, 583]. Delineating the effects of macronutrient consumption on renal 
function and risk for kidney disease in humans is challenging. Reliance on dietary surveys 
and self-reported data as well as adherence of participants to prescribed study diets, means 
that rigorous, longitudinal, randomised dietary studies in humans are extremely challenging. 
Where study of the kidney is concerned, this is further confounded by the challenges and 
ethical limitations in obtaining sequential renal tissue samples from biopsy, which are 
increasingly limited, especially without a clinical rationale due to their high risk for patients. 
For these reasons, rodent models offer an important alternative. Mice, as omnivorous 
grazers and broad scale food generalists, offer an important model organism with a suitable 
lifespan for the research of the chronic diseases of ageing; the use of which has significantly 
furthered our understanding of nutrition and ageing [584]. Despite decades of dietary 
research, the pervasive paradigm has been to examine individual macronutrients in 
isolation, with the assumption that a single macronutrient is implicit in disease risk. However, 
as intake is a closed system, if one macronutrient is manipulated, then by default at least 
one other macronutrient will also be changed. Furthermore, manipulations of the 
macronutrient content of the diet can have a profound effect on the quantities of food 
consumed between groups, due to compensatory feeding, further confounding the findings 
[585]. Therefore, in ad-libitum fed animal studies where a single macronutrient is the primary 
variable of interest, interpretation of the data can be confounded by effects of caloric intake. 
To resolve these issues, I have collaborated with researchers at the Charles Perkins Centre 
with the capacity and expertise to run large animal studies such as the one described in 
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chapter 5 of this thesis. Here, using a nutritional geometry approach in mice developed by 
our collaborators, I was able to undertake more comprehensive analysis of individual and 
interacting effects of macronutrients, consumed over a lifespan into late middle age on 
kidney disease risk. By design, this approach allowed assessment of the impact on the 
kidney of not only each macronutrient in isolation but their relative synergistic effects, as well 
as the effects of caloric consumption in ad libitum fed mice. These effects could be further 
delineated by sex, highlighting some important sex differences in the way the kidney is 
affected by diet. Therefore, I respectfully suggest that this study represents one of the most 
comprehensive examinations of the role of macronutrients on kidney aging and markers of 
renal decline, performed using rodent models to date.  
This research shows, that indeed macronutrient consumption over a lifetime associates with 
structural and functional changes in the kidneys. The most important finding from this study, 
is that low protein, often in conjunction with high or low carbohydrate intake was associated 
with lowest GFR, reduced renal klotho and increased renal inflammation (IL-23 and IL-1β) 
and a tendency towards greater renal fibrosis (although this did not reach significance). The 
signature of low protein towards poorer outcomes regarding the kidney was the most 
profound macronutrient outcome seen in this study. Most interesting, is that this finding 
challenges the widely held dogma that low protein diets are safer for the kidney. Certainly, 
our findings are controversial and contradict persisting ideas that very low protein 
consumption may be a contributing factor to the potent anti-ageing effects seen with caloric 
restriction [586]. Furthermore, these findings do not align with the relationships between 
macronutrient consumption and cardio-metabolic risk factors for kidney disease such as 
blood pressure, circulating lipid concentrations, and blood glucose previously published in 
this exact cohort of animals [346]. This suggests that the renal effects captured in this study 
are largely independent of cardio-metabolic risk factors normally considered to be the major 
dietary derived drivers of kidney disease. This is a highly novel finding and should be 
followed given that many therapies have failed to show benefit for CKD and a growing 
consensus that the underlying risk factors for kidney disease are yet to be fully elucidated.   
Another important contribution of this research is to highlight the key differences between 
males and females in their responses to macronutrient exposure. As an example, the 
relationship between the important early markers of renal injury, glomerular sclerosis or KIM-
1 and macronutrients differed between sexes. This strengthens the argument for including 
both sexes in the study of kidney disease and highlights that perhaps dietary guidelines may 
203 
 
need to be more individualised for the sexes, not just in regard to caloric intake, but also 
potentially macronutrient consumption.  
How well these findings can be extrapolated to humans, remains to be seen. For many 
years, the central ethos of dietary guidelines in much of the western world emphasised 
eating a low fat, high carbohydrate diet. Here in Australia, but also in a number of other 
westernised countries including USA and UK there has been a shift away from guidelines 
recommending low fat, high carbohydrate diets suggesting that the research evidence on 
which these guidelines were based, was not robust [583, 587]. Our study also highlights the 
importance of promoting and financially supporting well-designed randomised studies that 
can improve the evidence base for dietary policy and guidelines. Nutritional geometry, as 
used in the present study, is being increasingly applied to human studies to enable greater 
understanding of how interactions among various macronutrients impact on human health 
[584]. A nutritional geometry style analysis of existing large multicentre longitudinal studies 
where both renal and dietary information has been collected over an extended period of 
time, would be worthwhile in the future to determine if the relationships observed hold 
beyond this mouse model.  
It should be acknowledged that the geometric framework also has limitations. Given the 
large number of mice required for such a complex study design it was not possible to collect 
direct measures of renal function such as direct measures of GFR nor urine samples to 
assess the urinary albumin/creatinine ratio, each of which are gold standards in clinical care. 
Additionally, due to the large number of samples required for statistically robust analysis of 
this cohort, certain analyses, although preferable were prohibitively expensive. This is 
included the measurement of advanced glycation end products, CML, CEL and MGH1 in 
the kidney by LC-MS/MS. Although we did attempt to measure CML by ELISA in protein 
homogenate extracted from the kidney, the volume of homogenate required to reach the 
minimum detectable limit of the ELISA was too great and would have prevented 
measurement of KIM-1 and cytokine analysis that we also wished to perform. For this 
reason, we decided not to proceed with the CML analysis despite our interest in this 
pathway. 
One major factor that should also be considered in this study, is that the mouse model used, 
the C57BL/6J strain is relatively resistant to developing kidney disease. Therefore, all the 
data must be considered with this in mind, and this may explain why a more pronounced 
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renal disease was not seen. However, this has allowed us to gain novel data showing that 
impairment of kidney function after a lifetime of low protein intake is not necessarily linked 
to other metabolic risk factors such as adiposity and impaired glucose tolerance. We would 
suggest therefore, that a study of renal disease using nutritional geometry in a mouse model 
more susceptible to renal injury and with urine collection and direct measurement of GFR 
decline over time, would be highly informative.    
Finally, one important factor that this study does not address is the effect of the quality of 
protein and carbohydrate. There is significant evidence, certainly from humans that the 
quality of carbohydrates, proteins and fats used is important and may be as important as 
their relative quantities [38, 588]. As all the dietary components used in this study used the 
same source materials this was controlled across all diets.  
Concluding remarks 
In conclusion, this thesis aimed to investigate two key factors that link the western diet and 
both diabetic and non-diabetic kidney disease. Here we looked at how AGE consumption 
and endogenous AGE and sRAGE production influence the kidney and risk factors for CKD, 
and finally we look directly at the influence of dietary macronutrient consumption on renal 
function and structure. This research highlights that in rodent models AGEs from the diet 
can be absorbed into the circulation within 15 minutes of ingestion, and that further than this, 
they appear to perturb glucose homeostasis potentially through interactions with the GI tract. 
More attention needs to be paid to these compounds. In particular, more research is required 
to extrapolate findings from rodent models to humans, where the limitations of in vivo 
imaging and the technology available has limited research capacity in this field. Further to 
this, in the final results chapter, we also highlight that by middle age, the macronutrient 
intake can indeed shape renal functional outcomes, and in somewhat unexpected ways. 
Large scale, longitudinal clinical trials are required so that dietary guidelines and 
recommendations, particularly those for renal health, have a strong evidence base. 
Nutritional geometry and geometric framework style studies have the capacity to be 
extrapolated to humans and may form a platform for such longitudinal studies.    
 
205 
 
 
Bibliography 
1. Fotheringham, A.K., L.A. Gallo, and J.M. Forbes, Dietary AGEs in the Development 
and Progression of Chronic Kidney Disease, in Dietary AGEs and Their Role in 
Health and Disease. Boca Raton: CRC Press., J. Uribarri, Editor. 2018, CRC Press: 
Boca Raton. 
2. Meyer, C., et al., Role of human liver, kidney, and skeletal muscle in postprandial 
glucose homeostasis. American Journal of Physiology - Endocrinology And 
Metabolism, 2002. 282(2): p. E419-E427. 
3. Gerich, J.E., Role of the kidney in normal glucose homeostasis and in the 
hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Medicine, 
2010. 27(2): p. 136-142. 
4. Hoy, W.E., et al., A stereological study of glomerular number and volume: preliminary 
findings in a multiracial study of kidneys at autopsy. Kidney Int Suppl, 2003(83): p. 
S31-7. 
5. Menzel, S. and M.J. Moeller, Role of the podocyte in proteinuria. Pediatric nephrology 
(Berlin, Germany), 2011. 26(10): p. 1775-1780. 
6. Maher, J.F., Pathophysiology of renal hemodynamics. Nephron, 1981. 27(4-5): p. 
215-21. 
7. Wetzels, J.F.M., et al., Age- and gender-specific reference values of estimated GFR 
in Caucasians: The Nijmegen Biomedical Study. Kidney International, 2007. 72(5): p. 
632-637. 
8. Eckardt, K.-U., et al., Evolving importance of kidney disease: from subspecialty to 
global health burden. The Lancet, 2013. 382(9887): p. 158-169. 
9. Levey, A.S. and J. Coresh, Chronic kidney disease. The Lancet, 2012. 379(9811): p. 
165-180. 
10. Arpegard, J., et al., Comparison of heritability of Cystatin C- and creatinine-based 
estimates of kidney function and their relation to heritability of cardiovascular disease. 
J Am Heart Assoc, 2015. 4(1): p. e001467. 
11. Iijima, T., et al., Follow-up study on urinary type IV collagen in patients with early 
stage diabetic nephropathy. J Clin Lab Anal, 1998. 12(6): p. 378-82. 
12. Han, W.K., et al., Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human 
renal proximal tubule injury. Kidney Int, 2002. 62(1): p. 237-44. 
13. Schlondorff, D.O., Overview of factors contributing to the pathophysiology of 
progressive renal disease. Kidney International, 2008. 74(7): p. 860-866. 
206 
 
14. El Nahas, A.M. and A.K. Bello, Chronic kidney disease: the global challenge. The 
Lancet, 2005. 365(9456): p. 331-340. 
15. Webster, A.C., et al., Chronic Kidney Disease. The Lancet, 2017. 389(10075): p. 
1238-1252. 
16. Kagami, S., et al., Angiotensin II stimulates extracellular matrix protein synthesis 
through induction of transforming growth factor-beta expression in rat glomerular 
mesangial cells. The Journal of Clinical Investigation, 1994. 93(6): p. 2431-2437. 
17. Alpers, C.E., et al., Enhanced expression of "muscle-specific" actin in 
glomerulonephritis. Kidney Int, 1992. 41(5): p. 1134-42. 
18. Sam, R., et al., Glomerular epithelial cells transform to myofibroblasts: early but not 
late removal of TGF-beta1 reverses transformation. Transl Res, 2006. 148(3): p. 142-
8. 
19. Falke, L.L., et al., Diverse origins of the myofibroblast—implications for kidney 
fibrosis. Nature Reviews Nephrology, 2015. 11: p. 233. 
20. Weinstein, J.R. and S. Anderson, The aging kidney: Physiological changes. 
Advances in chronic kidney disease, 2010. 17(4): p. 302-307. 
21. Klemis, V., et al., Circulating fibronectin contributes to mesangial expansion in a 
murine model of type 1 diabetes. Kidney International, 2017. 91(6): p. 1374-1385. 
22. Reidy, K. and K. Susztak, Epithelial Mesenchymal Transition and Podocyte Loss in 
Diabetic Kidney Disease. American journal of kidney diseases : the official journal of 
the National Kidney Foundation, 2009. 54(4): p. 590-593. 
23. Tomino, Y., Pathogenesis and Treatment of Chronic Kidney Disease: A Review of 
Our Recent Basic and Clinical Data. Kidney and Blood Pressure Research, 2014. 
39(5): p. 450-489. 
24. Kriz, W., et al., Structural Analysis of How Podocytes Detach from the Glomerular 
Basement Membrane Under Hypertrophic Stress. Frontiers in Endocrinology, 2014. 
5: p. 207. 
25. Fine, L.G. and J.T. Norman, Chronic hypoxia as a mechanism of progression of 
chronic kidney diseases: from hypothesis to novel therapeutics. Kidney International, 
2008. 74(7): p. 867-872. 
26. Erkan, E., et al., Induction of renal tubular cell apoptosis in focal segmental 
glomerulosclerosis: roles of proteinuria and Fas-dependent pathways. J Am Soc 
Nephrol, 2005. 16(2): p. 398-407. 
27. Zoja, C., M. Abbate, and G. Remuzzi, Progression of renal injury toward interstitial 
inflammation and glomerular sclerosis is dependent on abnormal protein filtration. 
Nephrology Dialysis Transplantation, 2015. 30(5): p. 706-712. 
28. Erkan, E., P. Devarajan, and G.J. Schwartz, Mitochondria are the major targets in 
albumin-induced apoptosis in proximal tubule cells. J Am Soc Nephrol, 2007. 18(4): 
p. 1199-208. 
207 
 
29. Li, X., et al., PKC-delta promotes renal tubular cell apoptosis associated with 
proteinuria. J Am Soc Nephrol, 2010. 21(7): p. 1115-24. 
30. Biancone, L., et al., Alternative pathway activation of complement by cultured human 
proximal tubular epithelial cells. Kidney Int, 1994. 45(2): p. 451-60. 
31. Ohse, T., et al., Albumin induces endoplasmic reticulum stress and apoptosis in renal 
proximal tubular cells. Kidney Int, 2006. 70(8): p. 1447-55. 
32. Bohlender, J.M., et al., Advanced glycation end products and the kidney. American 
Journal of Physiology-Renal Physiology, 2005. 289(4): p. F645-F659. 
33. ANZDATA Registry. 41st Report, Chapter 1: Incidence of End Stage Kidney Disease, 
Australia and New Zealand Dialysis and Transplant Registry. 2018: Adelaide, 
Australia, Available at: http://www.anzdata.org.au. 
34. United States Renal Data System. 2018 USRDS annual data report: Epidemiology of 
kidney disease in the United States. 2018: National Institutes of Health, National 
Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, . 
35. Jha, V., et al., Chronic kidney disease: global dimension and perspectives. The 
Lancet, 2013. 382(9888): p. 260-272. 
36. Lozano, R., et al., Global and regional mortality from 235 causes of death for 20 age 
groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease 
Study 2010. The Lancet, 2012. 380(9859): p. 2095-2128. 
37. Collaborators, G.M.a.C.O.D., Global, regional, and national age–sex specific all-
cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic 
analysis for the Global Burden of Disease Study 2013. The Lancet, 2015. 385(9963): 
p. 117-171. 
38. Cordain, L., et al., Origins and evolution of the Western diet: health implications for 
the 21st century. The American Journal of Clinical Nutrition, 2005. 81(2): p. 341-354. 
39. Odermatt, A., The Western-style diet: a major risk factor for impaired kidney function 
and chronic kidney disease. American Journal of Physiology - Renal Physiology, 
2011. 301(5): p. F919-F931. 
40. Hariharan, D., K. Vellanki, and H. Kramer, The Western Diet and Chronic Kidney 
Disease. Current Hypertension Reports, 2015. 17(3): p. 16. 
41. Kazancioğlu, R., Risk factors for chronic kidney disease: an update. Kidney 
International Supplements, 2013. 3(4): p. 368-371. 
42. Federation, I.D., IDF Diabetes Atlas, 6th edn. 2015: Brussels, Belgium. 
43. Danaei, G., et al., National, regional, and global trends in fasting plasma glucose and 
diabetes prevalence since 1980: systematic analysis of health examination surveys 
and epidemiological studies with 370 country-years and 2.7 million participants. 
Lancet, 2011. 378(9785): p. 31-40. 
208 
 
44. Lee, C.M.Y., et al., The cost of diabetes in adults in Australia. Diabetes Research and 
Clinical Practice, 2013. 99(3): p. 385-390. 
45. Organisation, W.H., Global Report on Diabetes. 2016: World Health Organization, 20 
Avenue Appia, 1211 Geneva 27, Switzerland  
46. Atkinson, M.A. and G.S. Eisenbarth, Type 1 diabetes: new perspectives on disease 
pathogenesis and treatment. Lancet, 2001. 358(9277): p. 221-9. 
47. Forbes, J.M. and M.E. Cooper, Mechanisms of diabetic complications. Physiol Rev, 
2013. 93(1): p. 137-88. 
48. Thomas, N.J., et al., Frequency and phenotype of type 1 diabetes in the first six 
decades of life: a cross-sectional, genetically stratified survival analysis from UK 
Biobank. The Lancet Diabetes & Endocrinology, 2018. 6(2): p. 122-129. 
49. Daneman, D., Type 1 diabetes. Lancet, 2006. 367(9513): p. 847-58. 
50. Organization, W.H., Global Status report on noncommunicable diseases 2014. 
Geneva, 2012. 
51. Organization, W.H., Global Health Estimates: Deaths by Cause, Age, Sex and 
Country, 2000-2012. Geneva, WHO, 2014. 
52. Fagot-Campagna, A., et al., Type 2 diabetes among North adolescents: An 
epidemiologic health perspective. The Journal of pediatrics, 2000. 136(5): p. 664-
672. 
53. De Boer, I.H., et al., Temporal trends in the prevalence of diabetic kidney disease in 
the united states. JAMA, 2011. 305(24): p. 2532-2539. 
54. Freedman, B.I., et al., Genetic Factors in Diabetic Nephropathy. Clinical Journal of 
the American Society of Nephrology, 2007. 2(6): p. 1306-1316. 
55. Groop, P.-H., et al., The presence and severity of chronic kidney disease predicts all-
cause mortality in type 1 diabetes. Diabetes, 2009. 58(7): p. 1651-1658. 
56. Afkarian, M., et al., Kidney Disease and Increased Mortality Risk in Type 2 Diabetes. 
Journal of the American Society of Nephrology, 2013. 24(2): p. 302-308. 
57. Kearney, P.M., et al., Global burden of hypertension: analysis of worldwide data. The 
Lancet, 2005. 365(9455): p. 217-223. 
58. Klag, M.J., et al., Blood Pressure and End-Stage Renal Disease in Men. New 
England Journal of Medicine, 1996. 334(1): p. 13-18. 
59. Perry, H.M., Jr., et al., Early predictors of 15-year end-stage renal disease in 
hypertensive patients. Hypertension, 1995. 25(4 Pt 1): p. 587-94. 
60. Haroun, M.K., et al., Risk Factors for Chronic Kidney Disease: A Prospective Study 
of 23,534 Men and Women in Washington County, Maryland. Journal of the American 
Society of Nephrology, 2003. 14(11): p. 2934-2941. 
209 
 
61. Luke, R.G., Hypertensive nephrosclerosis: pathogenesis and prevalence Essential 
hypertension is an important cause of end-stage renal disease. Nephrology Dialysis 
Transplantation, 1999. 14(10): p. 2271-2278. 
62. Hill, G.S., Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens, 2008. 17(3): 
p. 266-70. 
63. Eaton, S.B., Humans, lipids and evolution. Lipids, 1992. 27(10): p. 814-820. 
64. Abrass, C.K., Cellular Lipid Metabolism and the Role of Lipids in Progressive Renal 
Disease. American Journal of Nephrology, 2004. 24(1): p. 46-53. 
65. Mulec, H., S.-A. Johnson, and S. Björck, Relation between serum cholesterol and 
diabetic nephropathy. The Lancet, 1990. 335(8704): p. 1537-1538. 
66. Yamagata, K., et al., Risk factors for chronic kidney disease in a community-based 
population: a 10-year follow-up study. Kidney Int, 2007. 71(2): p. 159-66. 
67. Su, S.-L., et al., Risk factors and their interaction on chronic kidney disease: A multi-
centre case control study in Taiwan. BMC Nephrology, 2015. 16(1): p. 83. 
68. Hall, J.E., et al., Is obesity a major cause of chronic kidney disease? Advances in 
Renal Replacement Therapy, 2004. 11(1): p. 41-54. 
69. Pinto-Sietsma, S.J., et al., A central body fat distribution is related to renal function 
impairment, even in lean subjects. Am J Kidney Dis, 2003. 41(4): p. 733-41. 
70. Foster, M.C., et al., Overweight, obesity, and the development of stage 3 CKD: the 
Framingham Heart Study. Am J Kidney Dis, 2008. 52(1): p. 39-48. 
71. Chang, A., et al., Lifestyle-related factors, obesity, and incident microalbuminuria: the 
CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Kidney 
Dis, 2013. 62(2): p. 267-75. 
72. Kramer, H., et al., Obesity and prevalent and incident CKD: the Hypertension 
Detection and Follow-Up Program. Am J Kidney Dis, 2005. 46(4): p. 587-94. 
73. Ejerblad, E., et al., Obesity and risk for chronic renal failure. J Am Soc Nephrol, 2006. 
17(6): p. 1695-702. 
74. Gelber, R.P., et al., Association between body mass index and CKD in apparently 
healthy men. Am J Kidney Dis, 2005. 46(5): p. 871-80. 
75. Lu, J.L., et al., Association of age and BMI with kidney function and mortality: a cohort 
study. Lancet Diabetes Endocrinol, 2015. 3(9): p. 704-14. 
76. Munkhaugen, J., et al., Prehypertension, obesity, and risk of kidney disease: 20-year 
follow-up of the HUNT I study in Norway. Am J Kidney Dis, 2009. 54(4): p. 638-46. 
77. Iseki, K., et al., Body mass index and the risk of development of end-stage renal 
disease in a screened cohort. Kidney International, 2004. 65(5): p. 1870-1876. 
210 
 
78. Vivante, A., et al., Body mass index in 1.2 million adolescents and risk for end-stage 
renal disease. Arch Intern Med, 2012. 172(21): p. 1644-50. 
79. Hsu, C.Y., et al., Body mass index and risk for end-stage renal disease. Ann Intern 
Med, 2006. 144(1): p. 21-8. 
80. Kovesdy, C.P., et al., Obesity and Kidney Disease: Hidden Consequences of the 
Epidemic. Canadian Journal of Kidney Health and Disease, 2017. 4: p. 
2054358117698669. 
81. Bagby, S.P., Obesity-Initiated Metabolic Syndrome and the Kidney: A Recipe for 
Chronic Kidney Disease? Journal of the American Society of Nephrology, 2004. 
15(11): p. 2775-2791. 
82. Owen, R.A. and R. Heywood, Age-Related Variations in Renal Structure and 
Function in Sprague-Dawley Rats. Toxicologic Pathology, 1986. 14(2): p. 158-167. 
83. Yu, B.P., et al., Life Span Study of SPF Fischer 344 Male Rats Fed AdLibitum or 
Restricted Diets: Longevity, Growth, Lean Body Mass and Disease. Journal of 
Gerontology, 1982. 37(2): p. 130-141. 
84. Gray, J.E., R.N. Weaver, and A. Purmalis, Ultrastructural Observations of Chronic 
Progressive Nephrosis in the Sprague-Dawley Rat. Veterinary Pathology, 1974. 
11(2): p. 153-164. 
85. Bolton, W.K. and B.C. Sturgill, Ultrastructure of the Aging Kidney, in Aging and Cell 
Structure: Volume 1, J.E. Johnson, Editor. 1981, Springer US: Boston, MA. p. 215-
250. 
86. Yu, B.P., E.J. Masoro, and C.A. Mcmahan, Nutritional influences on aging of Fischer 
344 rats: I. Physical, metabolic, and longevity characteristics. J Gerontol, 1985. 40(6): 
p. 657-70. 
87. Corman, B. and J.B. Michel, Glomerular filtration, renal blood flow, and solute 
excretion in conscious aging rats. Am J Physiol, 1987. 253(4 Pt 2): p. R555-60. 
88. Dodane, V., et al., Longitudinal study of solute excretion and glomerular ultrastructure 
in an experimental model of aging rats free of kidney disease. Laboratory 
investigation; a journal of technical methods and pathology, 1991. 64(3): p. 377-391. 
89. Li, Y.M., et al., Prevention of cardiovascular and renal pathology of aging by the 
advanced glycation inhibitor aminoguanidine. Proceedings of the National Academy 
of Sciences of the United States of America, 1996. 93(9): p. 3902-3907. 
90. Deji, N., et al., Structural and functional changes in the kidneys of high-fat diet-
induced obese mice. Am J Physiol Renal Physiol, 2009. 296(1): p. F118-26. 
91. Wang, H., et al., TNF-α Deficiency Prevents Renal Inflammation and Oxidative Stress 
in Obese Mice. Kidney and Blood Pressure Research, 2017. 42(3): p. 416-427. 
92. Jiang, T., et al., Diet-induced Obesity in C57BL/6J Mice Causes Increased Renal 
Lipid Accumulation and Glomerulosclerosis via a Sterol Regulatory Element-binding 
211 
 
Protein-1c-dependent Pathway. Journal of Biological Chemistry, 2005. 280(37): p. 
32317-32325. 
93. Hall, M.E., et al., Obesity, hypertension, and chronic kidney disease. International 
Journal of Nephrology and Renovascular Disease, 2014. 7: p. 75-88. 
94. Ghigliotti, G., et al., Adipose Tissue Immune Response: Novel Triggers and 
Consequences for Chronic Inflammatory Conditions. Inflammation, 2014. 37(4): p. 
1337-1353. 
95. Hunley, T.E., L.-J. Ma, and V. Kon, Scope and Mechanisms of Obesity-Related Renal 
Disease. Current opinion in nephrology and hypertension, 2010. 19(3): p. 227-234. 
96. Joles, J.A., et al., Early mechanisms of renal injury in hypercholesterolemic or 
hypertriglyceridemic rats. J Am Soc Nephrol, 2000. 11(4): p. 669-83. 
97. Schermer, B. and T. Benzing, Lipid–Protein Interactions along the Slit Diaphragm of 
Podocytes. Journal of the American Society of Nephrology, 2009. 20(3): p. 473-478. 
98. Sugerman, H., et al., Intra-abdominal pressure, sagittal abdominal diameter and 
obesity comorbidity. J Intern Med, 1997. 241(1): p. 71-9. 
99. Hall, J.E., The Kidney, Hypertension, and Obesity. Hypertension, 2003. 41(3): p. 625-
633. 
100. Piper, M.D.W. and A. Bartke, Diet and Aging. Cell Metabolism, 2008. 8(2): p. 99-104. 
101. Maddox, D.A., et al., Prevention of obesity-linked renal disease: Age-dependent 
effects of dietary food restriction. Kidney International, 2002. 62(1): p. 208-219. 
102. Baylis, C. and B. Corman, The aging kidney: insights from experimental studies. 
Journal of the American Society of Nephrology, 1998. 9(4): p. 699-709. 
103. Mirzaei, H., J.A. Suarez, and V.D. Longo, Protein and amino acid restriction, aging 
and disease: from yeast to humans. Trends in Endocrinology & Metabolism, 2014. 
25(11): p. 558-566. 
104. Davis, T.A., C.W. Bales, and R.E. Beauchene, Differential effects of dietary caloric 
and protein restriction in the aging rat. Exp Gerontol, 1983. 18(6): p. 427-35. 
105. Metges, C.C. and C.A. Barth, Metabolic consequences of a high dietary-protein 
intake in adulthood: assessment of the available evidence. J Nutr, 2000. 130(4): p. 
886-9. 
106. Brenner, B.M., T.W. Meyer, and T.H. Hostetter, Dietary protein intake and the 
progressive nature of kidney disease: the role of hemodynamically mediated 
glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, 
renal ablation, and intrinsic renal disease. N Engl J Med, 1982. 307(11): p. 652-9. 
107. Jones, M.G., K. Lee, and R. Swaminathan, The effect of dietary protein on glomerular 
filtration rate in normal subjects. Clin Nephrol, 1987. 27(2): p. 71-5. 
212 
 
108. Kontessis, P., et al., Renal, metabolic and hormonal responses to ingestion of animal 
and vegetable proteins. Kidney International, 1990. 38(1): p. 136-144. 
109. Chan, A.Y., et al., Functional response of healthy and diseased glomeruli to a large, 
protein-rich meal. Journal of Clinical Investigation, 1988. 81(1): p. 245-254. 
110. Bergstrom, J., M. Ahlberg, and A. Alvestrand, Influence of protein intake on renal 
hemodynamics and plasma hormone concentrations in normal subjects. Acta Med 
Scand, 1985. 217(2): p. 189-96. 
111. Nakamura, H., et al., Acute loading with proteins from different sources in healthy 
volunteers and diabetic patients. Journal of Diabetic Complications, 1991. 5(2): p. 
140-142. 
112. Nakamura, H., et al., Renal Effects of Different Types of Protein in Healthy Volunteer 
Subjects and Diabetic Patients. Diabetes Care, 1993. 16(8): p. 1071-1075. 
113. Bernstein, A.M., L. Treyzon, and Z. Li, Are High-Protein, Vegetable-Based Diets Safe 
for Kidney Function? A Review of the Literature. Journal of the American Dietetic 
Association, 2007. 107(4): p. 644-650. 
114. Knight, E.L., et al., The impact of protein intake on renal function decline in women 
with normal renal function or mild renal insufficiency. Ann Intern Med, 2003. 138(6): 
p. 460-7. 
115. Wrone, E.M., et al., Association of dietary protein intake and microalbuminuria in 
healthy adults: Third National Health and Nutrition Examination Survey. Am J Kidney 
Dis, 2003. 41(3): p. 580-7. 
116. Pijls, L.T., et al., Protein restriction, glomerular filtration rate and albuminuria in 
patients with type 2 diabetes mellitus: a randomized trial. Eur J Clin Nutr, 2002. 
56(12): p. 1200-7. 
117. Dussol, B., et al., A randomized trial of low-protein diet in type 1 and in type 2 diabetes 
mellitus patients with incipient and overt nephropathy. J Ren Nutr, 2005. 15(4): p. 
398-406. 
118. Robertson, L., N. Waugh, and A. Robertson, Protein restriction for diabetic renal 
disease. Cochrane Database Syst Rev, 2007(4): p. Cd002181. 
119. Pan, Y., L.L. Guo, and H.M. Jin, Low-protein diet for diabetic nephropathy: a meta-
analysis of randomized controlled trials. Am J Clin Nutr, 2008. 88(3): p. 660-6. 
120. Zhu, H.-G., et al., Efficacy of low-protein diet for diabetic nephropathy: a systematic 
review of randomized controlled trials. Lipids in health and disease, 2018. 17(1): p. 
141-141. 
121. Wiseman, M.J., et al., Dietary composition and renal function in healthy subjects. 
Nephron, 1987. 46(1): p. 37-42. 
122. Pettersen, B.J., et al., Vegetarian diets and blood pressure among white subjects: 
results from the Adventist Health Study-2 (AHS-2). Public health nutrition, 2012. 
15(10): p. 1909-1916. 
213 
 
123. Williams, A.J., F. Baker, and J. Walls, Effect of varying quantity and quality of dietary 
protein intake in experimental renal disease in rats. Nephron, 1987. 46(1): p. 83-90. 
124. Gopinath, B., et al., Carbohydrate Nutrition Is Associated with the 5-Year Incidence 
of Chronic Kidney Disease. The Journal of Nutrition, 2011. 141(3): p. 433-439. 
125. Juraschek, S.P., et al., Effect of glycemic index and carbohydrate intake on kidney 
function in healthy adults. BMC Nephrology, 2016. 17: p. 70. 
126. Wong, S.K., et al., Animal models of metabolic syndrome: a review. Nutrition & 
Metabolism, 2016. 13: p. 65. 
127. Kizhner, T. and M.J. Werman, Long-term fructose intake: Biochemical consequences 
and altered renal histology in the male rat. Metabolism, 2002. 51(12): p. 1538-1547. 
128. Gersch, M.S., et al., Fructose, but not dextrose, accelerates the progression of 
chronic kidney disease. American Journal of Physiology - Renal Physiology, 2007. 
293(4): p. F1256-F1261. 
129. Nguyen, S., et al., Sugar-Sweetened Beverages, Serum Uric Acid, and Blood 
Pressure in Adolescents. The Journal of Pediatrics, 2009. 154(6): p. 807-813. 
130. Zhu, P., et al., Serum Uric Acid Is Associated with Incident Chronic Kidney Disease 
in Middle-Aged Populations: A Meta-Analysis of 15 Cohort Studies. PLOS ONE, 
2014. 9(6): p. e100801. 
131. Weiner, D.E., et al., Uric Acid and Incident Kidney Disease in the Community. Journal 
of the American Society of Nephrology, 2008. 19(6): p. 1204-1211. 
132. Lin, J. and G.C. Curhan, Associations of Sugar and Artificially Sweetened Soda with 
Albuminuria and Kidney Function Decline in Women. Clinical Journal of the American 
Society of Nephrology, 2011. 6(1): p. 160-166. 
133. Declèves, A.-E., et al., Regulation of lipid accumulation by AMK-activated kinase in 
high fat diet–induced kidney injury. Kidney International, 2014. 85(3): p. 611-623. 
134. Wicks, S.E., et al., Diet-induced obesity and kidney disease - In search of a 
susceptible mouse model. Biochimie, 2016. 124: p. 65-73. 
135. Poplawski, M.M., et al., Reversal of Diabetic Nephropathy by a Ketogenic Diet. PLoS 
ONE, 2011. 6(4): p. e18604. 
136. Kang, H.M., et al., Defective fatty acid oxidation in renal tubular epithelial cells has a 
key role in kidney fibrosis development. Nature medicine, 2015. 21(1): p. 37-46. 
137. Yuzbashian, E., et al., Associations of dietary macronutrients with glomerular filtration 
rate and kidney dysfunction: Tehran lipid and glucose study. J Nephrol, 2015. 28(2): 
p. 173-80. 
138. Diaz-Lopez, A., et al., Cross-sectional associations between macronutrient intake 
and chronic kidney disease in a population at high cardiovascular risk. Clin Nutr, 
2013. 32(4): p. 606-12. 
214 
 
139. Gopinath, B., et al., Consumption of long-chain n-3 PUFA, alpha-linolenic acid and 
fish is associated with the prevalence of chronic kidney disease. Br J Nutr, 2011. 
105(9): p. 1361-8. 
140. Malhotra, R., et al., Dietary polyunsaturated fatty acids and incidence of end-stage 
renal disease in the Southern Community Cohort Study. BMC Nephrology, 2016. 17: 
p. 152. 
141. Dos Santos, A.L.T., et al., Association of dietary fat composition with kidney function 
decline in patients with type 2 diabetes. Diabetology & Metabolic Syndrome, 2015. 
7(Suppl 1): p. A36-A36. 
142. Poulsen, M.W., et al., Advanced glycation endproducts in food and their effects on 
health. Food Chem Toxicol, 2013. 60: p. 10-37. 
143. John, W.G. and E.J. Lamb, The maillard or browning reaction in diabetes. Eye, 1993. 
7(2): p. 230-237. 
144. Ulrich, P. and A. Cerami, Protein glycation, diabetes, and aging. Recent Prog Horm 
Res, 2001. 56: p. 1-21. 
145. Luevano-Contreras, C. and K. Chapman-Novakofski, Dietary advanced glycation end 
products and aging. Nutrients, 2010. 2(12): p. 1247-65. 
146. Skovsted, I.C., et al., Characterisation of a novel AGE-compound derived from lysine 
and 3-deoxyglucosone. Cell Mol Biol (Noisy-le-grand), 1998. 44(7): p. 1159-63. 
147. Singh, R., et al., Advanced glycation end-products: a review. Diabetologia, 2001. 
44(2): p. 129-146. 
148. Wells-Knecht, K.J., et al., New biomarkers of Maillard reaction damage to proteins. 
Nephrol Dial Transplant, 1996. 11 Suppl 5: p. 41-7. 
149. Mironova, R., et al., Evidence for non-enzymatic glycosylation in Escherichia coli. 
Molecular Microbiology, 2001. 39(4): p. 1061-1068. 
150. Baynes, J.W. and S.R. Thorpe, Role of oxidative stress in diabetic complications: a 
new perspective on an old paradigm. Diabetes, 1999. 48(1): p. 1-9. 
151. Genevieve, M., et al., Skin autofluorescence is associated with past glycaemic control 
and complications in type 1 diabetes mellitus. Diabetes & metabolism, 2013. 39(4): 
p. 349-354. 
152. Sugisawa, E., et al., Skin autofluorescence reflects integration of past long-term 
glycemic control in patients with type 1 diabetes. Diabetes care, 2013. 36(8): p. 2339-
2345. 
153. Meerwaldt, R., et al., Increased accumulation of skin advanced glycation end-
products precedes and correlates with clinical manifestation of diabetic neuropathy. 
Diabetologia, 2005. 48(8): p. 1637-1644. 
215 
 
154. Araszkiewicz, A., et al., Increased accumulation of skin advanced glycation end 
products is associated with microvascular complications in type 1 diabetes. Diabetes 
technology & therapeutics, 2011. 13(8): p. 837-842. 
155. Tanaka, K., et al., Skin autofluorescence is associated with severity of vascular 
complications in Japanese patients with Type 2 diabetes. Diabetic Medicine, 2012. 
29(4): p. 492-500. 
156. Yu, Y., et al., Advanced glycation end-products and methionine sulphoxide in skin 
collagen of patients with type 1 diabetes. Diabetologia, 2006. 49(10): p. 2488-98. 
157. Sun, J.K., et al., Protection from retinopathy and other complications in patients with 
type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care, 
2011. 34(4): p. 968-74. 
158. Nin, J.W., et al., Higher plasma levels of advanced glycation end products are 
associated with incident cardiovascular disease and all-cause mortality in type 1 
diabetes: a 12-year follow-up study. Diabetes Care, 2011. 34(2): p. 442-7. 
159. Wagner, Z., et al., Serum carboxymethyllysine predicts mortality in hemodialysis 
patients. Am J Kidney Dis, 2006. 47(2): p. 294-300. 
160. Busch, M., et al., The Advanced Glycation End Product Nε-Carboxymethyllysine Is 
Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 
2 Diabetic Kidney Disease and Hypertension. American Journal of Kidney Diseases. 
48(4): p. 571-579. 
161. Perkins, B.A., Abstract #0097 Advanced glycation end products and other markers 
of protein damage in early diabetic nephropathy in type 1 diabetes, in International 
Diabetes Federation, World Diabetes Congress. 2013, International Diabetes 
Federation: Melbourne. 
162. Goldin, A., et al., Advanced Glycation End Products: Sparking the Development of 
Diabetic Vascular Injury. Circulation, 2006. 114(6): p. 597-605. 
163. Bucciarelli, L.G., et al., RAGE is a multiligand receptor of the immunoglobulin 
superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci, 
2002. 59(7): p. 1117-28. 
164. Brett, J., et al., Survey of the distribution of a newly characterized receptor for 
advanced glycation end products in tissues. Am J Pathol, 1993. 143(6): p. 1699-712. 
165. Schmidt, A.M., et al., Isolation and characterization of two binding proteins for 
advanced glycosylation end products from bovine lung which are present on the 
endothelial cell surface. J Biol Chem, 1992. 267(21): p. 14987-97. 
166. Schmidt, A.M., et al., Advanced glycation endproducts interacting with their 
endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-
1) in cultured human endothelial cells and in mice. A potential mechanism for the 
accelerated vasculopathy of diabetes. J Clin Invest, 1995. 96(3): p. 1395-403. 
216 
 
167. Basta, G., et al., Advanced glycation end products activate endothelium through 
signal-transduction receptor RAGE a mechanism for amplification of inflammatory 
responses. Circulation, 2002. 105(7): p. 816-822. 
168. Li, J.H., et al., Advanced glycation end products induce tubular epithelial-
myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. 
The American journal of pathology, 2004. 164(4): p. 1389-1397. 
169. Yan, S.D., et al., Enhanced cellular oxidant stress by the interaction of advanced 
glycation end products with their receptors/binding proteins. Journal of Biological 
Chemistry, 1994. 269(13): p. 9889-9897. 
170. Kislinger, T., et al., N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands 
for receptor for advanced glycation end products that activate cell signaling pathways 
and modulate gene expression. J Biol Chem, 1999. 274(44): p. 31740-9. 
171. Boulanger, E., et al., Mesothelial RAGE activation by AGEs enhances VEGF release 
and potentiates capillary tube formation. Kidney Int, 2007. 71(2): p. 126-33. 
172. Somoza, V., et al., Dietary bread crust advanced glycation end products bind to the 
receptor for AGEs in HEK-293 kidney cells but are rapidly excreted after oral 
administration to healthy and subtotally nephrectomized rats. Ann N Y Acad Sci, 
2005. 1043: p. 492-500. 
173. Neeper, M., et al., Cloning and expression of a cell surface receptor for advanced 
glycosylation end products of proteins. J Biol Chem, 1992. 267(21): p. 14998-5004. 
174. Sugaya, K., et al., Three genes in the human MHC class III region near the junction 
with the class II: gene for receptor of advanced glycosylation end products, PBX2 
homeobox gene and a notch homolog, human counterpart of mouse mammary tumor 
gene int-3. Genomics, 1994. 23(2): p. 408-19. 
175. Kalea, A.Z., et al., Alternative splicing of the murine receptor for advanced glycation 
end-products (RAGE) gene. Faseb j, 2009. 23(6): p. 1766-74. 
176. Bierhaus, A., et al., Understanding RAGE, the receptor for advanced glycation end 
products. Journal of Molecular Medicine, 2005. 83(11): p. 876-886. 
177. Mahajan, N. and V. Dhawan, Receptor for advanced glycation end products (RAGE) 
in vascular and inflammatory diseases. International journal of cardiology, 2013. 
168(3): p. 1788-1794. 
178. Hudson, B.I., et al., Identification, classification, and expression of RAGE gene splice 
variants. The FASEB Journal, 2008. 22(5): p. 1572-1580. 
179. Schmidt, A.M., et al., The biology of the receptor for advanced glycation end products 
and its ligands. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 2000. 
1498(2): p. 99-111. 
180. Hofmann, M.A., et al., RAGE mediates a novel proinflammatory axis: a central cell 
surface receptor for S100/calgranulin polypeptides. Cell, 1999. 97(7): p. 889-901. 
217 
 
181. Hori, O., et al., The receptor for advanced glycation end products (RAGE) is a cellular 
binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage 
and amphoterin in the developing nervous system. J Biol Chem, 1995. 270(43): p. 
25752-61. 
182. Park, H., F.G. Adsit, and J.C. Boyington, The 1.5 A crystal structure of human 
receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique 
features determining ligand binding. J Biol Chem, 2010. 285(52): p. 40762-70. 
183. Yan, S.D., et al., RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's 
disease. Nature, 1996. 382(6593): p. 685-91. 
184. Sousa, M.M., et al., Interaction of the receptor for advanced glycation end products 
(RAGE) with transthyretin triggers nuclear transcription factor kB (NF-kB) activation. 
Lab Invest, 2000. 80(7): p. 1101-10. 
185. Chavakis, T., et al., The pattern recognition receptor (RAGE) is a counterreceptor for 
leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med, 
2003. 198(10): p. 1507-15. 
186. Ma, W., et al., RAGE binds C1q and enhances C1q-mediated phagocytosis. Cellular 
Immunology, 2012. 274(1): p. 72-82. 
187. Xue, J., et al., Advanced Glycation End Product Recognition by the Receptor for 
AGEs. Structure, 2011. 19(5): p. 722-732. 
188. Xie, J., et al., Structural basis for pattern recognition by the receptor for advanced 
glycation end products (RAGE). J Biol Chem, 2008. 283(40): p. 27255-69. 
189. Thornalley, P.J., Cell activation by glycated proteins. AGE receptors, receptor 
recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-
grand), 1998. 44(7): p. 1013-23. 
190. Xie, J., et al., Hexameric calgranulin C (S100A12) binds to the receptor for advanced 
glycated end products (RAGE) using symmetric hydrophobic target-binding patches. 
J Biol Chem, 2007. 282(6): p. 4218-31. 
191. Zong, H., et al., Homodimerization is essential for the receptor for advanced glycation 
end products (RAGE)-mediated signal transduction. J Biol Chem, 2010. 285(30): p. 
23137-46. 
192. Fritz, G., RAGE: a single receptor fits multiple ligands. Trends in Biochemical 
Sciences, 2011. 36(12): p. 625-632. 
193. Penfold, S.A., et al., Circulating high-molecular-weight RAGE ligands activate 
pathways implicated in the development of diabetic nephropathy. Kidney Int, 2010. 
78(3): p. 287-95. 
194. Taguchi, A., et al., Blockade of RAGE-amphoterin signalling suppresses tumour 
growth and metastases. Nature, 2000. 405(6784): p. 354-360. 
218 
 
195. Lander, H.M., et al., Activation of the receptor for advanced glycation end products 
triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated 
by oxidant stress. J Biol Chem, 1997. 272(28): p. 17810-4. 
196. Yeh, C.-H., et al., Requirement for p38 and p44/p42 Mitogen-Activated Protein 
Kinases in RAGE-Mediated Nuclear Factor-κB Transcriptional Activation and 
Cytokine Secretion. Diabetes, 2001. 50(6): p. 1495-1504. 
197. Grimm, S., et al., Advanced-glycation-end-product-induced formation of 
immunoproteasomes: involvement of RAGE and Jak2/STAT1. Biochem J, 2012. 
448(1): p. 127-39. 
198. Huang, J.S., et al., Role of receptor for advanced glycation end-product (RAGE) and 
the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F 
cells. J Cell Biochem, 2001. 81(1): p. 102-13. 
199. Huttunen, H.J., C. Fages, and H. Rauvala, Receptor for Advanced Glycation End 
Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the 
Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways. 
Journal of Biological Chemistry, 1999. 274(28): p. 19919-19924. 
200. Sorci, G., et al., Amphoterin stimulates myogenesis and counteracts the 
antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. Mol 
Cell Biol, 2004. 24(11): p. 4880-94. 
201. Hudson, B.I., et al., Interaction of the RAGE cytoplasmic domain with diaphanous-1 
is required for ligand-stimulated cellular migration through activation of Rac1 and 
Cdc42. J Biol Chem, 2008. 283(49): p. 34457-68. 
202. Yang, C.W., et al., Advanced glycation end products up-regulate gene expression 
found in diabetic glomerular disease. Proceedings of the National Academy of 
Sciences, 1994. 91(20): p. 9436-9440. 
203. Zeng, S., et al., Receptor for advanced glycation end product (RAGE)-dependent 
modulation of early growth response-1 in hepatic ischemia/reperfusion injury. Journal 
of hepatology, 2009. 50(5): p. 929-936. 
204. Xie, J., et al., Cellular signalling of the receptor for advanced glycation end products 
(RAGE). Cell Signal, 2013. 25(11): p. 2185-97. 
205. Lue, L.F., et al., Involvement of microglial receptor for advanced glycation 
endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation 
mechanism. Exp Neurol, 2001. 171(1): p. 29-45. 
206. Sasaki, N., et al., Immunohistochemical distribution of the receptor for advanced 
glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res, 
2001. 888(2): p. 256-262. 
207. Pullerits, R., et al., Decreased levels of soluble receptor for advanced glycation end 
products in patients with rheumatoid arthritis indicating deficient inflammatory control. 
Arthritis Res Ther, 2005. 7(4): p. R817-24. 
219 
 
208. Coughlan, M.T., et al., RAGE-induced cytosolic ROS promote mitochondrial 
superoxide generation in diabetes. Journal of the American Society of Nephrology, 
2009. 20(4): p. 742-752. 
209. Myint, K.-M., et al., RAGE control of diabetic nephropathy in a mouse model: effects 
of RAGE gene disruption and administration of low-molecular weight heparin. 
Diabetes, 2006. 55(9): p. 2510-2522. 
210. Sourris, K.C., et al., Receptor for AGEs (RAGE) blockade may exert its renoprotective 
effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 
(AT2) receptor. Diabetologia, 2010. 53(11): p. 2442-2451. 
211. Cai, W., et al., Oral glycotoxins determine the effects of calorie restriction on oxidant 
stress, age-related diseases, and lifespan. Am J Pathol, 2008. 173(2): p. 327-36. 
212. Buchs, A.E., et al., Increased expression of tissue factor and receptor for advanced 
glycation end products in peripheral blood mononuclear cells of patients with type 2 
diabetes mellitus with vascular complications. Exp Diabesity Res, 2004. 5(2): p. 163-
9. 
213. Wendt, T.M., et al., RAGE drives the development of glomerulosclerosis and 
implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J 
Pathol, 2003. 162(4): p. 1123-37. 
214. Soulis, T., et al., Advanced glycation end products and their receptors co-localise in 
rat organs susceptible to diabetic microvascular injury. Diabetologia, 1997. 40(6): p. 
619-28. 
215. Tanji, N., et al., Expression of Advanced Glycation End Products and Their Cellular 
Receptor RAGE in Diabetic Nephropathy and Nondiabetic Renal Disease. Journal of 
the American Society of Nephrology, 2000. 11(9): p. 1656-1666. 
216. Geroldi, D., et al., High levels of soluble receptor for advanced glycation end products 
may be a marker of extreme longevity in humans. J Am Geriatr Soc, 2006. 54(7): p. 
1149-50. 
217. Koyama, H., et al., Plasma level of endogenous secretory RAGE is associated with 
components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb 
Vasc Biol, 2005. 25(12): p. 2587-93. 
218. Forbes, J.M., et al., Receptor for advanced glycation end-products (RAGE) provides 
a link between genetic susceptibility and environmental factors in type 1 diabetes. 
Diabetologia, 2011. 54(5): p. 1032-42. 
219. Kalea, A.Z., A.M. Schmidt, and B.I. Hudson, RAGE: a novel biological and genetic 
marker for vascular disease. Clin Sci (Lond), 2009. 116(8): p. 621-37. 
220. Yonekura, H., et al., Novel splice variants of the receptor for advanced glycation end-
products expressed in human vascular endothelial cells and pericytes, and their 
putative roles in diabetes-induced vascular injury. Biochem J, 2003. 370(Pt 3): p. 
1097-109. 
220 
 
221. Park, L., et al., Suppression of accelerated diabetic atherosclerosis by the soluble 
receptor for advanced glycation endproducts. Nat Med, 1998. 4(9): p. 1025-1031. 
222. Bierhaus, A., et al., Loss of pain perception in diabetes is dependent on a receptor of 
the immunoglobulin superfamily. J Clin Invest, 2004. 114(12): p. 1741-51. 
223. Kislinger, T., et al., Receptor for advanced glycation end products mediates 
inflammation and enhanced expression of tissue factor in vasculature of diabetic 
apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol, 2001. 21(6): p. 905-10. 
224. Deane, R., et al., RAGE mediates amyloid-β peptide transport across the blood-brain 
barrier and accumulation in brain. Nature medicine, 2003. 9(7): p. 907-913. 
225. Lisanti, M.P., et al., Characterization of caveolin-rich membrane domains isolated 
from an endothelial-rich source: implications for human disease. J Cell Biol, 1994. 
126(1): p. 111-26. 
226. Stitt, A.W., et al., Advanced glycation end-product receptor interactions on 
microvascular cells occur within caveolin-rich membrane domains. Faseb j, 2000. 
14(15): p. 2390-2. 
227. Leslie, R.D.G., et al., Level of an Advanced Glycated End Product Is Genetically 
Determined: A Study of Normal Twins. Diabetes, 2003. 52(9): p. 2441-2444. 
228. Uribarri, J. and K.R. Tuttle, Advanced glycation end products and nephrotoxicity of 
high-protein diets. Clinical Journal of the American Society of Nephrology, 2006. 1(6): 
p. 1293-1299. 
229. Lorenzi, M., The polyol pathway as a mechanism for diabetic retinopathy: attractive, 
elusive, and resilient. Journal of Diabetes Research, 2007. 2007. 
230. Thornalley, P.J., Pharmacology of methylglyoxal: formation, modification of proteins 
and nucleic acids, and enzymatic detoxification--a role in pathogenesis and 
antiproliferative chemotherapy. Gen Pharmacol, 1996. 27(4): p. 565-73. 
231. Thornalley, P., A. Langborg, and H. Minhas, Formation of glyoxal, methylglyoxal and 
3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J, 1999. 344: p. 
109-116. 
232. Gugliucci, A. and T. Menini, Circulating advanced glycation peptides in 
streptozotocin-induced diabetic rats: evidence for preferential modification of IgG light 
chains. Life Sci, 1998. 62(23): p. 2141-50. 
233. Miyata, T., et al., Implication of an increased oxidative stress in the formation of 
advanced glycation end products in patients with end-stage renal failure. Kidney Int, 
1997. 51(4): p. 1170-81. 
234. Ott, C., et al., Role of advanced glycation end products in cellular signaling. Redox 
Biology, 2014. 2(0): p. 411-429. 
235. Ling, X., et al., Immunohistochemical distribution and subcellular localization of three 
distinct specific molecular structures of advanced glycation end products in human 
tissues. Lab Invest, 1998. 78(12): p. 1591-606. 
221 
 
236. Wagner, Z., et al., N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 
diabetes: role of renal function. Am J Kidney Dis, 2001. 38(4): p. 785-91. 
237. Makita, Z., et al., Reactive glycosylation endproducts in diabetic uraemia and 
treatment of renal failure. Lancet, 1994. 343(8912): p. 1519-22. 
238. Thomas, M.C., et al., Low-molecular-weight AGEs are associated with GFR and 
anemia in patients with type 2 diabetes. Kidney Int, 2004. 66(3): p. 1167-1172. 
239. O'brien, J. and P.A. Morrissey, Nutritional and toxicological aspects of the Maillard 
browning reaction in foods. Critical reviews in food science and nutrition, 1989. 28(3): 
p. 211-248. 
240. Goldberg, T., et al., Advanced glycoxidation end products in commonly consumed 
foods. J Am Diet Assoc, 2004. 104(8): p. 1287-91. 
241. Uribarri, J., et al., Advanced Glycation End Products in Foods and a Practical Guide 
to Their Reduction in the Diet. Journal of the American Dietetic Association, 2010. 
110(6): p. 911-916.e12. 
242. Mark, A.B., et al., Consumption of a Diet Low in Advanced Glycation End Products 
for 4 Weeks Improves Insulin Sensitivity in Overweight Women. Diabetes Care, 2014. 
37(1): p. 88-95. 
243. Scheijen, J.L.J.M., et al., Analysis of advanced glycation endproducts in selected food 
items by ultra-performance liquid chromatography tandem mass spectrometry: 
Presentation of a dietary AGE database. Food Chemistry, 2016. 190: p. 1145-1150. 
244. Finot, P.-A., The Absorption and Metabolism of Modified Amino Acids in Processed 
Foods. Journal of AOAC International, 2005. 88(3): p. 894-903. 
245. Seiquer, I., et al., Diets rich in Maillard reaction products affect protein digestibility in 
adolescent males aged 11-14 y. Am J Clin Nutr, 2006. 83(5): p. 1082-8. 
246. Hellwig, M., et al., N-ε-fructosyllysine and N-ε-carboxymethyllysine, but not 
lysinoalanine, are available for absorption after simulated gastrointestinal digestion. 
Amino Acids, 2014. 46(2): p. 289-299. 
247. Alamir, I., et al., Digestibility of extruded proteins and metabolic transit of N epsilon -
carboxymethyllysine in rats. Amino Acids, 2013. 44(6): p. 1441-9. 
248. Henle, T., AGEs in foods: do they play a role in uremia? Kidney Int Suppl, 2003(84): 
p. S145-7. 
249. He, C., et al., Dietary glycotoxins: inhibition of reactive products by aminoguanidine 
facilitates renal clearance and reduces tissue sequestration. Diabetes, 1999. 48(6): 
p. 1308-1315. 
250. Koschinsky, T., et al., Orally absorbed reactive glycation products (glycotoxins): an 
environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A, 1997. 
94(12): p. 6474-9. 
222 
 
251. Delgado-Andrade, C., et al., Study of the urinary and faecal excretion of Nepsilon-
carboxymethyllysine in young human volunteers. Amino Acids, 2012. 43(2): p. 595-
602. 
252. Sebekova, K., et al., Plasma concentration and urinary excretion of N epsilon-
(carboxymethyl)lysine in breast milk- and formula-fed infants. Ann N Y Acad Sci, 
2008. 1126: p. 177-80. 
253. Faist, V. and H.F. Erbersdobler, Metabolic transit and in vivo effects of melanoidins 
and precursor compounds deriving from the Maillard reaction. Annals of nutrition & 
metabolism, 2000. 45(1): p. 1-12. 
254. Forster, A., Y. Kuhne, and T. Henle, Studies on absorption and elimination of dietary 
maillard reaction products. Ann N Y Acad Sci, 2005. 1043: p. 474-81. 
255. Hultsch, C., et al., Biodistribution and catabolism of 18F-labeled N-ε-fructoselysine 
as a model of Amadori products. Nuclear Medicine and Biology, 2006. 33(7): p. 865-
873. 
256. Schwenger, V., et al., An oral load of the early glycation compound lactuloselysine 
fails to accumulate in the serum of uraemic patients. Nephrology Dialysis 
Transplantation, 2006. 21(2): p. 383-388. 
257. Liardon, R., et al., Identification of N.epsilon.-carboxymethyllysine: a new Maillard 
reaction product in rat urine. Journal of Agricultural and Food Chemistry, 1987. 35(3): 
p. 427-431. 
258. Miyata, T., et al., Renal catabolism of advanced glycation end products: The fate of 
pentosidine. Kidney Int, 1998. 53(2): p. 416-422. 
259. Bergmann, R., et al., Radio fluorination and positron emission tomography (PET) as 
a new approach to study the in vivo distribution and elimination of the advanced 
glycation endproducts N epsilon-carboxymethyllysine (CML) and N epsilon-
carboxyethyllysine (CEL). Nahrung, 2001. 45(3): p. 182-8. 
260. Somoza, V., et al., Dose‐dependent utilisation of casein‐linked lysinoalanine, N 
(epsilon)‐fructoselysine and N (epsilon)‐carboxymethyllysine in rats. Molecular 
nutrition & food research, 2006. 50(9): p. 833-841. 
261. Roncero-Ramos, I., et al., Metabolic transit of N(epsilon)-carboxymethyl-lysine after 
consumption of AGEs from bread crust. Food Funct, 2013. 4(7): p. 1032-9. 
262. Xu, H., et al., Biodistribution and elimination study of fluorine-18 labeled Nepsilon-
carboxymethyl-lysine following intragastric and intravenous administration. PLoS 
One, 2013. 8(3): p. e57897. 
263. Tessier, F.J., et al., Quantitative assessment of organ distribution of dietary protein-
bound (13) C-labeled N(varepsilon) -carboxymethyllysine after a chronic oral 
exposure in mice. Mol Nutr Food Res, 2016. 60(11): p. 2446-2456. 
223 
 
264. Tsutsui, A., et al., In vivo imaging of advanced glycation end products (AGEs) of 
albumin: first observations of significantly reduced clearance and liver deposition 
properties in mice. Org Biomol Chem, 2016. 14(24): p. 5755-60. 
265. Vlassara, H., The AGE-receptor in the pathogenesis of diabetic complications. 
Diabetes/Metabolism Research and Reviews, 2001. 17(6): p. 436-443. 
266. Miyata, T., et al., Accumulation of albumin-linked and free-form pentosidine in the 
circulation of uremic patients with end-stage renal failure: renal implications in the 
pathophysiology of pentosidine. J Am Soc Nephrol, 1996. 7(8): p. 1198-206. 
267. Makita, Z., et al., Advanced glycosylation end products in patients with diabetic 
nephropathy. New England Journal of Medicine, 1991. 325(12): p. 836-842. 
268. Nagai, R., et al., The ligand activity of AGE-proteins to scavenger receptors is 
dependent on their rate of modification by AGEs. Biochimica et Biophysica Acta 
(BBA) - Molecular Basis of Disease, 2007. 1772(11–12): p. 1192-1198. 
269. Leung, C., et al., Dietary glycotoxins exacerbate progression of experimental fatty 
liver disease. J Hepatol, 2014. 60(4): p. 832-8. 
270. Zhuang, A., et al., Increased liver AGEs induce hepatic injury mediated through an 
OST48 pathway. Scientific Reports, 2017. 7(1): p. 12292. 
271. Forbes, J.M., et al., Role of Advanced Glycation End Products in Diabetic 
Nephropathy. Journal of the American Society of Nephrology, 2003. 14(suppl 3): p. 
S254-S258. 
272. Harcourt, B.E., et al., Targeted reduction of advanced glycation improves renal 
function in obesity. Kidney Int, 2011. 80(2): p. 190-198. 
273. Tan, A.L., J.M. Forbes, and M.E. Cooper, AGE, RAGE, and ROS in diabetic 
nephropathy. Semin Nephrol, 2007. 27(2): p. 130-43. 
274. Zheng, F., et al., Prevention of diabetic nephropathy in mice by a diet low in 
glycoxidation products. Diabetes/metabolism research and reviews, 2002. 18(3): p. 
224-237. 
275. Stinghen, A.E.M., et al., Uremic Toxicity of Advanced Glycation End Products in CKD. 
Journal of the American Society of Nephrology, 2015. 
276. Patel, R., et al., Effect of Dietary Advanced Glycation End Products on Mouse Liver. 
PLOS ONE, 2012. 7(4): p. e35143. 
277. Bai, P., et al., Glycation alters collagen fibril organization. Connect Tissue Res, 1992. 
28(1-2): p. 1-12. 
278. Hadley, J.C., K.M. Meek, and N.S. Malik, Glycation changes the charge distribution 
of type I collagen fibrils. Glycoconj J, 1998. 15(8): p. 835-40. 
279. Barlovic, D.P., A. Soro-Paavonen, and K.A. Jandeleit-Dahm, RAGE biology, 
atherosclerosis and diabetes. Clin Sci (Lond), 2011. 121(2): p. 43-55. 
224 
 
280. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. 
Nature, 2001. 414(6865): p. 813-820. 
281. Bengmark, S., Impact of nutrition on ageing and disease. Curr Opin Clin Nutr Metab 
Care, 2006. 9(1): p. 2-7. 
282. Riboulet-Chavey, A., et al., Methylglyoxal impairs the insulin signaling pathways 
independently of the formation of intracellular reactive oxygen species. Diabetes, 
2006. 55(5): p. 1289-1299. 
283. Hagiwara, S., et al., Effects of pyridoxamine (K-163) on glucose intolerance and 
obesity in high-fat diet C57BL/6J mice. Metabolism, 2009. 58(7): p. 934-945. 
284. Hofmann, S.M., et al., Improved insulin sensitivity is associated with restricted intake 
of dietary glycoxidation products in the db/db mouse. Diabetes, 2002. 51(7): p. 2082-
9. 
285. Sandu, O., et al., Insulin resistance and type 2 diabetes in high-fat-fed mice are linked 
to high glycotoxin intake. Diabetes, 2005. 54(8): p. 2314-9. 
286. Coughlan, M.T., et al., Advanced glycation end products are direct modulators of 
beta-cell function. Diabetes, 2011. 60(10): p. 2523-32. 
287. Forbes, J.M., et al., Glucose homeostasis can be differentially modulated by varying 
individual components of a western diet. J Nutr Biochem, 2013. 24(7): p. 1251-7. 
288. Vaaler, S., K.F. Hanssen, and O. Aagenaes, The effect of cooking upon the blood 
glucose response to ingested carrots and potatoes. Diabetes Care, 1984. 7(3): p. 
221-3. 
289. Rizkalla, S.W., et al., Effect of baking process on postprandial metabolic 
consequences: randomized trials in normal and type 2 diabetic subjects. Eur J Clin 
Nutr, 2007. 61(2): p. 175-83. 
290. Unoki, H., et al., Advanced glycation end products attenuate cellular insulin sensitivity 
by increasing the generation of intracellular reactive oxygen species in adipocytes. 
Diabetes Research and Clinical Practice, 2007. 76(2): p. 236-244. 
291. Miele, C., et al., Human Glycated Albumin Affects Glucose Metabolism in L6 Skeletal 
Muscle Cells by Impairing Insulin-induced Insulin Receptor Substrate (IRS) Signaling 
through a Protein Kinase Cα-mediated Mechanism. Journal of Biological Chemistry, 
2003. 278(48): p. 47376-47387. 
292. Cassese, A., et al., In skeletal muscle advanced glycation end products (AGEs) inhibit 
insulin action and induce the formation of multimolecular complexes including the 
receptor for AGEs. J Biol Chem, 2008. 283(52): p. 36088-99. 
293. Vlassara, H., et al., Advanced glycation end products induce glomerular sclerosis and 
albuminuria in normal rats. Proceedings of the National Academy of Sciences, 1994. 
91(24): p. 11704-11708. 
294. Cai, W., et al., Oral advanced glycation endproducts (AGEs) promote insulin 
resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and 
225 
 
sirtuin 1. Proceedings of the National Academy of Sciences, 2012. 109(39): p. 15888-
15893. 
295. Zhao, Z., et al., Advanced Glycation End Products Inhibit Glucose-Stimulated Insulin 
Secretion through Nitric Oxide-Dependent Inhibition of Cytochrome c Oxidase and 
Adenosine Triphosphate Synthesis. Endocrinology, 2009. 150(6): p. 2569-2576. 
296. Coughlan, M.T. and J.M. Forbes, Temporal increases in urinary carboxymethyllysine 
correlate with albuminuria development in diabetes. Am J Nephrol, 2011. 34(1): p. 9-
17. 
297. Sebekova, K., et al., Renal effects of oral maillard reaction product load in the form 
of bread crusts in healthy and subtotally nephrectomized rats. Ann N Y Acad Sci, 
2005. 1043: p. 482-91. 
298. Peppa, M., et al., Fetal or neonatal low-glycotoxin environment prevents autoimmune 
diabetes in NOD mice. Diabetes, 2003. 52(6): p. 1441-1448. 
299. Peppa, M., et al., Adverse effects of dietary glycotoxins on wound healing in 
genetically diabetic mice. Diabetes, 2003. 52(11): p. 2805-13. 
300. Uribarri, J., et al., Dietary glycotoxins correlate with circulating advanced glycation 
end product levels in renal failure patients. American Journal of Kidney Diseases, 
2003. 42(3): p. 532-538. 
301. Chao, P.C., et al., Association of dietary AGEs with circulating AGEs, glycated LDL, 
IL-1alpha and MCP-1 levels in type 2 diabetic patients. Eur J Nutr, 2010. 49(7): p. 
429-34. 
302. Uribarri, J., et al., Restriction of advanced glycation end products improves insulin 
resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes 
Care, 2011. 34(7): p. 1610-6. 
303. Vlassara, H., et al., Protection against loss of innate defenses in adulthood by low 
advanced glycation end products (AGE) intake: role of the antiinflammatory AGE 
receptor-1. J Clin Endocrinol Metab, 2009. 94(11): p. 4483-91. 
304. Birlouez-Aragon, I., et al., A diet based on high-heat-treated foods promotes risk 
factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr, 2010. 
91(5): p. 1220-6. 
305. De Courten, B., et al., Diet low in advanced glycation end products increases insulin 
sensitivity in healthy overweight individuals: a double-blind, randomized, crossover 
trial. Am J Clin Nutr, 2016. 103(6): p. 1426-33. 
306. Hou, F.F., et al., Enhanced expression of receptor for advanced glycation end 
products in chronic kidney disease. J Am Soc Nephrol, 2004. 15(7): p. 1889-96. 
307. Semba, R.D., et al., Serum Carboxymethyl-Lysine, a Dominant Advanced Glycation 
End Product, Is Associated With Chronic Kidney Disease: The Baltimore Longitudinal 
Study of Aging. Journal of Renal Nutrition, 2010. 20(2): p. 74-81. 
226 
 
308. Witko-Sarsat, V., et al., Advanced oxidation protein products as a novel marker of 
oxidative stress in uremia. Kidney Int, 1996. 49(5): p. 1304-13. 
309. Klein, R., et al., The Relationship of Serum Soluble Receptor for Advanced Glycation 
End Products (sRAGE) and Carboxymethyl Lysine (CML) to the Incidence of Diabetic 
Nephropathy in Persons With Type 1 Diabetes. Diabetes care, 2017. 40(9): p. e117-
e119. 
310. Dalal, M., et al., Endogenous secretory receptor for advanced glycation end products 
and chronic kidney disease in the elderly population. Am J Nephrol, 2011. 33(4): p. 
313-8. 
311. Rebholz, C.M., et al., Association of plasma levels of soluble receptor for advanced 
glycation end products and risk of kidney disease: the Atherosclerosis Risk in 
Communities study. Nephrol Dial Transplant, 2015. 30(1): p. 77-83. 
312. Thomas, M.C., et al., The Relationship Between Levels of Advanced Glycation End-
Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 
Diabetes. Diabetes Care, 2015. 
313. Mcintyre, N.J., et al., Skin Autofluorescence and the Association with Renal and 
Cardiovascular Risk Factors in Chronic Kidney Disease Stage 3. Clinical Journal of 
the American Society of Nephrology : CJASN, 2011. 6(10): p. 2356-2363. 
314. Tanaka, K., et al., Skin autofluorescence is associated with renal function and 
cardiovascular diseases in pre-dialysis chronic kidney disease patients. Nephrol Dial 
Transplant, 2011. 26(1): p. 214-20. 
315. Smit, A.J. and E.G. Gerrits, Skin autofluorescence as a measure of advanced 
glycation endproduct deposition: a novel risk marker in chronic kidney disease. Curr 
Opin Nephrol Hypertens, 2010. 19(6): p. 527-33. 
316. Tanaka, K., et al., Skin autofluorescence is associated with the progression of chronic 
kidney disease: a prospective observational study. PLoS One, 2013. 8(12): p. 
e83799. 
317. Meerwaldt, R., et al., Skin Autofluorescence, a Measure of Cumulative Metabolic 
Stress and Advanced Glycation End Products, Predicts Mortality in Hemodialysis 
Patients. Journal of the American Society of Nephrology, 2005. 16(12): p. 3687-3693. 
318. Orchard, T.J., et al., The Association of Skin Intrinsic Fluorescence With Type 1 
Diabetes Complications in the DCCT/EDIC Study. Diabetes Care, 2013. 36(10): p. 
3146-3153. 
319. Weiss, M.F., et al., Mechanisms for the formation of glycoxidation products in end-
stage renal disease. Kidney Int, 2000. 57(6): p. 2571-2585. 
320. Peppa, M., et al., Glycoxidation and inflammation in renal failure patients. American 
Journal of Kidney Diseases, 2004. 43(4): p. 690-695. 
227 
 
321. Coughlan, M.T., et al., Advanced Glycation Urinary Protein-Bound Biomarkers and 
Severity of Diabetic Nephropathy in Man. American Journal of Nephrology, 2011. 
34(4): p. 347-355. 
322. Bierhaus, A., et al., Diabetes-associated sustained activation of the transcription 
factor nuclear factor-kappaB. Diabetes, 2001. 50(12): p. 2792-808. 
323. Shimizu, F., et al., Advanced glycation end-products induce basement membrane 
hypertrophy in endoneurial microvessels and disrupt the blood–nerve barrier by 
stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by 
pericytes. Diabetologia, 2011. 54(6): p. 1517-1526. 
324. Li, J.H., et al., Advanced glycation end products activate Smad signaling via TGF-
beta-dependent and independent mechanisms: implications for diabetic renal and 
vascular disease. Faseb j, 2004. 18(1): p. 176-8. 
325. Cooper, M.E., Pathogenesis, prevention, and treatment of diabetic nephropathy. The 
Lancet, 1998. 352(9123): p. 213-219. 
326. Sourris, K.C., B.E. Harcourt, and J.M. Forbes, A new perspective on therapeutic 
inhibition of advanced glycation in diabetic microvascular complications: common 
downstream endpoints achieved through disparate therapeutic approaches? Am J 
Nephrol, 2009. 30(4): p. 323-35. 
327. Twigg, S.M., et al., Advanced glycosylation end products up-regulate connective 
tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in 
human fibroblasts: a potential mechanism for expansion of extracellular matrix in 
diabetes mellitus. Endocrinology, 2001. 142(5): p. 1760-9. 
328. Isoda, K., et al., Glycated LDL increases monocyte CC chemokine receptor 2 
expression and monocyte chemoattractant protein-1-mediated chemotaxis. 
Atherosclerosis, 2008. 198(2): p. 307-12. 
329. Rüster, C., et al., Advanced glycation end-products induce cell cycle arrest and 
hypertrophy in podocytes. Nephrology Dialysis Transplantation, 2008. 23(7): p. 2179-
2191. 
330. Chuang, P.Y., et al., Advanced glycation endproducts induce podocyte apoptosis by 
activation of the FOXO4 transcription factor. Kidney International, 2007. 72(8): p. 965-
976. 
331. Gugliucci, A. and M. Bendayan, Renal fate of circulating advanced glycated end 
products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal 
proximal tubular cells. Diabetologia, 1996. 39(2): p. 149-160. 
332. Oldfield, M.D., et al., Advanced glycation end products cause epithelial-myofibroblast 
transdifferentiation via the receptor for advanced glycation end products (RAGE). J 
Clin Invest, 2001. 108(12): p. 1853-63. 
333. Ozdemir, A.M., et al., Effects of Advanced Glycation End Product Modification on 
Proximal Tubule Epithelial Cell Processing of Albumin. American Journal of 
Nephrology, 2008. 28(1): p. 14-24. 
228 
 
334. Gallicchio, M.A. and L.A. Bach, Uptake of advanced glycation end products by 
proximal tubule epithelial cells via macropinocytosis. Biochimica et Biophysica Acta 
(BBA) - Molecular Cell Research, 2013. 1833(12): p. 2922-2932. 
335. Takahashi, A., et al., Autophagy Inhibits the Accumulation of Advanced Glycation 
End Products by Promoting Lysosomal Biogenesis and Function in the Kidney 
Proximal Tubules. Diabetes, 2017: p. db160397. 
336. Liu, W.J., et al., Autophagy-Lysosome Pathway in Renal Tubular Epithelial Cells Is 
Disrupted by Advanced Glycation End Products in Diabetic Nephropathy. Journal of 
Biological Chemistry, 2015. 290(33): p. 20499-20510. 
337. Ejtahed, H.-S., et al., Dietary Advanced Glycation End Products and Risk of Chronic 
Kidney Disease. Journal of Renal Nutrition, 2016. 26(5): p. 308-314. 
338. Clarke, R., et al., Dietary Advanced Glycation End Products and Risk Factors for 
Chronic Disease: A Systematic Review of Randomised Controlled Trials. Nutrients, 
2016. 8(3): p. 125. 
339. Uribarri, J., et al., Single oral challenge by advanced glycation end products acutely 
impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care, 
2007. 30(10): p. 2579-82. 
340. Vlassara, H., et al., Inflammatory mediators are induced by dietary glycotoxins, a 
major risk factor for diabetic angiopathy. Proceedings of the National Academy of 
Sciences, 2002. 99(24): p. 15596-15601. 
341. Semba, R.D., et al., Dietary intake of advanced glycation end products did not affect 
endothelial function and inflammation in healthy adults in a randomized controlled 
trial. J Nutr, 2014. 144(7): p. 1037-42. 
342. Baye, E., et al., Effect of dietary advanced glycation end products on inflammation 
and cardiovascular risks in healthy overweight adults: a randomised crossover trial. 
Sci Rep, 2017. 7(1): p. 4123. 
343. Thomas, M.C., et al., Interactions between Renin Angiotensin System and Advanced 
Glycation in the Kidney. Journal of the American Society of Nephrology, 2005. 16(10): 
p. 2976-2984. 
344. Sebekova, K., et al., Effects of a diet rich in advanced glycation end products in the 
rat remnant kidney model. Am J Kidney Dis, 2003. 41(3 Suppl 1): p. S48-51. 
345. De Assis, A.M., et al., Dietary n-3 polyunsaturated fatty acids revert renal responses 
induced by a combination of 2 protocols that increase the amounts of advanced 
glycation end product in rats. Nutr Res, 2015. 35(6): p. 512-22. 
346. Solon-Biet, S.M., et al., The ratio of macronutrients, not caloric intake, dictates 
cardiometabolic health, aging, and longevity in ad libitum-fed mice. Cell Metab, 2014. 
19(3): p. 418-30. 
229 
 
347. Thornalley, P.J., The enzymatic defence against glycation in health, disease and 
therapeutics: a symposium to examine the concept. Biochem Soc Trans, 2003. 31(Pt 
6): p. 1341-2. 
348. Brownlee, M., The pathobiology of diabetic complications a unifying mechanism. 
Diabetes, 2005. 54(6): p. 1615-1625. 
349. Basta, G., A.M. Schmidt, and R. De Caterina, Advanced glycation end products and 
vascular inflammation: implications for accelerated atherosclerosis in diabetes. 
Cardiovasc Res, 2004. 63(4): p. 582-92. 
350. Hyogo, H., et al., Elevated levels of serum advanced glycation end products in 
patients with non-alcoholic steatohepatitis. Journal of Gastroenterology and 
Hepatology, 2007. 22(7): p. 1112-1119. 
351. Santos, J., et al., Development of Nonalcoholic Hepatopathy: Contributions of 
Oxidative Stress and Advanced Glycation End Products. International Journal of 
Molecular Sciences, 2013. 14(10): p. 19846. 
352. Takeuchi, M. and S. Yamagishi, Possible involvement of advanced glycation end-
products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des, 2008. 
14(10): p. 973-8. 
353. Chou, S.M., et al., Advanced glycation endproducts in neurofilament conglomeration 
of motoneurons in familial and sporadic amyotrophic lateral sclerosis. Molecular 
Medicine, 1998. 4(5): p. 324-332. 
354. Kaufmann, E., et al., The advanced glycation end-product Nɛ-(carboxymethyl)lysine 
level is elevated in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. 
Neuroscience Letters, 2004. 371(2): p. 226-229. 
355. Guerrero, E., et al., Recent advances in alpha-synuclein functions, advanced 
glycation, and toxicity: implications for Parkinson's disease. Mol Neurobiol, 2013. 
47(2): p. 525-36. 
356. Vélayoudom-Céphise, F.-L., et al., Skin autofluorescence predicts cardio-renal 
outcome in type 1 diabetes: a longitudinal study. Cardiovascular diabetology, 2016. 
15(1): p. 127-127. 
357. Soulis-Liparota, T., et al., Retardation by Aminoguanidine of Development of 
Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-
Induced Diabetic Rat. Diabetes, 1991. 40(10): p. 1328-1334. 
358. Coughlan, M.T., J.M. Forbes, and M.E. Cooper, Role of the AGE crosslink breaker, 
alagebrium, as a renoprotective agent in diabetes. Kidney International, 2007. 72: p. 
S54-S60. 
359. Uribarri, J., et al., Diet-derived advanced glycation end products are major 
contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann 
N Y Acad Sci, 2005: p. 461-6. 
230 
 
360. Perrone, L. and W.B. Grant, Observational and ecological studies of dietary 
advanced glycation end products in national diets and Alzheimer's disease incidence 
and prevalence. J Alzheimers Dis, 2015. 45(3): p. 965-79. 
361. Lin, R.Y., et al., Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein 
E-deficient mice. Atherosclerosis, 2003. 168(2): p. 213-20. 
362. Negrean, M., et al., Effects of low- and high-advanced glycation endproduct meals 
on macro- and microvascular endothelial function and oxidative stress in patients with 
type 2 diabetes mellitus. Am J Clin Nutr, 2007. 85(5): p. 1236-43. 
363. Cai, W., et al., High levels of dietary advanced glycation end products transform low-
density lipoprotein into a potent redox-sensitive mitogen-activated protein kinase 
stimulant in diabetic patients. Circulation, 2004. 110(3): p. 285-91. 
364. Somoza, V., et al., Dose-dependent utilisation of casein-linked lysinoalanine, 
N(epsilon)-fructoselysine and N(epsilon)-carboxymethyllysine in rats. Mol Nutr Food 
Res, 2006. 50(9): p. 833-41. 
365. Grossin, N., et al., Dietary CML-enriched protein induces functional arterial aging in 
a RAGE-dependent manner in mice. Mol Nutr Food Res, 2015. 59(5): p. 927-38. 
366. Li, M., et al., Increased Accumulation of Protein-bound N-(carboxymethyl)lysine in 
Tissues of Healthy Rats after Chronic Oral N-(carboxymethyl)lysine. J Agric Food 
Chem, 2015. 
367. Roncero-Ramos, I., et al., An Advanced Glycation End Product (AGE)-Rich Diet 
Promotes Nε-Carboxymethyl-lysine Accumulation in the Cardiac Tissue and Tendons 
of Rats. Journal of Agricultural and Food Chemistry, 2014. 62(25): p. 6001-6006. 
368. Uribarri, J., et al., Restriction of dietary glycotoxins reduces excessive advanced 
glycation end products in renal failure patients. J Am Soc Nephrol, 2003. 14(3): p. 
728-31. 
369. Bergmann, R., et al., Radio fluorination and positron emission tomography (PET) as 
a new approach to study the in vivo distribution and elimination of the advanced 
glycation endproducts Nϵ‐carboxymethyllysine (CML) and Nϵ‐carboxyethyllysine 
(CEL). Food / Nahrung, 2001. 45(3): p. 182-188. 
370. Hanssen, N.M., et al., Plasma levels of advanced glycation endproducts Nepsilon-
(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine, and pentosidine are not 
independently associated with cardiovascular disease in individuals with or without 
type 2 diabetes: the Hoorn and CODAM studies. J Clin Endocrinol Metab, 2013. 
98(8): p. E1369-73. 
371. Sourris, K.C., et al., Modulation of the cellular expression of circulating advanced 
glycation end-product receptors in type 2 diabetic nephropathy. Exp Diabetes Res, 
2010. 2010: p. 974681. 
372. Veronika, S., et al., Dose‐dependent utilisation of casein‐linked lysinoalanine, 
N(epsilon)‐fructoselysine and N(epsilon)‐carboxymethyllysine in rats. Molecular 
Nutrition & Food Research, 2006. 50(9): p. 833-841. 
231 
 
373. Chruszcz, M., et al., Serum albumins-unusual allergens. Biochimica et biophysica 
acta, 2013. 1830(12): p. 5375-5381. 
374. Valle-Riestra, J. and R.H. Barnes, Digestion of Heat-damaged Egg Albumen by the 
Rat. The Journal of Nutrition, 1970. 100(8): p. 873-882. 
375. Hull, G.L.J., et al., Nε-(carboxymethyl)lysine content of foods commonly consumed 
in a Western style diet. Food Chemistry, 2012. 131(1): p. 170-174. 
376. Foerster, A. and T. Henle, Glycation in food and metabolic transit of dietary AGEs 
(advanced glycation end-products): studies on the urinary excretion of pyrraline. 
Biochem Soc Trans, 2003. 31(Pt 6): p. 1383-5. 
377. Degen, J., et al., Metabolic Transit of Dietary Methylglyoxal. Journal of Agricultural 
and Food Chemistry, 2013. 61(43): p. 10253-10260. 
378. Meerwaldt, R., et al., Simple non-invasive assessment of advanced glycation 
endproduct accumulation. Diabetologia, 2004. 47(7): p. 1324-1330. 
379. Kellow, N.J., M.T. Coughlan, and C.M. Reid, Association between habitual dietary 
and lifestyle behaviours and skin autofluorescence (SAF), a marker of tissue 
accumulation of advanced glycation endproducts (AGEs), in healthy adults. 
European Journal of Nutrition, 2018. 57(6): p. 2209-2216. 
380. Nongnuch, A. and A. Davenport, The effect of vegetarian diet on skin 
autofluorescence measurements in haemodialysis patients. British Journal of 
Nutrition, 2015. 113(7): p. 1040-1043. 
381. Forbes, J., et al., Advanced glycation end products (AGEs) are cross-sectionally 
associated with insulin secretion in healthy subjects. Amino Acids, 2014. 46(2): p. 
321-326. 
382. Marshall, M.V., et al., Single-Dose Intravenous Toxicity Study of IRDye 800CW in 
Sprague-Dawley Rats. Molecular Imaging and Biology, 2010. 12(6): p. 583-594. 
383. Karachalias, N., et al., Increased protein damage in renal glomeruli, retina, nerve, 
plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat 
model of diabetes. Diabetologia, 2010. 53(7): p. 1506-1516. 
384. Schleicher, E.D., E. Wagner, and A.G. Nerlich, Increased accumulation of the 
glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes 
and aging. The Journal of Clinical Investigation, 1997. 99(3): p. 457-468. 
385. Peppa, M., et al., Glycoxidation and inflammation in renal failure patients. Am J 
Kidney Dis, 2004. 43(4): p. 690-5. 
386. Yubero-Serrano, E.M., et al., Effects of Sevelamer Carbonate on Advanced Glycation 
End Products and Antioxidant/Pro-Oxidant Status in Patients with Diabetic Kidney 
Disease. Clinical Journal of the American Society of Nephrology, 2015. 10(5): p. 759-
766. 
387. Tang, S.C., et al., Differential effects of advanced glycation end-products on renal 
tubular cell inflammation. Nephrology (Carlton), 2011. 16(4): p. 417-25. 
232 
 
388. Abdel-Misih, S.R.Z. and M. Bloomston, Liver Anatomy. The Surgical clinics of North 
America, 2010. 90(4): p. 643-653. 
389. Hansen, B., et al., Advanced glycation end products impair the scavenger function of 
rat hepatic sinusoidal endothelial cells. Diabetologia, 2002. 45(10): p. 1379-1388. 
390. Ciccocioppo, R., et al., Role of the advanced glycation end products receptor in 
Crohn’s disease inflammation. World Journal of Gastroenterology : WJG, 2013. 
19(45): p. 8269-8281. 
391. Yu, T., et al., Advanced glycation end products interfere with gastric smooth muscle 
contractile marker expression via the AGE/RAGE/NF-kappaB pathway. Exp Mol 
Pathol, 2017. 102(1): p. 7-14. 
392. Ames, J.M., et al., The effect of a model melanoidin mixture on faecal bacterial 
populations in vitro. British Journal of Nutrition, 2007. 82(6): p. 489-495. 
393. Mills, D.J.S., et al., Dietary glycated protein modulates the colonic microbiota towards 
a more detrimental composition in ulcerative colitis patients and non‐ulcerative colitis 
subjects. Journal of Applied Microbiology, 2008. 105(3): p. 706-714. 
394. Gardner, M.L., Gastrointestinal absorption of intact proteins. Annu Rev Nutr, 1988. 8: 
p. 329-50. 
395. Grunwald, S., et al., Transepithelial flux of early and advanced glycation compounds 
across Caco-2 cell monolayers and their interaction with intestinal amino acid and 
peptide transport systems. British Journal of Nutrition, 2006. 95(06): p. 1221-1228. 
396. Hellwig, M., et al., Transport of Free and Peptide-Bound Glycated Amino Acids: 
Synthesis, Transepithelial Flux at Caco-2 Cell Monolayers, and Interaction with Apical 
Membrane Transport Proteins. ChemBioChem, 2011. 12(8): p. 1270-1279. 
397. Serra, A., et al., Commercial processed soy-based food product contains glycated 
and glycoxidated lunasin proteoforms. Scientific Reports, 2016. 6: p. 26106. 
398. Takeuchi, M., et al., Assessment of the Concentrations of Various Advanced 
Glycation End-Products in Beverages and Foods That Are Commonly Consumed in 
Japan. PLOS ONE, 2015. 10(3): p. e0118652. 
399. Soboleva, A., et al., Probing Protein Glycation by Chromatography and Mass 
Spectrometry: Analysis of Glycation Adducts. Int J Mol Sci, 2017. 18(12). 
400. Gugliucci, A., Formation of Fructose-Mediated Advanced Glycation End Products 
and Their Roles in Metabolic and Inflammatory Diseases. Advances in Nutrition: An 
International Review Journal, 2017. 8(1): p. 54-62. 
401. Tolo, K., Penetration of human albumin through the oral mucosa of guinea-pigs 
immunized to this protein. Archives of Oral Biology, 1974. 19(3): p. 259-263. 
402. Tolo, K., P. Brandtzaeg, and J. Jonsen, Mucosal penetration of antigen in the 
presence or absence of serum-derived antibody: An in vitro study of rabbit oral and 
intestinal mucosa. Immunology, 1977. 33(5): p. 733-743. 
233 
 
403. Juul, F. and E. Hemmingsson, Trends in consumption of ultra-processed foods and 
obesity in Sweden between 1960 and 2010. Public Health Nutr, 2015. 18(17): p. 
3096-107. 
404. Fiolet, T., et al., Consumption of ultra-processed foods and cancer risk: results from 
NutriNet-Santé prospective cohort. BMJ, 2018. 360. 
405. Monteiro, C.A., et al., Ultra-processed products are becoming dominant in the global 
food system. Obes Rev, 2013. 14 Suppl 2: p. 21-8. 
406. Esmaillzadeh, A., et al., Dietary patterns, insulin resistance, and prevalence of the 
metabolic syndrome in women. Am J Clin Nutr, 2007. 85(3): p. 910-8. 
407. Sharma, C., et al., Advanced glycation End-products (AGEs): an emerging concern 
for processed food industries. Journal of Food Science and Technology, 2015. 
52(12): p. 7561-7576. 
408. Puddu, A., et al., Advanced Glycation End-Products affect transcription factors 
regulating insulin gene expression. Biochemical and Biophysical Research 
Communications, 2010. 395(1): p. 122-125. 
409. Borg, D.J., et al., Perinatal exposure to high dietary advanced glycation end products 
in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction. Islets, 2018. 
10(1): p. 10-24. 
410. Baye, E., et al., Consumption of diets with low advanced glycation end products 
improves cardiometabolic parameters: meta-analysis of randomised controlled trials. 
Scientific Reports, 2017. 7: p. 2266. 
411. Poulsen, M.W., et al., Effect of dietary advanced glycation end products on 
postprandial appetite, inflammation, and endothelial activation in healthy overweight 
individuals. Eur J Nutr, 2014. 53(2): p. 661-72. 
412. Stirban, A., et al., Leptin decreases postprandially in people with type 2 diabetes, an 
effect reduced by the cooking method. Horm Metab Res, 2008. 40(12): p. 896-900. 
413. Li, M., et al., Effects of Long-Term Exposure to Free Nε-(Carboxymethyl)lysine on 
Rats Fed a High-Fat Diet. Journal of Agricultural and Food Chemistry, 2015. 63(51): 
p. 10995-11001. 
414. Bachmanov, A.A., et al., Food Intake, Water Intake, and Drinking Spout Side 
Preference of 28 Mouse Strains. Behavior genetics, 2002. 32(6): p. 435-443. 
415. Parvaresh Rizi, E., et al., A high carbohydrate, but not fat or protein meal attenuates 
postprandial ghrelin, PYY and GLP-1 responses in Chinese men. PLOS ONE, 2018. 
13(1): p. e0191609. 
416. Zoccali, C., et al., Phosphate may promote CKD progression and attenuate 
renoprotective effect of ACE inhibition. J Am Soc Nephrol, 2011. 22. 
417. You, J., et al., Advanced Glycation End Products Impair Glucose-Stimulated Insulin 
Secretion of a Pancreatic β-Cell Line INS-1-3 by Disturbance of Microtubule 
234 
 
Cytoskeleton via p38/MAPK Activation. Journal of Diabetes Research, 2016. 2016: 
p. 9073037. 
418. Vlassara, H., et al., Oral AGE restriction ameliorates insulin resistance in obese 
individuals with the metabolic syndrome: a randomised controlled trial. Diabetologia, 
2016. 59(10): p. 2181-2192. 
419. Kuroshima, A., et al., Brown Adipose Tissue and Nonshivering Thermogenesis in 
Stressful States, in Thermotherapy for Neoplasia, Inflammation, and Pain, M. 
Kosaka, et al., Editors. 2001, Springer Japan: Tokyo. p. 118-126. 
420. Balcombe, J.P., N.D. Barnard, and C. Sandusky, Laboratory routines cause animal 
stress. Contemp Top Lab Anim Sci, 2004. 43(6): p. 42-51. 
421. De Vegt, F., et al., Hyperglycaemia is associated with all-cause and cardiovascular 
mortality in the Hoorn population: the Hoorn Study. Diabetologia, 1999. 42(8): p. 926-
31. 
422. Chang, C.M., et al., Acute and chronic fluctuations in blood glucose levels can 
increase oxidative stress in type 2 diabetes mellitus. Acta Diabetol, 2012. 49 Suppl 
1: p. S171-7. 
423. Su, G., et al., Association of glycemic variability and the presence and severity of 
coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol, 2011. 
10: p. 19. 
424. Penno, G., et al., HbA1c variability as an independent correlate of nephropathy, but 
not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And 
Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care, 2013. 36(8): 
p. 2301-10. 
425. Hsu, C.C., et al., HbA1c variability is associated with microalbuminuria development 
in type 2 diabetes: a 7-year prospective cohort study. Diabetologia, 2012. 55(12): p. 
3163-72. 
426. Sugawara, A., et al., HbA(1c) variability and the development of microalbuminuria in 
type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia, 2012. 55(8): p. 
2128-31. 
427. Deo, P., et al., Effects of Weight Loss on Advanced Glycation End Products in 
Subjects with and without Diabetes: A Preliminary Report. International Journal of 
Environmental Research and Public Health, 2017. 14(12): p. 1553. 
428. Kilhovd, B.K., et al., Increased serum levels of advanced glycation endproducts 
predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a 
population-based 18 year follow-up study. Diabetologia, 2007. 50(7): p. 1409-1417. 
429. Hanssen, N.M.J., et al., Plasma Advanced Glycation End Products Are Associated 
With Incident Cardiovascular Events in Individuals With Type 2 Diabetes: A Case-
Cohort Study With a Median Follow-up of 10 Years (EPIC-NL). Diabetes, 2015. 64(1): 
p. 257-265. 
235 
 
430. Tessier, F.J. and I. Birlouez-Aragon, Health effects of dietary Maillard reaction 
products: the results of ICARE and other studies. Amino Acids, 2012. 42(4): p. 1119-
31. 
431. Nin, J.W., et al., Higher Plasma Levels of Advanced Glycation End Products Are 
Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 
Diabetes: A 12-year follow-up study. Diabetes Care, 2011. 34(2): p. 442-447. 
432. Xie, J., et al., Cellular signalling of the receptor for advanced glycation end products 
(RAGE). Cellular Signalling, 2013. 25(11): p. 2185-2197. 
433. Malherbe, P., et al., cDNA cloning of a novel secreted isoform of the human receptor 
for advanced glycation end products and characterization of cells co-expressing cell-
surface scavenger receptors and Swedish mutant amyloid precursor protein. 
Molecular Brain Research, 1999. 71(2): p. 159-170. 
434. Yonekura, H., et al., Novel splice variants of the receptor for advanced glycation end-
products expressed in human vascular endothelial cells and pericytes, and their 
putative roles in diabetes-induced vascular injury. Biochemical Journal, 2003. 370(3): 
p. 1097-1109. 
435. Schlueter, C., et al., Tissue-specific expression patterns of the RAGE receptor and 
its soluble forms—a result of regulated alternative splicing? Biochimica et Biophysica 
Acta (BBA) - Gene Structure and Expression, 2003. 1630(1): p. 1-6. 
436. Nin, J.W., et al., Higher plasma soluble Receptor for Advanced Glycation End 
Products (sRAGE) levels are associated with incident cardiovascular disease and all-
cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes, 2010. 59(8): 
p. 2027-32. 
437. Colhoun, H.M., et al., Total soluble and endogenous secretory receptor for advanced 
glycation end products as predictive biomarkers of coronary heart disease risk in 
patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes, 2011. 
60(9): p. 2379-85. 
438. Fujisawa, K., et al., Circulating soluble RAGE as a predictive biomarker of 
cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis, 2013. 
227(2): p. 425-8. 
439. Kalousová, M., et al., Soluble Receptor for Advanced Glycation End Products in 
Patients With Decreased Renal Function. American Journal of Kidney Diseases, 
2006. 47(3): p. 406-411. 
440. Gohda, T., et al., Increased serum endogenous secretory receptor for advanced 
glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased 
renal function. Diabetes Res Clin Pract, 2008. 81(2): p. 196-201. 
441. Kajikawa, M., et al., Ratio of Serum Levels of AGEs to Soluble Form of RAGE Is a 
Predictor of Endothelial Function. Diabetes Care, 2015. 38(1): p. 119-125. 
236 
 
442. Singh, V.P., et al., Advanced Glycation End Products and Diabetic Complications. 
The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean 
Physiological Society and the Korean Society of Pharmacology, 2014. 18(1): p. 1-14. 
443. Bunn, H., K. Gabbay, and P. Gallop, The glycosylation of hemoglobin: relevance to 
diabetes mellitus. Science, 1978. 200(4337): p. 21-27. 
444. Roohk, H.V. and A.R. Zaidi, A Review of Glycated Albumin as an Intermediate 
Glycation Index for Controlling Diabetes. Journal of Diabetes Science and 
Technology, 2008. 2(6): p. 1114-1121. 
445. Schiekofer, S., et al., Acute hyperglycemia causes intracellular formation of CML and 
activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes, 
2003. 52(3): p. 621-33. 
446. Maessen, D.E., et al., Post-Glucose Load Plasma alpha-Dicarbonyl Concentrations 
Are Increased in Individuals With Impaired Glucose Metabolism and Type 2 Diabetes: 
The CODAM Study. Diabetes Care, 2015. 38(5): p. 913-20. 
447. Röder, P.V., et al., Pancreatic regulation of glucose homeostasis. Experimental & 
Molecular Medicine, 2016. 48(3): p. e219. 
448. Knop, F.K., et al., Reduced Incretin Effect in Type 2 Diabetes. Cause or 
Consequence of the Diabetic State?, 2007. 56(8): p. 1951-1959. 
449. Holst, J.J., et al., Roles of the Gut in Glucose Homeostasis. Diabetes Care, 2016. 
39(6): p. 884-892. 
450. Bagger, J.I., et al., Impaired regulation of the incretin effect in patients with type 2 
diabetes. J Clin Endocrinol Metab, 2011. 96(3): p. 737-45. 
451. Bagger, J.I., et al., Glucagon responses to increasing oral loads of glucose and 
corresponding isoglycaemic intravenous glucose infusions in patients with type 2 
diabetes and healthy individuals. Diabetologia, 2014. 57(8): p. 1720-5. 
452. Felicia, Y.T.Y., et al., Advanced Glycation End Products as Environmental Risk 
Factors for the Development of Type 1 Diabetes. Current Drug Targets, 2012. 13(4): 
p. 526-540. 
453. Kilhovd, B.K., et al., Serum levels of advanced glycation end products are increased 
in patients with type 2 diabetes and coronary heart disease. Diabetes Care, 1999. 
22(9): p. 1543-1548. 
454. Dasari, P.S., et al., Glycemic Variability Is Associated with Markers of Vascular Stress 
in Adolescents. The Journal of Pediatrics, 2016. 172: p. 47-55.e2. 
455. Basta, G., et al., Circulating soluble receptor for advanced glycation end products is 
inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol 
Metab, 2006. 91(11): p. 4628-34. 
456. Münch, G., et al., Advanced glycation endproducts in ageing and Alzheimer's 
disease. Brain Research Reviews, 1997. 23(1): p. 134-143. 
237 
 
457. Uribarri, J., et al., Circulating Glycotoxins and Dietary Advanced Glycation 
Endproducts: Two Links to Inflammatory Response, Oxidative Stress, and Aging. The 
journals of gerontology. Series A, Biological sciences and medical sciences, 2007. 
62(4): p. 427-433. 
458. Sebekova, K., et al., Plasma advanced glycation end products are decreased in 
obese children compared with lean controls. Int J Pediatr Obes, 2009. 4(2): p. 112-8. 
459. Nakamura, K., et al., Elevation of soluble form of receptor for advanced glycation end 
products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab 
Res Rev, 2007. 23(5): p. 368-71. 
460. Yamagishi, S., et al., Positive association between serum levels of advanced 
glycation end products and the soluble form of receptor for advanced glycation end 
products in nondiabetic subjects. Metabolism, 2006. 55(9): p. 1227-31. 
461. Nakamura, K., et al., Serum levels of soluble form of receptor for advanced glycation 
end products (sRAGE) are positively associated with circulating AGEs and soluble 
form of VCAM-1 in patients with type 2 diabetes. Microvascular Research, 2008. 
76(1): p. 52-56. 
462. Tan, K.C.B., et al., Association between serum levels of soluble receptor for 
advanced glycation end products and circulating advanced glycation end products in 
type 2 diabetes. Diabetologia, 2006. 49(11): p. 2756-2762. 
463. Brinkley, T.E., et al., Racial differences in circulating levels of the soluble receptor for 
advanced glycation endproducts in middle-aged and older adults. Metabolism, 2017. 
70: p. 98-106. 
464. Zaki, M., et al., Serum soluble receptor of advanced glycation end products and risk 
of metabolic syndrome in Egyptian obese women. EXCLI Journal, 2017. 16: p. 973-
980. 
465. Semba, R.D., et al., Fat Mass Is Inversely Associated with Serum Carboxymethyl-
Lysine, An Advanced Glycation End Product, in Adults. The Journal of Nutrition, 
2011. 141(9): p. 1726-1730. 
466. Gaens, K.H., et al., Protein-Bound Plasma Nepsilon-(Carboxymethyl)lysine Is 
Inversely Associated With Central Obesity and Inflammation and Significantly Explain 
a Part of the Central Obesity-Related Increase in Inflammation: The Hoorn and 
CODAM Studies. Arterioscler Thromb Vasc Biol, 2015. 35(12): p. 2707-13. 
467. Gaens, K.H., et al., Nepsilon-(carboxymethyl)lysine-receptor for advanced glycation 
end product axis is a key modulator of obesity-induced dysregulation of adipokine 
expression and insulin resistance. Arterioscler Thromb Vasc Biol, 2014. 34(6): p. 
1199-208. 
468. Brings, S., et al., Dicarbonyls and Advanced Glycation End-Products in the 
Development of Diabetic Complications and Targets for Intervention. International 
Journal of Molecular Sciences, 2017. 18(5): p. 984. 
238 
 
469. Williams, M.A., et al., Maternal plasma advanced glycation end products 
concentrations in response to oral 50-gram glucose load in mid-pregnancy: a pilot 
study. Clin Lab, 2012. 58(9-10): p. 1045-50. 
470. Wilkinson, J., J.S. Fleming, and D.G. Waller, Effect of food and activity on the 
reproducibility of isotopic GFR estimation. Nucl Med Commun, 1990. 11(10): p. 697-
700. 
471. Christiansen, J.S., M. Frandsen, and H.-H. Parving, Effect of intravenous glucose 
infusion on renal function in normal man and in insulin-dependent diabetics. 
Diabetologia, 1981. 21(4): p. 368-373. 
472. Chen, S., et al., Impact of glucose load in an oral glucose tolerance test on urinary 
albumin excretion varies with 2-h glucose levels. J Diabetes, 2016. 8(2): p. 206-13. 
473. Yu, M., et al., Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive 
rats. J Hypertens, 2003. 21(6): p. 1125-35. 
474. Moreno, C., M. Mistry, and R.J. Roman, Renal effects of glucagon-like peptide in rats. 
Eur J Pharmacol, 2002. 434(3): p. 163-7. 
475. Gutzwiller, J.P., et al., Glucagon-like peptide-1 is involved in sodium and water 
homeostasis in humans. Digestion, 2006. 73(2-3): p. 142-50. 
476. Raucci, A., et al., A soluble form of the receptor for advanced glycation endproducts 
(RAGE) is produced by proteolytic cleavage of the membrane-bound form by the 
sheddase a disintegrin and metalloprotease 10 (ADAM10). Faseb j, 2008. 22(10): p. 
3716-27. 
477. Braley, A., et al., Regulation of Receptor for Advanced Glycation End Products 
(RAGE) Ectodomain Shedding and Its Role in Cell Function. J Biol Chem, 2016. 
291(23): p. 12057-73. 
478. Cohen, M.J., et al., Early Release of soluble RAGE After Severe Trauma in Humans. 
The Journal of trauma, 2010. 68(6): p. 1273-1278. 
479. Jensen, L.J., et al., Dynamic changes in sRAGE levels and relationship with cardiac 
function in STEMI patients. Clin Biochem, 2015. 48(4-5): p. 297-301. 
480. Lam, J.K.Y., et al., Effect of insulin on the soluble receptor for advanced glycation 
end products (RAGE). Diabetic Medicine, 2013. 30(6): p. 702-709. 
481. Chang, J.T., et al., Glucagon-like peptide receptor agonists attenuate advanced 
glycation end products-induced inflammation in rat mesangial cells. BMC Pharmacol 
Toxicol, 2017. 18(1): p. 67. 
482. Ishibashi, Y., et al., Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end 
product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by 
suppressing AGE receptor (RAGE) expression. Biochemical and Biophysical 
Research Communications, 2010. 391(3): p. 1405-1408. 
483. Niquet-Léridon, C., et al., The rehabilitation of raw and brown butters by the 
measurement of two of the major Maillard products, Nε-carboxymethyl-lysine and 5-
239 
 
hydroxymethylfurfural, with validated chromatographic methods. Food Chemistry, 
2015. 177: p. 361-368. 
484. Lopez-Moreno, J., et al., Mediterranean Diet Supplemented With Coenzyme Q10 
Modulates the Postprandial Metabolism of Advanced Glycation End Products in 
Elderly Men and Women. The Journals of Gerontology: Series A, 2018. 73(3): p. 340-
346. 
485. Degenhardt, T.P., et al., The serum concentration of the advanced glycation end-
product Nε-(carboxymethyl)lysine is increased in uremia: Technical Note. Kidney 
International, 1997. 52(4): p. 1064-1067. 
486. Rule, A.D., et al., The association between age and nephrosclerosis on renal biopsy 
among healthy adults. Ann Intern Med, 2010. 152(9): p. 561-7. 
487. Anderson, S., H.G. Rennke, and R. Zatz, Glomerular adaptations with normal aging 
and with long-term converting enzyme inhibition in rats. Am J Physiol, 1994. 267(1 Pt 
2): p. F35-43. 
488. Emamian, S.A., et al., Kidney dimensions at sonography: correlation with age, sex, 
and habitus in 665 adult volunteers. AJR Am J Roentgenol, 1993. 160(1): p. 83-6. 
489. Denic, A., et al., The Substantial Loss of Nephrons in Healthy Human Kidneys with 
Aging. Journal of the American Society of Nephrology, 2017. 28(1): p. 313-320. 
490. Elsherbiny, H.E., et al., Nephron Hypertrophy and Glomerulosclerosis and Their 
Association with Kidney Function and Risk Factors among Living Kidney Donors. 
Clinical Journal of the American Society of Nephrology, 2014. 9(11): p. 1892-1902. 
491. Neugarten, J., et al., Glomerulosclerosis in aging humans is not influenced by gender. 
Am J Kidney Dis, 1999. 34(5): p. 884-8. 
492. Kaplan, C., et al., Age-related incidence of sclerotic glomeruli in human kidneys. Am 
J Pathol, 1975. 80(2): p. 227-34. 
493. Wiggins, J.E., et al., Podocyte Hypertrophy, “Adaptation,” and “Decompensation” 
Associated with Glomerular Enlargement and Glomerulosclerosis in the Aging Rat: 
Prevention by Calorie Restriction. Journal of the American Society of Nephrology, 
2005. 16(10): p. 2953-2966. 
494. Lindeman, R.D., J.D. Tobin, and N.W. Shock, Association between blood pressure 
and the rate of decline in renal function with age. Kidney Int, 1984. 26(6): p. 861-8. 
495. Fox, C.S., et al., Predictors of new-onset kidney disease in a community-based 
population. JAMA, 2004. 291(7): p. 844-850. 
496. Bleyer, A.J., et al., Tobacco, hypertension, and vascular disease: Risk factors for 
renal functional decline in an older population. Kidney International, 2000. 57(5): p. 
2072-2079. 
497. Sontrop, J.M., et al., Association between water intake, chronic kidney disease, and 
cardiovascular disease: a cross-sectional analysis of NHANES data. Am J Nephrol, 
2013. 37(5): p. 434-42. 
240 
 
498. Strippoli, G.F., et al., Fluid and nutrient intake and risk of chronic kidney disease. 
Nephrology, 2011. 16(3): p. 326-334. 
499. Nakayama, T., et al., Dietary fructose causes tubulointerstitial injury in the normal rat 
kidney. Am J Physiol Renal Physiol, 2010. 298(3): p. F712-20. 
500. Velasquez, M.T., et al., Effect of Carbohydrate Intake on Kidney Function and 
Structure in SHR/N-cp Rats: A New Model of NIDDM. Diabetes, 1989. 38(6): p. 679-
685. 
501. Le Couteur, D.G., et al., The Evolution of Research on Ageing and Nutrition. The 
Journals of Gerontology: Series A, 2014. 69(1): p. 1-2. 
502. Solon-Biet, S.M., et al., Macronutrient balance, reproductive function, and lifespan in 
aging mice. Proceedings of the National Academy of Sciences, 2015. 112(11): p. 
3481-3486. 
503. Cogger, V.C., et al., Dietary macronutrients and the aging liver sinusoidal endothelial 
cell. American Journal of Physiology - Heart and Circulatory Physiology, 2016. 
310(9): p. H1064-H1070. 
504. Hew, J., et al., The Effects of Dietary Macronutrient Balance on Skin Structure in 
Aging Male and Female Mice. PLOS ONE, 2016. 11(11): p. e0166175. 
505. Holmes, A.J., et al., Diet-Microbiome Interactions in Health Are Controlled by 
Intestinal Nitrogen Source Constraints. Cell Metabolism, 2017. 25(1): p. 140-151. 
506. Le Couteur, D.G., et al., The Influence of Macronutrients on Splanchnic and Hepatic 
Lymphocytes in Aging Mice. The Journals of Gerontology: Series A, 2015. 70(12): p. 
1499-1507. 
507. Gallo, L.A., et al., Once daily administration of the SGLT2 inhibitor, empagliflozin, 
attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db 
mice. 2016. 6: p. 26428. 
508. Juraschek, S.P., et al., Effect of a high-protein diet on kidney function in healthy 
adults: results from the OmniHeart trial. Am J Kidney Dis, 2013. 61(4): p. 547-54. 
509. Sugiura, H., et al., Reduced Klotho expression level in kidney aggravates renal 
interstitial fibrosis. American Journal of Physiology-Renal Physiology, 2012. 302(10): 
p. F1252-F1264. 
510. Koh, N., et al., Severely reduced production of klotho in human chronic renal failure 
kidney. Biochem Biophys Res Commun, 2001. 280(4): p. 1015-20. 
511. Torres, P.U., et al., Klotho: An antiaging protein involved in mineral and vitamin D 
metabolism. Kidney International, 2007. 71(8): p. 730-737. 
512. Kurosu, H., et al., Suppression of Aging in Mice by the Hormone Klotho. Science, 
2005. 309(5742): p. 1829-1833. 
241 
 
513. Weiner, I.D., W.E. Mitch, and J.M. Sands, Urea and Ammonia Metabolism and the 
Control of Renal Nitrogen Excretion. Clin J Am Soc Nephrol, 2015. 10(8): p. 1444-
58. 
514. Bankir, L., R. Roussel, and N. Bouby, Protein- and diabetes-induced glomerular 
hyperfiltration: role of glucagon, vasopressin, and urea. Am J Physiol Renal Physiol, 
2015. 309(1): p. F2-23. 
515. Child, S.C., et al., Urea kinetics varies in Jamaican women and men in relation to 
adiposity, lean body mass and protein intake. Eur J Clin Nutr, 1997. 51(2): p. 107-15. 
516. Nath, K.A., S.M. Kren, and T.H. Hostetter, Dietary protein restriction in established 
renal injury in the rat. Selective role of glomerular capillary pressure in progressive 
glomerular dysfunction. J Clin Invest, 1986. 78(5): p. 1199-205. 
517. Schwingshackl, L. and G. Hoffmann, Comparison of High vs. Normal/Low Protein 
Diets on Renal Function in Subjects without Chronic Kidney Disease: A Systematic 
Review and Meta-Analysis. PLOS ONE, 2014. 9(5): p. e97656. 
518. Levey, A.S., et al., Effect of Dietary Protein Restriction on the Progression of Kidney 
Disease: Long-Term Follow-Up of the Modification of Diet in Renal Disease (MDRD) 
Study. American Journal of Kidney Diseases, 2006. 48(6): p. 879-888. 
519. Puelles, V.G., et al., Glomerular number and size variability and risk for kidney 
disease. Curr Opin Nephrol Hypertens, 2011. 20(1): p. 7-15. 
520. Matsell, D.G., et al., The impact of small kidneys. Pediatric Nephrology, 2015. 30(9): 
p. 1501-1509. 
521. Kandasamy, Y., et al., Reduced nephron endowment in the neonates of Indigenous 
Australian peoples. J Dev Orig Health Dis, 2014. 5(1): p. 31-5. 
522. Carrero, J.J., et al., Etiology of the Protein-Energy Wasting Syndrome in Chronic 
Kidney Disease: A Consensus Statement From the International Society of Renal 
Nutrition and Metabolism (ISRNM). Journal of Renal Nutrition, 2013. 23(2): p. 77-90. 
523. Volek, J.S., et al., Body composition and hormonal responses to a carbohydrate-
restricted diet. Metabolism, 2002. 51(7): p. 864-70. 
524. Bouquegneau, A., et al., Anorexia nervosa and the kidney. Am J Kidney Dis, 2012. 
60(2): p. 299-307. 
525. Ko, G.J., et al., Dietary protein intake and chronic kidney disease. Current opinion in 
clinical nutrition and metabolic care, 2017. 20(1): p. 77-85. 
526. Wakefield, A.P., et al., A diet with 35 % of energy from protein leads to kidney damage 
in female Sprague–Dawley rats. British Journal of Nutrition, 2011. 106(5): p. 656-663. 
527. Van Der Heijden, R.A., et al., Obesity-induced chronic inflammation in high fat diet 
challenged C57BL/6J mice is associated with acceleration of age-dependent renal 
amyloidosis. Scientific Reports, 2015. 5: p. 16474. 
242 
 
528. Declèves, A.-E., et al., AMPK Mediates the Initiation of Kidney Disease Induced by a 
High-Fat Diet. Journal of the American Society of Nephrology : JASN, 2011. 22(10): 
p. 1846-1855. 
529. Bonventre, J.V., Kidney injury molecule-1 (KIM-1): a urinary biomarker and much 
more. Nephrol Dial Transplant, 2009. 24(11): p. 3265-8. 
530. Ichimura, T., et al., Kidney injury molecule-1 is a phosphatidylserine receptor that 
confers a phagocytic phenotype on epithelial cells. J Clin Invest, 2008. 118(5): p. 
1657-68. 
531. Tian, L., et al., Kidney Injury Molecule-1 is Elevated in Nephropathy and Mediates 
Macrophage Activation via the Mapk Signalling Pathway. Cellular Physiology and 
Biochemistry, 2017. 41(2): p. 769-783. 
532. Ho, A.W., C.K. Wong, and C.W. Lam, Tumor necrosis factor-alpha up-regulates the 
expression of CCL2 and adhesion molecules of human proximal tubular epithelial 
cells through MAPK signaling pathways. Immunobiology, 2008. 213(7): p. 533-44. 
533. Navarro, J.F. and C. Mora-Fernández, The role of TNF-α in diabetic nephropathy: 
Pathogenic and therapeutic implications. Cytokine & Growth Factor Reviews, 2006. 
17(6): p. 441-450. 
534. Su, H., C.T. Lei, and C. Zhang, Interleukin-6 Signaling Pathway and Its Role in Kidney 
Disease: An Update. Frontiers in immunology, 2017. 8: p. 405-405. 
535. Navarro-González, J.F. and C. Mora-Fernández, The Role of Inflammatory Cytokines 
in Diabetic Nephropathy. Journal of the American Society of Nephrology, 2008. 19(3): 
p. 433-442. 
536. Stenvinkel, P., et al., IL-10, IL-6, and TNF-alpha;: Central factors in the altered 
cytokine network of uremia--;The good, the bad, and the ugly. Kidney International, 
2005. 67(4): p. 1216-1233. 
537. Ernandez, T. and T. Mayadas, Immunoregulatory role of TNFα in inflammatory kidney 
diseases. Kidney International, 2009. 76(3): p. 262-276. 
538. Ramseyer, V.D. and J.L. Garvin, Tumor necrosis factor-α: regulation of renal function 
and blood pressure. American journal of physiology. Renal physiology, 2013. 
304(10): p. F1231-F1242. 
539. Haller, H., et al., Monocyte chemoattractant protein-1 and the kidney. Current Opinion 
in Nephrology and Hypertension, 2016. 25(1): p. 42-49. 
540. Vesey, D.A., et al., Interleukin-1β stimulates human renal fibroblast proliferation and 
matrix protein production by means of a transforming growth factor-β-dependent 
mechanism. Journal of Laboratory and Clinical Medicine, 2002. 140(5): p. 342-350. 
541. Kitching, A.R., et al., IL-1RI deficiency ameliorates early experimental renal interstitial 
fibrosis. Nephrology Dialysis Transplantation, 2009. 24(10): p. 3024-3032. 
243 
 
542. Lemos, D.R., et al., Interleukin-1β Activates a MYC-Dependent Metabolic Switch in 
Kidney Stromal Cells Necessary for Progressive Tubulointerstitial Fibrosis. Journal 
of the American Society of Nephrology, 2018. 29(6): p. 1690-1705. 
543. Tesmer, L.A., et al., Th17 cells in human disease. Immunological reviews, 2008. 223: 
p. 87-113. 
544. Paust, H.-J., et al., The IL-23/Th17 Axis Contributes to Renal Injury in Experimental 
Glomerulonephritis. Journal of the American Society of Nephrology, 2009. 20(5): p. 
969-979. 
545. Goto, K., et al., Leptin deficiency down-regulates IL-23 production in glomerular 
podocytes resulting in an attenuated immune response in nephrotoxic serum 
nephritis. Int Immunol, 2016. 28(4): p. 197-208. 
546. Hu, M.-C., M. Kuro-O, and O.W. Moe, Klotho and kidney disease. Journal of 
nephrology, 2010. 23 Suppl 16(Suppl 16): p. S136-S144. 
547. Zhao, Y., et al., Klotho Depletion Contributes to Increased Inflammation in Kidney of 
the db/db Mouse Model of Diabetes via RelA (Serine)536 Phosphorylation. Diabetes, 
2011. 60(7): p. 1907-1916. 
548. Kremsdorf, R.A., et al., Effects of a high-protein diet on regulation of phosphorus 
homeostasis. The Journal of clinical endocrinology and metabolism, 2013. 98(3): p. 
1207-1213. 
549. Erben, R.G. and O. Andrukhova, FGF23-Klotho signaling axis in the kidney. Bone, 
2017. 100: p. 62-68. 
550. Ferguson, M.A. and S.S. Waikar, Established and Emerging Markers of Kidney 
Function. Clinical Chemistry, 2012. 58(4): p. 680-689. 
551. Palatini, P., Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes 
and pre-hypertension. Nephrology Dialysis Transplantation, 2012. 27(5): p. 1708-
1714. 
552. Magee, G.M., et al., Is hyperfiltration associated with the future risk of developing 
diabetic nephropathy? A meta-analysis. Diabetologia, 2009. 52(4): p. 691-7. 
553. Rea, D.J., et al., Glomerular volume and renal histology in obese and non-obese 
living kidney donors. Kidney Int, 2006. 70(9): p. 1636-41. 
554. Buettner, R., J. Schölmerich, and L.C. Bollheimer, High-fat Diets: Modeling the 
Metabolic Disorders of Human Obesity in Rodents. Obesity, 2007. 15(4): p. 798-808. 
555. Gunstone, F., Oils and Fats in the Food Industry. 2009, Hoboken: Hoboken: Wiley. 
556. King, D.E., Dietary fiber, inflammation, and cardiovascular disease. Mol Nutr Food 
Res, 2005. 49(6): p. 594-600. 
557. Krishnamurthy, V.M., et al., High dietary fiber intake is associated with decreased 
inflammation and all-cause mortality in patients with chronic kidney disease. Kidney 
Int, 2012. 81(3): p. 300-6. 
244 
 
558. Xu, H., et al., Dietary Fiber, Kidney Function, Inflammation, and Mortality Risk. 
Clinical Journal of the American Society of Nephrology : CJASN, 2014. 9(12): p. 
2104-2110. 
559. Lewis, E.J., et al., The effect of angiotensin-converting-enzyme inhibition on diabetic 
nephropathy. The Collaborative Study Group. N Engl J Med, 1993. 329(20): p. 1456-
62. 
560. Maschio, G., et al., Effect of the angiotensin-converting-enzyme inhibitor benazepril 
on the progression of chronic renal insufficiency. The Angiotensin-Converting-
Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med, 
1996. 334(15): p. 939-45. 
561. Lewis, E.J., et al., Renoprotective effect of the angiotensin-receptor antagonist 
irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001. 
345(12): p. 851-60. 
562. Brenner, B.M., et al., Effects of losartan on renal and cardiovascular outcomes in 
patients with type 2 diabetes and nephropathy. N Engl J Med, 2001. 345(12): p. 861-
9. 
563. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular 
filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. 
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet, 
1997. 349(9069): p. 1857-63. 
564. Giatras, I., J. Lau, and A.S. Levey, Effect of angiotensin-converting enzyme inhibitors 
on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. 
Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study 
Group. Ann Intern Med, 1997. 127(5): p. 337-45. 
565. Vallon, V., R.C. Blantz, and S. Thomson, Glomerular Hyperfiltration and the Salt 
Paradox in Early Type 1 Diabetes Mellitus: A Tubulo-Centric View. Journal of the 
American Society of Nephrology, 2003. 14(2): p. 530-537. 
566. Yacoub, R., et al., Advanced glycation end products dietary restriction effects on 
bacterial gut microbiota in peritoneal dialysis patients; a randomized open label 
controlled trial. PLOS ONE, 2017. 12(9): p. e0184789. 
567. Meijers, B.K.I. and P. Evenepoel, The gut–kidney axis: indoxyl sulfate, p-cresyl 
sulfate and CKD progression. Nephrology Dialysis Transplantation, 2011. 26(3): p. 
759-761. 
568. Snelson, M., et al., Abstract: Resistant starch ameliorates heat treated diet-induced 
gut permeability and renal dysfunction in experimental diabetes. Journal of Nutrition 
& Intermediary Metabolism, 2017. 8(Proceedings of the Nutrition Society of Australia 
40th Annual Scientific Meeting, Melbourne, Australia). 
569. Vlassara, H. and G.E. Striker, AGE restriction in diabetes mellitus: a paradigm shift. 
Nature Reviews Endocrinology, 2011. 7: p. 526. 
245 
 
570. Vlassara, H. and J. Uribarri, Advanced Glycation End Products (AGE) and Diabetes: 
Cause, Effect, or Both? Current Diabetes Reports, 2013. 14(1): p. 453. 
571. Drucker, D.J., The role of gut hormones in glucose homeostasis. The Journal of 
Clinical Investigation, 2007. 117(1): p. 24-32. 
572. Tan, A.L., et al., Disparate effects on renal and oxidative parameters following RAGE 
deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic 
nephropathy. Am J Physiol Renal Physiol, 2010. 298(3): p. F763-70. 
573. Cai, W., et al., Reduced Oxidant Stress and Extended Lifespan in Mice Exposed to 
a Low Glycotoxin Diet: Association with Increased AGER1 Expression. The American 
Journal of Pathology, 2007. 170(6): p. 1893-1902. 
574. Sayej, W.N., et al., Advanced Glycation End Products Induce Obesity and 
Hepatosteatosis in CD-1 Wild-Type Mice. Biomed Res Int, 2016. 2016: p. 7867852. 
575. Challier, M., et al., Increased Serum Concentrations of Soluble Receptor for 
Advanced Glycation Endproducts in Patients with Type 1 Diabetes. Clinical 
Chemistry, 2005. 51(9): p. 1749-1750. 
576. Nakamura, K., et al., Serum levels of sRAGE, the soluble form of receptor for 
advanced glycation end products, are associated with inflammatory markers in 
patients with type 2 diabetes. Molecular medicine (Cambridge, Mass.), 2007. 13(3-
4): p. 185-189. 
577. Gopal, P., et al., Decreased plasma sRAGE levels in COPD: influence of oxygen 
therapy. Eur J Clin Invest, 2012. 42(8): p. 807-14. 
578. Yonchuk, J.G., et al., Circulating soluble receptor for advanced glycation end 
products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung. Am 
J Respir Crit Care Med, 2015. 192(7): p. 785-92. 
579. Gross, S., et al., Low Levels of sRAGE Are Associated With Increased Risk for 
Mortality in Renal Transplant Recipients. Transplantation, 2007. 84(5): p. 659-663. 
580. Selvin, E., et al., sRAGE and risk of diabetes, cardiovascular disease and death. 
Diabetes, 2013: p. DB_121528. 
581. Dozio, E., et al., Relationship between soluble receptor for advanced glycation end 
products (sRAGE), body composition and fat distribution in healthy women. 
European Journal of Nutrition, 2017. 56(8): p. 2557-2564. 
582. Salonen, K.M., et al., A drop in the circulating concentrations of soluble receptor for 
advanced glycation end products is associated with seroconversion to autoantibody 
positivity but not with subsequent progression to clinical disease in children en route 
to type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2017. 33(4): p. 
e2872. 
583. Dehghan, M., et al., Associations of fats and carbohydrate intake with cardiovascular 
disease and mortality in 18 countries from five continents (PURE): a prospective 
cohort study. The Lancet, 2017. 390(10107): p. 2050-2062. 
246 
 
584. Simpson, S.J. and D. Raubenheimer, The Nature of Nutrition, Chapter 2: The 
Geometry of Human Nutrition. 2012, Oxford: Princeton University Press. 
585. Simpson, S.J., et al., Dietary protein, aging and nutritional geometry. Ageing 
Research Reviews, 2017. 39(Supplement C): p. 78-86. 
586. Solon-Biet, Samantha m., et al., Dietary Protein to Carbohydrate Ratio and Caloric 
Restriction: Comparing Metabolic Outcomes in Mice. Cell Reports, 2015. 11(10): p. 
1529-1534. 
587. Harcombe, Z., et al., Evidence from randomised controlled trials did not support the 
introduction of dietary fat guidelines in 1977 and 1983: a systematic review and meta-
analysis. Open Heart, 2015. 2(1): p. e000196. 
588. Chalvon-Demersay, T., et al., Animal Models for the Study of the Relationships 
between Diet and Obesity: A Focus on Dietary Protein and Estrogen Deficiency. 
Frontiers in nutrition, 2017. 4: p. 5-5. 
247 
 
Appendix 1 Permission to reproduce figures from a publication.   
The original article can be found by following the link below. 
https://www.sciencedirect.com/science/article/pii/S1550413114000655 
ELSEVIER LICENSE 
TERMS AND CONDITIONS 
Feb 10, 2019 
 
 
 
This Agreement between Glycation and Diabetes Complications-Mater Research 
("You") and Elsevier ("Elsevier") consists of your license details and the terms and 
conditions provided by Elsevier and Copyright Clearance Center. 
License Number 4496411454816 
License date Dec 26, 2018 
Licensed Content Publisher Elsevier 
Licensed Content 
Publication 
Cell Metabolism 
Licensed Content Title The Ratio of Macronutrients, Not Caloric Intake, Dictates 
Cardiometabolic Health, Aging, and Longevity in Ad Libitum-Fed 
Mice 
Licensed Content Author Samantha M. Solon-Biet,Aisling C. McMahon,J. William O. 
Ballard,Kari Ruohonen,Lindsay E. Wu,Victoria C. Cogger,Alessandra 
Warren,Xin Huang,Nicolas Pichaud,Richard G. Melvin,Rahul 
Gokarn,Mamdouh Khalil,Nigel Turner,Gregory J. Cooney et al. 
Licensed Content Date Mar 4, 2014 
Licensed Content Volume 19 
Licensed Content Issue 3 
Licensed Content Pages 13 
Start Page 418 
End Page 430 
Type of Use reuse in a thesis/dissertation 
Portion figures/tables/illustrations 
Number of 
figures/tables/illustrations 
1 
248 
 
Format electronic 
Are you the author of this 
Elsevier article? 
No 
Will you be translating? No 
Original figure numbers Figure 5 and Figure 6 
Title of your 
thesis/dissertation  
Novel dietary factors in diabetic and non-diabetic kidney disease 
Expected completion date Feb 2019 
Estimated size (number of 
pages) 
150 
Requestor Location Glycation and Diabetes Complications-Mater Research-UQ 
Level 4, 37 Kent St, 
 
 
Woolloongabba, QLD 4102 
Australia 
Attn: Glycation and Diabetes Complications-Mater Research-UQ 
 
Publisher Tax ID GB 494 6272 12 
Total 0.00 AUD 
  
Terms and Conditions 
  
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier.  By clicking "accept" in connection 
with completing this licensing transaction, you agree that the following terms and conditions 
apply to this transaction (along with the Billing and Payment terms and conditions 
established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your 
Rightslink account and that are available at any time at http://myaccount.copyright.com).  
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject 
to the terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has 
appeared in our publication with credit or acknowledgement to another source, permission 
must also be sought from that source.  If such permission is not obtained then that material 
  
249 
 
may not be included in your publication/copies. Suitable acknowledgement to the source 
must be made, either as a footnote or in a reference list at the end of your publication, as 
follows: 
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of 
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE 
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The 
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with 
permission from Elsevier." 
4. Reproduction of this material is confined to the purpose and/or media for which permission 
is hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be 
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions 
and/or any other alterations shall be made only with prior written authorization of Elsevier 
Ltd. (Please contact Elsevier at permissions@elsevier.com). No modifications can be made 
to any Lancet figures/tables and they must be reproduced in full.  
6. If the permission fee for the requested use of our material is waived in this instance, please 
be advised that your future requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the 
combination of (i) the license details provided by you and accepted in the course of this 
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment 
terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed 
immediately upon issuance of the license at the end of the licensing process for the 
transaction, provided that you have disclosed complete and accurate details of your proposed 
use, no license is finally effective unless and until full payment is received from you (either 
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions.  If 
full payment is not received on a timely basis, then any license preliminarily granted shall 
be deemed automatically revoked and shall be void as if never granted.  Further, in the event 
250 
 
that you breach any of these terms and conditions or any of CCC's Billing and Payment terms 
and conditions, the license is automatically revoked and shall be void as if never 
granted.  Use of materials as described in a revoked license, as well as any use of the 
materials beyond the scope of an unrevoked license, may constitute copyright infringement 
and publisher reserves the right to take any and all action to protect its copyright in the 
materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and 
their respective officers, directors, employees and agents, from and against any and all claims 
arising out of your use of the licensed material other than as specifically authorized pursuant 
to this license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, 
assigned, or transferred by you to any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a writing 
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any 
purchase order, acknowledgment, check endorsement or other writing prepared by you, 
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment 
terms and conditions.  These terms and conditions, together with CCC's Billing and Payment 
terms and conditions (which are incorporated herein), comprise the entire agreement between 
you and publisher (and CCC) concerning this licensing transaction.  In the event of any 
conflict between your obligations established by these terms and conditions and those 
established by CCC's Billing and Payment terms and conditions, these terms and conditions 
shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described 
in this License at their sole discretion, for any reason or no reason, with a full refund payable 
to you.  Notice of such denial will be made using the contact information provided by 
251 
 
you.  Failure to receive such notice will not alter or invalidate the denial.  In no event will 
Elsevier or Copyright Clearance Center be responsible or liable for any costs, expenses or 
damage incurred by you as a result of a denial of your permission request, other than a refund 
of the amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied 
permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only 
unless your license was granted for translation rights. If you licensed translation rights you 
may only translate this content into the languages you requested. A professional translator 
must perform all translations and reproduce the content word for word preserving the 
integrity of the article. 
16. Posting licensed content on any Website: The following terms and conditions apply as 
follows: Licensing material from an Elsevier journal: All content posted to the web site must 
maintain the copyright information line on the bottom of each image; A hyper-text must be 
included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at 
http://www.elsevier.com; Central Storage: This license does not include permission for a 
scanned version of the material to be stored in a central repository such as that provided by 
Heron/XanEdu. 
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier 
homepage at http://www.elsevier.com . All content posted to the web site must maintain the 
copyright information line on the bottom of each image. 
 
Posting licensed content on Electronic reserve: In addition to the above the following 
clauses are applicable: The web site must be password-protected and made available only to 
252 
 
bona fide students registered on a relevant course. This permission is granted for 1 year only. 
You may obtain a new license for future website posting.  
17. For journal authors: the following clauses are applicable in addition to the above: 
Preprints: 
A preprint is an author's own write-up of research results and analysis, it has not been peer-
reviewed, nor has it had any other value added to it by a publisher (such as formatting, 
copyright, technical enhancement etc.). 
Authors can share their preprints anywhere at any time. Preprints should not be added to or 
enhanced in any way in order to appear more like, or to substitute for, the final versions of 
articles however authors can update their preprints on arXiv or RePEc with their Accepted 
Author Manuscript (see below). 
If accepted for publication, we encourage authors to link from the preprint to their formal 
publication via its DOI. Millions of researchers have access to the formal publications on 
ScienceDirect, and so links will help users to find, access, cite and use the best available 
version. Please note that Cell Press, The Lancet and some society-owned have different 
preprint policies. Information on these policies is available on the journal homepage. 
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an 
article that has been accepted for publication and which typically includes author-
incorporated changes suggested during submission, peer review and editor-author 
communications. 
Authors can share their accepted author manuscript: 
 immediately 
o via their non-commercial person homepage or blog 
o by updating a preprint in arXiv or RePEc with the accepted 
manuscript 
o via their research institute or institutional repository for internal 
institutional uses or as part of an invitation-only research 
collaboration work-group 
253 
 
o directly by providing copies to their students or to research 
collaborators for their personal use 
o for private scholarly sharing as part of an invitation-only work group 
on commercial sites with which Elsevier has an agreement 
 After the embargo period 
o via non-commercial hosting platforms such as their institutional 
repository 
o via commercial sites with which Elsevier has an agreement 
In all cases accepted manuscripts should: 
 link to the formal publication via its DOI 
 bear a CC-BY-NC-ND license - this is easy to do 
 if aggregated with other manuscripts, for example in a repository or other 
site, be shared in alignment with our hosting policy not be added to or 
enhanced in any way to appear more like, or to substitute for, the published 
journal article. 
Published journal article (JPA): A published journal article (PJA) is the definitive final 
record of published research that appears or will appear in the journal and embodies all value-
adding publishing activities including peer review co-ordination, copy-editing, formatting, 
(if relevant) pagination and online enrichment. 
Policies for sharing publishing journal articles differ for subscription and gold open access 
articles: 
Subscription Articles: If you are an author, please share a link to your article rather than 
the full-text. Millions of researchers have access to the formal publications on ScienceDirect, 
and so links will help your users to find, access, cite, and use the best available version. 
Theses and dissertations which contain embedded PJAs as part of the formal submission can 
be posted publicly by the awarding institution with DOI links back to the formal publications 
on ScienceDirect. 
If you are affiliated with a library that subscribes to ScienceDirect you have additional 
private sharing rights for others' research accessed under that agreement. This includes use 
for classroom teaching and internal training at the institution (including use in course packs 
and courseware programs), and inclusion of the article for grant funding purposes. 
254 
 
Gold Open Access Articles: May be shared according to the author-selected end-user 
license and should contain a CrossMark logo, the end user license, and a DOI link to the 
formal publication on ScienceDirect. 
Please refer to Elsevier's posting policy for further information. 
18. For book authors the following clauses are applicable in addition to the above:   Authors 
are permitted to place a brief summary of their work online only. You are not allowed to 
download and post the published electronic version of your chapter, nor may you scan the 
printed edition to create an electronic version. Posting to a repository: Authors are 
permitted to post a summary of their chapter only in their institution's repository. 
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be 
submitted to your institution in either print or electronic form. Should your thesis be 
published commercially, please reapply for permission. These requirements include 
permission for the Library and Archives of Canada to supply single copies, on demand, of 
the complete thesis and include permission for Proquest/UMI to supply single copies, on 
demand, of the complete thesis. Should your thesis be published commercially, please 
reapply for permission. Theses and dissertations which contain embedded PJAs as part of 
the formal submission can be posted publicly by the awarding institution with DOI links 
back to the formal publications on ScienceDirect. 
  
Elsevier Open Access Terms and Conditions 
You can publish open access with Elsevier in hundreds of open access journals or in nearly 
2000 established subscription journals that support open access publishing. Permitted third 
party re-use of these open access articles is defined by the author's choice of Creative 
Commons user license. See our open access license policy for more information. 
Terms & Conditions applicable to all Open Access articles published with Elsevier:  
255 
 
Any reuse of the article must not represent the author as endorsing the adaptation of the 
article nor should the article be modified in such a way as to damage the author's honour or 
reputation. If any changes have been made, such changes must be clearly indicated. 
The author(s) must be appropriately credited and we ask that you include the end user license 
and a DOI link to the formal publication on ScienceDirect. 
If any part of the material to be used (for example, figures) has appeared in our publication 
with credit or acknowledgement to another source it is the responsibility of the user to ensure 
their reuse complies with the terms and conditions determined by the rights holder. 
Additional Terms & Conditions applicable to each Creative Commons user license: 
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new works 
from the Article, to alter and revise the Article and to make commercial use of the Article 
(including reuse and/or resale of the Article by commercial entities), provided the user gives 
appropriate credit (with a link to the formal publication through the relevant DOI), provides 
a link to the license, indicates if changes were made and the licensor is not represented as 
endorsing the use made of the work. The full details of the license are available at 
http://creativecommons.org/licenses/by/4.0. 
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts, 
abstracts and new works from the Article, to alter and revise the Article, provided this is not 
done for commercial purposes, and that the user gives appropriate credit (with a link to the 
formal publication through the relevant DOI), provides a link to the license, indicates if 
changes were made and the licensor is not represented as endorsing the use made of the work. 
Further, any new works must be made available on the same conditions. The full details of 
the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0. 
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article, 
provided this is not done for commercial purposes and further does not permit distribution 
of the Article if it is changed or edited in any way, and provided the user gives appropriate 
credit (with a link to the formal publication through the relevant DOI), provides a link to the 
license, and that the licensor is not represented as endorsing the use made of the work. The 
256 
 
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0. 
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY 
NC ND license requires permission from Elsevier and will be subject to a fee.  
Commercial reuse includes: 
 Associating advertising with the full text of the Article 
 Charging fees for document delivery or access 
 Article aggregation 
 Systematic distribution via e-mail lists or share buttons 
Posting or linking by commercial companies for use by customers of those companies. 
  
20. Other Conditions:  
  
v1.9 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or 
+1-978-646-2777.   
 
  
257 
 
Appendix 2 Animal Ethics approval certificate 
 
